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Abstract 
Abstract 
There is a great desire for the synthesis of new heteroaromatic compounds, which 
have a range of applications from pharmaceuticals to materials. These industries require 
large numbers of heterocyclic derivatives for their screening programmes, however many 
common routes for the synthesis of aromatic heterocycles do not allow for the flexible 
introduction of a diverse range of substituents. 
Our approach involves the use of tetrafluoropyridazine as a scaffold for the 
synthesis of a diverse range of heteroaromatic systems. Perfluorinated heteroaromatic 
compounds, such as tetrafluoropyridazine, are highly reactive towards displacements by 
nucleophilic species. Sequential nucleophilic aromatic substitution reactions of 4,5,6-
trifluoropyridazin-3(2H)-one have been studied and a range of polysubstituted systems 
synthesised. Similarly, reactions of tetratluoropyridazine with dinucleophiles have been 
utilised to yield ring-fused products, many of which are rare heterocyclic substructures. 
This approach has allowed the synthesis of a small library of compounds based on 
the pyridazine ring system with moderate skeletal and substituent diversity. The synthesis 
of some non-halogenated products by displacement of all ring fluorine atoms has also been 
reported. 
F 
F~F 
~,N_,lO 
H 
X 
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Chapter 1 
The Synthesis and Chemistry of Pyridazine Derivatives 
1.1 Aromatic Heterocycles 
The use of aromatic heterocycles has become ubiquitous in recent years in a variety 
of applications, ranging from pharmaceuticals to materials and, as a result, the chemistry of 
heteroaromatic systems has been studied in detail. This thesis discusses the chemistry of 
highly fluorinated pyridazines, one class of heterocycle that has undergone little study in 
the past. Consequently, this chapter will offer a general introduction to heteroaromatic 
chemistry, before a more detailed discussion of pyridazine chemistry and corresponding 
fluorinated systems. 
1.1.1 Reactivity of Aromatic Heterocycles 
The chemistry of benzene and five membered heteroaromatic rings such as pyrrole1 
are dominated by electrophilic aromatic substitution, due to the electron rich nature of the 
aromatic ring. However, in the case of six membered nitrogen heteroaromatics, which are 
the focus of this thesis, electrophilic aromatic substitution reactions proceed extremely 
slowly and, in many cases, not at all. Instead these heterocycles, such as pyridine, react 
with electrophiles, such as methyl iodide, at the ring nitrogen, forming, for example, 
positively charged pyridinium salts2• Under relatively forcing conditions, electrophilic 
substitution at a carbon atom of the pyridine ring can proceed, for example 3-
chloropyridine 2 is produced by reaction of pyridine 1 with chlorine gas and aluminium 
(III) chloride at 115°C3 (Scheme 1.1 ), but these reactions are extremely difficult to perform 
as the pyridinium cations produced initially are highly unreactive towards electrophiles. 
0 Cl2 UCI AIC13 h N N 
1 115°C 2 
33% 
Scheme 1.1 
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Instead, the chemistry of six membered nitrogen heteroaromatics is dominated by 
reactions involving nucleophilic species. For example, pyridine derivatives react with 
sodium amide at the 2-position to yield 2-amino pyridine systems 3. This is known as the 
Chichibabin reaction4, and formally involves the nucleophilic substitution of hydride ion by 
the powerful anionic nucleophile NH2- (Scheme 1.2). 
0 N Toluene 
1 i aq. worl<-up 
Scheme 1.2 
Nucleophilic substitution reactions involving pyridine and related heterocyclic 
derivatives proceed much more efficiently when a good leaving group is attached to the site 
of nucleophilic attack. This is typically halide, although sulfonyl, nitro and alkoxy groups 
may also be used5• The highest reactivity towards nucleophilic displacement is observed 
when the leaving group is present at a position a.- or y- to the ring nitrogen. For example, 
3,4-dibromopyridine 4 reacts selectively with ammonia at the 4-position. Also, fluorine is 
more readily displaced than heavier halogens, demonstrated by selective displacement of 
the fluorine atom of2-fluoro-4-chloropyridine 6 with alkoxide nucleophiles (Scheme 1.3)6• 
Br 5Br Cl Cl CrBr NH3 (aq) n NaOEt n h 160°C h EtOH, 50°C N N N F Nh OEt 
4 5, 65% 6 7, 81% 
Scheme 1.3 
These observations can be explained by consideration of the mechanism of 
nucleophilic aromatic substitution of halogenated pyridine systems. The presence of the 
2 
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electronegative ring nitrogen means that pyridine carbon atoms are much more electron 
deficient than in benzene systems, and are therefore susceptible to attack by nucleophiles. 
Well established nucleophilic aromatic substitution reactions proceed via an addition-
elimination mechanism (SNAr or SNAE) comprising of two key steps (Scheme 1.4); i) slow, 
reversible attack of the nucleophile to form a negatively charged, tetrahedral intermediate 
known as a Meisenheimer complex, and ii) elimination of the leaving group to form the 
substituted product. 
6~uc "'"i);===~=1 ==!!:!:=. ~c ii) k2 N N Nuc 6 N 
Scheme 1.4 
Although generally short lived intermediates, Meisenheimer complexes have been 
isolated and characterised spectroscopically, particularly in the case of activated 
polynitrobenzenes 8 (Figure l.l) 7• 8• 
MeO OEt 
o2NVN02 I e 
0 
N02 
8 
Figure 1.1 
The observation that the displacement of halide in halogenated systems proceeds in 
the order F >> Cl- Br > I provides further evidence for the above mechanism9• It is well 
established that the bond strength of C-X bonds decreases in the order C-F > C-CI > C-Br > 
C-1 and, therefore, the high reactivity of fluorine towards nucleophilic displacement 
suggests that bond breaking does not occur in the rate determining step. Consequently, 
addition of the nucleophile must be rate determining. This step is accelerated in more 
electron deficient heterocycles, which is supported by the fact that fluorine is the most 
electronegative ofthe halogens. 
3 
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The preference for substitution a- and y- to ring nitrogen in halogenated 
heteroaromatic derivatives can be explained by the stability of the corresponding 
Meisenheimer intermediates2 (Scheme 1.5). The negative charge can be stabilised via 
delocalisation onto the electronegative ring nitrogen for a- and y-substituted systems, but 
this is not possible when the halogen atom is P- to ring nitrogen. Substitution, therefore, 
proceeds via the most stable Meisenheimer intermediate. 
a-to Ring u- ()_Nuc u Nitrogen N X ~ X N Nuc 
ax e Nuc crNuc P-to Ring 
- Q-x Nitrogen ~ ~ N N N 
X N6 Nuc X Nuc y-to Ring 6 ~0 6 Nitrogen I ) .. ~ ~ N N) N 
Scheme 1.5 
1.1.2 The Diazines 
This thesis is concerned with the production of highly functionalised pyridazine 
systems from tetrafluoropyridazine, so a brief discussion of diazine chemistry is appropriate 
before pyridazines are considered in more detail. The structures of the three diazines 
(pyridazine, pyrimidine and pyrazine) consist of two nitrogen atoms in a six membered 
aromatic ring (Figure 1.2). 
0 N N eN ) N N () N 
Pyridazine Pyrimidine Pyrazine 
Figure 1.2 
4 
Chapter 1: The Synthesis and Chemistry of Pyridazine Derivatives 
The basicity of the diazines is reduced, relative to pyridine, due to the electron 
withdrawing effect of the second ring nitrogen destabilising the protonated cation. Of the 
three diazines, pyridazine is the most basic, this is hypothesised to be due to the 'alpha 
effect' whereby reduced repulsion of the two adjacent nitrogen lone pairs slightly stabilises 
the protonated form 10• 
Diazines are correspondingly more reactive towards nucleophilic substitution than 
pyridine systems, due to the additional electron withdrawing effect of the second ring 
nitrogen2• Again, sites a- and y- to ring nitrogen are activated towards nucleophilic attack, 
in other words, all sites in diazines are activated except for the 5-position of pyrimidines. 
Therefore, halogen substituents at both the 3- and 4-positions in pyridazine derivatives are 
expected to be highly reactive towards nucleophilic displacement. 
The diazines are less reactive towards electrophiles than pyridine derivatives, which 
is reflected in their lower basicity. In general, electrophilic attack occurs via addition to 
ring nitrogen to give diazinium cations. Addition to both ring nitrogens is generally 
extremely difficult as this would result in the formation of a dication 10, although it is 
possible with powerful alkylating agents such as trialkyloxonium salts (Scheme 1.6)11 • 
Electrophilic substitution at carbon in diazines is rare, although some halogenation 
reactions are known, requiring extremely forcing conditions. 
0 N N 0Me3+ BF4- 0 Me~N NGl 
I 
Me 
9 10,21% 
Scheme 1.6 
1.1.3 Oxy-heteroaromatics 
Oxy-pyridines and oxy-diazines generally exist as the keto tautomer, and are known 
as pyridones or diazinones. The pyridone tautomer is favoured by the use of polar solvents 
such as acetonitrile and water, whilst in hydrocarbon solvents and the gas phase the 
hydroxy-pyridine tautomer is favoured (Scheme 1. 7) 12• 
5 
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~ Polar Solvent 
r!LNAOH 
11a 
Scheme 1.7 
~ 
r:LNAo 
H 
11b 
The degree of aromaticity of oxy-heteroaromatic systems depends on the relative 
contribution of the pyridazinium canonical form. Calculations on 2-pyridone suggest that it 
is only around 25 kJ mor1 less aromatic than pyridine itself 3 and similar X-ray crystal 
structure analysis has estimated that pyridazin-3(211)-one llb to be around 20 kJ mor1 less 
aromatic than 3-hydroxypyridazine lla 14• These results suggest that solvation factors are 
significant in favouring the slightly less aromatic pyridazinone tautomer. 
1.2 Uses of Pyridazine Derivatives 
Pyridazine based systems have been shown to have numerous practical applications, 
and the forthcoming section will outline some ofthese. 
1.2.1 Pyridazine Derivatives in Medicinal Chemistry 
Heteroaromatic scaffolds, such as pyridazine derivatives, have been shown to be 
'privileged structures' in medicinal chemistry, and many drug discovery programmes 
utilise a pyridazine as a core scaffold. Examples are far too numerous to give more than a 
flavour of the chemistry reported in the literature in this section, however it should be noted 
that pyridazine based systems are less common in the literature than those based on 
pyridine or the other diazines. 
Examples of commercially available pharmaceutical pyridazines (Figure 1.3) 
include hydralazine 15, an antihypertensive which acts as a vasodilator, azelastine 15, a 
bronchodilator used in the treatment of asthma, and minaprine16, an antidepressant which 
acts as an acetylcholinesterase inhibitor. 
6 
~N ~N 
HN,NH2 
Hydralazine 
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Cl 
~ -..-:N 
I 
--" O N'CN-Me 
Azelastine Minaprine 
Figure 1.3 
Various pyridazine based heterocyclic scaffolds have been utilised in recent 
medicinal chemistry programmes against a range of biological targets and physiological 
effects (Figure 1.4). The phthalazinone 12 has been screened as an anti-HIV agent17, whilst 
the activity of 13 for the treatment of cancer by inhibiting the repair of DNA in cancer cells 
damaged by radiotherapy has been examined 18• 19• 14 has been shown to act as a selective 
agonist at the GABAA receptor a3 subunit, with potential application in the treatment of 
anxiet/0• Compound 15 entered Phase 2 clinical trials as a diuretic antihypertensive 
agene', whilst 16 shows antifungal activity against a range of species22 • 17 has been 
demonstrated to be a potential agent for pain relieF3• 
Cl 
Me 
12 13 14 
Me 
Me ~:__rN=}-Q-Me 
II __ )=N' Me 
15 16 17 
__ F~re 1.4 
7 
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1.2.2 Pyridazine Derivatives in Materials Chemistry 
Various aromatic heterocycles, including pyridazine systems, have been utilised in 
materials chemistry, in applications including liquid crystal displays (LCDs) and as organic 
light emitting diode devices (OLEOs). 
There is a particular need for molecules which emit blue light in electroluminescent 
displays. A family of pyrrolopyridazine derivatives have been synthesised as potential 
small molecule blue emitters24• Compound 18 (Figure 1.5) was shown to emit light in the 
blue wavelengths of the spectrum, and had the best quantum yield of the compounds 
screened in the library. 
F 
18 
Figure 1.5 
1.2.3 Pyridazine Derivatives as Ligands 
Pyridazine derivatives have been utilised as ligands for binding to metal atoms, with 
application in catalysis, medicinal chemistry and supramolecular chemistry. For example 
phthalazine ligand 19 has been developed as a ligand for osmium in the Sharpless 
asymmetric dihydroxylation reaction of alkenes, giving the diol with excellent 
enantioselectivicyl5• Lanthanum-(111) complexes of phthalazin-1 (2J/)-one 20, which bind 
via carbonyl oxygen, have been shown to have DNA binding ability which leads to 
antitumour activity26 (Figure 1.6). 
8 
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DHQD 
I N Ph«" Ph ~ ....,;N 
DHQD 
19 20 
Figure 1.6 
Ligand 21 has been developed with the ability to bind up to four copper ions to 
form multimetallic complexes27 • Meanwhile, coordination polymers have been synthesised 
from pyridazino[4,5-d]-pyridazine 2228 and 4,4'-bipyridazine 2329 in reaction with Cu2+, 
Zn2+ and Ag + ions to give bridged and ladder supramolecular assemblies (Figure 1. 7). 
NX"N II I N h ....,;N N~ II  h "N I I 
....,;N 
23 
21 
Figure I. 7 
1.3 Syntheses of Pyridazine Derivatives 
The pyridazine ring system can be assembled by two main routes (Scheme 1.8). 
The obvious disconnection is at the two imine type nitrogens, yielding a 1 ,4-dicarbonyl 
compound and hydrazine (Route a), whilst another common approach is via the 
cycloaddition of 1 ,2,4,5-tetrazines with dienophiles (Route b), proceeding with loss of 
molecular nitrogen. The forthcoming section will describe both of these approaches in 
detail. 
9 
a) R --~R ==> ~- ~~J N, ._., 
N ' 
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R 
+ ~R ~0) 
Scheme 1.8 
1.3.1 Condensation of 1,4-Dicarbonyl Compounds with Hydrazine 
For a 1,4-dicarbonyl compound to yield a pyridazine directly, there must be a 
double bond at the position ~- to both carbonyl groups. Although these unsaturated 
dicarbonyl derivatives are less common than their saturated counterparts, they have been 
widely utilised in the synthesis of pyridazine systems. For example, the condensation of 
the anthracenyl substituted unsaturated 1,4-dicarbonyl compound 24 with hydrazine gives 
the anthracenyl substituted pyridazine 25 (Scheme 1.9i0• 
NH2NH2.H20 
OH 
0 Benzene 
0 
24 25 
Scheme 1.9 
Knochel et a/. have developed the synthesis of functionalised a.,~-dicarbonyl 
compounds via iodine-copper exchange of a vinylic iodide 26 followed by trapping with an 
acyl halide electrophile to yield a 1 ,4-unsaturated diketone 27, which were condensed with 
hydrazine to yield polyfunctional pyridazine systems 28 in excellent yield (Scheme 1.1 0)31 • 
Pentro 
~I 
Ph 
26 
1) (NPhylbCuli 
THF 
-100°C, 15 min., 
2) 0 0 ~ Cl 
rt, 30 min 
Pent'YDOO 
~ 0 
Ph I !J 
27,78% 
Reflux, 15 min 
Pent)!uN'N 
~I 0 
Ph I !J 
28,96% 
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Aromatic systems substituted with carbonyl groups in an ortho relationship also 
possess an unsaturated I ,4-dicarbonyl structural motif, and, on reaction with hydrazine, 
yield pyridazines fused to an aromatic ring. A-ring pyridazine analogues of the natural 
products podophyllotoxin32 and etoposide33 have been synthesised by this approach 
(Scheme l.II ). The natural product 29 is degraded using BCb and BaC03 to hydrolyse the 
acetal subunit and the resultant diol is converted into the ditriflate 30. Stille coupling using 
a vinyl tin reagent yields a dialkene 31, which is doubly dihydroxylated using Os04 I 
NMO. Each diol is then oxidatively cleaved using lead tetraacetate to furnish the required 
ortho-dialdehyde 33 which yields the desired pyridazine analogue 34 on condensation with 
hydrazine and appropriate deprotection. 
QH 
~~0 
MeOvo:. 
OMe 
Podophyllotoxin 
QH 
tXXX;o 1) BCI3 DCM, -78°C 
0 ~ : ····i 
2) BaC03 ¥0 Acetone I H20 Reflux 
MeO OMe 3) Tf20 
OMe DMAP, DCM, 0°C 
29 
QH 
N::ccx;-..:::, I I 0 1) NH2NH2 
N" .o , ··'\{ ,. EtOH, -50°C 
- 0 2) Et3N-HF h MeCN,25°C 
MeoY'oMe 
OMe 
34, 77% over 2 steps 
QH 
T«):(XX) I o 
T«) .o : ···\< ¥0 
MeO OMe 
OMe 
30, 39% over 3 steps 
QH 
N::ccx;-..:::, 
I I 0 
N:-.. .o : ···\< 
~SnBu3 
Pd(PPh3)4 
LiCI 
M.o¥o:. 
OMe 
A-ring Pyridazine 
Podophyllotoxin 
QH 
Dioxane. 95°C 
~0 
M.o¥o:. 
Pb(OAc)4 
OMe 
31,65% 
1
1) TBSOTf 
2,6-lutidine, DCM 
2) Os04, NMO 
Acetone I H20 
I-..:::, o 
DCM I Benzene 
HO~OH <?TBS 
HO .o : ····i 0
:oavo:. 
OMe 
32, ~1% over 2 ~ps 
Scheme 1.11 
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Saturated I ,4-dicarbonyl compounds are much more accessible than their 
unsaturated counterparts and, consequently, have been more widely utilised in pyridazine 
synthesis. Their condensation with hydrazine necessarily affords a non-aromatic 
dihydropyridazine, which requires forcing conditions or the presence of an oxidant to 
achieve aromatisation. 
DDQ has been used as a common oxidant in the aromatisation of pyridazine 
derivatives formed from saturated 1 ,4-dicarbonyls, such as 35. A one pot microwave 
assisted synthesis of pyridazine systems 36 has been developed using stoichiometric DDQ 
as oxidant (Scheme 1.12)34• In the absence of DDQ a mixture of dihydropyridazine 
derivatives were obtained. Similarly, Nicolaou et al. have developed the use of Pt02 as a 
mild oxidant for the synthesis of aromatic pyridazine derivatives 3835 from saturated 
dicarbonyl compounds 37. 
0 C02Me NH2NH2H20 R\~~~~C02Me ~R2 R1 AcOH, DDQ N,N...-:: R2 R1, R2 =Alkyl/ Aryl 
0 MW, 120-150°C 
35 36 
8 examples 
48 - 65% yield 
oy 1. NH2NH2 ~ c) .... ·· '\ 2. Pt02 
37 38,90% 
Scheme 1.12 
If a suitable leaving group can be introduced into a dihydropyridazine, then 
aromatisation can be achieved by elimination with no oxidation being required. This 
strategy was utilised in the synthesis of a small library of six substituted pyridazin-3(2/i)-
one analogues36, in which the dihydropyridazin-3(2/i)-one compounds produced were 
functionalised with a hydroxyl group as leaving group (Scheme 1.13 ). The required I ,4-
dicarbonyl unit was assembled by the [3+2] dipolar cycloaddition of substituted nitrile 
oxide derivatives 39 with acrylate ester systems 40. The resultant dihydroisooxazole 41 
was ring opened using either molybdenum hexacarbonyl or catalytic hydrogenation, 
yieldingo-a ct'-'hydroxy-y'-keto ester"42 -Which wa:s ring closed-using-hydrazin·e at·room 
12 
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temperature to give the 4-hydroxydihydropyridazin-3(2H)-one 43. Elimination ofwater to 
yield the aromatised pyridazin-3(2H)-one 44 was then carried out by refluxing with dilute 
ethanolic hydrochloric acid. 
Ph NCO 
OR 
NCS 39 
R~R2 
-------;~ ll. !'co R1 N-o 2 
R = Alkyl/ Aryl 
R2 =HI Me 
41 
R~R2 
N,NAO 
H 
44 
6 examples 
Yield 75 - 89% 
Scheme 1.13 
H2 / Raney Ni 
HCI R R
2
0H 
'(to EtoH 
H 
43 
Similarly, 3,5-disubstituted pyridazines have been synthesised by a Rh catalysed 
reductive cross-aldolisation approach to the synthesis of P-hydroxy-y-ketoaldehydes37, 
again functionalised with a hydroxyl leaving group between the 1 ,4-dicarbonyl unit to 
allow aromatisation of the resultant dihydropyridazine by elimination (Scheme 1.14 ). An 
a-p unsaturated aldehyde 45 was reacted with a glyoxal derivative 46 in the presence of a 
Rh catalyst under a hydrogen atmosphere, with the active species being effectively a Rh 
enolate. The resultant 1 ,4-dicarbonyl compound 47 was then cyclised with hydrazine to 
yield an aromatic pyridazine derivative 48. 
0 0 FH + Arr(lH 
R 0 
45 46 
R = H, Me 
Rh(COD)20Tf (1-5 mol%) 
PPh3 (2.4- 12 mol%) 
KOAc 
DCE 
H2 (1 atm) 
Ar~ NHzNHz 
~R) H ___ .._. 
47 
Scheme 1.14 
~r 
48 
6 examples 
30_-_62%,yield 
13 
Chapter 1: The Synthesis and Chemistry of Pyridazine Derivatives 
1.3.2 Cycloadditions of 1,2,4,5-Tetrazines 
An alternative approach to the synthesis of pyridazine derivatives is via the 
cycloaddition of 1,2,4,5-tetrazines with suitable dienophiles38, which is known as the 
Carboni-Lindsey reaction, discovered in 195939• It proceeds via a [4+2] cycloaddition of 
the 41t azadiene component of the tetrazine and a 21tw dienophile component, producing a 
bicyclic intermediate that extrudes nitrogen to give the pyridazine product. For the 
synthesis of aromatic pyridazine systems an alkyne is required as dienophile, if an alkene 
derivative is used then a dihydropyridazine ring is formed, and a subsequent oxidation step 
is required to achieve aromaticity. 
R 
[4+2] 
Scheme 1.15 
Kinetic studies ofthe cycloaddition ofalkynyl boronates with tetrazines have shown 
that it is pseudo-first order with respect to the tetrazine which is consistent with a concerted 
mechanism40• Computational methods have been used to show that the cycloaddition 
process is indeed concerted and proceeds via an early, reactant-like transition state41 which 
is highly synchronous. The extrusion of molecular nitrogen from the intermediate is rapid 
and highly exothermic and the bicyclic intermediates have never been observed, so the rate 
determining step is therefore the formation of the intermediate. 
This is an inverse electron demand Diels-Alder type reaction which is accelerated 
by the presence of electron withdrawing groups on the tetrazine and electron donating 
groups on the dienophile component. The key orbital interaction is between the LUMO of 
the diene and the HOMO of the dienophile. This has been supported by kinetic studies42, 
comparing reactivity of a range of alkenyl and alkynyl dienophiles with a I ,2,4,5-tetrazine 
diester. These results showed that the presence of electron withdrawing groups on the 
__ alkene~can~decrease ,rates_ of cycloaddition,_(Table'--l.l) .. ~However,.steric.,factors~are_also 
important, in that substituted alkenes were Jess reactive than unsubstituted ethylene. Trans-
14 
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alkenes were shown to be up to ten times more reactive than the equivalent cis alkene, as 
they are less sterically hindered. Alkynes are significantly less reactive dienophiles than 
alkenes. 
Dienophile Dienophlle 
36300 330 
~OEt 21700 
48.4 
~CN 0.94 
25.4 
6590 
74 
~OMe 25400 
878 
Table 1.1 
Similarly, more electron deficient tetrazines are more reactive towards the 
cycloaddition process, for example, 3,6-dichloro-1 ,2,4,5-tetrazine 49 reacts efficiently with 
the silyl enol ether shown below (Scheme 1.16), whilst the more electron rich 3,6-(bis-
methylsulfonyl)-1 ,2,4,5-tetrazine 51 is unreactive toward this dienophile43 • 3,4-(Bis(3,4-
dimethoxybenzoyl)-1 ,2,4,5-tetrazine demonstrated limited reactivity towards electron 
deficient alkynes such as methyl propiolate, although this did require extended reaction 
times at high temperatures to achieve satisfactory conversion. 
15 
Cl 
N~N + 
II I 
NYN 
Cl 
49 
SMe 
N~N + 
II I 
NYN 
SMe 
51 
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c;:t-OTMS Toluene Reflux 
c;:t-OTMS Toluene Reflux 
Scheme 1.16 
N»: II N h-
CI 
50 
No Reaction 
More interesting is the chemistry of unsymmetrical tetrazine derivatives, as these 
present questions regarding the regioselectivity of the cycloaddition process. 
Unsymmetrical tetrazines can be prepared by nucleophilic displacement of the readily 
available 3,6-bis(methylthio )-1 ,2,4,5-tetrazine 51, which is highly reactive towards 
nucleophilic displacement due to its four ring nitrogen atoms (c.f. the reactivity of diazines 
compared to pyridine). Thus, 3-methoxy-6-methylthio-1 ,2,4,5-tetrazine 52, prepared by 
displacement of an SMe group with methanol in the presence of a catalytic amount of 
sodium methoxide44, was reacted in cycloadditions with a range of enamines, enol ethers 
and alkynes (Scheme 1.17). The oxygen or nitrogen leaving group present on the enol 
ether or enamine enabled elimination to the aromatic pyridazine 53. In the case of alkyne 
dienophiles, a 1: 1 mixture of the two possible regioisomers was produced, but with 1, 1-
disubstituted enamines and enol ethers, cycloadducts were produced regiospecifically. 
rt 
N?':e Ph 
II 
N h-
+ 
DCM 
OMe 
52 53,90% 
Scheme 1.17 
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The study of regioselective cycloadditions of dienophiles to unsymmetrical 
tetrazines has since been extended by Boger, who has studied the cycloaddition reactions of 
N-acyl-6-amino-3-methylthio-1,2,4,5-tetrazines, such as 5445, which were found to proceed 
with excellent regioselectivity (Scheme 1.18). 
NHBOC 
N~N 
II I 
NYN 
SMe 
54 
+ 
Dioxane 
80°C, 16h 
Scheme 1.18 
~~:Me 
SMe 
55,75% 
In general, this regioselectivity can be explained by consideration of electrostatic 
interactions, or by FMO theory (Figure 1.8). If electrostatics are considered, the electron 
rich terminus of the dienophile attaches itself to the most electron poor carbon of the 
tetrazine. Alternatively, overlap of the largest orbital coefficient in the HOMO of the 
dienophile and the LUMO of the tetrazine gives the same regioselectivity. 
NHBOC 
o+l ------- ~ N~N ------
11 I ---~+ N~r:-J-----""MeO OMe 
~~~~------~~[  \~;::-;,• 
II I 
N?r:-J-----""Me6 - OMe 
SMe SMe 
LUMO HOMO 
Figure 1.8 
Solid supported tetrazines containing an amide linker to a solid support and sulfone 
or thioether substituents have been shown to undergo regioselective cycloaddition reactions 
with a range of alkene, enol ether and enamine dienophiles (Scheme l.I9t6• An interesting 
_:__-~ _,__,_•·,.::___ _-_:_~-"- -- ~--~ __ ::___- -"-~_____:_=:__-_·-- __:_-..:;...:...:~--~-· __ _:.-~~-=--------=- ;:_'______:.=____=----=....:_ .:::.=...--..:..~-- -- ~- ._- -~----=--- --"·-"".·'_::____::-'--'-.'--::.__.::______-
'switch' of regioselectivity is observed on oxidation of the thioether 56 substituent to the 
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sulfone 58. This is because the electron withdrawing ability of the substituents is in the 
order S02Me > NBOC > SMe, so oxidation of SMe to S02Me reverses the regioselectivity 
of the process. 
1)(\0 
Dioxane, reflux 
2) CF3C02H, DCM 
3) K2C03, MeOH/THF 
56 
1) 
Dioxane, reflux 
2) CF3C02H, DCM 
3) K2C03, MeOH/THF 
58 
Scheme 1.19 
OH 
~I~() l):s: 
57,35% 
OH 
~ 
HN 
I 
N,N..-: S0
2
Me 
59,72% 
Alternative dienophiles to alkynes and enamines that have been utilised include 
heteroaromatics such as imidazole or indole. Snyder has developed the chemistry of 
heteroaromatic dienophiles in cycloaddition processes, and, in a synthesis of the proposed 
structure of the natural product zarzissine, imidazole 61 was employed as a dienophile to 
give the fused imidazo-pyridazine 63 (Scheme 1.20)47• The reaction occurred efficiently 
even at -78°C, confirming the reactive nature of imidazole as a dienophile, and the electron 
deficient nature of the tetrazine. The spectral data of this compound did not agree with that 
obtained from natural zarzissine and so the structure of the natural product is still 
unconfirmed. 
18 
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Scheme 1.20 
1)AcOH, HCI 
Reflux 3h 
2) KOH (aq) 
H 
N):N II ~NH2 
N h- N 
63,75% 
over 3 steps 
Indole is another heteroaromatic dienophile utilised in cycloaddition reactions. As 
part of a synthesis of staurosporine analogues the synthesis of various pyridazino[4,5-
b ]indole derivatives 65 and 67 were required. These were synthesised by an inverse 
electron demand Diels-Aider reaction of dimethyl 1,2,4,5-tetrazine-3,6-dicarboxylate 64 
with indole (Scheme 1.21)48• Similarly, the unsymmetrical tetrazine 66 undergoes 
regioselective cycloaddition with indole to give a single ring fused product49• 
C02Me N~N 
II I + 
NYN 
C02Me 
64 
OlMe 
N "'N + 
II I 
NYN 
C02Me 
66 
~~\ 
vv 
~~\ 
vv 
DCM 
DCM 
Scheme 1.21 
~?b 
C02Me 
65,95% 
;lb 
C02Me 
67,72% 
Ketones and aldehydes have also been shown to be effective dienophiles for related 
inverse electron demand Diels-Aider reactions with cycloaddition occurring via the enol 
tautomer. Various ketones and aldehydes have been reacted under microwave irradiation 
with 3,6-di-(pyridin-2-yl)-1 ,2,4,5-tetrazine 68 to yield substituted pyridazine systems 
(§cll.~I_!!t! J-l~):0~_ _ Tile_ pigh__t~ll!IJ~rl!t\Jre~ ~nd Pl'~ssu_r_e~ _encountereQ.. )n _mjc_t:_()"~·Itve _ 
conditions cause a shift in the keto-enol equilibrium towards the enol tautomer, increasing 
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the efficiency of the reaction. However, in many cases, two possible enol isomers are 
obtained, leading to a mixture of cycloadducts 69 and 70. 
2 N N "N 
II I 
No./-N 
N:::--~~ 
68 
+ 
0 
MW, 150°C, 30 min 
+ ~ 
69, 15% 70,35% 
Scheme 1.22 
Organocatalysis is an area of much current research, offering potential advantages 
over traditional metal catalysed reactions. A proline catalysed inverse electron demand 
Diels-Alder reaction of ketones with 1 ,2,4,5-tetrazine 71 has recently been developed 
(Scheme 1.23)51 • A screen of conditions showed that 5 mol% proline in DMSO was the 
best catalytic system and that the catalytic cycle occurred via the enamine. Again, in the 
case of unsymmetrical ketones, two possible enamines may be formed, so a mixture of 
regioisomeric pyridazines 73 and 74 are obtained. 
Ar 0 Ar N~N 6 L-proline (5 mol%) N~ II I + NYN II DMSO, rt, 29h  ~ 
Ar Ar 
71 72, 98% 
Ar Ar Ar 
N~N 0 L-proline (5 mol%) + ~ NT + N?: II I DMSO, rt, 29h II II NYN o o 
Ar Ar Ar 
71 73,42% 74,58% 
Scheme 1.23 
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1.4 Functionalisation of Pyridazine Rings 
The above strategies for the synthesis of pyridazine rings are useful but they can be 
limited if the introduction of a diverse range of substituents is required, for example in a 
medicinal chemistry development programme. Substituents are limited to those that can 
easily be introduced in the starting materials ( 1 ,4-dicarbonyl compound or tetrazine 
derivative and dienophile). Consequently, efficient synthetic routes are required for the 
rapid synthesis of a diverse range of heteroaromatic compounds such as pyridazine 
derivatives. 
A better strategy for diversity oriented synthesis52' 53 is to functionalise a pre-formed 
pyridazine scaffold. Halo-pyridazine derivatives are often good precursors for these 
functionalisation approaches, which include nucleophilic substitution, palladium catalysed 
cross-couplings and metallation reactions. This section will describe the chemistry of 
pyridazines with respect to each ofthese functionalisation reactions. 
1.4.1 Palladium Catalysed Cross-Coupling Processes 
The chemistry of cross-coupling reactions is an area of much current interest, and 
can only be considered briefly here with regard to pyridazines. They involve the coupling 
of an aryl or vinyl halide with an organometallic under (typically) Pd(O) catalysis. The 
mechanism of cross-coupling processes is well established and is summarised below for the 
Stille reaction (Scheme 1.24i4• 
Reductive 
Elimination 
Ar""x 
__J Oxidative 
\Addition 
Scheme 1.24 
X 
I II 
Ar,...Pd Ln r R_...SnBu3 
-0 Transmetallation 
X .... SnBu3 
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The oxidative addition step is generally rate determining, and the ease of oxidative 
addition increases with decreasing C-X bond strength. Thus, the rate of oxidative addition 
generally increases in the order C-1 > C-Br > C-CI > C-F. Oxidative addition can be 
considered as a nucleophilic attack of the palladium complex on the aryl halide and, thus, is 
accelerated by the inclusion of electron-rich ligands on the palladium atom. Ligands that 
are commonly used in cross-coupling processes are typically phosphines such as PPh3, 
PCy3 and PtBu3, but more recently alternative ligands such as N-heterocyclic carbenes have 
been developed. 
Transmetallation varies with the named cross-coupling process, and is possible for a 
range of metals including boron (Suzuki-Miyaura), tin (Stille), copper (Sonogashira), 
magnesium (Kumada) and zinc (Negishi). 
The final reductive elimination step furnishes the desired coupled product and 
restores the catalyst. This step is accelerated in sterically crowded Pd complexes, so 
reductive elimination is assisted by bulky ligands. 
The palladium catalysed cross-coupling chemistry of pyridazines has been recently 
reviewed55' 56, and is of much interest, particularly in the synthesis of aryl-pyridazines. For 
example the 6-substituted 3-iodopyridazines 76 and 78 were reactive in Stille57 and 
Suzuki58 couplings respectively to give biaryl products 77 and 79 (Scheme 1.25). 
NaOMe MeO~ 
_M_e_O_H __ .,.. N,NAI 
Reflux, 12h 
In I N ~ 
'N NH2 
78 
ArB(OHh 
Pd(PPh3)4 
Na2C03 
Toluene, reflux 
76,92% 
Ar~ 
~,NANH2 
79 
7 examples 
63 - 92% yield 
Scheme 1.25 
77,93% 
The chemistry of 5-bromo-6-phenylpyridazin-3(211)-one has been extensively 
studied in 5rtifie59:-sonogasfiira60 an<r-Hecl(61 - couplings (Sclieme 1.26). - For efficient 
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reaction of the parent pyridazin-3(2H}-one, the ring NH was protected as a methoxymethyl 
derivative 80. Coupling with vinyl tin reagents proceeded in almost quantitative yield59 
whilst Sonogashira coupling with a range of alkynes was high yielding to give the 
heteroaryl-acetylene 8160• Heck couplings were more sensitive to conditions but the 
coupled products were obtained in moderate to good yield if the bulky phosphine P(o-
tolyl)J was used as ligand61 • The products of these reactions have shown interest as 
potential platelet aggregation inhibitors. 
R 
Br II Phil R Pd(PPh3)2CI2 (1 mol%) Ph 1-...::::::: + # Cui, NEt3 N,N 0 
DMF, 60°C, 3-6h 
N,N 0 
MeO) MeO) 
80 81 
7 examples 
78 - 90% yield 
Scheme 1.26 
More interesting is the regioselective cross-coupling of polyhalogenated pyridazine 
systems62• For example, the greater reactivity of bromide compared to chloride in cross-
coupling processes is demonstrated in the selective arylation of 4-bromo-6-chloro-3-
phenylpyridazine 82 to give 4-aryl-6-chloro-3-phenylpyridazines 83 (Scheme 1.27)63• 
Oxidative addition occurs selectively with a range of electron rich and electron deficient 
boronic acids at the weaker C-Br bond to give products arising from replacement of 
bromine. 
Br 
Ph~ 
~'N~CI 
82 
ArB(OH)2 
Pd(PPh3)4 (0.6 mol%) 
Na2C03 
DME/H20 
Scheme 1.27 
Ar 
Ph~ 
~'N~CI 
83 
7 examples 
70 - 96% yield 
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The cross-coupling of aryl chlorides is of much interest, as these are often more 
readily available than aryl bromides or iodides, yet the increased strength of the C-CI bond 
means they are sometimes unreactive under standard conditions64• In general, catalysts 
containing bulky, electron rich phosphines are required to assist the oxidative addition and 
reductive elimination steps. Both 3,6-dichloropyridazine and 4,5-dichloropyridazin-3(2H)-
one are readily commercially available and have been utilised in cross-coupling 
processes65 • 
3,6-Dichloropyridazine 84 could be selectively mono-arylated using 1.2 equivalents 
of boronic acid under microwave irradiation conditions66 (Scheme 1.28). Optimisation of 
conditions showed the most effective catalyst to be Pd(PPh3) 2Ch (3 mol%) in acetonitrile I 
water (3:2) with Na2C03 as base. Coupling with a range of boronic acids furnished the 
mono-arylated product 85 in good yield and the remaining chlorine atom could be 
displaced by a range of amines. With particularly electron rich boronic acids, such as 4-t-
butylphenyl and 2-methoxyphenyl boronic acids, yields were reduced due to the formation 
of some disubstituted product. 
ArB(OHh 
PdCI2(PPh3h (3 mol%) 
Na2C03 (1.5 eq) 
MeCN I H20 (3:2) 
MW, 120°C, 10 min 
Scheme 1.28 
Ar~ 
~--NACI 
85 
10 examples 
70 - 96% yield 
Similarly, utilisation of 3,6-dichloropyridazine 84 in Negishi couplings with aryl 
and alkyl zinc derivatives gave the monosubstituted products 86 selectively (Scheme 
1.29)67 • A second coupling with an organozinc compound yielded unsymmetrical 3,6-
disubstituted pyridazines 87. 
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Cl 
84 
R1ZnX 
Pd(PPh3)4 (5 mol%) 
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Cl 
N~ II o
R1 
86 
10 examples 
27 - 92% yield 
R1 =Alkyl, aryl 
R2ZnX 
Pd(PPh3)4 (5 mol%) 
THF, rt 
Bn, Propargyl 
Scheme 1.29 
~-\ N~ 
R1 
87 
3 examples 
70 - 80% yield 
R1 =Aryl 
R2 = n-Bu, Ph, Bn 
4,5-Dichloropyridazin-3(2/i)-one 88 has been utilised in Suzuki68• 69, Stille69 and 
Sonogashira70 couplings with excess boronic acid or alkyne to give disubstituted products 
89 (Scheme 1.30). However, to minimise the formation of isomers in mono-coupling 
reactions of 4,5-dichloropyridazin-3(2/i)-one, careful optimisation of conditions was 
required71 • The catalyst that gave the best regioselectivity was found to be Pd(PEh)2Ch, 
and, if reactions were run at room temperature in DMF, the 5-substituted isomer 90 was 
formed almost exclusively. 
Cl Ar aCI ArB(OHh aAr 
N N 0 Pd(PPh3)4 (3 mol%) N N 0 
Na2C03 (1.5 eq) I I R R Toluene I H20 88 89 
R=Me,Ph Reflux 6 examples 
87 - 1 00% yield 
Cl Ph aCI PhB(OHh cc NN 0 Pd(PEthCI2 (5 mol%) Na2C03 (aq) 'N 0 I I 
Me DMF, rt Me 
88 90 
Scheme 1.30 
Pseudo-halides, such as aryl triflates or tosylates, can also be used as coupling 
partners in cross-coupling reactions. Trifluoromethanesulfonic acid 6-methyl-pyridazin-3-
yl ester 90 was synthesised by reaction of 6-methylpyridazin-3(2/i)-one with triflic 
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anhydride. The pyridazinyl triflate was then reacted with a range of aryl stannanes and 
boronic acids in Stille and Suzuki couplings72• Efficient reaction occurred with electron 
rich organometallics, such as the thiophene derivative 91, although for electron poor 
organometallic systems, such as 2-pyridyl boronic acid, yields were poor. 
Men s 
Pd(PPh3)4 (5 mol%) Me I~ ~'N~ OTt + [)-snBu3 LiCI N,N~ s 
Dioxane I II 
80-85°C, 4h 
90 91 92,77% 
Scheme 1.31 
C-F activation is an area of current interest and, in general, is beyond the scope of 
this review. Only in recent years has the activation of strong C-F bonds become feasible 
with the development of highly active catalysts. A single application of C-F coupling has 
been applied to pyridazine derivatives; a Kumada-type coupling of an aryl Grignard reagent 
94 and 3-fluoro-6-phenylpyridazine 93 using a nickel catalyst (Scheme 1.32)73 • Despite the 
appearance of this reaction as a simple nucleophilic substitution, the uncatalysed process 
did not proceed. 
Phn I + 
N ~ 
'N F 
93 
~MgBr 
MeO~ 
94 
NiCI2(dppe) (5 mol%) 
THF, rt, 18h 
Scheme 1.32 
Ph'!) I~ 
---N- UOMe 
95,59% 
An alternative approach is the synthesis of organometallic pyridazines, such as 
pyridazinyl boronic acids, which can then be cross-coupled with aryl halides. The general 
approach to heteroaromatic boronic acids is by lithiation, followed by boronation. This 
approach has recently been utilised by Bryce et al. (Scheme 1.33), who synthesised a range 
of pyridazinyl boronic acids and their pinacol esters (which are more stable with respect to 
protodeboronation)74• Lithiation occurred selectively adjacent to the directing methoxy 
group, followed by boro_n~ti_<:>n with ~(()H'rh apc,l forJ!!at_!9!1_ ~J lhlU~inac_o} -~~ter J9~giy!! 
- ' ~ '0.__ ---·----~--- '-- ~-22 _------'..:.._~-=--·------- __ . __ __:_ __ -------~ 
stable and isolable pyridazinyl boronic esters 97 which were then subjected to Pd catalysed 
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cross-coupling conditions to give a range of polysubstituted pyridazine systems 98 in 
moderate to good yield. 
Ar~ 
~, .. A 2) B(O;Prh 
N,N...-:: OMe 3) Pinacol, Toluene 
1) LOA, -78°C, THF 
96 
rt, 19h 
Ar"(YB(pin) 
r:tNAOMe 
97 
Scheme 1.33 
98 
12 examples 
18 - 77% yield 
A novel approach to the synthesis of pyridazinyl boronic ester derivatives has been 
taken by Harrity et al. who utilised the aforementioned Carboni-Lindsey cycloaddition of a 
I ,2,4,5-tetrazine with alkynyl boronic esters 100 (Scheme 1.34)75• 76• Regioselective 
cycloadditions with unsymmetrical tetrazines 99 were developed. The pyridazinyl boronic 
esters produced could be functionalised by Suzuki coupling to give systems such as 103, or 
by oxidation to the pyridazin-4(1H)-one 105. Dichloropyridazinone systems were 
amenable to further diversification by regioselective Suzuki coupling as an approach to the 
synthesis of an array of pyridazinone derivatives 106. 
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-J+ 
+ 
99 
~tr~:X 
N~Me 
R 
102 
R = C02Me 
104 
0, /0 
B 
II 
Ph 
100 
+ Phi 
[(t-Bu)JPH]BF4 (12 mol%) 
K3P04 ~~:: 
MeCN, 50°C, 90 min 
Na2C03, i-PrOH 
Reflux, 30min 
Cl 
H~~f( 
Cl 
105 
Scheme 1.34 
R 
103, 57% 
1) NaH, THF, 0°C 
2) BnBr, reflux 
3) PhB(OHh 
Pd(PPh3)4 (3 mol%) 
Na2C03 
Toluene, reflux 
Bn~~( 
Cl 
106,62% 
Similarly, alkynyl silicon, germanium and tin reagents have been utilised in 
cycloaddition processes with 1 ,2,4,5-tetrazines to give organometallic substituted 
pyridazine systems 77• 78• Pyridazinyl stannanes were utilised in Stille couplings to give 
arylated products. 
1.4.2 Metallation 
The synthesis of functionalised pyridazine derivatives via metallated intermediates 
and trapping of the car bani on with electrophiles is a popular approach. Two strategies are 
commonplace; metal-halogen exchange79 and metal-hydrogen exchange79-81 and these will 
be considered in tum. 
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i) Metal-Halogen Exchange 
Examples of metal-halogen exchange are relatively rare on the pyridazine scaffold. 
Metal-halogen exchange generally proceeds much more rapidly than metal-hydrogen 
exchange, and is most effective on bromo- and iodo-heteroaromatics. The rate of metal-
halogen exchange decreases with increasing C-X bond strength, so is extremely slow for C-
CI systems, and virtually unknown for C-F bonds. 
Lithium-halogen exchange has been carried out on 4-iodo-3,6-dimethoxypyridazine 
and 3-iodo-6-methoxypyridazine 107 using lithium metal under sonication (Scheme 
1.35)82 • The heteroaromatic organolithium derivatives produced were trapped using a 
range of electrophiles including aldehydes and disulfides to yield substituted derivatives 
108. 
1) Li (2.2 eq) 
Electrophile (1.1 eq) 
THF, rt, 0.5h, )))) 
2) EtOH 
En E=SPh, PhCH(OH), 
1 C5H11CH(OH) 
N,N~ OMe Yields = 38 - 72% 
108 
Scheme 1.35 
Magnesium-halogen exchange is also a synthetically useful process, and has been 
performed on pyridazine scaffolds using Grignard reagents, and also lithium tri-n-
butylmagnesate (Scheme 1.36). Reaction of 4-iodo-3,6-dimethoxypyridazine 109 with i-
PrMgCI gave the corresponding pyridazine Grignard reagent 110, which was reacted with a 
range of electrophiles83• Similarly, 4,5-diiodo-3,6-dimethoxypyridazine 112a and 4,5-
dibromo-3,6-dimethoxy-pyridazine 112b could undergo selective mono-metallation to give 
monosubstituted products 11383 and 3-iodo-6-phenylpyridazine 114 underwent magnesium-
halogen exchange with lithium tri-n-butylmagnesate84• The organomagnesium 
intermediates are much more stable than their corresponding organolithium derivatives, so 
magnesium-halogen exchange reactions can be carried out at much higher temperatures. 
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1) i-PrMgCI 
THF, rt, 0.5h 
MgCI E 
MeOn MeOn 7 examples 
1 2) e 1 "::::: 35 - 73% yield 
N,N..-:: OMe ----l~ N,N'- OMe 
110 
E 
1) i-PrMgCI MeO~X 12 examples 
__ T_H_F_, rt_,_o_.S_h___ ~'- _;l 30- 80% yield 
2) E+(1.1 eq) N,N'- OMe 
1) n-Bu3Mgli (0.35 eq) 
THF, -10°C, 2.5h 
113 
Scheme 1.36 
5 examples 
50 - 62% yield 
111 
ii) Metal-Hydrogen Exchange 
Metallation by metal-hydrogen exchange is a much more common approach to the 
synthesis offunctionalised pyridazine derivatives. The pKa values of the two aromatic C-H 
bonds in pyridazine have been estimated to be 31.1 (para to ring nitrogen) and 37.9 (ortho 
to ring nitrogen)85, therefore, strong organometallic bases, such as BuLi or LOA are 
required to achieve deprotonation. The site ortho to ring nitrogen is thought to be less 
acidic due to the electronic repulsion between the nitrogen lone pair and the carbanion that 
develops at the adjacent site. 
Lithiation of pyridazine 9 is possible using L TMP at -75°C (Scheme 1.37); this 
deprotonation occurs at C3 86 and this is likely to be due to coordination ofthe ring nitrogen 
to the lithium atom, directing deprotonation to the adjacent site, despite its lower acidity. 
Similarly, lithium mediated zincation ofpyridazine proceeds mainly at C3 (117), with up to 
20% competing zincation at C4 (118) depending on reaction conditions87 • A benefit of 
zinc-hydrogen exchange is the stability of the organozinc reagent which allows reactions to 
be performed at room temperature or higher. 
30 
Chapter 1: The Synthesis and Chemistry of Pyridazine Derivatives 
0 
1) LTMP (4 eq) u THF, -75°C, 6 min 4 examples 16 - 32% yield N,N..,; 2>e N N E 
9 116 
1) ZnCI2TMEDA (0.5 eq) I 
0 L TMP (1.5 eq) u ()I ~ THF, TMEDA + + Reflux, 2h N ~'N..,; N,N..,; N I N N I 
9 2) 12 117 118 119 
83 9 8 
89% conversion 
Scheme 1.37 
A popular recent approach is that of directed ortho metallation88 (DaM), in which 
deprotonation is directed ortho to a ring substituent. Such directing groups (DMG = X, 
CF3, OR, SR, S(O)R, S02R, NHCOR, CONHR) function either by stabilising an adjacent 
carbanion, for example, by an inductive or resonance electron withdrawing effect, or by 
coordinating to a lithium base, forcing deprotonation to occur at a neighbouring C-H bond. 
Halogen atoms may be used as directed metallation groups (Scheme 1.38), for 
example, a mixture of three chloro-fluoropyridazines 120, 121 and 122 each underwent 
metallation adjacent to a halogen substituent89• 3-Chloro-6-fluoropyridazine 120 undergoes 
selective lithiation with LDA or L TMP ortho to the fluorine substituent to afford 123, 
because fluorine is more able to stabilise an adjacent carbanion. 
Cl F Cl Cl F Cl 
1) LTMP (1.2 eq) N~E N~E N~ + N~ + N~ THF, 0°C ~~+ I I I I I I I I + I I ;:,-.. ~ ;:,-.. 2) E+ N;:,-.. E N~ N;:,-.. 
F F Cl F F Cl 
120 121 122 123 124 125 
Scheme 1.38 
The use of ether functionalities as directing metallating groups is also commonplace 
(Scheme 1.39), such as in the lithiation of 3-chloro-6-methoxypyridazine 12690• Lithiation 
ortho to the methoxy substituent to produce 127 was favoured, particularly when the steric 
_ <!~'1!~11Q_ qf the __ lithium ~~~mide.iJa~_was incr~~~d. __ I! hll!Lb~en~s_!iiila!~f!Jh!!J .the _(iir:~cting 
ability of an alkoxy substituent is intermediate between a fluorine and chlorine atom89• 
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Cl 1) LiNR2 (1.2 eq) Cl Cl N~ THF, 0°C N~ N~E I I I I + I I ~ 2) E+ N~ E N~ 
OMe OMe OMe 
126 127 128 
Lithium Amide Base Ratios of Isomers 
LDA 60 40 
LTMP 80 20 
~ik 97 3 
Scheme 1.39 
Sulfur based DMGs include thioethers, sulfoxides and sulfones (Scheme 1.40)91 • 
Lithiation of 3-phenylsulfinyl-6-methoxypyridazine 129 occurs adjacent to the sulfoxide 
substituent selectivell2• If aldehydes were employed as the electrophile, two 
diastereoisomers were obtained with poor stereoselectivity. Sulfone directing groups 131 
were slightly less effective, with a mixture of regioisomers 132 and 133 being obtained. 
SO Ph 1) LDA (1.2 eq) SO Ph N? THF, -75°C NlE 4 examples II II 64 - 90% yield  h- 2) E+ N h- ( dr 60:40- 75:25) 
OMe OMe If E = Aldehyde 
129 130 
N?Ph 1) LDA (2.2 eq) Ph::yPh N?: THF, -75°C II II II N h- 2) PhCHO N h- +  h- Ph 
OMe OMe OMeOH 
131 132 133 
70 30 
Scheme 1.40 
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Amides and thioamides have been shown to be particularly effective ortho directing 
groups (Scheme 1.41 ). Thus, 4-N-tert-butylpyridazinecarboxamide directs lithiation ortho 
to its amide substituent, and 3-chloro-6-N-tert-butylpyridazinecarboxamide 134 
demonstrates that the ortho directing effect of an amide substituent is stronger than a 
chlorine atom 93 • 
134 
1) LTMP 
THF, -75°C 
Scheme 1.41 
135 
Therefore an approximate order of directing metallation group ability has been 
estimated to be CONR2 ~ NRCOR > CN ~ S02R ~ S(O)R >OAr> OR~ CF3 ~ F > Cl88 • 
A more powerful DMG will direct substitution ortho to itself in the presence of a weaker 
DMG by more effectively stabilising an adjacent carbanion, or coordinating more strongly 
to an approaching lithium base. 
Lithiation enables the reaction of a wide range of electrophiles with the pyridazine 
scaffold. However, its application in array and large scale synthesis may be limited by the 
low temperatures and inert atmosphere conditions required for its reactions. 
1.4.3 Nucleophilic Aromatic Substitution 
Nucleophilic substitution reactions of halopyridazine derivatives have been 
extensively studied, particularly for chlorinated systems. Suitable nucleophiles include 
amines, alkoxides, thiols and carbanion equivalents such as Grignard or organolithium 
reagents. 3,6-Dichloropyridazine and 4,5-dichloropyridazin-3(2H)-one have proven to be 
particularly popular substrates. The pyridazine ring system is activated at all ring sites by 
the presence of an ortho- or para-ring nitrogen, ensuring the majority of nucleophilic 
substitution reactions on this scaffold are efficient processes. 
Reaction of 3,6-dichloropyridazine 84 with a range of Nl-alkylimidazoles in excess 
)'ieh:l~g yarl_Qu§ _g~(LI!liclg_oliul_!l) sal~l36 with~PQtentiaLapplication as .precursors to, N-
heterocyclic carbenes as ligands for catalysis (Scheme 1.42)94• 
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+ 
Cln I 
N ...-; 
'N Cl 
+ 
R 
I 
N [4 
N 
84 
Scheme 1.42 
A combinatorial chemistry approach to the synthesis of disubstituted pyridazines 
was taken by Schultz et a/. (Scheme 1.43)95, who immobilised 3,6-dichloropyridazine on a 
solid support by reacting with various solid supported amines 138, which were synthesised 
by reductive amination. The remaining chlorine atom could, in many cases, be displaced 
by reaction with amines, including anilines, which required the presence of a strong base 
such as KOt-Bu. Cleavage from the resin using TF A I Me2S gave an array of disubstituted 
pyridazines 141. 
QOI(Y'OMe 
Y'cHO 
OMe 
137 
NaBH(OAch 
THF I AcOH 
138 
141 
Many examples 
Purity- 90% 
Yield - 80 - 85% 
TFA 
Scheme 1.43 
N:>: II N ~ 
Cl 
OlEA 
BuOH 
90°C 
Me ('!f,O'Q(I 
..., I --..::::: ~1 
~ N~ 
OMe ~-NACI 
139 
Corey has developed a pyridazine based catalyst for the enantioselective 
dihydroxylation of o1efins starting from 3,6-dichloropyridazine (Scheme 1.44)96• 
Nucleophilic displacement of one chlorine atom with the alcohol functionality of 
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dihydroquinidine 142 in the presence of sodium hydride was followed by palladium 
catalysed displacement of the second chlorine with the proline based fragment 144. The 
ligand 145 effected the dihydroxylation of alkenes in good yields (67- 99%) and with a 
high degree ofstereocontrol (e.e. 90- 99%). 
MeO~N Cl 
- - + N? NaH 
;,----\ N11 " DMF ~,: ;; 
142 
MeO~N 
'. .·• N=N cf:-v-CI 
H 
143,91% 
Scheme 1.44 
Pd2(dbab 
rac-BINAP 
Cs2C03 
Dioxane I CHCI3 
30h, 55 - 60°C 
Nucleophilic displacement reactions of 4,5-dichloropyridazin-3(2H)-one have also 
been examined and the presence of two chemically non-equivalent chlorine atoms in this 
system allow for two possible monosubstituted isomers to be produced upon reaction. 
Most interesting, particularly for an industrial setting where purification routes must be 
simple and efficient, are regioselective displacements, in which a single chlorine atom is 
substituted preferentially. 
4,5-Dichloropyridazin-3(2H)-one demonstrates an interesting variation in 
regioselectivity in solvents of different polarity (Table 1.2r. In solvents of low dielectric 
constant (i.e. relatively non-polar), such as CCI4 and THF, substitution occurs 
regioselectively at the 4-position, whilst in solvents ofhigh dielectric constant (e.g. DMF, 
DMSO) substitution at the 5-position is preferred. In solvents of intermediate dielectric 
constant (e.g. i-PrOH, Acetone, MeCN), mixtures of isomers are obtained. Thus, a 
variation in reaction solvent polarity allows a simple regioselective route to both substituted 
isomers. 
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Cl Solvent Cl OEt (xCI NaOEt (xOEI (xCI + 
N N 0 
+ 
N N 0 NN 0 
I I I Ph Ph Ph 
88b 146 147 
Solvent Dielectric Yield 4- isomer Yield 5- isomer 
Constant, & 1% 1% 
CCI4 2.23 89 0 
THF 7.32 87 0 
EtOH 24.3 0 89 
MeCN 36.2 36 53 
DMF 36.7 0 88 
DMSO 49.0 0 75 
Table 1.2 
Nucleophilic aromatic substitution approaches have been used extensively in the 
formation of ring fused systems and with fluorinated pyridazines, and these will be 
described in Sections 1.5 and 1.6. 
1.5 Ring Fused Pyridazine Systems 
Ring fused pyridazines98• 99 have seen numerous practical applications, particularly 
in the synthesis of potential pharmaceutical products. The synthetic approaches outlined 
above for the synthesis of polyfunctional pyridazines are relevant to the synthesis of ring 
fused systems, and selected examples will be provided to exemplify these techniques. 
1.5.1 Cyclisation Step Forms Pyridazine Ring 
The first conceptual approach towards the formation of ring fused pyridazines is 
when the key ring-forming step also forms the pyridazine ring. Section 1.2 outlined the 
major routes for the formation of pyridazine rings: a) condensation of 1,4-dicarbonyl and 
hydrazine and b) inverse electron demand Diets-Alder reaction of 1 ,2,4,5-tetrazine and 
dienophile. 
_________ The reaction of cxclic ld:-dicarbonyLc_omp_ounds_W,ith h)'drazine~wilLyield_a_ring __ 
fused system (Scheme 1.45). For example, the H-imidazo[1,2-a]pyridine 148 functionalised 
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with two adjacent carbonyl groups was reacted with hydrazine to yield the tricyclic ring 
structure 149100• Similarly, the reaction of isoxazole 150 with hydrazine gave a 
isoxazolo[3,4-d]-pyridazin-7(6H)-one 151, as an intermediate in the synthesis of potential 
PDE5 inhibitors101 • 
EtOH, rt 
148 
EtOH, rt 
Scheme 1.45 
~N R1 ~;~N >=N} 
R2 
149 
R\ R2 = H, Me 
Yield = 30 - 89% 
HN-N 
O=t§Me 
I ~ 
N,o 
151 
The cycloaddition of I ,2,4,5-tetrazine derivatives with a suitable dienophile 
proceeds with extrusion of molecular nitrogen to yield pyridazine ring systems. The use of 
cyclic dienophiles such as indole48 and imidazole47 yield a ring fused pyridazine derivative. 
For example, cycloaddition of the enol tautomer of furocoumarin 152 with 3,6-
bis(methoxycarbonyl)-1 ,2,4,5-tetrazine 64 yielded tetracycle 153 as a potential DNA 
intercalator (Scheme 1.46)102• 
C02Me Me02C 0 N~N p-TsOH 1)CQ -:;? + II I NYN DCM C02 Me 0 0 0 100°C, sealed tube 0 0 
C02Me 
152 64 153,74% 
Scheme 1.46 
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Intramolecular inverse electron demand Diels-Alder cycloaddition of a tethered 
alkyne with a 1 ,2,4,5-tetrazine has also been shown to give ring fused pyridazines (Scheme 
1.47). Nucleophilic attack of an alcohol 103 or amine104 functionalised with a terminal 
alkyne on bromo-tetrazine 154 yields tetrazine 155, functionalised with a side chain alkyne, 
which is capable of acting as an intramolecular dienophile. Cycloaddition yields a ring 
fused pyridazine derivative 156 on heating in refluxing benzene and five, six and seven 
membered fused rings have been synthesised in moderate to good yields. 
~ SMe SMe SMe N~N N~N HX n C5H5 N:6 t_yN II II I Reflux  ..o 
NYN 
n( X - N2 )n 
Br X 
154 155 156 
X= 0, n = 1,2 Yield = 43 - 68% 
X= NH, n = 3 
Scheme 1.47 
1.5.2 Cyclisations of Suitable 1,2-Difunctional Pyridazines 
Difunctional pyridazines can be expected to react with suitable difunctionalised 
reagents to give cyclic systems. Such pyridazines may be functionalised with nucleophilic 
groups or suitable leaving groups to allow nucleophilic displacement. 
Pyridazines functionalised with two adjacent nucleophilic groups (e.g. NRH, OH, 
SH) would be expected to react with suitable dielectrophilic species, such as carboxylic 
acid derivatives, to form cyclic products. For example, 5-amino-4-hydroxypyridazinones 
157, synthesised readily from 4,5-dichloropyridazin-3(2H)-one 88, have been shown to 
react with 1,1 '-carbonyldiimidazole to yield 1,3-oxazolo[4,5-d]-pyridazin-2(3H),7(6H)-
diones 158 (Scheme 1.48)105• The reaction was most efficient when the pyridazin-3(2H)-
one ring NH was functionalised, such as with a phenyl group. Reaction with alkyl and aryl 
carboxylic acids yielded 1,3-oxazolo[4,5-d]-pyridazinones 159 via two successive 
condensation reactions. 
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1) NaN02 
DMF /H20 
Reflux 
2) HCOONH4 
Pd I C (10 mol%) 
EtOH, reflux 
Chapter I: The Synthesis and Chemistry of Pyridazine Derivatives 
;cOH 
~'N~O 
I 
R1 
157 
R1 =Ph, 66% 
R1 = H, 33% 
Scheme 1.48 
Dioxane 
Reflux, 30 min 
R1 = H 
R2 = Alkyl, aryl 
4 examples 
Yields = 60 - 80% 
0 
HN-{ No 
~'N~O 
I 
R1 
158 
R1 =Ph, 93% 
R1 = H, 42% 
A pyridazine ring functionalised with adjacent nucleophilic and electrophilic 
functionality would be expected to react with a tethered electrophile-nucleophile to yield a 
ring fused system. For example 4-chloro-5-hydroxy-2-(tetrahydro-2H-pyranyl)-pyridazin-
3(2H)-one 160 reacts with substituted phenylethyl-2-chloroacetamides via a Smiles 
rearrangement to yield [6,6] ring fused products 161 (Scheme 1.49). Bromination of the 
pendant phenyl ring, reduction of the lactam, followed by palladium catalysed C-0 
cyclisation yielded tetracyclic products 162 containing a seven membered oxazepine ring. 
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"mf Lei c1 
~'N~O 
I 
THP 
C\.J\ 
o: 
I 
THP 
160 161 
63 - 79% yield 
Scheme 1.49 
1) NBS, DMF 
100°C 
2) NaBH4 
MeOH, rt 
3) Pd(OAcb 
dppf 
K2C03 
2;, 
o: 
I 
THP 
162 
10 examples 
26- 71% yield 
A key aspect of this thesis is the reaction of dinucleophiles with polyhalogenated 
pyridazines. Reactions of suitable dinucleophiles, such as diamines, diols, amino-alcohols 
and amino-thiols, with 4,5-dichloropyridazine106- 108, 4,5-dichloropyridazin-3(2H)-one106• 
109
-
111 and 3,4,5-trichloropyridazine106• 112• 113 are known. As an example, the reaction of 
dinucleophiles with 3,4,6-trichloropyridazine 163106• 114• 115 are shown in Scheme 1.50. 
Initial attack is likely to occur at the 4-position para to activating ring nitrogen, followed 
by cyclisation onto the adjacent chlorine atom. When amino-thiol derivatives were heated 
in the presence of weak acid (AcOH) Smiles rearrangement resulted in the production of a 
different regioisomer 166. 
~-Ny~~~ 
c1AAs~N 
167,63% 
~-NyO~R 
c1AAo~ 
164,47% 
1) N::CNH2 
II 
N 4 SH 
KOH 
2)conc. HCI 
R~'0yOH 
~OH 
NaH 
DME 
CCNH2 
1) 
SH 
UCI KOH,MeOH 
Cl Cl 2)conc. HCI 
163 
1J I 
j CC
NH2 
4 SH 
KOH,MeOH 
2)Ac0H 
~-NyS~ 
CIAAN~ 
H 
166,92% 
Scheme 1.50 
H 
t:!'NYN~ 
CIAAS~ 
165,58% 
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1.5.3 Cyclisations Involving Pyridazine Ring Nitrogen 
The ring nitrogen of a pyridazine is relatively nucleophilic and can therefore be 
utilised in reactions with electrophiles to form cyclic systems, particularly if there is some 
other functionality adjacent to ring nitrogen, to yield nitrogen-bridged products. 
Cyclisation of a pyridazine ring nitrogen onto an adjacent hydrazide was achieved 
using triphenylphosphonium bromide in a Mitsunobu-type reaction to improve the leaving 
group ability of the oxygen (Scheme 1.51 ). The resultant 1 ,2,4-triazolo[ 4,3-b ]pyridazines 
170116 were then further functionalised before biological screening as potential GABAA 
receptor inhibitors. 
~~ NY 
Cl 
84 
1) L TMP, TMSCI 
THF, -78°C 
2) NH2NH2 
DIPEA 
THF, reflux 
168, 67% 
ArCOCI 
NEt3 
Et20, 0°C 
Cl 
169,59-96% 
Scheme 1.51 
Ar~~~~ 
I I 
N" SiMe3 
Cl 
170,91-97% 
A regioselective Buchwald-Hartwig coupling reaction was utilised in the synthesis 
of novel tricyclic scaffolds 173 by reaction of 3-aminopyridazine 171 with 2,3-
dibromopyridine 172 (Scheme 1.52)117• Initial coupling of the amino group occurred at C2 
of the pyridine ring, whilst intramolecular C-N bond formation at the pyridazine ring 
nitrogen occurred at C3 to give a fused system. 
Br~ 
+ ~ •. J 
Br N 
172 
Pd2(dbah (2 mol%) 
XANTPHOS (4.4 mol%) 
Cs2C03 
DME, 140°C, 24h 
Scheme 1.52 
173, 81% 
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1.5.4 Cyclisations onto Unfunctionalised Pyridazine Rings 
Although pyridazine rings are poorly reactive in electrophilic aromatic substitution 
processes, with highly reactive electrophiles such as nitrenes, or under palladium catalysis, 
such reactions become feasible for cyclisation processes. 
The indolo-pyridazine scaffold 175 has been synthesised by nitrene insertion onto a 
pyridazine ring (Scheme 1.53)118• The action of heat on the aryl azide 174 led to the 
formation of a nitrene, with elimination of molecular nitrogen. This nitrene then underwent 
cyclisation onto the adjacent pyridazinone ring to form a fused system. 
0 0 
~. o-DCB 
174 175,72% 
Scheme 1.53 
Maes et a/. also have developed a synthesis of 5H-pyridazino[ 4,5-b ]-indoles and 
benzofurans utilising an intramolecular Heck-type reaction as the key cyclisation step 
(Scheme 1.54)119• Nucleophilic substitution of 5-chloro-2-methyl-6-phenylpyridazin-
3(2H)-one 176a with o-iodophenol yielded 177, which underwent palladium catalysed 
cyclisation onto the pyridazinone ring to furnish cyclic product 178. However, high 
catalyst loadings of20 mol% were required for effective cyclisation to occur. In the case of 
anilines, which were not sufficiently nucleophilic to attack the pyridazinone ring in the first 
step, palladium catalysed Buchwald-Hartwig amination was required to effect the initial 
substitution, which was followed by a second palladium catalysed cyclisation step under 
more forcing conditions to give the required 5H-pyridazino[4,5-b]-indoles 180. 
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Scheme 1.54 
1.6 Fluorinated Pyridazine Derivatives 
A key focus of this thesis is the chemistry of tetrafluoropyridazine and its 
derivatives. Perfluoroheterocyclic chemistry has been extensively documented in theses of 
the Durham group, so just a brief introduction regarding the chemistry of 
tetrafluoropyridazine is appropriate here. 
Perfluorination, that is fluorination at all available ring sites, of a six-membered 
heteroaromatic120, dramatically increases the reactivity of the system towards nucleophilic 
substitution due to the high electronegativity of fluorine, which is the most electronegative 
element in the periodic table. The high strength of the C-F bond does not inhibit 
nucleophilic aromatic substitution to any significant degree, as the bond-breaking step is 
not rate-determining. 
Tetrafluoropyridazine 181 has been shown to react selectively with a range of 
nucleophiles at the 4-position. The results are summarised in Table 1.3 121-129• 
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F Nuc 
F'(:( Nuc F'(~( ~'N/- F + N /-
'N F 
181 
Nucleophile Conditions Yield/% Reference 
NaOMe MeOH, 0°C 80 113 
NH3 H20, 0°C 90 113 
EhNH NMP, 18°C 90 113 
n-BuNH2 NMP, 20°C 84 114 
PhNH2 NMP, 20°C 68 114 
BnNH2 NMP, 20°C 36 114 
rF"Ne 
Sulfolane, 60°C 57 115 
,..N-J 
·F3C 
tcF3CF2- Sulfolane, 90°C 33 116 
t(CF3)2CF Sulfolane, 1 0°C 35 117 
t (CF3)3C- Sulfolane, 20°C 80 118 
t90 
Sulfolane, 20°C 87 119 
t CF3CF=CCF3- Sulfolane, 1 05°C 5 120 
• CF3S- MeCN, 20°C 89 121 
*Formed from reaction of reaction ofperfluoro-1-methyl-1,3-diazacyclopent-2-ene and CsF 
t Formed from reaction ofperfluoroalkene I alkyne and CsF 
1\ Formed from reaction ofCF2S and CsF 
Table 1.3 
Substitution at C4 is favoured for three key reasons: i) the activating influence of 
ring nitrogen para to the site of attack allowing delocalisation of the negative charge in the 
Meisenheimer intermediate onto the electronegative ring nitrogen; ii) C4 has the maximum 
number of activating ortho- and meta-fluorine atoms, which activate by inductive electron 
withdrawal from the site of attack; iii) the lack of a deactivating para fluorine atom. 
Fluorine atoms para to a site of nucleophilic attack have been shown to be slightly 
deactivating130-132• This is thought to be due to electronic repulsion between the fluorine 
lone pairs and the developing negative charge at the para carbon destabilising the transition 
state (Figure 1.9). Ortho-fluorine atoms have a similar deactivating effect on the 
Meisenheimer intermediate, however, this effect is outweighed by the inductive activation 
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on the initial state dramatically increasing the electrophilicity of the site of attack. Both 
initial-state effects and transition-state effects must be taken into account when considering 
the preferred site of attack on a perfluoroaromatic ring. 
NuX 
~ Electronic Repulsion 
: F:f in Transition State 
Figure 1.9 
Polysubstitution reactions of tetrafluoropyridazine have been performed (Scheme 
1.55), with di- and tri-substituted derivatives prepared using methoxide121 , thiophenoxide 121 
and perfluoroalkyl anions123• 125• 129• The second substitution has been shown in a few 
isolated cases to occur at C5, para to the second activating ring nitrogen. All four fluorine 
atoms have been successfully displaced under forcing conditions using sodium methoxide 
and sodium thiophenoxide121 • 
OMe 
F~OMe 
~'Nj__F 
70% 
OMe 
MeO~OMe 
~'Nj__F 
80% MeOH, 0°C 
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NaOMe (2 eq) 55% 
F2CJ.CF3 , - - _A.oMe (3 eq) 
KF, sulfolane, 80°C F / MeOH, ooc 
SCF3 FnF OMe 
FnSCF3 CF2S (2 eq) I CsF I '-'::: NaOMe (5 eq) MeOnOMe 
1 '-'::: MeOH 60°C I '-'::: 
N ...,; MeCN, 20°C N,N...,; F ' N ...,; 
'N F 'N OMe 
82% 7 j ~NaSPh (2 eq) 95% NaSPh (4.5 eq) MP, 0°C 
NMP, 20°C NaSPh (3 eq) 
NMP, 0°C 
SPh SPh SPh PhS~SPh Fn'-'::: SPh F~SPh ~, .. A ~,N}__F 
N SPh N,N...,; SPh 
85% 55% 11% 
Scheme 1.55 
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Under strongly acidic conditions different regiochemistry is observed in 
nucleophilic aromatic substitution processes of tetrafluoropyridazine. Substitution of 
methanol in concentrated sulfuric acid occurs ortho to ring nitrogen to yield 183, whilst 
acid hydrolysis gives 4,5,6-trifluoropyridazin-3(2H)-one 182133• These reactions are 
believed to proceed via the tetrafluoropyridazinium cation, and the selectivity can be 
explained because attack at C3 gives a more conjugated nucleophilic addition complex. 
F H20 F MeOH F 
·n· FrrF FrrF ~'N 0 cone. H2S04 cone. H2S04 ~'N~ OMe N ..-: 
H 'N F 
182, 75% 181 183,65% 
F F n ~""' FnF ·u- F F F F I 0e ~ Nuc I I I N,~ F Nuc 'N ~ F N,N F I F I I H I H H H 
Scheme 1.56 
However, to date, no nucleophilic aromatic substitution reactions of 4,5,6-
trifluoropyridazin-3(2H)-one have been reported in the literature, so the factors determining 
regioselectivity of attack around this ring system are not established. 
1.7 Fluorine in Medicinal Chemistry 
The synthesis of polysubstituted derivatives from perfluorinated heteroaromatics 
should allow the incorporation of fluorine into these systems if not all fluorine atoms are 
displaced. Fluorinated compounds have been shown to have great application in the 
pharmaceutical industry, and it is thought that around 20- 25% of drugs contain at least 
one fluorine atom134• Examples of such fluorinated pharmaceutical products are shown in 
Figure 1.10 and include Cerivastatin, a pyridine-based drug, used in the treatment of 
atherosclerosis, Ciprobay, a quinolone antibiotic, Brequinar, an anti-tumour and an 
immunosuppressive agent and Prozac, a selective serotonin reuptake inhibitor, which can 
act as an anti-depressant by increasing the amount of serotonin in the brain. 
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Figure 1.10 
Fluorine can impart several advantageous properties on a potential drug candidate, 
and these effects are the focus of much recent study in an attempt to better understand the 
influence of fluorine incorporation on a range of properties. 
1.7.1 Effects of Fluorine on Physicochemical Properties 
i} pKa 
The introduction of a fluorine substituent can have a profound influence on the 
acidity or basicity of a molecule, due to its significant inductive electron-withdrawing 
effect. This effect is moderately predictable and changes in pK8 on increasing fluorination 
tend to be linear (Figure 1.11 )135 • For example, the acidity of acetic acid derivatives is 
increased in a stepwise fashion on successive a-fluorinations. Similarly, the pKaH of 
protonated ~-fluorinated ethylamine derivatives decreases in an approximately linear 
relationship on increasing fluorine incorporation. 
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The pKa of a potential drug target can have a significant influence on its 
pharmacokinetic properties, such as bioavailability134. Relatively low basicity is often 
required to ensure a significant proportion of a drug molecule is in an unprotonated state, 
and, therefore, more able to cross lipophilic cell membranes. However, an increase in 
basicity has often been shown to increase binding affinity of a drug to its target receptor 
protein. Finding an appropriate pKa to maximise these competing effects is a delicate 
balancing act136, and fluorine incorporation can be a useful tool to modulate a drug 
candidate's acidity. 
ii) Lipophilicity 
The lipophilicity of a 'drug-like' molecule must lie in a narrow range, as stated by 
Lipinski to be log P < 5137• A drug must be sufficiently lipophilic to be able to cross 
phospholipid bilayer cell membranes, but if lipophilicity is too great then it may become 
immobilised in the lipid core, or problems with poor solubility may result. 
Introduction of fluorine is one approach to altering a molecule's lipophilicity. 
Typically, particularly in aromatic and polyfluorinated systems, fluorination results in an 
increase in lipophilicity because good orbital overlap between carbon and fluorine atoms 
results in the C-F bond being very non-polarisable134• However, in certain systems, such as 
short alkyl chains, or in the vicinity of an oxygen atom, fluorination results in a decrease in 
lipophilicity due to an increase in polarity. 
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1.7.2 Effects of Fluorine on Metabolism 
Many potential drug candidates encounter difficulties when tested in vivo due to 
problems with metabolic pathways rendering the drug inactive. In particular, many such 
compounds are susceptible to oxidative pathways, particularly those involving Cytochrome 
P450 monooxygenases 134• 
One approach to improving this low metabolic stability is by introduction of 
fluorine atoms at sites particularly sensitive to oxidation. These are often para sites in 
aromatic rings, which readily undergo oxidation to phenols. For example, in the cholesterol 
absorption inhibitor Ezetimib (Figure 1.12), para-fluorination and other structural 
modifications reduced metabolism to such levels whereby the required dose for activity 
could be decreased by 55 times, whilst increasing activity 400-fold134• 
Benzylic Demethylation 
Oxidation 1 
Phenyl -~ OMe 
Oxidation ~lP-r- I 
-- :::,..... 
0 N 
R;ng / Q 
Opening OMe 
-o-cH F --:... (YOH 
c====~> o~~ Q 
F 
l 
Demethylation 
SCH48461 Ezetlmib 
ED50 2.2mg/kg/day ED50 0.04mg/kg/day 
Figure 1.12 
However, fluorination can in certain cases increase metabolic stability to levels 
where the drug persists in vivo and is not excreted in an acceptable timeframe. 
Replacement of a fluorine atom by a methyl group to give the COX-2 inhibitor Celecoxib 
(Figure 1.13) decreases the biological half-life from 220 hours to a more suitable 3.5 
hours 135' 138• 
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ty. (rat) 220h 
Figure 1.13 
1. 7.3 Effects of Fluorine on Protein Binding 
Celecoxib 
ty. (rat) 3.5h 
Both steric and electronic factors may significantly influence the binding of a drug 
to its target, and introduction of fluorine may influence both ofthese aspects. 
i) Steric Factors 
In the past it has been suggested that fluorine may replace hydrogen with minimum 
steric perturbation, however this has been shown not to be the case. The van der Waals 
radius of a fluorine atom (1.47 A) is significantly larger than hydrogen (1.20 A), and is in 
fact more similar to oxygen (1.52 A)139• Fluorine atoms have therefore been used as 
bioisosteric replacements for hydroxyl groups, especially if it is necessary to remove the 
hydrogen bond donor character of an OH. Trifluoromethyl groups have been shown to be 
significantly larger in size than a methyl substituent, in fact being more similar in size, if 
not in shape, to an iso-propyl group, both having an effective Vander Waals radius of2.20 
A\39. 
These steric effects may have a significant influence on molecular conformation, 
which is very relevant when considering binding to proteins. For example, 
methoxybenzene is planar, whilst trifluoromethoxybenzene has its OCF3 substituent 
orthogonal to the plane of the aromatic ring 134• 
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ii) Electrostatic Interactions 
Electronic interactions between a C-F bond and a target receptor are moderately 
poorly understood, although recent work by Diederich and MUller is beginning to change 
this situation. 
Although a C-F bond is highly polarised, it has been shown to be a poor hydrogen 
bond acceptor due to the tightly held nature of fluorine ' s lone pairs140• However, other 
electrostatic interactions, such as dipole-dipole and charge-dipole interactions have been 
shown to be significant. 
Crystallographic analysis of fluorinated aromatics bound to the active site of the 
enzyme thrombin (Figure 1.14) have shown dipole-dipole attractions between C-F bonds 
and C=O and C=N groups, adopting a Burgi-Dunitz type trajectory 141 -143• Attractive 
interactions between C-F bonds and C-Hand N-H bonds have also been observed. These 
attractions may be utilised, for example, to stabilise the binding of an inhibitor to an active 
site. 
~\' 
R F~ 
\ ,,' ,, 
~,, 
0--\ 
N-H 
< R 
Figure 1.14 
Dipolar interactions may also have a significant influence upon molecular 
conformation, which is significant in the binding of drug molecules into active sites of 
enzymes, which often have a small, complex shape. For example, a C-F bond dipole will 
orientate itself anti to an adjacent polar group, such as a carbonyl group140• Vinyl fluorides 
have a dipole orientated in a similar direction, and a similar molecular shape to amides, as 
which they have been successfully employed as bioisosteric replacements (Figure 1.15). 
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Figure 1.15 
The strongest observed intermolecular attractions involving fluorine are those 
involving a C-F bond and an adjacent group bearing a formal positive charge. There is a 
strong gauche preference in these systems, as demonstrated in the conformation of 3F-
GABA derivatives (Figure 1.16)140• 
9 F e H3N~C02 
3F-GABA (S) 
Disfavoured 
H 
~ e co F NH 2 @ 3 
F and NH3 +gauche :. Favoured 
Figure 1.16 
Molecular orbital interactions involving fluorine can also affect molecular 
conformation (Figure 1.17). For example, in alkyl systems bearing two vicinal fluorine 
atoms, there is a strong preference to adopt a gauche conformation140• This is due to a 
hyperconjugative interaction between the C-F cr* orbital and C-H cr orbitals on an adjacent 
carbon. 
F 
C-Hu H C-Fu* 
HJ 
F F 
Hff.Z-- H~H 
H H H H F H 
Figure 1.17 
Fluorine has therefore been shown to have a significant influence on various drug 
properties, including physicochemical (pKa, lipophilicity), metabolism, and steric and 
electrostatic factors affecting molecular confonnation and binding to receptors144· 145• Its 
incorporation~into··a"drug···candidate-therefore-has~the"potential~toimprove·eaftinity-;-wllilst 
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reducing side-effects, and fluorine has demonstrated to be a valuable tool for the medicinal 
chemist. 
1.8 Conclusion 
The chemistry of pyridazine derivatives is of significant current interest, particularly 
to pharmaceutical and materials chemists who require the efficient synthesis of a diverse 
range of heteroaromatic derivatives for screening programmes. The pyridazine ring system 
is most readily assembled by the condensation of a I ,4-dicarbonyl compound with 
hydrazine or by the cycloaddition of a I ,2,4,5-tetrazine derivative with a dienophile. Once 
formed, pyridazine derivatives, particularly halo-pyridazines, can be further functionalised 
by a range of nucleophilic substitution, palladium catalysed cross-coupling and metallation 
processes. 
However, there has been little study on the reactivity of polyfluorinated pyridazine 
derivatives such as tetrafluoropyridazine. The preparation of fluorinated derivatives is of 
particular interest in medicinal chemistry for the potential improved properties fluorine can 
impart on drug molecules. This thesis will focus on the synthesis of polyfunctional 
pyridazine derivatives by sequential nucleophilic aromatic substitution reactions and on the 
formation of ring fused pyridazine systems by reaction with dinucleophiles. 
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Chapter 2 
Syntheses of Polyfunctional Pyridazin-3(2H}-one Systems from 
l etrafluoropyridazi ne 
2.1 Aims and Approach 
This thesis aims to describe the synthesis of a range of polyfunctional heterocyclic 
systems from a perfluorinated heteroaromatic precursor tetrafluoropyridazine. Such 
pyridazine systems are desirable in a range of applications ranging from pharmaceuticals to 
materials, yet their syntheses can be very difficult, owing to poor reactivity and 
regioselectivity of parent heteroaromatic systems. 
As described in Chapter 1, traditional routes to pyridazine ring systems involve 
either the condensation of 1 ,4-dicarbonyl compounds with hydrazine, or the cycloaddition 
of 1 ,2,4,5-tetrazines with alkynes and whilst these can be effective and high-yielding 
approaches towards pyridazine derivatives, they may be limited in their potential to yield 
structurally diverse systems in large numbers using parallel synthesis approaches that are 
widely utilised in the pharmaceutical industry. There is still a need for efficient, high 
yielding syntheses of pyridazine derivatives that allow for the introduction of a high degree 
of diversity. 
The approach of the Durham group involves the use of perfluorinated 
heteroaromatic scaffolds to yield polysubstituted products. For example, such highly 
fluorinated systems have been demonstrated to react with a range of nucleophiles under 
mild conditions. Such an approach may present potential benefits in terms of improved 
reactivity and regioselectivity and may also be suitable for diversity-oriented synthesis. 
Little work has been previously described on the chemistry oftetrafluoropyridazine, 
so the fundamental reactivity of the system must first be established before more complex 
molecules can be prepared. In particular, no substitution reactions of 4;5,6-
trifluoropyridazin-3(2H)-one have been reported, so the first aspect of this work focuses on 
determining the factors that control regioselectivity in this system. In theory, all three 
fluorine atoms in 4,5,6-trifluoropyridazin-3(2H)-one may be activated towards sequential 
displacement by nucleophiles_to yleld p()lys,ubstitll!ed systems-'_(~<;h_~lll_e ~.1). _ 
- ----'-- '- - _ _:___ __ - -- ::______ --~'------- - - -- ~- - ---- ----· ---
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Scheme 2.1 
As well as allowing for the introduction of substituent diversity, our approach also 
has the potential to provide some degree of scaffold diversity. The reaction of 
tetrafluoropyridazine with dinucleophilic species may, potentially, yield ring-fused 
systems, and the wide variety of dinucleophiles available should allow for the synthesis of a 
diverse range of fused pyridazine ring systems (Scheme 2.2). Such scaffolds will possess 
C-F bonds that, in theory, will be reactive towards displacement by nucleophiles thereby 
enabling the synthesis of libraries of compounds based on a particular scaffold. 
Furthermore, the use of functionalised dinucleophiles may provide an additional diversity 
point on the scaffold remote from the pyridazine ring. For example, brominated 
dinucleophiles would potentially allow palladium catalysed cross-coupling and metallation 
reactions to be performed. 
F (\ N~ Nu~ F'!~( FUN""' Nuc4 Nuc1 Nuc2 N ....,; N,N....,; F 
'N F 
Nunuc, j Br 
Br Ar 
N~ N~ Nuc3 ArB(OH)z Nuc4 FtiNuc, Pd Cat FtiNuc, 
N,N....,; F N,N....,; F 
Scheme 2.2 
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Finally, the chemistry of the related perhalogenated heteroaromatic 
tetrachloropyridazine will be explored as a potential scaffold (Scheme 2.3). Reactions of 
such perchlorinated heteroaromatics have been under-utilised in the past, mainly due to 
difficulties in product identification but now rapid X -ray crystallography techniques make 
the identification of products from the reactions of perchlorinated systems feasible. As well 
as being reactive in nucleophilic aromatic substitution processes, tetrachloropyridazine may 
be able to be utilised in metal-halogen exchange and palladium catalysed cross-coupling 
processes, allowing for a greater degree of substituent diversity. 
1) Buli 
2) E+ 
Cl 
CI~CI 
~'N~CI 
Nuc 
__ N_uc_ ...... ci~CI 
~'N~CI 
ArB(OHh j Pd cat 
Ar 
CI~CI 
~'N~CI 
Scheme 2.3 
The following chapters describe the synthesis of a range of polyfunctional 
pyridazine derivatives based on the approaches described in this section. 
2.2 Polysubstituted Pyridazin-3(2H)-one Derivatives 
The pharmaceutical industry has a continuing requirement for the synthesis of a 
diverse range of polysubstituted pyridazin-3(2H)-ones bearing a varied range of ring 
substituents because many such compounds have been utilised as commercially available 
drugs and agrochemicals. Examples include the anti-platelet clotting agent Zardaverine, 
the anti-inflammatory Emorfazone and herbicides Pyridaben and Norflurazon, which are 
shown in~figureo2,1-below. 
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Figure 2.1 
In Chapter I we discussed how perfluorinated heteroaromatics are highly reactive 
towards nucleophiles and pentafluoropyridine has been subjected to sequential nucleophilic 
attack to yield trisubstituted derivatives146 (Scheme 2.4). Perfluorinated heteroaromatics 
typically demonstrate improved reactivity and regioselectivity in reactions with 
nucleophiles compared to chlorinated or brominated analogues and these sequential 
displacements on pentafluoropyridine proceed in an entirely regioselective fashion. This is 
ideal for the pharmaceutical industry, which requires rapid and efficient purification 
protocols for both the high throughput synthesis of large numbers of analogues for 
screening programmes and also for plant-scale synthesis of a final drug target. 
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F N F 
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)l __ ~ 
F N F 
185 
Scheme 2.4 
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Sequential displacement of perfluorinated heteroaromatics with a range of 
nucleophiles should allow the production of polyfunctional systems. One such system is 
4,5,6-trifluoropyridazin-3(2/i)-one, whose synthesis is known from the commercially 
available tetrafluoropyridazine. However, to date no nucleophilic aromatic substitution 
reactions of 4,5,6-trifluoropyridazin-3(2/i)-one have been reported in the literature, so the 
fundamental reactivity of this system towards nucleophiles must first be determined, 
examining regioselectivity as the nucleophilic species is varied. Use of a range of amines, 
alcohols, thiols and carbon-centred nucleophiles in first, second and third substitution 
processes may allow for the synthesis of an array of diversely substituted pyridazin-3(2/i)-
one derivatives (Scheme 2.5). 
F~F 
~--N~O 
H 
Nuc = NH2R, NHR2, ROH, 
RSH, RMgBr 
Scheme 2.5 
2.3 Synthesis and Structure of 4,5,6-Trifluoropyridazin-3(2H)-one 
Literature procedures were followed to accomplish the acid hydrolysis of 
tetrafluoropyridazine 181 to yield 4,5,6-trifluoropyridazin-3(2/i)-one 182 (Scheme 2.6) 133• 
This material was sufficiently pure after extraction and washing to be used in further 
synthetic steps or could be recrystallised from toluene to yield analytically pure material. 
Yields were excellent, ranging from 78- 90% (higher than those reported in the literature) 
and the hydrolysis proved to be equally efficient on reaction scales ranging from 1 - 1 Og. 
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The product was further characterised here by X-ray crystallography, which 
confirmed that 4,5,6-trifluoropyridazin-3(2H)-one 182 does indeed exist as the 
pyridazinone tautomer, at least in the solid state (Figure 2.2). This is demonstrated by the 
short C=O bond length of 1.23 A, which is more typical of a C=O double bond ( ~ 1.20 A), 
rather than a C--0 single bond ( ~ 1.43 A). Intermolecular hydrogen bonding is observed in 
the lattice between ring NH groups and pyridazinone C=O groups. 
Bond 
C(1 )-0(1) 
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N(1)-C(4) 
N(1)-N(2) 
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Figure 2.2: X-rey Crystal Structure of 4,5,6-Trifluoropyridazin-3(2H)-one 182 
In contrast, 2-substituted-3,5,6-trifluoro-4-hydroxypyridines, were shown by 
crystallography to exist as the pyridinol tautomer147• This may be due to reduced electronic 
repulsion of the nitrogen lone pairs in the pyridazin-3(2H)-one compared to the pyridazinol, 
which is not a factor in the pyridine system, which suffers a loss in aromaticity on forming 
the pyridone tautomer (Figure 2.3). 
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N "' /J. N,N·· 0 in pyridazinone tautomer 0 'N OH w 0 H 
OH 
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Figure 2.3 
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4,5,6-Trifluoropyridazin-3(2/i)-one shows some evidence of tautomerisation in 
CDCh solution, with two separate 1 H NMR resonances being visible, with the pyridazinone 
ring NH displaying a 1H signal at -11.4 ppm, and the hydroxyl tautomer at -1.8ppm. 
These tautomers are in a 2: I ratio (NH/OH) by NMR integration. However, only one set of 
three resonances is displayed in the 19F NMR, although signals from the two tautomers may 
be overlaid on top of each other. 
2.4 Nucleophilic Substitution Reactions of 4,5,6-Trifluoropyridazin-3(2H)-one 
To date, no examples of nucleophilic aromatic substitution reactions of 4,5,6-
trifluoropyridazin-3(2/i)-one have been reported in the literature. Nucleophilic substitution 
reactions with a range of nucleophiles of varying steric and electronic properties, including 
primary and secondary amines, anilines, alkoxides, thiolates and Grignard reagents, were 
attempted to determine the reactivity of this scaffold, in particular to examine any variation 
in regioselectivity depending on the nature of the nucleophile. Three possible 
monosubstituted isomers could be obtained by reaction of 4,5,6-trifluoropyridazin-3(2/i)-
one, whose fluorine atoms are all non-equivalent (Figure 2.4). 
F 
F~F 
~'N~O 
H 
+ Nuc 
F 
F'O:Nuc I + 
N,N 0 
H 
Figure 2.4 
Nuc 
F~F 
~'N~O 
H 
F 
Nuc'(xF 
+ I 
N,N 0 
H 
The nucleophilic aromatic substitutions were run under standard conditions to 
ensure that any data obtained from the isomer ratios were comparable. Each reaction was 
run at 25°C in acetonitrile using a standard pyridazinone concentration of 3.33 J..lmol dm-3. 
Two equivalents of nucleophile were used in each case, the first to act as a nucleophile and 
displace fluoride, and the second to act as a base to neutralise the HF which is eliminated in 
this reaction. Reactions were monitored by 19F NMR of the crude reaction mixture and 
isomer ratios of products were obtained by integration of these spectra. Reactions were 
al!ow~~ t~ procet~ __ up!}I-'- 19F NMR _(}( th£ cr!l~~ r~a~tton mjxt!J_r~ suggested_ C_Qmplete 
conversion of starting material. 
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2.4.1 Nucleophilic Substitution Reactions with Amines 
A range of primary, secondary and aromatic amines were chosen to provide a 
representative sample of nitrogen nucleophiles with different steric and electronic 
properties. 
Reaction with primary amines proceeded efficiently at room temperature to give 
complete conversion to substituted products in a few hours. Primary amines were shown to 
give mixtures of two monosubstituted isomers (Table 2.1 ), where substitution at the 4-
position is favoured marginally over the 5-position, with no evidence of any substitution 
occurring at the 6-position. The products were readily separable by column 
chromatography, which was pleasing as regioisomers can often be very difficult to separate. 
F 
F~F 
~-N_,lO 
H 
Nucleophile 
~NH2 
Ph/""-.NH2 
a Isolated Yield 
+ 
NHR1 
MeCN 
rt 
F~F 
~-N_,lO 
H 
Yield 4-lsomer 8 Yield 5- Isomer a Ratio 4:5- Isomers b 
188a, 40% 
F H 
FnN, 
1 n-Bu 
N,N 0 
H 
189a, 41% 
F H 
FnN'-/Ph 
N,N 0 
H 
190a, 49% 
lNH 
F~F 
~-N_,lO 
H 
188b, 13% 
n-Bu,NH 
FnF ~-N 0 
H 
189b, 31% 
Ph 
l._NH 
FnF 
N,N 0 
H 
190b, 29% 
60:40 
57:43 
61:39 
b Ratios-determined by.19F NMR·oferuile·reacticin'miXture-
Table 2.1 
61 
Chapter 2: Syntheses of Po/yfunctiona/ Pyridazin-3(2H)-one Systems from Tetrafluoropyridazine 
In the case of secondary amine nucleophiles (Table 2.2), again mixtures of 4- and 5-
monosubstituted products were obtained, with the 4-substituted regioisomer being favoured 
in a ratio of~ 3:1. The major isomer could be isolated by either recrystallisation or 
chromatography. 
F F NR1R2 
FUF R
1R2NH MeCN FUNR
1
R2 FUF ~-N 0 + (2eq) rt I + I N,N 0 N,N 0 
H H H 
Nucleophlle Yield 4- Isomer a Yield S. Isomer a Ratio 4:5- Isomers b 
F I n-Bu,N....-
/'-../'N_.... FUN, B 
FUF H 
I n- u 
73:27 
N,N 0 ~-N 0 H 
H 
191a, 46% 
~N_.... 
F I 
lN....-FuN~ H 
N,N 0 
FUF H 73:27 
N,N 0 
H 
192a,49% 192b, 16% 
0 'J-xO 0 
FUF 
79:21 
H 'N 0 H ~-N 0 
H 
193a, 52% 
Co) F ('o Co) 
FUNJ N N 
H N,N 0 FUF 77:23 H ~-N 0 
H 
194a, 59% 194b, 12% 
l) F ( l) 
FUN--./ H 77:23 
N,N 0 FUF 
H N,N 0 
H 
1958,46% 195b, 9% 
• Not Isolated a Isolated Yield b Ratio from integration of 19F NMR of crude reaction mixture 
Table 2.2 
62 
·-"-
Chapter 2: Syntheses ofPolyfonctional Pyridazin-3(2H)-one Systems from Tetrajluoropyridazine 
The use of substituted anilines led to a significant increase in regioselectivity (Table 
2.3), with the ratio of 4- and 5-monosubstituted isomers now being greater than 9: I. 
Isolated yields were generally obtained by recrystallisation, and were not optimised. 
Impressively, for relatively unreactive nucleophiles such as anilines, reaction proceeded 
efficiently at room temperature in under 24 hours. Both electron-withdrawing and electron-
donating substituents present on the phenyl ring were tolerated, and did not have a 
significant effect on either regioselectivity or reaction yield. 
+ 
Nucleophile 
ONH2 
~ Me 
Br 
ONH2 
~ 
F 
ONH2 
~ 
ArNH2 
(2eq) 
MeCN 
rt 
Yield 4- Isomer a 
Ae 
Fy 
F~NH 
~-N--lO 
H 
196a, 61% 
Me ¢ F 
FnNH 
N,N 0 
H 
197a, 56% 
Br ¢ F 
FnNH 
N,N 0 
H 
198a, 42% 
F ¢ F 
FnNH 
N,N 0 
H 
1998, 52% 
F NHAr 
F~NHAr+ F~F 
~-N--lO ~-N--lO 
H H 
Yield 5- Isomer a Ratio 4 : 5- Isomers b 
f"""'YOMe 
HN~ 
F~F 
~-N--lO 
H 
HN 
OMe 
FnF ~-N 0 
H 
HN 
OBr 
FnF 
N,N 0 
H 
HN 
OF 
FnF ~-N 0 
H 
90: 10 
90: 10 
96:4 
91:9 
• Not Isolated 
-
8 Isolated Yield- -b Ratio-froin integration of 19F NMR of crude reaction mixture 
Table 2.3 
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In all cases, reactions of tetrafluoropyridazine with amine nucleophiles proceed at 
the 4- and 5-positions, with no reaction observed at the 6-position. These sites are para to 
activating ring nitrogen and allow stabilisation of the negative charge generated in the 
Meisenheimer intermediate onto an electronegative group (Scheme 2.7). In the case of C4 
this is the pyridine-type ring nitrogen, whist attack at C5 allows delocalisation onto the 
carbonyl group. Attack at C4 and C5 maximises the number of activating ortho-tluorine 
and oxygen substituents. 
C4 attack 
F e 
F~Nuc ,~~ ------~ 
(N,N 0 
H 
CS attack 
Scheme 2.7 
F 
F~Nuc 
~'N--lO 
H 
Nuc 
F~F 
~'N--lO 
H 
It appears that as the 'soft' character of the attacking nucleophiles is increased 
(anilines > secondary amines > primary amines)148, the regioselectivity of the reaction 
increases. It is not immediately obvious as to why the 4-position should react preferentially 
with soft nucleophiles, this must be a relatively subtle influence as a small change in 
nucleophile character gives a relatively large change in nucleophilic attack selectivity. The 
4-position, between a C-F and C=O bond may be marginally softer than the 5-position, 
between two highly electron withdrawing C-F bonds (Figure 2.5). 
Figure 2.5 
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Product identification is most simply carried out by analysis of C-F coupling 
constants in a 13C NMR spectrum. Carbon atoms bonded to fluorine are readily identifiable 
by their extremely large 1 JcF coupling constant of ~ 230Hz. In these difluorinated 
pyridazin-3(211)-one systems C-F carbon atoms are displayed as doublets of doublets, with 
the size of the secondary coupling constant being indicative of which isomer has been 
obtained. In a 4-substituted isomer 13C NMR C-F signals also display a moderate 
secondary coupling eJCF ~ 17 - 33Hz). However, in the case of 5-monosubstituted 
systems, the secondary COUpling COnStants are much smaller eJcF ~ 8 - 13Hz), as the 
carbon and fluorine atoms are further separated. 
It was thought that a similar analysis of 19F NMR coupling constants could allow 
for product identification (Table 2.4), but these are notoriously unreliable. However, in this 
case 4-substituted isomers consistently showed a greater 31FF coupling constant of 
approximately 26 - 30Hz, whilst 5-substituted isomers gave a smaller 4JFF coupling 
constant of 20 - 25Hz. Although these ranges are close together, and an absolute value of 
the JFF coupling constant may be fairly ambiguous, if coupling constants for both isomers 
can be obtained, the larger JFF value represents the 4-substituted isomer, which has ortho 
fluorine atoms. 
F Nuc 
FUNuc 
N,N 0 
FnF 
N,N 0 
H H 
Substituent 3 JFF 4- isomer I Hz 4 JFF 5- isomer I Hz 
~NH 26.4 24.7 
BuNH 27.4 23.5 
Ph.......--..NH 27.5 22.9 
~N...._ 26.7 22.4 
(0) 29.5 20.7 
N 
NEt2 27.0 22.4 
Table 2.4 
19F NMR chemical shifts are not informative in this case as both 4- and 5-
substituted isomers possess one fluorine atom-or tho ·to-ring n itrogen.-ano-one fluorine ·atom 
65 
Chapter 2: Syntheses of Poly.fimctional Pyridazin-3(2H)-one Systems from Tetrajluoropyridazine 
para to ring nitrogen. Fluorine atoms ortho to ring nitrogen show a characteristic 19F NMR 
chemical shift of~ -100 ppm, whilst fluorine atoms not ortho to ring nitrogen have a 19F 
NMR chemical shift of~ -140 ppm. 
Finally, product identification for three of these derivatives, namely the 4-
benzylamino 190a, 5-butylamino 189b and 4-piperidino 193a derivatives (Figure 2.6), was 
unambiguously confirmed by X-ray crystallography and structures agreed with product 
assignment obtained from NMR data. The crystal structure in the two primary amino cases 
showed there to be two separate orientations of the alkyl chain in the unit cell. 
a) 
b) 
c) 
' Cll~_(:: 
CBA:~·~' 
-,-
Bond 
C(1)-0(1) 
N(2)-C(1) 
N(1)-C(4) 
N(1 )-N(2) 
Bond 
C(4)-0(1) 
N(1 )-C(4) 
N(2)-C(1) 
N(1 )-N(2) 
Bond 
C(1 )-0(1) 
N(2)-C(4) 
N(1 )-C(1) 
N(1 )-N(2) 
Bond Length I A 
1.252 
1.355 
1.291 
1.365 
Bond Length I A 
1.2567 
1.2758 
1.355 
1.3539 
Bond Length I A 
1.244 
1.285 
1.362 
1.362 
Figure 2.6: Crystal structures of a) 4-(benzylamino)-5,6-difluoropyridazin-3(2H)-one 
190a; b) 5-(buty/amino)-4,6-difluoropyridazin-3(2H)-one 189b; c) 5,6-di.fluoro-4-
(piperidin-1-y/)-pyridazin-3 (2H)-one 19~a 
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The monosubstitution reactions appear to be equally efficient on a range of reaction 
scales, giving similar results on scales between O.lg and 5g. The reactions did appear in 
certain cases to be relatively sensitive to concentration (Table 2.5), for example in the 
reaction of 4,5,6-trifluoropyridazin-3(211)-one a moderate increase in selectivity in favour 
of the 4-isomer 194a was observed on increasing concentration. However, using 
benzylamine and butylamine as nucleophile, concentration of starting material was shown 
to not have a significant effect. Concentrations of reagents can have a significant influence 
on factors such as solvation and hence affect regioselectivity. 
F~F + 
~'N~O 
H 
182 
Concentration I mol dm-3 
0.13 
0.20 
0.25 
F ("o 
MeCN FuN~ 
rt 
N,N 0 
H 
194a 
%4- isomer 
77 
81 
92 
Table 2.5 
(o) 
N 
+ FnF ~'N 0 
H 
194b 
%5- isomer 
23 
19 
8 
The reproducibility of these results was tested by repetition of the reaction of 
morpholine with 4,5,6-trifluoropyridazin-3(211)-one under standard conditions 
(Temperature= 25°C, Solvent= acetonitrile, Concentration= 0.20 mol dm-3) (Figure 2.7). 
These showed the ratios of isomers obtained to be consistent between runs, giving a 
standard deviation of 0.032 and a standard error of 0.010. This suggests that the isomer 
ratios can be reported to± I%, which is likely to be due to the error in the integration of the 
NMR spectrum, rather than any inconsistency of the reaction itself and the isomer ratios 
presented can be used with a great degree of confidence for the reaction conditions used. 
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Sample 
Figure 2.7 
2.4.2 Nucleophilic Substitution Reaction with Thiolate Ions 
With reactive nucleophiles, such as thiolate anions, it proved particularly difficult to 
control the nucleophilic substitution reactions of 4,5,6-trifluoropyridazin-3(2/i)-one to give 
monosubstituted products selectively (Scheme 2.8). Reaction of a single equivalent of 
sodium methanethiolate with 4,5,6-trifluoropyridazin-3(2/i)-one gave approximately 50% 
conversion to the disubstituted product 200, suggesting that the monosubstituted product is 
in fact more reactive towards nucleophilic substitution than 4,5,6-trifluoropyridazin-3(2/i)-
one. Reaction of 4,5,6-trifluoropyridazin-3(2/i)-one with two equivalents of sodium 
methanethiolate gave a single product 200, disubstituted at the 4- and 5-positions and X-ray 
crystallography confirmed the structure of this product (Figure 2.8). 
F 
F~F + ~'N~O 
H 
182 
NaSMe 
x equivalents 
MeCN 
rt,6h 
x = 1 eq 
x = 2 eq 
Scheme 2.8 
SMe 
F~SMe 
~'N~O 
H 
200 
20% yield (50% conversion) 
55% yield (100% conversion) 
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Bond 
C(1)-0(1) 
N(1)-C(4) 
N(2)-C(1) 
N(1)-N(2) 
i~' 
.-. . ...........-~,,_ 
\t~cjl 
~/~ ., .. 
.,11\....___T, -' ~-,~·:>~ . ~ot 
N2 
i...._."l 
Bond Length I A 
1.241 
1.287 
1.372 
1.354 
\ ~· 
Bond 
N(2)-C( 1 )-C(2) 
0(1 )-C(1 )-N(2) 
C(1)-N(2)-N(1) 
0(1 )-C(1 )-C(2) 
Bond Angle I 0 
114.9 
120.3 
127.0 
124.8 
Figure 3.8: X-ray crystal structure of6-fluoro-4,5-bis(methylthio)pyridazin-3(2H)-one 200 
Carbanions a- to sulfur are known to be stabilised 149 and this, therefore, activates 
sites ortho to sulfur towards nucleophilic aromatic substitution as the Meisenheimer 
intermediate is stabilised. It is thought that this stabilisation is a stereoelectronic effect, 
namely the delocalisation of the carbanion into the cr * orbital of the adjacent C-S bond 
(Figure 2.9). 
Me 
\ 
F. s F~Me ~,N,tO 
H 
Figure 2.9 
2.4.3 Nucleophilic Substitution Reactions with Basic Nucleophiles 
However, when more basic nucleophiles such as alkoxides (NaOMe, NaOEt, 
NaOPh), Grignard reagents (PhMgBr) or bulky secondary amines (e.g. diisopropylamine, 
~,2,(),_6:!~tra!}!~thylpjgeridine) were_ reacted,_ with-~l,5,6-trifluoropyridazin"3(H)-one -no 
substituted products could be isolated. Instead, a rapid, exothermic darkening of the 
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reaction mixture was observed and, on workup, a complex reaction mixture was obtained. 
The desired substituted product could in certain cases be observed in trace quantities ( < 
5%) by GC-MS, but the major components of the reaction mixture could not be identified. 
It is likely that in the presence of basic nucleophiles the relatively acidic pyridazin-
3(2/J)-one ring NH is deprotonated and this nitrogen anion then undergoes a rapid 
decomposition or polymerisation process. 
A potential solution to this would be to use the less reactive alcohol, rather than the 
sodium salt as nucleophile. Unfortunately, treatment of 4,5,6-trifluoropyridazin-3(2/J)-one 
with methanol under reflux conditions returned only the starting material, suggesting that 
alcohols are not sufficiently nucleophilic to react with 4,5,6-trifluoropyridazin-3(2/J)-one 
without deprotonation. 
Therefore, the monosubstitution reactions of 4,5,6-trifluoropyridazin-3(2/J)-one are 
mainly limited to those with amine nucleophiles, as nucleophiles of increased basicity lead 
to decomposition of the starting material rather than nucleophilic substitution. 
2.5 Syntheses of Disubstituted Pyridazin-3(2H}-one Derivatives 
To prepare a series of disubstituted pyridazin-3(2/J)-ones representative 
monosubstituted examples were reacted with the same range of nucleophiles to examine 
reactivity. Monosubstituted pyridazin-3(2/J)-ones were chosen with primary amine 
(butylamino), secondary amine (morpholino) and aromatic amine (p-bromoanilino) 
substituents at the 4-position of the pyridazin-3(2/J)-one ring as a range of first substituents 
with varying steric and electronic properties. 
2.5.1 Reactions of 4-Morpholino-5,6-difluoropyridazin-3(2H}-one with Amine 
Nucleophiles 
Reaction of 4-morpholino-5,6-difluoropyridazin-3(2/J)-one 194a proceeded 
efficiently with a range of amine nucleophiles to give the 4,5-disubstituted products in good 
yields (Table 2.6). The reactions did not proceed at room temperature so instead 
microwave -irradiation -was--used-to -effect- the -suostitutiori.- ~u ridef these-- conditions-die 
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reactions proceed, in general, to I 00% conversion and give a single product. Isolated 
yields are obtained by a single recrystallisation from acetonitrile, and are not optimised. 
F ("o 
F~NJ ~-N--lO 
H 
194a 
+ NRR'H 
Nucleophile Product Isolated Yield(%) Nucleophile 
~NH2 
UNH2 
* Only 70% conversion by 19F NMR 
55% 
56% 
62% 
/'N~ 
H 
Table 2.6 
NRR'("O 
F~NJ ~-N--lO 
H 
Product Isolated Yield (%) 
54% 
. 
25% 
43% 
206 
The replacement of a fluorine atom with an amine substituent ensures that this 
system is significantly less reactive than 4,5,6-trifluoropyridazin-3(2H)-one. No reaction 
was observed at room temperature, and the conversion was best effected by heating the 
reaction mixture to reflux for 72 hours, or using microwave irradiation at l50°C for 30 
minutes. This is because the replacement of a highly electron-withdrawing fluorine atom 
with an amine substituent renders the heteroaromatic ring significantly less electron 
deficient, so much less reactive towards nucleophilic displacement. 
The products were identified as the 4,5-disubstituted derivatives, rather than 4,6-
disuostituttil~from examinatlon-oYtt1elr 19FNMR cllemiCaT 5hitts~ wllich range from :::-94 -
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-l 01 ppm. These chemical shifts are characteristic of fluorine that is deshielded by an ortho 
ring nitrogen, indicating the presence of a fluorine atom at the 6-position, therefore 
substitution of the 5-fluorine must have occurred. 
Reaction of the parent scaffold with anilines was also examined, however these 
were not sufficiently nucleophilic to react under standard microwave irradiation conditions. 
Instead, the sodium salt of 4-bromoaniline was prepared by deprotonation with sodium 
hydride, and this was heated to reflux with 4-morpholino-5,6-difluoropyridazin-3(2/i)-one 
194a (Scheme 2.9) to yield both 4,5- (207a) and 4,6- (207b) disubstituted products in an 
approximately 1: 1 ratio in l 00% conversion. Separation of the isomers proved difficult, 
and was achieved by mass directed HPLC, although pure samples of each isomer could 
only be obtained in 11% and 7% yield. 
It seems likely that use of a less reactive aniline nucleophile led to more of the 
thermodynamically stable 4,6-disubstituted product, which has less steric clashing between 
its substituents. More reactive nucleophiles give the 4,5-disubstituted compound 
selectively as the kinetic product, by reaction at the most electrophilic site. 
194a 
r(YNHNa 
Br~ 
NaH,THF 
Reflux, 3d 
Br~ 
~NH fO 
F~N~ 
~,N,.lO 
H 
207a, 11% 
ISOMER RATIO 53 
Scheme 2.9 
+ 
¢.rn 
HN~N~ 
~,N,.lO 
H 
207b, 7% 
47 
2.5.2 Reaction of 4-(4-Bromophenylamino)-5,6-difluoropyridazin-3(2H)-one with Amine 
Nucleophiles 
Reaction also proceeded effectively with the 4-bromoanilino substituted pyridazin-
3(2/i)-one 198a and a range of primary amine nucleophiles to produce the 4,5-disubstituted 
products 208 and 209 (identified as described previously from analysis of 19F NMR 
chemical shifts). Isolated yields were excellent, obtained by filtration of the reaction 
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mixture through a short column of silica gel. The reaction with the sulfur nucleophile 
sodium ethanethiolate also provided the disubstituted product 212 in excellent yield. 
However, the reaction of 198a with secondary amines such as diethylamine and 
morpholine was extremely slow, even under forcing microwave irradiation conditions. 
Conversion to the desired disubstituted products 210 and 211 was around 20% by crude 19F 
NMR, and mass directed automated purification allowed the isolation ofthis in around 15% 
yield. It is likely that the poor yields in these cases are due to steric hindrance, which 
indicates the difficulties in placing a bulky secondary amine ortho to a sterically demanding 
aniline substituent. 
Nucleophlle 
FnF"': ~n ~ I ""' + Nuc 
'N 0 ,_, Br 
MeCN 
MW, 150°C, 30 min 
H 198a 
Product Isolated Yield (%) Nucleophlle Product Isolated Yield (%) 
----~------------------------~~ 
A 
Bu,NHY 
F~NH 
~'N~O 
I 
H 
208 
210 
90 15 
211 
45 NaSEt 90 
212 
18 
Table 2.7 
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These steric effects were further exemplified in the reaction of 198a with a second 
equivalent of 4-bromoaniline (Scheme 2.1 0), which again required formation of the sodium 
salt by deprotonation with NaH to achieve reaction. This yielded only the 4,6-disubstituted 
product 213 in poor yield and demonstrates the large steric clashing between two adjacent 
aromatic rings. The second substituent is therefore forced to the less reactive, although less 
sterically hindered 6-position, to give the thermodynamic product. The product in this case 
was identified by analysis of its 19F NMR chemical shift, which at -139 ppm is 
characteristic of fluorine that is not ortho to ring nitrogen. 
F N '-'::: nF ~ N O'QBr 
H 
198a 
MeCN 
MW, 150°C, 30min 
Scheme 2.10 
GY~yL~~ Br~ ~'N---lO ~Br 
H 
213, 16% 
2.5.3 Reaction of 4-Butylamino-5,6-difluoropyridazin-3(2H)-one and 4-benzylamino-5,6-
difluoropyridazin-3(2H)-one with Amine Nucleophiles 
Surprisingly, when the two 4-primary amino substituted pyridazin-3(2H)-ones 4-
butylamino-5,6-difluoropyridazin-3(2H)-one 189a and 4-benzylamino-5,6-difluoro-
pyridazin-3(2H)-one 190a were heated with an amine nucleophile under microwave 
irradiation at 150°C, even for extended periods of time of up to one hour, conversion to the 
desired disubstituted product was observed to be less than 5% by LC-MS and 19F NMR of 
the crude reaction mixture. This was in contrast to the 4-secondary amino and 4-anilino 
derivatives, which generally reacted very efficiently in high yield under these conditions as 
described above. 
It was noted that methylation of the amine substituent NH allowed further 
substitution processes to proceed effectively. Thus, reaction of 4-(N-butyi-N-
methylamino )-5,6-difluoropyridazin-3(2H)-one 191a with n-butylamine (Scheme 2.11) 
yielded the disubstituted product 214 in good yield, confirming that this lack of reactivity 
was related to the degree of substitution on the amine substituent nitrogen, rather than any 
specific issues with a butyl or benzyl substituent. This suggests that secondary amine 
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substituents at the 4-position allow further nucleophilic displacements to proceed whilst 4-
primary amino pyridazin-3(2H)-ones are unreactive towards further substitution. 
+ 
H2N~ 
MW, 150°C, 80 min 
MeCN 
191a 
Scheme 2.11 
The possibility of an unfavourable conformation ofthe pendant alkyl chain blocking 
further substitution was not supported by examination of the crystal structure. It was 
postulated that an intramolecular hydrogen bond between the primary amino NH and the 
adjacent pyridazin-3(2H)-one C=O may force the alkyl chain into a position that blocks the 
remaining fluorine atoms (Figure 2.1 Oa). Such a hydrogen bond would, of course, not be 
present if the substituent was derived from a secondary amine. However, there was no 
evidence for the presence of such a hydrogen bond in the solid state (Figure 2.10c), and this 
would be even less likely under the high temperatures used experimentally. MM2 
molecular mechanics simulations also suggested that in the minimum energy conformation 
of this molecule there was minimum steric influence by the pendant alkyl group (Figure 
2.10b) 
~ ~ FnN,H FnN,H I I I I 
N " I N " I 
'N 0 'N 0 
a) H H b) 
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c) 
Figure 2.10: a) Postulated deactivated conformation of 4-primary amino pyridazin-3(2H)-
ones; b) MM2 molecular mechanics minimum energy coriformation of 4-(butylamino)-5,6-
di.fluoropyridazin-3(2H)-one 189a c) X-rey crystal structure of 4-(benzylamino)-5,6-
difluoropyridazin-3(2H)-one 190a showing no evidence of intramolecular hydrogen 
bonding; 
Another explanation that is unlikely is deprotonation of the NH of the amine 
substituent by the nucleophile. 1H NMR of the 4-butylamino 189a, 5-butylamino 189b and 
4-morpholino 194a pyridazin-3(2H)-one derivatives in CD3CN were measured before and 
after the addition of diethylamine as a potential base. This showed the disappearance of the 
ring NH signal at approximately 1 0 ppm due to rapid exchange in all three cases, but the 
amine substituent NH was unaffected, suggesting that it was not sufficiently acidic to be 
deprotonated to any significant extent under these conditions (Scheme 2.12). It is unlikely 
that the pKa of an amine substituent will be such to allow deprotonation by another amine. 
Ff HNEt2 Ff FnNH CD3CN, rt FnNH 
N,N 0 N,N 0 
H e 
189a 
F ("o HNEt2 F ("o FnNJ CD3CN, rt FnNJ 
N,N 0 N,N 0 
H e 
194a 
Scheme 2.12 
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A simple consideration of the inductive electron donating character of these groups 
cannot explain this observation, as a secondary amine substituent could be expected to be a 
more powerful electron donor than a primary amine, due to its two electron donating alkyl 
groups. 
An analysis of the 13C NMR chemical shifts of various 4-substituted-5,6-
difluoropyridazin-3(2H)-ones (Table 2.8) suggests that the primary amino substituted 
derivatives are in fact the most electron rich. The C5 carbon, which is the site most 
reactive towards nucleophilic displacement, of 4-secondary amino and 4-bromoanilino 
derivatives are up to 6 ppm deshielded relative to 4-primary amino derivatives. 
Substituent 13C li 5- position I ppm Substituent 13C li 5- position I ppm 
~NH 131.2 NEt2 136.5 
BuNH 130.8 D 132.2 Ph~NH 131.7 HN 
~N/ 136.5 fY 131.9 
HN 
~N....__ 135.0 
OBr 0 136.2 137.4 HN 
H 
OF (0) 132.6 137.0 HN 
N 
Table 2.8 
The observation that the 4-primary amino pyridazin-3(2H)-ones are more electron 
rich than 4-secondary amino pyridazin-3(2H)-ones is likely to be a stereoelectronic effect. 
A small primary amine substituent with a single alkyl chain can easily be oriented in the 
same plane as the pyridazin-3(2H)-one ring, whilst steric repulsion between the two alkyl 
substituents of a secondary amine and the adjacent C-F and C=O bonds is likely to force 
the amine substituent to be twisted out of the plane ofthe pyridazin~3(2H)-one ring. This 
will lead to better orbital overlap in the case ofthe in-plane primary amine substituent, so in 
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fact these less sterically bulky substituents act as more effective electron donating groups, 
and render the pyridazin-3(2/:1)-one ring less electron deficient, so less reactive towards 
nucleophilic substitution. 
This twisting of the alkyl substituent was observed in the crystal structure of 5,6-
difluoro-4-(piperidin-1-yl)pyridazin-3(2/:1)-one, shown by the torsion angle between C 1 
and C5 on the diagram, which is 50°, and C3 and C9, which is 15°. If the two rings were in 
the same plane, these two torsion angles would be expected to have the same value. This 
twisting, therefore, means there is less effective orbital overlap in this secondary amine 
substituted system, so it is a worse electron donor, and therefore less deactivating towards 
further nucleophilic substitution. 
a) 
F F.~~ ~ H 0 
b) 
More efficient 
electron donor 
Figure 2.11: a) X-ray crystal structure of 5,6-difluoro-4-(piperidin-1-yl)-pyrid-azin-3(2H)-
one 193a; b) Postulated conformations and orbital interactions in 4-primary amino and 4-
secondary amino pyridazin-3(2H)-ones 
A similar stereoelectronic effect is observed in the basicity of dimethylaniline 
derivatives150• o-Dimethylaminotoluene 216 is a stronger base than dimethylaniline 215 by 
almost I~pK-unit, much~n1ore-than-coitl0-"be-expected~by-the inductiveelectrori donation of 
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the ortho methyl substituent (Figure 2.12). This observation has been explained by a steric 
interaction between the methyl and amine substituents impeding resonance delocalisation 
of the nitrogen lone pair into the aromatic ring and therefore increasing the basicity of o-
dimethylaminotoluene 216. 
6"' 
215 
pKaH 5.1 
M•D"' 
216 
pKaH 5.9 
Figure 2.12 
It was thought that Lewis acid activation may reduce electron density on the ring, 
and thus allow the second substitution process to proceed. However, on addition of 
BF3.Et20 to 4-benzylamino-5,6-difluoropyridazin-3(2/1)-one 190a, followed by reaction 
with diethylamine at reflux, only the starting material was obtained (Scheme 2.13). 
F ~ F~~~ 
~'N~O 
H 
190a 
2. NHEt2 , THF, reflux 
Scheme 2.13 
Starting 
Material 
2.5.4 Substitutions on 5-Substituted-4,6-Difluoropyridazin-3(2H)-ones 
Although the major products of monosubstitution with amine nucleophiles in all 
cases were substituted at the 4-position, several of the corresponding 5-monosubstituted 
isomers could be successfully isolated. Reactions of 4,6-difluoro-5-morpholinopyridazin-
3(2/1)-one and 5-(butylamino)-4,6-difluoropyridazin-3(2/1)-one with nucleophiles have 
been examined. 
4,6-Difluoro-5-morpholinopyridazin-3(2/1)-one 194b reacted with amine 
nucleophiles in moderate to good yield at the most activated 4-position to give the 4,5-
disubstltuted derlvative~~at7 and 2t8 (S-chem~2.14). The isolated yield was reduced when 
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diethylamine was used as nucleophile compared to n-butylamine, due to steric hindrance of 
attack of a bulky secondary amine nucleophile ortho to a bulky ring substituent. 
Co) Co) N H 
N F,r.:c~ FnF MeCN + ~NH2 N,N 0 ~'N 0 MW, 150°C, 15 min H 
H 217,96% 
194b 
0 
Co) C) ( 
N FnN~ FnF MeCN + /'N~ N,N 0 ~'N 0 H MW, 150°C, 15 min H 
H 218,50% 
194b 
Scheme 2.14 
In contrast to the 4-primary amino pyridazin-3(2H)-ones which were completely 
unreactive towards further nucleophilic displacements, 5-(butylamino)-4,6-
difluoropyridazin-3(2H)-one 189b reacted, albeit very slowly upon prolonged heating, with 
a second equivalent of n-butylamine to give the 4,5-disubstituted product 219 (Scheme 
2.15). Extended microwave irradiation at 150°C for 3 hours gave 65% conversion to the 
disubstituted product by 19F NMR, which could be isolated by mass directed automated 
purification in moderate yield. 
~NH 
F~F 
~'N~O + ~NH2 
H 
189b 
MeCN 
MW, 150°C, 3h 
Scheme 2.15 
~NH 
F~~~ 
~'N~O 
H 
219,45% 
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2.5.5 Reaction of Monosubstituted Pyridazin-3(2H)-ones with Oxygen Nucleophiles 
Both 4-morpholino-5,6-difluoropyridazin-3(2H}-one 194a (Table 2.9) and 4-(4-
bromophenyl-amino )-5,6-difluoropyridazin-3(2H}-one 198a (Table 2.1 0) were reacted with 
a range of sodium alkoxide and phenoxide salts using THF as solvent. 
Although the decomposition that occurred on reaction of 4,5,6-trifluoropyridazin-
3(2H}-one was not observed, conversions to disubstituted products were still extremely 
low, even after extended reflux or microwave irradiation periods and, in several cases, 
mixtures of 4,5- and 4,6-disubstituted products were obtained. Product isolation was 
difficult in all cases, due to the low conversions and difficult separation of regioisomers, 
and was accomplished in low isolated yield by mass directed HPLC. 
F ("o 
F~N~ + RONa ~'NAo 
Br 
H 
194a 
Nucleophile 
't 
ONa 
r(YONa 
~ 
Conversion(%) 
50 
0 
48 
THF 
reflux, 3d 
Yield 5- isomer 
Qo [a 
F~N~ ~'NAo 
H 
220a, 19% 
Br~ 
~o ('o 
F~N~ 
~'NAo 
H 
221a, 23% 
a Isomer ratios determined by integration of crude 19F NMR spectra 
Table 2.9 
Yield 6- isomer Ratio 5:6- Isomers a 
68:32 
100:0 
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Br Br ¢ ¢ F OR 
THF Ft.:c + RONa MW, 120°C FnNH + N,N 0 N,N 0 
H H 
198a 
Nucleophile Conversion (%) % 5-isomer %&-isomer 
0 0Na 
Qo [o QF fo 
7 FnN~ OnN~ 
N,N 0 N,N 0 
H H 
222a* 222b* 
~ F ('o O~N~ 
~'N~O 
~ON a 21 
H 
223a* 223b, 9% 
~ON a 
v 12 
~ ~no H F N ""=: 
N OUBr 
H 
224a, 7% 
-1-oNa o 
a Isomer ratios determined by integration of crude 19F NMR spectra 
* Not isolated 
Table 2.10 
Br ¢ F ORaNH 
'N 0 
H 
Ratio 5:6- Isomers a 
40:60 
19: 81 
100: 0 
It is likely that this lack of reactivity is due to the presence of the acidic pyridazin-
3(2/f)-one ring NH which may interact with relatively basic alkoxide nucleophiles, which 
deactivates the system towards nucleophilic aromatic substitution. With extremely 
hindered, and highly basic nucleophiles such as sodium tert-butoxide, no conversion is 
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observed. This is likely to be due to the bulky tert-butoxide acting exclusively as a base, 
rather than a nucleophile, as proton abstraction is a less sterically demanding process. 
Ring deprotonation may lead to the observed decrease in regioselectivity compared 
to the amine nucleophiles, as nucleophilic substitution on a deactivated negatively charged 
system is more likely to give the thermodynamic 4,6-disubstituted product. 
2.6 Displacement of Fluorine from 6-Fiuoro-4,5-diamino Pyridazin-3(2H)-one Systems 
The displacement of the final ring fluorine from 5-(benzylamino)-6-fluoro-4-
morpholinopyridazin-3(2H)-one 203 and 5-( diethylamino )-6-fluoro-4-morpholino-
pyridazin-3(2H)-one 205 was attempted using amine or alkoxide nucleophiles under 
forcing microwave irradiation conditions, however it did not proceed to any appreciable 
extent (Scheme 2.16). With highly reactive nucleophiles such as thiolate anions, the 
desired trisubstituted product could be observed by LC-MS in trace quantities (< 5%), but 
was not isolable. The fluorine atom at the 6-position of 4,5-disubstituted pyridazin-3(2H)-
ones is therefore resistant to nucleophilic attack under the conditions investigated. 
Ph Ph 
HN) ("o MeCN HN) ("o + NaSMe II ... Fx~c~ MW, 150°C, 1h Me/S,(~(~ 
N,N 0 N,N 0 
H H 
203 225, < 5% conversion 
lNJ ("o MeCN lNJ ("o Fx~:c~ + NaSMe MW, 150°C, 1h M•/SX~(~ 
N,N 0 N,N 0 
H H 
205 226, < 5% conversion 
Scheme 2.16 
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2.7 Conclusions 
4,5,6-Trifluoropyridazin-3(2H)-one has proven to be an excellent scaffold for the 
synthesis of nitrogen functionalised pyridazin-3(2H)-ones. An array of 4,5-disubstituted 6-
fluoro pyridazin-3(2H)-ones have been synthesised starting from tetrafluoropyridazine. 
Acid hydrolysis of tetrafluoropyridazine affords 4,5,6-trifluoropyridazin-3(2H)-one in 
excellent yield, which has then been reacted with a range of nucleophilic species to 
examine its reactivity towards nucleophiles. A selection of some of the systems 
synthesised are shown in figure 2.13. 
F H ~ 
·tiO ·ix~u ·i~c~ NH ~'N 0 I .0 F N,N 0 
·n· N,N 0 H ~'N 0 H H 
H 
lNJ ('o lNH fo ls ~NH 
ix" ix" FixN__) FixN__) F N ~ F N ~ 
N O'OBr N O'OBr N,N 0 'N 0 
H H H H 
Figure 2.13 
Monosubstitution reactions of 4,5,6-trifluoropyridazin-3(2H)-one with a broad 
selection of nitrogen nucleophiles proceed to give a mixture of 4- and 5-substituted 
regioisomers, which are readily separable. The regioselectivity of such monosubstitution 
reactions increases as the soft electronic character of the nucleophile increases, being 
highest for anilines (up to 96: 4 in favour of 4-isomer). 
The second substitution proceeds regioselectively at the 5-position for the 4-
morpholino and 4-bromoanilino pyridazin-3(2H)-one systems in reactions with a range of 
amines. With bulky nucleophiles such as secondary amines or anilines, yields can be 
reduced, and in some cases some 4,6-disubstituted product may result from substitution of 
the less sterically hindered 6-position. 
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However, difluoro-pyridazin-3(2H)-ones functionalised with a primary amine 
substituent at the 4-position are unreactive towards a second substitution step. This effect 
is thought to be stereoelectronic in origin, resulting from effective donation from the amine 
lone pair into the aromatic system. 
Also, both 4,5,6-trifluoropyridazin-3(2H)-one and monosubstituted systems fail to 
give substitution products in high yield in reaction with basic nucleophiles, such as 
alkoxides. This is likely to be due to deprotonation of the acidic pyridazin-3(2H)-one ring 
NH, which either deactivates the system towards further substitution, or in the case of 
4,5,6-trifluoropyridazin-3(2H)-one leads to decomposition. 
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Chapter 3 
Chemistry of N-Functionalised Polyfluoropyridazin-3(2H)-one 
Derivatives 
3.1 Introduction 
Although 4,5,6-trifluoropyridazin-3(2/i)-one proved to be an excellent scaffold for 
regioselective functionalisation in reactions involving amines, reactions with nucleophiles 
such as alkoxides and Grignard reagents were limited by the basicity of the nucleophile. It 
is thought that interaction of the base with the relatively acidic pyridazin-3(2/i)-one ring 
NH leads to deactivation of the system towards substitution, or to decomposition or 
polymerisation of the starting material. 
We expect that alkylation of the ring NH to prevent competing deprotonation will 
allow the potential range of nucleophiles compatible with this system to be expanded. A 
suitable protecting group should be identified that can be easily introduced, is stable to the 
reaction conditions and can be readily removed when no longer required (Scheme 3.1). A 
similar range of nucleophilic substitutions will be performed on the protected derivatives as 
described in Chapter 2, however the reactions of alkoxide nucleophiles in particular will be 
examined to determine the feasibility of efficiently introducing oxygen substituents onto 
the ring. 
F 
F~F 
~,N_,.lo 
H 
F 
_P_ro_te_ct---1~ F~F 
~,N_,.lo 
I 
R 
Nuc1 Nuc2 Nu-~----1~ F~Nuc1 _o_e_pr_o_te_ct--. 
Scheme 3.1 
~,N_,.lo 
I 
R 
The only report of N-alkylation of 4,5,6-trifluoropyridazin-3(2/i)-one 182 was 
described by Chambers et a/. in 1968, utilising diazomethane as the alkylating agent 
(Scheme 3.2). This produced the corresponding N-methylated compound 227a in good 
yield, along with the a-methylated compound 227b in a 3 : I ratio. 
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F F F 
F'(:( CH2N2 Fi~( F'(~( ~'N 0 ~'N 0 + ~,N....-: o,Me Et20, 20°C 
H I Me 
182 227a, 60% 227b, 20% 
Scheme 3.2 
However, the use of diazomethane presents a serious toxicity and explosion hazard, 
and its safe use requires specialist equipment. It was therefore decided to seek out 
alternative strategies for the N-alkylation of 4,5,6-trifluoropyridazin-3(2/1)-one, and these 
are described in the forthcoming sections. 
3.2 Attempted Alkylation of 4,5,6-Trifluoropyridazin-3(2H)-one 
Attempted reaction of 4,5,6-trifluoropyridazin-3(2/1)-one 182 with the strong 
alkylating agents benzyl bromide and methyl iodide in acetonitrile under microwave 
irradiation at 150°C returned only the starting material (Scheme 3.3). It can therefore be 
considered that the ring NH of 4,5,6-trifluoropyridazin-3(2/1)-one 182 is not sufficiently 
nucleophilic to react with a range of alkyl halide electrophiles. 
F~F 
~'N~O 
H 
182 
BnBr/ Mel 
Starting Material 
MeCN Only 
MW, 150°C, 30 min 
Scheme 3.3 
A potential method of activating the pyridazin-3(2/1)-one ring NH is by 
deprotonation with base to give a nitrogen anion, which will have higher nucleophilicity 
than the uncharged species. A range of bases were employed to effect the deprotonation, 
and several alkyl and acyl electrophiles were tested as potential trapping partners (Table 
3.1 ). The electrophile was used in excesses up to 10 equivalents in an attempt to effect the 
desired transformation but, in all cases, a brown emulsion was obtai~e<j p_n a_ql!_e~ms W()fkl!P 
--:: -- - -_ -- --~-- ------=- . - --
- . ·- - ---
that could not be dispersed on increasing salt concentration or sonication. The desired 
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alkylated product was observed in trace quantities (1-2 %) by GC-MS and the reaction 
mixture was complex and the major reaction components could not be identified. 
F F Fi.:( Base Fi.:( ~'N 0 RX II ~ < 5% conversion 'N 0 
H I 
182 R 
Base Conditions Electrophiles Used 
LOA -78°C to 0°C, THF BnBr, Mel 
NaH 0°C, THF BnBr,Mel 
NaHC03 0°C, THF Mel, Me2C03, Me2S04, AcCI 
NaOEt 0°C, THF Mel 
Table 3.1 
It seems likely that the decomposition process observed with basic nucleophiles is 
occurring on deprotonation, and that this process is much more rapid than reaction with the 
electrophile, even when this is present in large excess. 
4,5,6-Trifluoropyridazin-3(2H)-one has been shown to be extremely base sensitive 
and it is incompatible with bases as weak as sodium hydrogen carbonate. Basic conditions 
should therefore be avoided in any N-functionalisation strategy. 
3.3 N-Arylation of 4,5,6-Trifluoropyrldazin-3(2H)-one 
N-Arylated pyridazin-3(2H)-one derivatives are potentially very desirable systems 
as the introduction of anN-aryl group offers an additional point of molecular diversity, and 
many N-aryl oxy-heteroaromatics are known to be biologically active. Protection of the 
pyridazin-3(2H)-one ring NH by N-arylation is another potential solution to the difficulties 
encountered with the decomposition of 4,5,6-trifluoropyridazin-3(2H)-one in the presence 
of base. 
The N-arylation of various substituted pyridazin-3(2H)-one derivativce~, inclu~ing 
4,5,6~trichloropyridazin-3(2H)-one and 4,5-dichloropyridazin-3(2H)-one 88, has been 
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reported using lead (IV) acetate and a range of benzene derivatives (Scheme 3.4)151 • The 
use of substituted benzene derivatives results in the formation of a mixture of ortho 228a 
and para 228b substituted regioisomers but if benzene itself is used as the coupling partner 
then a single N-phenylated product necessarily results. 
;lc1 
~'N~O 
H 
88 
+ 
Pb(OAc)4 ~Me __ z_n_C_I2 ________ ~ 
~ Reflux 
Scheme 3.4 
Cl Cl 6:CI 6:CI 
NN 0 + NN 0 CrMe ¢ I 
Me 
228a, 32% 228b, 22% 
No mechanism was discussed but it is likely that this reaction proceeds via an 
aryllead intermediate 229 which undergoes nucleophilic displacement by the pyridazin-
3(2H)-one ring NH to give a disubstituted organolead compound 230, which can furnish 
the N-arylated product 231 by reductive elimination (Scheme 3.5). The role of the Lewis 
acid is likely to be in activating the acetate leaving groups on the organolead species. 
Ortho- and para-substituted products result from the initial ortho- and para-directed 
electrophilic substitution of lead tetracetate onto a substituted aromatic ring. 
Cl aCI Cl 
s 
Cl CC' N N: 0 CC' Hlo~ NN 0 NN 0 EAS Red. Elim. 6 A o~b-OAc o~b-OAc AcO-Pb-OAc - Pb(OAch I OAc OAc OAc 
229 230 231 
Scheme 3.5 
This process was examined as a possible strategy for the N-arylation of 4,5,6-
tritluoropyridazin-3(2H)-one 182 where benzene was chosen as the coupling_ pa,rtner. 
=-- - - - - ---- ·- - -
Conditions were screened to optimise the conversion of this reaction, in which 
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stoichiometry of lead(IV) acetate, zinc(II) chloride, as well as temperature and time were 
varied (Table 3.2). Microwave irradiation was used to allow rapid optimisation of 
conditions. Lead(IV) acetate (1.5 equivalents) and zinc(II) chloride (1.0 equivalents) were 
found to be optimal, but an increase in the reaction time or temperature had minimal effect 
on conversion. Conversions, which were determined by integration of crude 19F NMR 
spectra, were slightly reduced under standard thermal reflux conditions. 
F Pb(OAc)4 F FnF ZnCI2 FnF ~-N 0 Benzene ~-N 0 MW 
H 6 
182 232 
Equiv Pb(OAc)4 Equiv ZnCiz Tem~/°C Time/ min Conversion 
1.1 1.0 150 5 49 
1.5 1.0 150 5 64 
2.0 1.0 150 5 46 
1.1 1.5 150 5 52 
1.1 2.0 150 5 51 
1.5 1.0 150 10 63 
1.5 1.0 160 5 64 
1.5 1.0 170 5 58 
1.5 1.0 Reflux 960 55 
Table 3.2 
The reaction was scaled up to a 2g scale and the desired N-arylated product 232 
isolated in moderate yield (Scheme 3.6). Separation from the starting material and metal 
salts was carried out effectively by flash column chromatography on silica gel, which 
allowed unreacted starting material to be recycled. 
F F 
'ix' Pb(OAc)4 , ZnCI2 'ix' ~-N 0 Benzene ~-N 0 MW, 150°C 
H 6 
182 232,42% 
Scheme 3.6 
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Nucleophilic aromatic substitution processes of the N-phenyl pyridazin-3(21:1)-one 
232 were studied to examine its reactivity and to determine whether the aryl substituent 
affected regioselectivity. Sodium methoxide, benyzlamine and morpholine were chosen as 
representative examples of alkoxide, primary amine and secondary amine nucleophiles 
respectively. As for the unprotected pyridazin-3(21:1)-one, substitution reactions were 
carried out at room temperature in acetonitrile, using the same concentration (3.33 ~ol 
dm-3) to allow direct comparisons between the protected and unprotected compounds to be 
drawn. The exception to this methodology was the reaction with sodium methoxide, with 
which methanol was used as solvent to improve solubility of the nucleophile. 
F F Nuc 
Ft.xF 
MeCN 
Ft.xNuc Ft.xF + Nuc RT I + ~-N 0 N,N 0 N,N 0 I I Ph I Ph Ph 
232 
Nucleophlle Yield 4- Isomer a Yield 5- Isomer a Ratio 4:5- Isomers b 
F Me,0 
NaOMec Fi.xO'Me Ft.xF 
N,N 0 ~-N 0 
I 
Ph I Ph 
233a* 233b, 64% 
Ph 
F H l_NH 
Ph/"""-.NH2 
Ft.xN'-./Ph 
Ft.xF 
'N 0 ~-N 0 I Ph I 
Ph 
234a, 40% 234b, 30% 
(0) 
F ('o (o) 
Ft.xNJ 
N 
Ft.xF N N,N 0 ~-N 0 H I Ph I 
Ph 
235a, 58% 235b* 
a Isolated Yields 
b Isomer ratios determined by integration of crude 19F NMR spectra 
c Solvent used was methanol 
*Not-isolated 
Table 3.3 
7:93 
60:40 
85:15 
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The isomer ratios obtained with primary amines suggest that the N-phenyl 
substituent has a minimal influence on the reactivity of the system by comparison to results 
obtained for nucleophilic substitution reactions of unprotected 4,5,6-trifluoropyridazin-
3(2H)-one using the same nucleophiles and under identical conditions. For example, for 
benzylamine the ratio ofregioisomers is virtually unchanged between the unarylated and N-
phenylated pyridazin-3(2H)-ones (60 : 40 N-phenyl vs. 61 : 39 unarylated), whilst with 
morpholine selectivity is marginally increased (85 : 15 N-phenyl vs. 77 : 23 unarylated), 
although this is not significantly different. 
A significant change in regioselectivity on N-arylation would not be expected 
because it is not possible to stabilise the negative charge that develops in the Meisenheimer 
intermediates resultant from attack at either C4 or C5 by delocalisation onto the phenyl ring 
(Scheme 3.7). 
C4Attack 
F F F F 
FnF 
Fti Fti FixNuc ~'N 0 + Nuc I) Nuc ,. ._ ~ Nuc N,N 0 r:f:N 0 N,N 0 6 6 6 6 
CSAttack 
F 
FnF u ):): Nuc ~'N 0 F F F F FnF + Nuc I .. .. I I ~'N 0 6 N,N 0 N,N g 6~ 6 6 
Scheme 3.7 
N-Phenylation allowed the reaction of basic oxygen nucleophiles with the 
trifluoropyridazin-3(2H)-one ring system to proceed in high conversion. The use of sodium 
methoxide as nucleophile afforded the 5-methoxy compound 233b as major product with 
high regioselectivity (7 : 93). This is the opposite major product to that obtained with 
amines, which favoured substitution at the 4-position. This supports the hypothesis 
described in the previous chapter that the 5-position is the 'harder' site electronically and 
reacts preferentially with hard nucleophiles, whereas the 4-position is 'softer' and reacts 
92 
Chapter 3: Chemistry of N-Functionalised Polyjluoropyridazin-3(2H)-one Derivatives 
with soft nucleophiles. Oxygen nucleophiles are much harder than amines, so demonstrate 
high regioselectivity for attack at the 5-position. 
N-Phenylation has been shown to allow the reaction of 4,5,6-trifluoropyridazin-
3(2/f)-one with nucleophiles more basic than amines, such as alkoxides, as planned in the 
strategy. However, the procedure described here is not ideal for all applications. The use 
of toxic reagents such as lead tetraacetate and benzene will be discouraging to highly 
regulated industries, such as pharmaceuticals. Also, whilst N-arylation gives biologically 
interesting N-phenyl-pyridazin-3(2/f)-ones, it is not possible to remove the N-aryl group if 
a pyridazin-3(2/f)-one unsubstituted at nitrogen is desired. Consequently, other N-
protecting groups were sought. 
3.4 N-Protected Pyridazin-3(2H)-ones 
To allow the synthesis of oxygen containing pyridazin-3(2/f)-ones that are not 
functionalised at ring nitrogen, a readily removable protecting group was sought. Such a 
protecting group should not require basic conditions for its introduction, as the base 
sensitivity of 4,5,6-trifluoropyridazin-3(2/f)-one will most likely lead to its decomposition. 
The protecting group should not affect the reactivity of the pyridazin-3(2/f)-one ring too 
dramatically, should be able to be removed under mild conditions and must also be 
compatible with the necessarily basic conditions required in nucleophilic displacements. 
Consequently, protecting group introduction and removal under acidic conditions would be 
advantageous. 
Many standard amine protecting groups such as BOC, Fmoc, CBz and benzyl 
require basic conditions for their introduction. However, the tetrahydropyranyl group 
(THP), whilst traditionally known as an alcohol protecting group, is introduced using 
mildly acidic conditions and removed under more strongly acidic conditions. THP 
protection at the ring NH of pyridazin-3(2/f)-ones has been previously reported for the 
preparation of the N-tetrahydropyranyl derivative of 4,5-dichloropyridazin-3(2/f)-one 
(Scheme 3 .8) 152• 
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Cl 
Cl (:( cc 0 TsOH (cat) NN 0 + NN 0 0 THF, reflux 6 H 
88 236 
Cl Cl 6:CI 6:CI 
H+ 
N ~~0 NN 0 l{) 6 9 
Scheme 3.8 
We envisaged that an analogous procedure could provide a suitable strategy for the 
protection of 4,5,6-trifluoropyridazin-3(2H)-one 182 as its N-tetrahydropyranyl derivative. 
Reaction of 4,5,6-trifluoropyridazin-3(2H)-one with 3,4-dihydropyran in the presence of 
catalytic (8 mol%) p-toluenesulfonic acid yielded the desired 4,5,6-trifluoro-2-(tetrahydro-
2H-pyran-2-yl)pyridazin-3(2H)-one 237 in good yield (Scheme 3.9). An optimal reflux 
period of 3 hours was observed, shorter periods resulted in incomplete conversion, whilst 
longer reaction times provided an increased amount of an unidentified by-product. 
F FnF I + 
N,N 0 
H 
182 
THF, reflux, 3h 
TsOH (8 mol%) 0 0 
Scheme 3.9 
F 
F~F 60 
237,60% 
X-ray crystallography was used to confirm that protection had, indeed, occurred on 
the ring nitrogen, as opposed to the carbonyl oxygen (Figure 3.1). The use of the 
tetrahydropyranyl group as a nitrogen protecting group is relatively unusual, but its 
chemical properties make it ideal for our purpose. 
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Bond Bond Length I A Bond Bond Angle I 0 
C(1)-0(1) 1.2202 N(2)-C( 1 )-C(2) 113.31 
N(1 )-C(4) 1.2751 0( 1 )-C( 1 )-N(2) 122.93 
N(2)-C(1) 1.3893 C(1 )-N(2)-N(1) 125.59 
N(1 )-N(2) 1.3596 0(1)-C(1)-C(2) 123.76 
Figure 3.1 : X-ray Crystal Structure of 4,5,6-trifluoro-2-(tetrahydro-2H-pyran-2-yl)-
pyridazin-3(2H)-one 237 
4,5,6-Tritluoro-2-(tetrahydro-2H-pyran-2-yl)pyridazin-3(2l:l)-one 237 was then 
examined as a potential scaffold for sequential nucleophilic aromatic substitution reactions 
to determine the effect of N-alkylation on these processes (Table 3.4). The standard range 
of alkoxide and primary, secondary and aromatic amine nucleophiles were reacted under 
standard conditions, namely by stirring at room temperature in acetonitri le at a 
concentration of 3.33 llfllOl dm-3. These conditions are identical to those used in the 
monosubstitution reactions of 4,5,6-trifluoropyridazin-3(2!:1)-one, allowing direct 
comparisons to be drawn between the reactivity of the protected and unprotected 
derivatives. Products were identified as described previously in Chapter 2 by analysis of 
13C NMR Jcr coupling constants. 
The stability of the THP protecting group was shown to be high under the reaction 
conditions and the products were stable to column chromatography on silica. The one 
exception observed to this was in the reaction of N-THP-4,5,6-trifluoropyridazin-3(2!:1)-one 
with p-anisidine, with which a significant amount of the deprotected substituted product 
196a was observed. This is likely to be because p-anisidine is the weakest base of the 
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nucleophiles examined and so is the least effective at neutralising the HF formed as by-
product. IfHF accumulates this could lead to deprotection of the THP group. 
F F Nuc Nuc 
Ft.:( + Nuc 
MeCN, RT Fy):Nuc FnF Fy):Nuc ~'N 0 (2eq) N,N 0 + 'N 0 + N_N 0 
6 6 6 6 
237 
Nucleophlle Yield 4- isomer a Yield 5- isomer a Yield Disubstltuted 8 Ratio 4: 5: Di- isomers b 
F H Bu,NH 
~NH2 FUN'Bu FnF 
N,N 0 ~-N 0 
I 
THP I THP 
238a,46% 238b, 34% 
Co) F ("o FnN~ 
N N,N 0 H I 
THP 
239a* 
HN~c 
A 
H2N 
DOMe 'ix~'Cl ~-N 0 I h OMe 
I 
THP 
240a, 20%d 
OPh 
~ONa 
h 
FnF ~'N 0 
I 
THP 
241b* 
~0 
~ONa FnF ~-N 0 
I 
THP 
242b* 
a Isolated yields 
b Isomer ratios determined by integration of crude 19F NMR spectra 
c No conversion - starting material returned 
0 C) ('o 
FnN~ 
N,N 0 
I 
THP 
239c, 45% 
OPh 
FnOPh 
N,N 0 
I 
THP 
241c, 55% 
~0 
FnO~ 
N,N 0 
I 
THP 
242c, 35% 
d A significant amount of substituted, deprotected compound formed (protected : deprotected 40 : 60) 
• Solvent used was THF 
* Not isolated 
Table 3.4 
55:45:0 
12:0:88 
>95:0:0 
0:15:85 
0:34:66 
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The results obtained with butylamine again suggest that the substitution of the ring 
NH has a minimal effect on the selectivity of attack (55 : 45 protected vs. 57 : 43 
unprotected). Similarly, the use of aniline derivatives favours substitution at the 4-position 
with high regioselectivity. Indeed, in this case, the use of p-anisidine resulted in 
substitution at the 4-position exclusively, with no 5-substituted isomer being detected in the 
crude 19F NMR of the reaction mixture. 
However, with more reactive amine nucleophiles, such as morpholine, a tendency to 
form the disubstituted product was observed. This was unexpected, as it was thought that 
the presence of a second equivalent of amine nucleophile was required to neutralise the HF 
by-product of the reaction, so it was thought reaction with two equivalents of amine could 
only result in monosubstitution. However, various other basic sites are available, including 
amines on the product, and even the solvent acetonitrile is mildly basic. 
The reaction of alkoxide nucleophiles with this protected system was again feasible, 
and again reaction with two equivalents of nucleophile resulted in formation of mainly the 
disubstituted products. 
To obtain monosubstitution more selectively, the stoichiometry of the reaction was 
reduced to one equivalent of nucleophile in the reactions that gave significant amounts of 
disubstitution (Table 3.5). This resulted in the formation of mainly the desired 
monosubstituted products, although with alkoxide nucleophiles trace amounts of 
disubstituted products were again observed. The ratio of monosubstituted isomers obtained 
with morpholine was again similar to that obtained using the unprotected pyridazin-3(211)-
one (71 : 29 protected vs. 77 : 23 unprotected), demonstrating that NH protection has a 
minimal influence on regioselectivity. 
The major monosubstituted isomer obtained using alkoxide nucleophiles has been 
shown to be substituted at the 5-position. This is also in agreement with the hypothesis that 
this is the harder site electronically, as it is ortho to two highly electronegative C-F bonds. 
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F F Nuc Nuc 
FnF + Nuc MeCN, rt FixNuc FnF FixNuc 
N,N 0 (1eq) N,N 0 + ~-N 0 + N,N 0 
6 6 6 6 
237 
Nucleophlle Conversion I "'o Yield 4- isomer a Yield 5- isomer a Yield Disubstltuted a Ratio 4:5:01- Products b 
88 
F ("o 
FnN~ 
N,N 0 
I 
THP 
239a, 58% 
F 
FnO-..._./ 
N,N 0 
NaOEt 91 
I 
THP 
243a* 
a Isolated Yields 
b Isomer ratios determined by integration of crude 19F NMR spectra 
c Solvent used was EtOH 
• Not Isolated 
(o) 
N 
FnF ~-N 0 
I 
THP 
239b* 
/'-o 
FnF 
N,N 0 
I 
THP 
243b, 68% 
Table 3.5 
71 :29: 0 
/'-o 
FnO-..._./ 7: 80: 13 
N,N 0 
I 
THP 
243c* 
Deprotection of the THP group occurs readily under standard acidic THP 
deprotection conditions (Scheme 3 .I 0). Thus, reflux of a range of oxygen and nitrogen 
substituted N-THP pyridazin-3(2H)-ones m the presence of stoichiometric p-
toluenesulfonic acid in ethanol yielded the NH deprotected pyridazin-3(2H)-one in high 
yield. This strategy provides an efficient route to the unprotected pyridazin-3(2H)-ones, 
particularly those functionalised with oxygen substituents (e.g. 244). 
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OPh 
F~OPh 
~0 
241c 
TsOH 
EtOH, reflux, 8h 
0 
(N) ("o 
F~N~TsOH ~- •• ~ _E...:...tO-'-H-. -re-flu-x-, 8-h• 60 
239c 
3.5 Conclusions 
OPh 
F~OPh 
~-N~O 
H 
244,67% 
204,72% 
Scheme 3.10 
238b 
Bu,NH 
TsOH F~F 
~-N~O EtOH, reflux, 8h 
H 
189b, 77% 
Functionalisation of the acidic ring NH allows the range of potential nucleophiles 
compatible with these systems to be expanded to include nucleophiles of high basicity, 
such as alkoxides (Scheme 3.11 ). This has increased the potential substituent diversity that 
can be introduced into this system. 
Simple alkylation does not proceed due to the sensitivity of 4,5,6-tritluoropyridazin-
3(2/1)-one towards base, however N-functionalisation is feasible using a lead-mediated 
arylation reaction, or by acid catalysed THP protection. 
N-Protection does not alter the reactivity of the pyridazin-3(2/1)-one scaffold 
significantly, so similar ratios of isomers are obtained with and without protection. The use 
of alkoxide nucleophiles favours attack at the harder 5-position of the pyridazin-3(2/1)-one 
ring, compared to softer amine nucleophiles which favour attack at the 4-position. 
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F F 
F'(~( F 0 FnF Pb(OAch FnF 
'N 0 ZnCI2 0 'N 0 
6 Benzene 'N 0 TsOH (cat) 6 MW H THF, reflux 
232 182 237 
F OR FnF RONa FnF 
N,N 0 ROH, rt 
I 'N 0 
R I R 
R =Ph, THP 
Scheme 3.11 
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Chapter 4 
Syntheses of Ring-Fused Pyridazine Systems from 
Tetrafluoropyridazine 
Reactions of perfluorinated heteroaromatics with dinucleophilic species have the 
potential to yield ring fused systems. Previous work in the Durham group has been 
directed towards the synthesis of fused pyridine systems by reaction of pentafluoropyridine 
184 and substituted tetrafluoropyridine compounds with appropriate dinucleophiles 
including ethylenediamine and amidine derivatives (Scheme 4.1)153-155• The ring fused 
scaffolds produced possessed fluorine atoms which were also susceptible to displacement 
by nucleophiles to introduce substituent diversity. 
H F Me,Nl 
FnF 
Me_..N~N'Me 
FuN-Me NaOMe H 
I ""' NaHC03 MeOH F N F Reflux,2d 
Me,Nl Me,Nl 
---• FnN-Me-~=:=~:-::-t-- FnN-Me 
F N OMe Reflux, 2d EtO N"' OMe F N F MeCN, reflux, 5d 
184 
F 
F~F 
)L.~ 
F N F 
184 
245,97% 
Ph 
1. A 
H2N NH 
NaHC03 
MeCN, reflux, 16h 
2. LOA, THF 
-78°C to rt, 24h 
Ph 
HN~ 
FnN I~ 
F N"' F 
248,87% 
over 2 steps 
Scheme 4.1 
246, 76% 247, 77% 
THF/DMSO 
MW, 180°C, 30 min 
It can be envisaged that reaction of tetrafluoropyridazine with dinucleophiles should 
allow for the synthesis of ring fused pyridazine systems in a similar fashion. Again, 
displacement of the remaining fluorine atoms after annelation would yield substituted 
systems, allowing both skeletal and substituent diversity to be developed from a simple 
precursor (Scheme 4·:2). 
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Nues 
Scheme 4.2 
4.2 Reactions of Tetrafluoropyridazine with 1,2-Dinucleophiles 
I ,2-Dinucleophiles are species with nucleophilic functionality on adjacent carbon 
atoms, such as diamines, diols and dithiols, and would be expected to yield [6,6]-ring fused 
products on reaction with tetrafluoropyridazine. Examples of commercially available 1,2-
dinucleophiles are shown in Figure 4.1. 
H2N~NH2 HS~SH CtNH2 
SH 
H2N~OH HO~OH 
CtOH 
H2N~SH OH 
Figure 4.1 
4.2.1 Nitrogen Containing 1,2-Dinucleophiles 
Reaction of tetrafluoropyridazine 181 with ethylenediamine (Scheme 4.3) gave an 
uncyclised amine derivative 250 at room temperature, which was not isolated but was 
observed by 19F NMR. The intermediate product underwent cyclisation on heating to give 
a mixture of two ring fused systems, the major regioisomer 251a being cyclised at the 4-
and 5-positions, with a small amount (14% ofthe crude reaction mixture by 19F NMR) of 
the 3,4-cyclised derivative 251b. The major product was identified by the observation of 
only one resonance in its 19F NMR spectrum and similar equivalences in its 1H and 13C 
NMR spectra due to its symmetry. 
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NaHC03 
MeCN,rt 
H2N~NH nHNl 
n 
_R_e_flu_x ___ F '-"::: NH 
F I '-"::: F I + 
N,N....:: F 
N,N-" F 
250 
19F NMR 
-92.3 
-104.0 
-156.8 
Scheme 4.3 
251a, 26% 
ISOMER RATIO 86 
251b 
14 
Use of a secondary diamine derivative, .N,N'-dimethylethylenediamine, yields the 
4,5-cyclised product 252 exclusively in good yield (Scheme 4.4). In this case the reaction 
proceeds at room temperature and uncyclised product is not observed on monitoring the 
reaction by 19F NMR. 
181 
NaHC03 
MeCN, rt 
Scheme 4.4 
The increased selectivity in the case of N,N'-dimethylethylenediamine is most likely 
due to the milder reaction conditions required to achieve cyclisation, ensuring that the 
kinetic product is formed exclusively via reaction at the two most activated sites para to 
ring nitrogen. At reflux temperature, which is required to achieve cyclisation using the less 
nucleophilic ethylenediamine, some of the 3,4-cyclised product 251b is formed which is 
likely to be more thermodynamically stable for steric reasons. Less selectivity is observed 
at higher reaction temperatures. 
It would appear reasonable to suggest that these cyclisations proceed via initial 
nucleophilic attack of a single amine, followed by an intramolecular 6-exo-trig cyclisation 
of the second nucleophilic group preferentially onto the most activated site para to ring 
nitrogen, which also has an activating ortho-tluorine. 
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4.2.2 Sulfur Containing 1,2-Dinucleophiles 
Similarly to the reactions with diamine derivatives, reaction oftetrafluoropyridazine 
with ethane- I ,2-dithiol yields a symmetrical cyclised derivative 253 as a single regioisomer 
at room temperature in acetonitrile (Scheme 4.5). The use of reactive thiol nucleophiles 
ensure that the reaction proceeds efficiently and that no uncyclised product is observed by 
19F NMR analysis. 
/"-.. .SH 
+ HSr "-../' 
MeCN, rt 
Scheme 4.5 
4.2.3 Oxygen Containing 1,2-Dinucleophiles 
sl Fn~ s 
N /.: 
'N F 
253,85% 
Diols were not sufficiently nucleophilic to react with tetrafluoropyridazine, even at 
reflux temperature, for example, reflux of ethylene glycol with tetrafluoropyridazine in 
THF returned only the starting materials. Therefore, activation of either the 
tetrafluoropyridazine electrophile or the diol nucleophile is required to achieve substitution. 
It is known that, in the presence of concentrated strong acid, protonation of 
tetrafluoropyridazine occurs at ring nitrogen to form the tetrafluoropyridazinium cation133, 
which has been shown to react with oxygen nucleophiles at the 3-position and this approach 
was used in the synthesis of 4,5,6-trifluoropyridazin-3(2H)-one. It could, therefore, be 
envisaged that reaction of tetrafluoropyridazine with a diol in concentrated sulfuric acid 
could lead to substitution at the 3-position. 
This was indeed the case on reaction of tetrafluoropyridazine with ethylene glycol 
in concentrated sulfuric acid which yielded a 3-substituted pyridazine 254, but a significant 
amount of 4,5,6-trifluoropyridazin-3(2H)-one 182 was also produced in the reaction, 
formed by hydrolysis from water present in the sulfuric acid (Scheme 4.6). 
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F F F FnF cone. H2S04 FnF FnF + HO~OH ~'N 0 0°C ~,N...-:: O~OH + N,N...-:: F 
H 
181 Isolated Yield 254,25% 182,30% 
NMRYield 44% 52% 
Scheme 4.6 
The uncyclised alcohol could most likely be transformed into the annulated 
derivative by reaction with strong base to achieve deprotonation, but the low yield 
precluded development ofthis strategy. 
An alternative strategy for the synthesis of cyclised derivatives by reaction of 
tetrafluoropyridazine with diols is via activation of the nucleophile by deprotonation with 
strong base. This was achieved initially using n-BuLi to deprotonate ethylene glycol and 
catechol (Scheme 4.7). Annulated products 255 and 258 were obtained but nucleophilic 
attack by Bu- was also observed in significant amounts, rendering the reaction mixture 
relatively complex. 
F ~ FixF HOD Buli Bu Bu 0 .. FixF FixBu I + THF, -7S°C 0'(-;( N,N...-:: F HO ,:; + I + I ~ 
N,N...-:: F N,N...-:: F N,N...-:: F 
181 255,59% 256 257 
+ other unidentified 
by products 
F ("o FixF HO) Buli .. 0'(-;( I + 
N,N...-:: F HO THF, -7S°C N,N...-:: F 
181 258 
Scheme 4.7 
The formation of these by-products was prevented by the use of sodium hydride as 
base, which is non-nucleophilic and in this case the cyclic derivative 255 was produced in 
good yield (Scheme 4.8). 
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F F FnF CCOH NaH FnO:o ~'Nh F + OH THF, 0°C N h I~ 'N 0 
181 255,75% 
Scheme 4.8 
It should be noted that the cyclic derivative 255 produced in this case had 
undergone annulation between the 3- and 4-positions, the opposite regioisomer to that 
observed with nitrogen and sulfur nucleophiles. This was confirmed by the lack of 
symmetry observed in its NMR spectra, displaying two separate 19F resonances at 
-96 ppm, characteristic of fluorine ortho to ring nitrogen, and -152 ppm that is not 
deshielded by ortho ring nitrogen. 
To probe the mechanism of this unexpected result, tetrafluoropyridazine was 
reacted with sodium phenoxide to determine whether initial nucleophilic attack occurred at 
the 3- or 4-positions with oxygen nucleophiles. The 4-phenoxy derivative 259 was 
produced selectively (Scheme 4.9), suggesting that these reactions proceeded via initial 
nucleophilic attack at the 4-position, followed by cyclisation onto the 3-position. The 
regiochemistry of this product was confirmed by examination of its 19F NMR spectrum, 
which showed the presence of two fluorine atoms deshielded by the ortho ring nitrogen at 
-86 and -95 ppm and a fluorine resonance at -140 ppm that is not ortho to ring nitrogen. 
F 
F~F + 
~'N~F 
181 
~OH 
~ 
NaH 
THF, 0°C 
Scheme 4.9 
F 
F~O~ 
~'N~F v 
259,68% 
To examine whether potential coordination of the basic pyridazine ring nitrogen to 
the cation of the salt is directing the regioselectivity of this process the reaction of 
tetrafluoropyridazine with N,N' -dimethylethylenediamine in the presence of n-BuLi was 
performed (Scheme 4.1 0). This simply yielded the 4,5-cyclised product 252 as was the 
case i!l_ the"ab~~ce <>f str<mg'--b~s~ wbLch.does not_support potentiaLcoordination.ofthe 
cation to the ring nitrogen directing substitution to the site ortho to itself. 
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Buli 
THF, -78°C 
Scheme 4.10 
The difference in regioselectivity observed with oxygen dinucleophiles is therefore 
most probably an electronic effect, in that the 'hard' oxygen anion cyclises preferentially at 
the 'hardest' site of the pyridazine ring. It is well established that the sites ortho to 
electronegative ring nitrogen in perfluorinated heteroaromatics are the hardest sites, and 
examples of preferential reaction of oxygen nucleophiles at these sites are known in the 
literature. For example, perfluoroisoquinoline 260 reacts selectively with sulfur 
nucleophiles at the 6-position to give 261, whilst harder oxygen nucleophiles undergo 
regioselective substitution at the !-position, ortho to ring nitrogen, to produce 262 (Scheme 
4.11)156. 
FWF"' ~ F + NaSH 
_., N F /./ ...-:: 
F F 
260 
Fw~ F I / N F __,__, ...-:: 
F F 
260 
MeOH 
F F 
HSw~F I / N F /./ ...-:: 
F F 
261, 88% 
_E_to_H _ _.. )c»· 
F 0~ 
~NO 
262,81% 2 
Scheme 4.11 
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4.2.4 Reactions of 4,5,6-Trifluoropyridazin-3(2H)-one with Dinucleophiles 
4,5,6-Trifluoropyridazin-3(2H)-one 182 was reacted with N,N'-dimethylethylene-
diamine under analogous conditions to those used with tetrafluoropyridazine to yield a 
single [6,6]-ring fused product 263 regioselectively, formed by cyclisation between the 4-
and 5-positions (Scheme 4.12). 
F F'!-F + ~'N~O 
H 
182 
H 
/N~N/ 
H 
MeCN 
rt 
Scheme 4.12 
Two 4-substituted difluoropyridazin-3(2H)-ones were also reacted with N,N'-
dimethylethylenediamine under microwave irradiation, which lead to replacement of both 
remaining fluorine atoms to provide non-halogenated products 264 and 265 (Scheme 4.13). 
The structure of264 was confirmed by X-ray crystallography (Figure 4.2) and showed the 
presence of hydrogen bonded dimers interlinked into chains by n-stacking interactions in 
the solid state. 
F ('o 
F~N_J + 
~'N~O 
H 
194a 
199a 
H 
/N~N/ 
H 
MeCN 
MW, 20min, 150°C 
MeCN 
MW, 30min, 150°C 
Scheme 4.13 
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02 
~ / ) 
-
_, I' 
'I \ \ 9 Bond Bond Length I A 
., ¥~- C(1 )-0(1) 1.2518 .,... -'! 
' N5 
N(1)-C(4) 1.3012 
".)( !"' 
N(2)-C(1) 1.3587 
N(1 )-N(2) 1.3589 
;·y'~ Bond Bond Angle I 0 N(2)-C(1 )-C(2) 115.92 0(1)-C(1)-N(2) 119.02 
C(1 )-N(2)-N(1) 126.79 
., 8' 0(1 )-C(1 )-C(2) 125.05 
Figure 4.2: X-ray Crystal Structure of 5,6, 7,8-tetrahydro-5,8-dimethyl-4-
morpholinopyrazino[2,3-c}pyridazin-3(2H)-one 264 
These reactions demonstrated that displacement of the final ring fluorine in 
pyridazin-3(2H)-one systems is feasible if the final displacement is an entropically 
favourable intramolecular reaction. As discussed earlier, 4,5-disubstituted 6-
fluoropyridazin-3(2H)-one derivatives were unreactive towards displacement of the fmal 
ring fluorine in intermolecular displacement reactions under the conditions described in 
Chapter 2. 
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4.3 Reactions of [6,6]-Ring Fused Scaffolds with Nucleophiles 
The [6,6]-ring fused products that arise from reaction of tetrafluoropyridazine and 
4,5,6-trifluoropyridazin-3(2/1)-one with 1,2-dinucleophiles have remaining fluorine atoms 
on their aromatic ring, so have the potential to participate in further nucleophilic aromatic 
substitution reactions. Reactions with primary, secondary and aromatic amines, alkoxide 
and thiolate nucleophiles were explored to determine the scope for further functionalisation. 
Both 5,8-difluoro-1 ,2,3,4-tetrahydro-1 ,4-dimethylpyrazino[2,3-d]pyridazine 252 
and 8-fluoro-1 ,2,3,4-tetrahydro-1 ,4-dimethylpyrazino[2,3-d]pyridazin-5( 6/1)-one 263 
proved to be unreactive towards further nucleophilic displacement reactions under the 
microwave irradiation conditions examined. Generally, only starting material was observed 
on analysis of the crude reaction mixture by LC-MS, however low conversions to the 
substituted products (< 20%) were observed in the case of reactive thiolate nucleophiles, 
although the substituted derivatives could not be isolated. 
+ 
HNEt2 
NaSMe 
HNEt2 
+ NaSMe 
NaOMe 
MeCN 
No Reaction 
MW, 150°C, 30min I Low Conversion 
MeCN 
No Reaction 
MW, 150°C, 30min I Low Conversion 
Scheme 4.14 
It is likely that in this case replacement oftwo electron-withdrawing fluorine atoms 
by two less activating nitrogen atoms deactivate the system sufficiently to make further 
substitution reactions difficult. 
The product of substitution of tetrafluoropyridazine by catechol 255 was also 
reacted With a range ofhucleopllilic species tifioer microwave irradiatfon ana in tfiis case 
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substituted derivatives were isolated in good yield with primary and secondary amines, as 
well as with the alkoxide nucleophile sodium methoxide (Table 4.1 ). 4-Fiuoroaniline was 
not sufficiently nucleophilic to react under these conditions, whilst sodium methanethiolate 
gave a complex mixture of mono- (270) and di- (269) substituted products that were 
inseparable (Scheme 4.15). 
F 
Fn"'=: OX) + 
N /- I / 
'N 0 _,_, 
MeCN Nuc Fn"'=: OX) 
N /- I / 
'N 0 _,_, 
Nuc 
MW, 150°C, 20min 
255 
Nucleophile Product Isolated Yield I % 
71 
80 
o* 
NaOMe 66 
* Starting Material Returned 
Table 4.1 
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SMe 
MeCN MeS~O 
NaSMe MW, 150°C, 20min ~'-~ )) 
N 0 
269 
NMRYields 48% 
Scheme 4.15 
+ F~O~ ~'N~O~ 
270 
31% 
Examination of the 19F chemical shifts of the substituted derivatives suggested that 
substitution had occurred at the 4-position, as the chemical shift of the remaining fluorine 
atom ranged from -86 to -93 ppm, which is characteristic of fluorine deshielded by adjacent 
ring nitrogen. 
A crystal structure of the 5-allylamino derivative 267 (Figure 4.3) confirmed both 
that these compounds underwent selective substitution at the 5-position, and that annulation 
had previously occurred between the 3- and 4-positions of the pyridazine ring in reaction 
with catechol. Again, networks held together in the solid state by hydrogen bonding and 1t-
stacking were observed. 
Bond Bond Length I A 
C(1 )-0(2) 1.3698 
C(2)-0(1) 1.3714 
N(1 )-C(1) 1.3172 
N(1 )-N(2) 1.3527 
C(4)-N(2) 1.301 
Figure 4.3: X-ray Crystal Structure of 3-F/uoro-4-a//ylamino-9, 1 0-dioxa-1,2-diaza-
anthracene 267 
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The dioxygenated annulated 255 derivative undergoes regioselective substitution at 
the 5-position of the pyridazine ring, para to activating ring nitrogen. It is likely that these 
derivatives are more reactive than the dinitrogen fused systems as oxygen is both more 
electronegative and a less effective electron donor than nitrogen. Also, the 3,4-dioxygen 
cyclised scaffold possesses a more reactive C-F bond para to activating ring nitrogen, 
whilst the 4,5-dinitrogen cyclised scaffolds possess only less activated C-F bonds ortho to 
ring nitrogen. This activating effect of para ring nitrogen is demonstrated in the increased 
reactivity of tetrafluoropyridazine 181 relative to tetrafluoropyrazine 272 (kpyridazine I kpyrazine 
~ 500), which has no fluorine atoms para to ring nitrogen (Scheme 4.16)157• 
F Dioxane I H20, rt NH2 F'(~( + NH3 krel = 496 FnF 
N /- N,N/- F 
'N F 
181 271 
F)[NXF 
Dioxane I H20, rt 
F)[NXNH2 + NH3 krel = 1 
F N F F N F 
272 273 
Scheme 4.16 
4.4 Reactions of Tetrafluoropyridazine with 1,1-Dinucleophiles 
1, 1-Dinucleophiles possess two nucleophilic functional groups attached to the same 
carbon atom and examples include amidines, amides, thioamides and 2-aminopyridines 
(Figure 4.4). They would be expected to yield [5,6]-ring fused systems on reaction with 
tetrafluoropyridazine. 
Figure 4.4 
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4.4.1 Reactions of Tetrafluoropyridazine with Amidine and Thioamide Derivatives 
Reaction of tetrafluoropyridazine with amidine dinucleophiles should yield [5,6]-
ring fused imidazopyridazine scaffolds that are potentially biologically interesting as 
pyridazine analogues of purines. 
Reaction of tetrafluoropyridazine with benzamidine hydrochloride in acetonitrile at 
reflux temperature in the presence of four equivalents of sodium bicarbonate yielded the 4-
substituted uncyclised amidine derivative 274 (Scheme 4.17). 
MeCN 
181 274,75% 
Scheme 4.17 
It was thought that treatment of this uncyclised amidine with strong, non-
nucleophilic base should allow for the synthesis of the cyclic derivative via a more 
nucleophilic deprotonated intermediate. A range of bases were reacted with the uncyclised 
amidine at 0°C in an attempt to effect the desired cyclisation. Reactions were performed on 
a 0.1g scale and were monitored by I9p NMR. n-BuLi and LiHMDS gave a complex 
product mixture, whilst LOA resulted in the formation of two new products. 
The reaction with LDA was scaled up in an attempt to allow product isolation and 
identification (Scheme 4.18). The desired cyclic scaffold 276 was observed in small 
quantities by GC-MS and 19F NMR, however, the reaction mixture was moderately 
complex. No products could be obtained cleanly, but NMR and GC-MS analysis suggested 
that the major component of the reaction mixture 275 had undergone nucleophilic attack by 
diisopropylamine as well as the desired cyclisation. It is not clear as to whether this 
nucleophilic attack occurred before or after cyclisation. 
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274 
NMRYield 
275 
56% 
Scheme 4.18 
276 
8% 
Furthermore, tetrafluoropyridazine was reacted with excess (2.5eq) benzamidine 
under microwave irradiation at 150°C for 50 minutes. This gave a complex reaction 
mixture from which products could not be isolated, but GC-MS suggested that the major 
component of the reaction mixture was a cyclic derivative 277 that had again undergone 
nucleophilic attack by a second equivalent ofbenzamidine. 
MeCN 
MW, 150°C, 50 min 
181 277 
NMR Yield 42% 
Scheme 4.19 
Therefore, a base of even lower nucleophilicity than diisopropylamine was required 
to allow the reaction to proceed without further nucleophilic attack. HOnig's base 
(diisopropylethylamine) was chosen because of its extreme steric demand, although its pKa 
(11.4) is unlikely to be sufficiently basic to allow deprotonation of the amidine, so 
microwave irradiation conditions were employed in an attempt to effect the cyclisation. 
Indeed, the desired cyclic derivative 276 was obtained in good yield after irradiation at 
180°C for 15 minutes (Scheme 4.20). 
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Ph Ph 
HNANH 
DIPEA HN~ MeCN FrrN FT:( MW, 180°C, 15 min ,~ ~'N~ F N,N~ F 
181 276,62% 
Scheme 4.20 
The product 276 was identified as an isomer cyclised between the 4- and 5-positions 
by the symmetry observed by NMR, due to tautomerism rendering both imidazole-type 
nitrogens equivalent. The 19F NMR signal was at -89 ppm, characteristic of fluorine ortho 
to deshielding ring nitrogen. 
The reaction of tetrafluoropyridazine with the cyclic amidine dinucleophile 2-
iminopiperidine yielded the tricyclic scaffold 278 at reflux in acetonitrile (Scheme 4.21 ). 
In this case no uncyclised amidine derivative was observed and the reaction proceeded 
under milder conditions than those observed with benzamidine due to the enhanced 
nucleophilicity ofthe cyclic system. 
181 
("! .HCI 
+ l_NANH 
H 
MeCN, reflux, 16h 
Scheme 4.21 
This derivative displayed two separate 19F NMR resonances as this is a non-
symmetrical system and the chemical shifts observed (-93 and -95 ppm) were both 
characteristic of fluorine ortho to ring nitrogen. It is not possible in this case to determine 
whether the piperidine or imine-like nitrogen attacked the pyridazine ring first due to the 
symmetry of the pyridazine ring system but related reactions involving pentafluoropyridine 
showed initial nucleophilic attack to occur through the piperidine ring nitrogen158• 
Reaction of tetrafluoropyridazine with thioacetamide proceeded to give the cyclic 
derivl!tiye __ 2'Z9 in a._singL~ step at_Jeflux in acetonitrile in the-presence ofsodium hydrogen 
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carbonate (Scheme 4.22). Milder conditions were required than for amidines due to the 
increased nucleophilicity of sulfur relative to nitrogen. 
MeCN, reflux 
Scheme 4.22 
Interestingly, compound 279 displayed unusual equivalences in its NMR spectra, 
showing a single 19F NMR resonance at -82 ppm and two 13C signals representing the four 
pyridazine ring carbons, suggesting that replacement of NH by S has a minimal influence 
on the NMR properties of the system and that this gives a spectrum that appears to be 
derived from a symmetrical system. 
4.4.2 Reaction of Tetrafluoropyridazine with 2-Aminopyridine Derivatives 
2-Aminopyridine derivatives possess an analogous I, 1-dinucleophile relationship to 
amidine derivatives and could be expected to form [5,6]-ring fused systems in a similar 
way. 
Indeed, reaction of tetrafluoropyridazine with 2-aminopicoline under microwave 
irradiation in acetonitrile yielded a novel tricyclic aromatic ring system 280, cyclised 
between the 4- and 5-positions (Scheme 4.23). Product identity and regiochemistry were 
again determined by 19F NMR, displaying resonances at -90 and -92 ppm, characteristic of 
fluorine deshielded by ortho ring nitrogen. 
F 
Fn~ F 
N /.: 
'N F 
181 
Scheme 4.23 
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The analogous reaction of tetrafluoropyridazine and 2-amino-5-bromo-3-picoline 
yielded the corresponding tricyclic derivative 281 (Scheme 4.24), but the electron 
withdrawing effect of the bromine had a significant effect on reactivity by reducing the 
nucleophilicity of the pyridine and a longer reaction time of 2 hours, compared to ten 
minutes in the absence of bromine, was required. 
+ BrlX MeCN 
N NH2 MW, 150°C, 2h 
2.5 eq 
181 
Scheme 4.24 
Monitoring of this reaction by 19F NMR at regular intervals showed the steady 
consumption of starting material and formation of the cyclised product, with no evidence of 
any intermediate uncyclised products. This suggested that the rate determining step of this 
reaction was the initial nucleophilic attack of the aminopyridine and this was followed by a 
rapid cyclisation step. It is not possible in this case to determine whether the amino group 
or pyridine ring nitrogen attacked the pyridazine ring first due to the symmetry of the 
pyridazine system, however the site of initial attack in pentatluoropyridine has been shown 
to be the pyridine ring nitrogen158• 
Introduction of further electron withdrawing groups onto an aminopyridine reduced 
nucleophilicity to levels where reaction did not proceed. For example, 2-amino-5-bromo-3-
nitropyridine was unreactive towards tetrafluoropyridazine (Scheme 4.25), and starting 
material was returned, even after microwave irradiation at 180°C for 20 minutes. 
Br~N02 MeCN 
+ ~ .. A 
N NH2 MW, 180°C, 20 min 
No Reaction 
Scheme 4.25 
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A Scifinder and Beilstein search (performed on 22/10/08) on this tricyclic 
tetraazafluorene ring system showed that only three examples of this heteroaromatic 
substructure have been reported in the literature100, ensuring that this is a potentially 
interesting scaffold for the synthesis of functionalised derivatives. 
It was observed that solutions of these tricyclic derivatives were highly fluorescent 
in UV light and so absorption and fluorescence UV spectra of 280 were measured (Figure 
4.5). Fluorescence spectroscopy gave the emission maximum at 360 nm, which is in the 
UV region of the electromagnetic spectrum, however a significant shoulder on this 
emission peak stretched into the blue visible region of the spectrum at around 400 nm, 
leading to the blue appearance of the samples under UV light. This fluorescence is likely to 
be due to the conjugated nature of this extended aromatic system. 
2.5 
1.5 
0.5 
100 200 300 400 500 600 700 
Wavelength I nm 
Figure 4.5: UV Absorption and fluorescence spectra of280 
4.5 Functionalisation of [5,6]-Ring Fused Scaffolds 
Again, all the [5,6]-ring fused scaffolds produced possess remaining ring fluorine 
atoms which may be susceptible towards nucleophilic displacement to obtain systems with 
- - " .. ,_- - . - -
--
a diverse range of functionality, as models for library synthesis of analogues. 
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4.5.1 Functionalisation of 1H-Imidazo[4,5-d]pyridazine Systems 
Reaction of 4,7-difluoro-2-phenyl-IH-imidazo[4,5-djpyridazine 276 with two 
equivalents of the nucleophiles n-butylamine and sodium methanethiolate (Table 4.2) 
yielded the corresponding disubstituted systems resulting from replacement of both 
remaining ring fluorine atoms. In the case of n-butylamine this required the second 
equivalent to act as a nucleophile, as opposed to a base to neutralise the HF formed as a by-
product in the reaction. 
Ph 
HN~ MeCN 
FtiN + Nuc 
I "'-'::: 2 eq. MW, 150°C, 20 min N,N...e: F 
276 
Nucleophile 
NaSMe 
Product 
282 
Ph 
HN~ 
MestiN 1'-':::: 
N,N-"' SMe 
283 
* Yield Reported with unidentified impurities 
Table 4.2 
Ph 
HN~ 
Nuc~N 
~-N~Nuc 
Isolated Yield 
35% 
32%* 
These results highlight the increased reactivity of these (5,6]-ring fused systems 
relative to the [6,6]-fused systems described in the earlier part of this chapter. This is 
because in the [6,6]-fused systems the nitrogen substituents are effectively two deactivating 
amine groups, whereas in the above [5,6]-imidazo-pyridazine the extra conjugation 
provided by the additional aromatic ring provides extra stabilisation to the negative charge 
that develops in the Meisenheimer intermediate on substitution (Scheme 4.26). 
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Ph 
HN-{~ 
+ Nuc--.. F~N 1"-'::: 
N, Nuc 
(_~ F 
+ Nuc --• 
Scheme 4.26 
Ph 
HN"t( 
F~N (~Nuc 
'N F 
'N~ 'N~ F~N, -F~N, 
~"~:t-Nuc ~---~ N F N Nuc 
Halogenation of the pendant phenyl ring attached to the heteroaromatic system 
would provide an additional diversity point for functionalisation. However, attempted 
bromination of the phenyl ring using elemental bromine and an iron catalyst in refluxing 
dichloromethane returned only the starting material (Scheme 4.27). It is likely that the 
attachment of a nitrogen rich heterocycle to the phenyl ring is sufficiently electron 
withdrawing to deactivate the system towards electrophilic substitution and render it 
unreactive under the conditions examined. 
DCM, reflux 
Scheme 4.27 
Starting Material 
Returned 
Similarly, the tricyclic ring fused scaffold 278 formed from reaction of 
tetrafluoropyridazine with the cyclic amidine 2-iminopiperidine reacts with nucleophiles 
under similar microwave irradiation conditions (Table 4.3). Reaction of scaffold 278 with 
morpholine and butylamine led to regioselective substitution, forming a single regioisomer 
in the case of morpho line. With the reactive sulfur nucleophile, sodium methanethiolate, a 
single monosubstituted product resulted, however a significant amount of disubstituted 
product was formed, resulting from r~pJI:!ce~nent of both ringJll!_ori_l}e __ '!~Qrns, -~hj~ was not 
~~- - -- - . __ _____:__ - __ . - - - - - - - ---
separable from the monosubstituted isomer by chromatography. The aromatic amine 
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nucleophile, aniline, was not sufficiently nucleophilic to effect the displacement reaction, 
and unsubstituted starting material was returned, even after extended microwave 
irradiation. 
Q MeCN Q Q 
FUN 
+ Nuc 
Fti 
+ 
NuctiN 
+ 
I": MW, 150°C, 20min I": 
N,N..-:: F N,N-" Nuc N,N..-:: F 
278 
Isolated Yield Ratio 1- Substituted Ratio 4- Substituted Nucleophile 1- Substituted Product Product Product 
56* 
72 
No Reaction 
NaSMe Not Isolated 
*Isolated as mixture of 1- and 4- monosubstituted regioisomers 
Table 4.3 
Q 
NuctiN 
N,N..-:: Nuc 
Ratio Disubstituted 
Product 
Q 
MestiN I": 
N,N..-:: SMe 
286c 
44 
The major isomer of the morpholino derivative 285a was shown to be substituted at 
the l-posH1on by X-ray crystallography (Figure 4.6), because definitive product 
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identification was extremely difficult by NMR. In the unit cell, a complex alternating 
arrangement of the tricyclic rings was observed that was held together by n-stacking and 
dipolar interactions. 
Bond Bond Length I A Bond Bond Length I A 
N(1)-C(4) 1.337 C(9)-C(8) 1.520 
N(1)-N(2) 1.376 C(8)-C(7) 1.523 
N(2)-C(1) 1.292 C(6)-C(7) 1.531 
C(1 )-C(2) 1.395 C(6)-N(5) 1.492 
N(4)-C(2) 1.372 N(5)-C(5) 1.323 
N(4)-C(9) 1.477 N(5)-C(3) 1.383 
C(3)-C(4) 1.428 
Figure 4.6: X-ray Crystal Structure of 4-.fluoro-1 -morpholin-4-yl-5,6, 7,8-tetrahydro-
2, 3, 4b, 9-tetraaza-.fluorene 285a 
Attack at this site allows delocalisation of the negative charge formed in the 
Meisenheimer intermediate around the whole imidazopyridazine ring system, whilst attack 
at C4 allows delocalisation only around the pyridazine ring (Scheme 4.28). Although 
crystal structures of the other derivatives could not be obtained, the similarity of their 
respective NMR spectra to this derivative would suggest that they too are substituted at the 
1-position. 
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Q 
F'¢iN I~ 
N,N-' F 
e Nuc 
Attack atC4 
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Q 
F'dN 
01 
P"~ 
N<:N F 
e Nuc 
Q 
.,. Fti/-N 
N, F 
'N Nuc 
NFn9N -~------ Q "' - ., Nu;j('N 
_1\J c F I 
tl'0'N F N~N F 
Scheme 4.28 
Q 
FrrN I~ 
N,N Nuc 
H 
Substitution of the thiazolopyridazine scaffold 279 was achieved successfully using 
morpholine as nucleophile (Scheme 4.29), but it is not clear without crystallography 
whether this compound underwent substitution adjacent to sulfur or nitrogen and, 
unfortunately, crystals suitable for X-ray diffraction could not be obtained. Isolated yields 
of both products were moderate due to significant formation of tarry by products and the 
use of several other nucleophiles including butylamine, sodium methanethiolate and aniline 
under identical conditions led to total decomposition of the starting material. 
+ 
279 
DIPEA 
MeCN 
MW, 150°C, 20min + 
287a 
Isomer Ratio 58 : 42 
Unclear which Product is Major Isomer 
Scheme 4.29 
4.5.2 Functionalisation of Tetraazafluorene Scaffolds 
Non-symmetrical tetraazafluorene scaffolds have the potential to give regioisomeric 
nucleophilic monosubstitution products by displacement of either fluorine atom. 1,4-
Diftyoro-8-methy1 .. 2;3,4b;9-tetraaza .. fluorene 180 reacts with- nucleophiles - under 
microwave irradiation in acetonitrile (Table 4.4) to give both substituted isomers, however 
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substitution is favoured at the 1-position, being almost exclusive in the case of 
diethylamine. In each case only the major isomer was isolated as a pure sample by 
chromatography or recrystallisation and characterised spectroscopically. 
Q- Q-~ Nuc (2.5 eq) N 
'\ ti" + F N MeCN F '"-':: N ti MW,150"C,10 min ~-
N,N F N Nuc 
280 
Nucleophile 
NaOMe 
Isolated Product 
Q-
F~N 
~'N~OMe 
288,40% 
290,70% 
Table 4.4 
Isomer Ratio 
76:24 
79: 21 
95:5 
The two possible regioisomers obtained from mono~ubstitution on tpis scaffold are 
difficult to distinguish by a simple consideration of their NMR spectra. X-ray 
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crystallography of the 1-diethylamino derivative 290 proved the structure of this compound 
(Figure 4.7), and the similarity of the NMR data of the other two derivatives to the known 
structure would suggest that they too are substituted at the 1-position. 
Bond Bond Length I A Bond Bond Length I A 
N(1)-C(1) 1.3409 C(9)-C(8) 1.3565 
N(1 )-N(2) 1.3719 C(8)-C(7) 1.4217 
N(2)-C(4) 1.2908 C(6)-C(7) 1.3681 
C(3)-C(4) 1.3954 C(6)-C(5) 1.4216 
N(3)-C(3) 1.3802 N(4)-C(5) 1.3356 
N(3)-C(9) 1.3794 N(4)-C(2) 1.3732 
C(2)-C(1) 1.4388 
Figure 4. 7: X-Ray Crystal Structure of Diethyl-(4-jluoro-8-methyl-2,3,4b,9-tetraaza-
.fluoren-l-yl)-amine 290 
This regioselectivity can be explained by a consideration of the mechanism of this 
process. Attack at C 1 allows the negative charge in the Meisenheimer intermediate to be 
delocalised around the whole tricyclic aromatic system, whilst attack at C4 allows charge to 
be delocalised only around the pyridazine ring (Scheme 4.30). The reaction therefore 
proceeds via the most stabilised ( delocalised) Meisenheimer intermediate. 
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Attack at C1 
Q- c~ eQ- Q-N '\ ·~' ·,tr · .. 'ti •ri' 1"-':: p-"-':: ~F 1"-':: N,~ F N-t~ F N,N Nuc 
e Nuc Nuc H 
Nuc 
Attack at C4 
Q- Q- Q- Q-Nu~ '\ 
·w Nw· .. Ni!i 1"-':: '\ F "-':: F N Nucti' c;!J,N,;; F N C N' I 8
-....A'N F 
'N F N,N,;; F 
Scheme 4.30 
Attempts were then carried out to functionalise the tricyclic tetraazafluorene 
scaffolds using chemistry other than nucleophilic aromatic substitution. In particular, the 
bromine atom present in scaffold 281 could potentially be used for palladium catalysed 
cross-coupling reactions, or for debromo-metallation processes and trapping with an 
electrophile. 
Suzuki-Miyaura coupling of 281 with phenyl boronic acid proceeded in moderate 
yield under reflux in a biphasic mixture oftoluene and water (Scheme 4.31). Conditions 
were not optimised and this may improve the yield as cross-coupling processes are known 
to be highly sensitive to factors such as catalyst, ligand, solvent and base. 
281 
PhB(OHh 
Pd(OAch (5 mol%) 
PPh3 (15 mol%) 
Toluene I H20 
Cs2C03 
90°C, 16h 
Scheme 4.31 
291,41% 
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Attempts were carried out to utilise lithium-halogen exchange at the bromine atom 
of scaffold 281, followed by attempted trapping with W, allyl bromide and acetyl chloride 
under rigorously anhydrous conditions. In the case of W as electrophile successful 
trapping was observed, however the use of the alkyl electrophiles also formed this hydro-
product. As conditions were anhydrous, it is likely that the the lithio derivative formed is a 
highly stabilised anion and this ensures that the trapping process is very slow, and does not 
proceed until the reaction is quenched using a large excess of water. 
"'Q- H "'Q-Q- H lj ~ 1) n-BuLi lj ~ 1) n-BuLi Q-
·n· THF. -78°C .. ·n· THF. -78°C ·n· .. I~ 2) H20 2)AcCI ·n· I~ I~ I~ N,N....: F N,N....: F N,N....: F OR~Br N,N....: F 
281 280,46% 281 280 
Scheme 4.32 
4.6 Conclusion 
A range of ring fused systems have been synthesised by reaction of 
tetrafluoropyridazine with dinucleophiles. Many of the ring fused heterocycles synthesised 
here have seen little attention previously due to difficulties in their syntheses using standard 
methodologies. Reaction with 1 ,2-dinucleophiles such as diamines, diols and dithiols 
yields [6,6]-ring fused systems, whilst the use of 1, 1-dinucleophiles such as amidines, 
thioamides and 2-aminopyridines afford [5,6]-ring fused systems. A selection of the 
scaffold frameworks synthesised are shown along with the number of Scifinder 'hits' for 
each parent scaffold in Figure 4.8. This shows the scarcity ofthe majority of the scaffolds 
developed with only significant numbers of analogues of the imidazopyridazine and 
thiazolopyridazine scaffolds synthesised. 
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HNl s1 (X OX) aNH as 1'::::: 
N N N N N N 0 ~ 
70 27 32 
(Y B Q Q 6N '::::: '::::: '::::: ()N N N N N '::::: N N 
N N 
860 988 2 10 
Figure 4.8: Scifinder 'hits' for Scaffolds Synthesised (Accessed 1112/08) 
The ring fused scaffolds produced have fluorine atoms which can be displaced in 
further substitution reactions, which often proceed with a high degree of regiocontrol. This 
strategy has yielded a range of fused pyridazine derivatives with moderate skeletal and 
substituent diversity. 
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Chapter 5 
Chemistry of Tetrachloropyridazine 
5.1 Introduction 
Tetrachloropyridazine 292 is also susceptible towards nucleophilic displacement 
chemistry, but the decreased strength of the C-CI bond relative to the C-F bond means that 
tetrachloropyridazine could, potentially, offer other synthetic possibilities compared to 
tetrafluoropyridazine in cross-coupling and metallation processes (Figure 5.1 ). 
Nuc 
~ 
ClnCI 
N,N..-< Cl 
Cl Ar 
ClnCI ArB(OH)z ClnCI 
Pd Cat N ..-< N ...-; 
'N Cl 'N Cl 
292 1)~ 2)e E 
ClnCI 
N ..-< 
'N Cl 
Figure 5.1 
The palladium catalysed cross-coupling of chlorinated aromatic systems was 
initially seen as a difficult synthetic problem, but the development of new ligands and 
conditions has now reached the stage where such reactions are now feasible. Indeed, for 
many systems cross-coupling can be successfully achieved using standard catalysts, such as 
Pd(PPh3) 4• However, to date, very few examples of palladium catalysed reactions of 
perchlorinated heteroaromatics have been reported in the literature. 
Dechloro-metallation of perchloroheteroaromatic systems is another potentially 
useful process as this will allow reaction with electrophilic species, which are typically 
unreactive towards electron-poor pyridazine derivatives. Generally, metal-halogen 
exchange is observed in brominated s~st:llls _and is extr~mely diffic_ult ill chlorinat~d 
systems, however, both lithiation and magnesiation processes have been observed in 
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perchlorinated heteroaromatic derivatives, such as pentachloropyridine159• However, the 
corresponding chemistry has not been explored using tetrachloropyridazine as the substrate. 
The difficulty in characterising highly chlorinated systems has hampered the 
development of the chemistry of perchlorinated systems because of the lack of effective 
structural probes for NMR. 13C NMR may offer some potential in assigning product 
structures, but, to date, it has proved difficult to correlate experimental and calculated 
chemical shifts. Therefore, it is likely that X-ray crystallography, which today is a rapid 
and highly informative technique, may be most appropriate in deducing product identity. 
5.2 Synthesis of Tetrachloropyridazine 
Tetrachloropyridazine 292 can be synthesised in good yield in a two step process 
starting from dichloromaleic anhydride 293 (Scheme 5.1). Firstly, ring expansion of 
dichloromaleic anhydride with hydrazine hydrate yields 4,5-dichloro-3,6-dihydroxy-
pyridazine 294, which is followed by chlorination with phosphorus(V) oxychloride to 
produce tetrachloropyridazine, in 76% overall yield based on the mass of dichloromaleic 
anhydride used. This process was applicable to large scale chemistry, being carried out in 
I OOg batches. However, on such a large scale safety precautions must be taken on 
quenching the phosphorus(V) oxychloride, which is highly exothermic. 
:b: 0 0 0 
293 
Cl 
HO~CI 
~'N~OH 
294,91% 
Scheme 5.1 
Cl 
CI~CI 
~'N~CI 
292,84% 
(Overall Yield= 76%) 
5.3 Nucleophilic Aromatic Substitution Reactions of Tetrachloropyridazine 
5.3.1 Monosubstitution 
A single example of nucleophilic substitution involving tetrachloropyridazine as the 
electrophile has been previously reported, namely reaction with dimethylformamide, which 
has ~been claimed to pr~~ide~th~ 3-dilitethylami~o d~rivativ~ i~ g~od yi~ld (Sch~~e 5.2)160• 
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DMF, reflux 
Scheme 5.2 
It was decided to examine the regioselectivity of attack of various amine 
nucleophiles on tetrachloropyridazine, achieved by stirring two equivalents of amine with 
tetrachloropyridazine at room temperature in acetonitrile. Reaction of a broad selection of 
primary and secondary aliphatic amines resulted in the regioselective formation of a single 
monosubstituted isomer (Table 5.1). Consumption of starting material was 100% as 
observed by TLC and GC analysis and purities of products obtained were good; 
analytically pure material was obtained in moderate yield by a single recrystallisation. 
Product Isolated Yield R1R2NH Product Isolated Yield 
------------------------------~--
43% 
l 
~NH 49% 
54% 25% 
47% 
45% 
Table 5.1 
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Structural determination by X-ray crystallography of the benzylamino 297 and 
diethylamino 299 derivatives confirmed that substitution had occurred at the 4-position, 
para to activating ring nitrogen (Figure 5.2). 
a) b) 
Bond Bond Length I A Bond Bond Length I A 
N(1)-C(4) 1.3216 N(1 )-C(4) 1.3187 
N(1 )-N(2) 1.3526 N(1)-N(2) 1.3511 
N(2)-C(1) 1.3057 N(2)-C(1) 1.3162 
C(1)-C(2) 1.4348 C(1 )-C(2) 1.4287 
C(2)-C(3) 1.4036 C(2)-C(3) 1.3971 
C(3)-C(4) 1.3998 C(3)-C(4) 1.4054 
Figure 5.2: X-r~ Crystal Structures of a) N-benzyl-3,5,6-trichloropyridazin-4-amine 297 
and b) 3,5,6-trichloro-N,N-diethylpyridazin-4-amine 299 
Comparison of 13C NMR chemical shifts of the primary amine substituted products 
to the benzylamino derivative and secondary amine substituted products to the 
diethylamino derivative would suggest that substitution has occurred at C4 in all cases 
(Table 5.2). 
133 
Chapter 5: Chemistry ofTetrach/oropyridazine 
MeCN,rt 
R1 R2 Ocsl ppm SC4/ ppm Seal ppm Sc3/ ppm 
Bn H 116.8 141.4 144.1 154.8 
Me H 115.8 142.1 143.6 154.8 
t-Bu H 121.7 142.9 148.4 155.0 
Et Et 133.2 146.4 155.1 155.4 
Piperidino 129.7 146.8 152.8 155.5 
Morpholino 130.3 145.5 152.7 155.7 
Table 5.2 
Such highly regioselective reactions are quite unusual in the reactions of 
perchloroheteroaromatics, since, for example pentachloropyridine reacts with nucleophiles 
to give mixtures of regioisomeric products substituted at the 4- and 2-positions, which is 
thought to be due to competing substitution at the less sterically hindered 2-position. In the 
case oftetrachloropyridazine, the additional activation provided by the second ring nitrogen 
must outweigh any steric preference for reaction at the less hindered site. 
The observed regioselectivity is in disagreement with the findings of Lee et al. 160 
who suggested that reaction oftetrachloropyridazine in refluxing DMF, which results in the 
formation of dimethylamine by thermal decomposition, proceeds exclusively at the 3-
position, the opposite isomer to that observed in this study. It is likely that in the harsher 
conditions used in their experiment, thermodynamic control resulted in the formation of the 
less sterically hindered isomer. However, at room temperature kinetic control results in 
reaction at the most activated site para to ring nitrogen. 
Repetition of the reaction of tetrachloropyridazine with diethylamine under 
microwave irradiation at 150°C in acetonitrile resulted in the formation of both 4- and 3-
monosubstituted isomers in a ratio of 85 : 15 respectively (Scheme 5.3 ), demonstrating that 
some of the thermodynamic product is formed under more forcing conditions, although it is 
not the major product. Product identity was assigned by comparison of spectral data to the 
pure sample obtained at room temperature. 
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MeCN 
MW, 150°C 
299a 
ISOMER RATIO 85 
Scheme 5.3 
A less nucleophilic aromatic amine nucleophile, aniline, did not react with 
tetrachloropyridazine at room temperature, so elevated temperatures were employed to 
effect the substitution. In refluxing acetonitrile 4- and 3-monosubstituted isomers were 
produced in a 68 : 32 ratio respectively by integration of the crude 1 H NMR spectrum, and 
conversion and purity was high (Scheme 5.4). However, separation of the two 
regioisomers was difficult, as they co-eluted on column chromatography leading to very 
low isolated yields, although analytically pure samples of both isomers were obtained. A 
crystal structure of the minor isomer confirmed it to be substituted at the 3-position, 
confirming that the major product was the 4-substituted isomer (Figure 5.3). 
O'NH2 MeCN + --------~ Reflux,22h 
292 
ISOMER RATIO 
Scheme 5.4 
302a, 10% 
68 
Bond 
N(1)-C(6) 
N(1)-N(2) 
N(2)-C(3) 
C(3)-C(4) 
C(4)-C(5) 
C(5)-C(6) 
Cl 
CI~CI 
~-N~ 
302b, 6% 
32 
Bond Length I A 
1.310 
1.349 
1.338 
1.430 
1.359 
1.409 
Figure 5.3: X-ray Crystal Structure of 4,5,6-trichloro-N-phenylpyridazin-3-amine 302b 
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5.3.2 Disubstitution 
For tetrachloropyridazine to be a good scaffold for sequential nucleophilic 
substitution reactions a second substitution step should also proceed efficiently and with 
high regioselectivity. 
The second substitution step did not proceed at room temperature or in refluxing 
acetonitrile, for example, reaction of 4-benzylamino-3,5,6-trichloropyridazine 297 with a 
second equivalent of benzylamine, or reaction of 4-diethylamino-3,5,6-trichloropyridazine 
299 with a second equivalent of diethylamine at reflux returned only the starting materials. 
Under microwave irradiation conditions, disubstitution reactions began to become 
feasible. For example, 4-diethylamino-3,5,6-trichloropyridazine 299 reacted with a second 
equivalent of diethylamine with a high degree of regiocontrol (Scheme 5.5). The major 
product 303 was unsymmetrically substituted as it displayed two sets of signals for the CH2 
and CH3 groups in its 1 H and 13C NMR spectra. NOESY correlation spectroscopy would 
suggest that the product is 4,6-disubstituted, rather than 5,6-disubstituted because no cross 
signals between the two alkyl groups are observed. 
MeCN 
MW, 150°C, 30 min 
299 
Scheme 5.5 
However, when 4-diethylamino-3,5,6-trichloropyridazine was reacted with sodium 
methoxide a complex mixture of all three possible disubstituted isomers was obtained in a 
ratio of 50 : 33 : 17 and as separation of these regioisomers was not possible by 
chromatography it is not possible to assign a structure to any of these systems. It is likely 
that the decreased steric demand and increased nucleophilicity of sodium methoxide 
relative to diethylamine leads to this decrease in selectivity. Similarly, 4-benzylamino-
3,5,6-trichloropyridazine reacts with a second equivalent of benzylamine to give an 
inseparable,mixture of all three"possible regioisomers in"a~ratio of43 : 30 : '17. 
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Consequently, 4-amino-trichloropyridazine derivatives are deactivated towards 
sequential displacement reactions with nucleophiles. Forcing microwave irradiation 
conditions are required to achieve conversion, and regioselectivity can be low. 
5.4 Ring Fused Systems from Tetrachloropyridazine 
Tetrachloropyridazine has the potential to react with dinucleophilic species in an 
analogous fashion to tetrafluoropyridazine to provide ring fused pyridazine scaffolds. 
Tetrachloropyridazine was reacted with some of the dinucleophiles that led to successful 
annelation with tetrafluoropyridazine to compare the reactivity of the fluorinated and 
chlorinated systems. 
Reaction of tetrachloropyridazine with N ,N' -dimethylethylenediamine proceeded to 
give a mixture of cyclic products in a ratio of 8:3 on stirring at room temperature in 
acetonitrile (Scheme 5.6). The major product 304a was shown to be cyclised between the 
4- and 5-positions, both para to activating ring nitrogen, by the presence of single 
resonances in the 1 H and 13C NMR spectra for the CH2 and CH3 signals, due to the 
symmetry of the system. The structure of the major product was also confirmed by X -ray 
crystallography (Figure 5.4 ). 
Cl 
CIUCI H + /N~N/ 
N,N"" Cl H 
292 
'Nl 
MeCN CIUN, 
RT, 65h N,N-" Cl 
304a, 32% 
ISOMER RATIO 8 
Scheme 5.6 
Bond 
+ 
Cl I CI~N) ~-N~N 
I 
304b, 17% 
3 
Bond Length I A 
N(1)-C(1) 1.313 
N(1 )-N(1A) 1.351 
~ }~ * *-~~-~)_>~~-~-~~_> ___ ~:_:~-~-1--
Figure 5.4: X-r_ay Crystql ~!ructu_re of 5,8-dkN!JfQ:1,21 3,4-tetrahygro-1,4-
dimethylpyrazino[2,3-d}pyridazine 304a 
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This result is in contrast to that obtained with tetrafluoropyridazine, which gave a 
single regioisomer, cyclised between the 4- and 5-positions, on reaction with N,N'-
dimethylethylenediamine under identical conditions to those used here. This demonstrates 
the increased reactivity of the fluorinated system, which undergoes rapid ann elation to give 
the kinetic product by reaction at both of the most reactive sites para to ring nitrogen. 
Also, the increased steric demand of the chlorinated system leads to some cyclisation at the 
less hindered 3-position, ortho to ring nitrogen, to give some of the thermodynamic 
product. 
Similarly, the reaction of 1, 1-dinucleophiles such as amidines could be expected to 
yield corresponding [5,6]-ring fused products. As was the case for tetrafluoropyridazine, 
reaction of tetrachloropyridazine with benzamidine hydrochloride yielded a 
monosubstituted uncyclised product 305 in refluxing acetonitrile (Scheme 5.7). 
Cl 
Cln~ Cl 
N ~ 
'N Cl 
292 
Ph 
HNANH 
Ph .HCI NaHC03 CI~CI 
+ HNANH2 MeCN, reflux ~'N~CI 
305,43% 
Scheme 5.7 
All attempts to induce the cyclisation proved unsuccessful (Scheme 5.8) including 
the use of strong bases such as LOA or NaH, or the microwave irradiation technique in the 
presence ofHUnig's base which successfully effected the cyclisation of the polyfluorinated 
analogue. This demonstrates the decreased reactivity of polychlorinated heteroaromatics 
relative to polyfluorinated heteroaromatics in nucleophilic displacement processes. 
LOA, -78°C, THF 
or DIPEA, MeCN, 
MW, 150°C 
Scheme 5.8 
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5.5 Metallation 
Although metal-halogen exchange reactions at C-CI bonds are generally considered 
to be difficult, such reactions have been successfully accomplished using perchlorinated 
heteroaromatic substrates. For example, pentachloropyridine 306 has been shown to 
undergo lithiation reactions whose regiochemistry is solvent dependent (Scheme 5.9)161 • In 
methylcyclohexane lithiation of pentachloropyridine occurs mainly at the 2-position, whilst 
in diethyl ether a 4-lithio derivative is formed. 
Cl ClnCI n-Buli 
I /: Methylcyclohexane 
Cl N Cl rt 
306 
Cl ClnCI n-Buli 
I /: Et20, rt 
Cl N Cl 
306 
Cl ClnCI 
I ,-:; 
Cl N Li 
307 
Li ClnCI 
I /: 
Cl N Cl 
309 
Scheme 5.9 
Cl 
CI~CI 
)l .. ~ Cl N H 
308,40% 
H 
CI~CI 
)l .. ~ Cl N Cl 
310,36% 
The potential to carry out metallation reactions on tetrachloropyridazine would be 
desirable, as this would allow the introduction of functionality that is complimentary to that 
which can be introduced using nucleophilic substitution reactions. 
On addition of both n-BuLi and t-BuLi to a solution of tetrachloropyridazine in 
THF at -78°C a rapid darkening of the solution was observed and a complex product 
mixture was obtained after aqueous work-up (Scheme 5.10). 13C NMR and GC-MS 
showed the major component of the reaction mixture was starting material, however the 
significant number of by-products could not be identified. 
Cl 
Cln~ Cl 
N /: 
'N Cl 
n-Buli I t-Buli 
II .. 
Scheme 5,] 0_ 
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Attempted formation of a Grignard reagent from tetrachloropyridazine failed to 
initiate, even on heating of the reaction mixture, or on addition of initiators such as iodine 
or I ,2-dibromoethane (Scheme 5.11 ). 
Mg, THF 
II .. 
Scheme 5.11 
It would therefore seem that, under the conditions examined, metallation of 
tetrachloropyridazine is very difficult and was not investigated further. 
5.6 Palladium Catalysed Cross-Coupling Reactions 
The cross-coupling of chloroheteroaromatics has been extensively examined in 
recent years and is now commonly used in the synthesis of C-C bonds. However, the study 
of perchlorinated heteroaromatic compounds as substrates in palladium catalysed cross-
couplings has been limited to a single recent report on the regioselective Suzuki cross-
coupling of tetrachloropyrimidine 162• To date, the chemistry of tetrachloropyridazine in 
palladium catalysed cross-coupling processes has not been examined. 
Cross-coupling reactions are typically sensitive to conditions such as solvent, 
catalyst and base used in the reaction. Therefore, a range of these potential factors were 
screened in small scale reactions oftetrachloropyridazine with phenyl boronic acid, and the 
results analysed by GC-MS, which are summarised in Table 5.3. 
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Cl Solvent Cl Ph Ph 
ClnCI Pd Cat (5 mol%) PhnCI ClnCI ClnCI + PhB(OH)2 Base .. + I + 
N,N..-.: Cl Reflux,23h N,N..-.: Cl N,N..-.: Cl NQI,( Cl 
I 
eO 
292 311a 311b 311c 
Reaction Solvent Pd Catalyst Base Conversion Ratio 311 a:b:c 
Toluene Pd(PPh3)4 Cs2C03 72 75: 15:8 
2 THF Pd(PPh3)4 Cs2C03 43 63: 37:0 
3 MeCN Pd(PPh3)4 Cs2C03 13 56:30: 14 
4 DMF Pd(PPh3)4 Cs2C03 0 
5 Toluene Pd(PPh3)48 Cs2C03 77 58:23: 19 
6 Toluene Pd /C Cs2C03 0 
7 Toluene Pd(PPh3)4 KF 62 69 : 18 :13 
8 Toluene Pd(PPh3)4 KCI 0 
a 1 0 mol% catalyst used 
Table 5.3 
These results suggest that the best combination of solvent and base is toluene and 
CsC03. The increase in catalyst loading from 5 mol% to 10 mol% led to a slight increase 
in conversion, but a decrease in regioselectivity was also observed. Alternative ligands to 
PPh3 were not screened in the reaction as it was hoped to develop a process using readily 
available starting materials. 
Our optimised conditions were used in a larger scale cross-coupling reaction to 
allow product isolation and identification (Scheme 5.12). Some N-oxide by-product 311c 
was also observed in the screening reactions, and is most likely formed due to incomplete 
deoxygenation of the reaction mixture by sparging with argon. Therefore a freeze-pump-
thaw technique was employed in this larger scale reaction to ensure more rigorous solvent 
deoxygenation, which eliminated formation of this by-product. Isolated yields of both 
isomers was moderate due to difficult purification in both separation of the isomers and 
removal ofthe Ph3P and Ph3P=O by-products. 
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311a, 32% 
ISOMER RATIO 71 
Scheme 5.12 
Ph 
ClnCI 
+ I 
N ~ 
'N Cl 
311b, 9% 
29 
X-ray crystallography of the major isomer 311a showed it to be substituted at the 3-
position (Figure 5.5), which is the opposite site of substitution to that obtained with 
nucleophilic attack. This is likely to be due to the reduced steric hindrance at this site as 
formation of the tetrasubstituted palladium intermediates obtained in the catalytic cycle is 
quite a sterically demanding process and proceeds most efficiently when the site of 
substitution does not have two ortho-substituents. The crystal structure shows the two 
rings to be almost orthogonal to each other and stacking of phenyl and pyridazine rings 
occurs in the unit cell. 
Bond 
N(1 )-C(4) 
N(1 )-N(2) 
N(2)-C(1) 
C(1)-C(2) 
C(2)-C(3) 
C(3)-C(4) 
Bond Length I A 
1.3188 
1.3430 
1.3387 
1.4130 
1.3839 
1.4036 
Figure 5.5: X-ray Crystal Structure of 3,4,5-trichloro-6-phenylpyridazine 311a 
142 
Chapter 5: Chemistry ofTetrachloropyridazine 
However, when this cross-coupling was repeated with a range of boronic acids, the 
results were substrate sensitive and unpredictable (Table 5.4). Substitution was 
successfully achieved using 4-methylbenzene boronic acid and (E)-2-phenylvinylboronic 
acid. In both cases purification was difficult and the reported yield is of product 
contaminated with some Ph3P and Ph3P=O. In the absence of a crystal structure it has been 
assumed that the major regioisomers are substituted at the less hindered 3-position, by 
analogy to the products obtained in the reaction with phenyl boronic acid. 
(E)-2-Phenylvinylboronic acid gave a single regioisomer, the reasons for which are 
unclear as it could be expected that regioselectivity of the cross-coupling would be 
controlled by the regioselectivity of the initial oxidative addition oftetrachloropyridazine to 
the palladium complex, which should be independent of the boronic acid used. This would 
suggest that isomerisation of the intermediate formed by oxidative addition is possible and 
that the reaction is under thermodynamic control. Therefore, it may be the case that (E)-2-
phenylvinylboronic acid is a more sterically demanding boronic acid and forces cross-
coupling to occur exclusively at the less hindered position. 
No conversion was obtained with cyano and dimethylamino substituted aryl boronic 
acids or with thiophene boronic acid. It is not clear as to why this particular range of 
boronic acids should fail to give any cross-coupled product and suggests that this process is 
particularly sensitive to conditions and more research needs to be carried out to develop 
these reactions into generally applicable processes. For example, a range of bulky, 
electron-rich phosphine ligands are available for the efficient cross-coupling of chloro-
heteroaromatics. 
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Boronic Acid 
s ~B(OH)2 
(H0)2B~Ph 
a Isolated Yields 
+ RB(OH)2 
Toluene 
Reflux, 16h 
Conversion (%) % 3- isomer a 
0 
Me 
100 
0 
100 
312a, 24%c 
PhnCI Cl 
1""::::: 
N,Nh Cl 
313a, 33%c 
Cl 
Cl 
b Isomer Ratios determined by integration of crude 1H NMR spectra 
c Isolated yields of product contaminated with Ph3P and Ph3P=O 
* Not isolated 
Table 5.4 
5.7 Conclusions 
%4-lsomera Isomer Ratio b 
Me 
65:35 
Cl Cl 
I 
N,N'- Cl 
312b* 
100: 0 
Tetrachloropyridazine has been used as a scaffold for the synthesis of 
polysubstituted systems, however it appears to be less useful than tetratluoropyridazine. 
Monosubstitiitioh -readions witli amines proceed with high regioselectivity at the 4-
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position, but a second displacement of chlorine requires forcing microwave conditions and 
often proceeds with low regioselectivity. 
Formation of cyclic systems is less efficient than the analogous reactions of 
tetrafluoropyridazine, proceeding with less regiocontrol, and the cyclisation step did not 
proceed in the case of amidines. 
Attempted metallation of tetrachloropyridazine did not proceed, whilst palladium 
catalysed cross-coupling reactions appeared to be very sensitive towards the substrate used 
and require more work to obtain a more general process. 
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Chapter 6 
Conclusions 
This thesis has described the synthesis of a range of polyfunctional systems from 
the perfluorinated heteroaromatic tetrafluoropyridazine by nucleophilic aromatic 
substitution of ring fluorine atoms. Such heterocyclic systems are likely to be of great 
interest in applications ranging from pharmaceuticals to materials. 
4,5,6-Trifluoropyridazin-3(21/)-one has been shown to be an excellent scaffold for 
the production of amine substituted pyridazin-3(21/)-one derivatives (Scheme 6.1 ). 
Substitution occurs at the two fluorine atoms para to activating ring nitrogen, with 
selectivity for the 4-position generally increasing as the 'soft' electronic character of the 
nucleophile is increased. In the case of aromatic amine nucleophiles regioselectivity in 
favour of the 4-isomer can be as high as 95 : 5, however, in cases where the regioselectivity 
is lower separation of the two isomers is readily achieved by chromatography and gives 
access to both 4- and 5-substituted isomers. 
MeCN 
+ Nuc 
rt 
Scheme 6.1 
F 
F'(xNuc I + 
N,N 0 
H 
Nuc 
F~F 
~,N_,lO 
H 
Ratios of isomers range from 
4-bromoaniline (96:4) 
Butylamine (57:43) 
A second sequential substitution on 4-substituted 5,6-difluoropyridazin-3(21/)-ones 
proceeds regioselectively at the 4-position with a range of amine nucleophiles (Scheme 
6.2), except in the case of displacement reactions on 4-(primary amino) substituted systems, 
which did not proceed to any useful extent. This was most likely because of better orbital 
overlap in the Jess sterically demanding primary amino systems, which rendered a primary 
amine substituent a more efficient electron donor and therefore more deactivating. 
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Nuc 
MeCN 
F 
FnNRR' I + Nuc 
MW, 150°C F~R ~'N~O N,N 0 
H H 
R = Morpholino, 4-bromoanilino Yields 15 - 90% 
If R = Primary amino reaction fails 
Scheme 6.2 
Alkoxide nucleophiles failed to give useful yields of isolable products, which was 
thought to be due to their basicity leading to deprotonation of the pyridazin-3(2H)-one ring 
NH. As such, a strategy for protection ofthis site was sought and two synthetically viable 
routes were found (Scheme 6.3). Firstly, an N-arylation using lead(JV) acetate in benzene, 
and also protection as an N-(tetrahydropyranyl) derivative. In both cases the protecting 
group was found to have a minimum influence on regioselectivities and yields of 
substitution processes. Deprotection of the THP derivative is also feasible under standard 
conditions. This protecting group strategy has expanded the range of potential nucleophiles 
that are compatible with polyfluoropyridazin-3(2H)-one systems to more basic systems 
such as alkoxides. 
F 
F~F 
~~0 
Pb(OAc)4 
ZnCI2 
Benzene 
Reflux 
DHP 
TsOH 
THF, Reflux 
Scheme 6.3 
F 
F~F 60 
This sequential nucleophilic displacement methodology has been shown to have the 
potential to synthesise a range of 6-fluoro-disubstituted pyridazin-3(2H)-ones. 
Furthermore, it has been shown that parallel synthesis techniques are appropriate for use in 
these reactions, allowing the rapid synthesis of a diverse range of compounds, which will 
be extremely useful in the lead generation stage of drug discovery. 
Tjl~ rea__cJion pfclifl!n~1tQH!llnucleophiles withJetrafluoropyridazine hasallowedcthe 
synthesis of various ring fused systems, many of which are novel core scaffolds (Scheme 
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6.4). Several [6,6]-ring fused systems have been synthesised by reaction with diamine, diol 
and dithiol derivatives, whilst [5,6]-ring fused systems have been obtained by reaction with 
amidine, thioamide and 2-aminopyridine derivatives. 
Q ONH FrrN H I~ 
N,N/- F NaHC03 
MeCN, reflux 
F F'f:( ~'N/- F 
Scheme 6.4 
NaHC03 
MeCN, rt 
The ring fused scaffolds possess additional ring fluorine atoms that in the majority 
of cases are susceptible to regioselective displacement reactions (Scheme 6.5). In certain 
cases displacement of all ring fluorine atoms is possible to give non-halogenated products. 
MeCN 
MW, 150°C 
Scheme 6.5 
The variety of dinucleophiles that are available will enable this strategy to be used 
for the synthesis of a range of heterocyclic species with moderate structural diversity, 
whilst substituent diversity can be increased by reaction of the scaffolds produced with a 
range of functionalised nitrogen, oxygen, sulfur and carbon nucleophiles. Again, the 
amenability of this approach to parallel synthesis methodology will allow for the synthesis 
of libraries of compounds based on different core scaffolds, which will be of significant 
interest to the development of medicinal chemistry programmes. 
Calculations performed at GlaxoSmithKiine on many of the compounds described 
in this thesis show that they fit the 'Lipinski guidelines' which describe the lipophilicity, 
hydrogen bond properties and molecular weight of a potential successful drug candidate. 
The results of these calculations are provided in Appendix 2 on the attached CD-ROM. 
- . - . - - -_ - - - -
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Overall, this strategy of sequential fluorine displacement in polytluorinated 
heteroaromatics has been shown to have great potential for the synthesis of polyfunctional 
systems (Scheme 6.6) and is a versatile approach for the synthesis of diverse heterocyclic 
derivatives which are highly desired in a range of applications. 
fN'MefO 
Me_..NnN-.__) 
Me I 
0 fluorine 
atoms 
fN' H N,N 0 
Me .... Ntx""' NO""' H --1-fl-uo_rl_n_e __ 
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0' e HN' ro 
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Chapter 7 
Experimental 
7.1 Technical Detail 
Reagents 
Tetrafluoropyridazine was obtained from ABCR, whilst all starting materials were 
obtained commercially (Sigma-Aldrich, Alfa-Aesar) or from GlaxoSmithKline's chemical 
stores, Stevenage and used without further purification. Solvents were dried using either 
literature procedures or via the Innovative Technology solvent purification system. 
Reactions and Purification 
Reactions were performed under an atmosphere of argon gas using dry solvents. 
Microwave reactions were performed on a Biotage Initiator 60 EXP. Reactions were 
monitored by 19F NMR or TLC on silica gel TLC plates. 
Chromatography 
Column chromatography was carried out on silica gel (Fluorochem, Merck no. 
I 09385, particle size 0.040- 0.063nm) unless otherwise stated or using a Biotage Horizon 
or Isco Companion flash chromatography system using pre-packed silica columns. Mass 
directed HPLC was performed on a Supelco LCABZ++ column using MicroMass 
MassLynx v4.0 software. 
Melting Points 
Melting points were recorded using a Gallenkamp melting point apparatus at 
atmospheric pressure and are uncorrected. 
Infra-Red Spectroscopy 
IR spectra were obtained using a Perkin Elmer 1600 Series FTIR using a Golden 
Gate attachment and analysed using GRAMS Analyst software. 
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NMR Spectroscopy 
NMR spectra were recorded m the deutarated solvent stated, using 
tetramethylsilane and trichlorofluoromethane as an internal references on a Varian Mercury 
400, Bruker Avance 400 or Bruker DPX400 operating at 400MHz eH NMR), 376MHz 
( 19F NMR) and lOOMHz (13C NMR), or a Varian Inova 500 operating at 500MHz (1H 
NMR), 470MHz (19F NMR) and 125MHz (13C NMR), or a Varian VNMRS-700 operating 
at 700MHz (1H NMR), 658MHz (19F NMR) and 175MHz (13C NMR). Chemical shifts are 
given in ppm and coupling constants are recorded in Hertz. 
Mass Spectrometry 
Mass spectra were recorded on a Thermoquest Trace GC-MS spectrometer (in 
electron ionisation mode), a Micromass LCT LC-MS spectrometer (in electrospray ES+ 
mode) or a Waters ZQ mass spectrometer coupled to a Waters Acquity HPLC system 
(operating in electrospray positive or negative mode). Exact mass measurements were 
performed on a Thermo-Finnigan L TQ-FT spectrometer, a Bruker Daltonics 7T FTICR-MS 
or a Micromass Q-TOF hybrid quadrupole mass spectrometrer, operating in electrospray 
positive mode. 
Gas I Liquid Chromatography 
Gas chromatography was carried out on a Thermo TRACE GC. Analytical HPLC 
was performed on an Analytical Varian LC (5ml/min). 
Elemental Analysis 
Elemental analyses were obtained using an Exeter Analytical E-440 Elemental 
Analyser, or by Butterworth Laboratories Ltd., Teddington, UK. 
X-ray Crystallography 
All crystallographic data was collected on a Bruker SMART-6000 CCD (J.MoKa., 
ro-scan, 0.3° I frame) at T = 120K. The structures were solved using direct methods and 
refined by full-matrix least squares on F2 for all data using SHELXTL software. All non-
hydrogen atoms were refined with anisotropic displacement parameters, H-atoms were 
located on the difference map and,refined isotropically. 
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7.2 Experimental to Chapter 2 
4, 5, 6-Trifluoropyridazin-3(2H)-one 182 
F 
Fn~4 F 61 
N,N 3 0 
H 
182 
Tetrafluoropyridazine (1.20g, 7.89mmol) was dissolved in concentrated sulfuric 
acid (12ml) at 0°C. Water (48ml) was added dropwise using a dropping funnel, after which 
the mixture was allowed to warm to room temperature and was stirred for 1.5 hours. After 
this period the mixture was extracted with diethyl ether (3 x 25ml), and the organic extracts 
washed with saturated sodium sulfate solution (25ml), before being dried (MgS04), filtered 
and evaporated to yield a crude cream solid, which was recrystallised from toluene to yield 
4,5,6-trifluoropyridazin-3(2H)-one133 182 (1.07 g, 90%) as white crystals; 8H (300 MHz, 
CDCh) 11.4- 11.8 (IH, br s, NH), 1.80 (1H, br s, OH); 8F (282 MHz, CDCb) -101.7 (IF, 
dd, 3JFF 25.7, 4JFF 16.2, F6), -136.9 (IF, dd, 3JFF 15.5, 4JFF 16.2, F4), -143.5 (lF, dd, 3JFF 
25.7, 31rF 15.5, F5); mlz (EI+) 151 ([Mt, 5%), 150 ([M-Ht, 97), 122 (25), 121 (21), 93 
(1 00), 74 (68), 31 ([CFt, 1 00). Crystals suitable for X-ray diffraction were grown from 
slow evaporation of dichloromethane. 
4-( Ally/amino )-5, 6-difluoropyridazin-3 (2H)-one 188a and 5-( ally/amino )-4, 6-difluoro-
pyridazin-3(2H)-one 188b 
F ~ LNH FnNH FnF 
N,N 0 ~'N 0 H H 
188a 188b 
Allylamine (0.100ml, 1.33mmol) was mixed with 4,5,6-trifluoropyridazin-3(2/i)-
one (100mg, 0.666mmol) in a Radleys Greenhouse tube under nitrogen. Acetonitrile (5ml) 
was adoed -and lne triixiure stirre(f at room temperature for 48 hours. After this period the 
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solvent was evaporated, and the residue dissolved in dichloromethane (I Om I). Water 
(1 Oml) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1Om!). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator, 
followed by purification by flash column chromatography (elutant cyclohexane : ethyl 
acetate 5:1 to 2:1 gradient over 20 minutes) to yield 4-(allylamino)-5,6-difluoropyridazin-
3(2H)-one 188a (0.050g, 40%) as a white solid; mp 103- 105°C (Found [MHt 188.06294. 
C7H7F2N30 requires [MHt 188.06299); Vmax I cm-1 1072, 1139, 1292, 1367, 1453, 1587, 
1640 (CO amide), 2859 (br, NH), 3293 (tH); oH (400MHz, CDCb) 4.14 (2H, ddd, 3JHH6.2, 
6.0, 5JHF 1.8, NHCH2CH=CH2), 5.24 (1H, dd, 3JHH 10.3, 2JHH 1.3, NHCH2CH=CH2), 5.27 
(IH, dd, 3JHH 15.6, 2JHH 1.3, NHCH2CH=Ctk:z), 5.62 (1H, br t, 3JHH 6.0 NHCH2CH=CH2), 
5.93 (IH, ddt, 3JHH 15.6, 10.3, 6.0, NHCH2CH=CH2), 11.00 (1H, br s, ring NH); oc 
(100MHz, CDCh) 46.3 (d, 4JCF 6.4, NHCH2CH=CH2), 117.1 (s, NHCH2CH=CH2), 131.2 
(dd, 1JcF260.4, 2JCF32.8, C5), 131.8(d, 2JcF 8.8, C4), 133.6 (d, 5JcF 1.6, NHCH2CH=CH2), 
149.0 (dd, 1JcF 230.9, 2JCF 17.6, C6), 159.8 (d, 3JCF 11.2, C3); OF (376MHz, CDCb) -106.1 
(lF, d, 3hF26.4, F6), -161.9 (IF, d, 3hF26.4, F5); m/z (ES-) 186 (100%, [M-HD. 
The minor isomer 5-(allylamino)-4,6-difluoropyridazin-3(2H)-one 188b was also 
obtained (0.0168g, 13%) as a white solid; mp 143 - 144°C (Found [MHt 188.06304. 
C7H1F2N30 requires [MHt 188.06299); Vmax I cm-1 998, 1040, 1099, 1166, 1363, 1432, 
1525, 1589, 1621 (CO amide), 2853 (br, NH), 3278 (CH); oH (600MHz, MeOD) 4.02 (2H, 
dd, 3JHH 5.1, 5JHF 1.5, NHCH2CH=CH2), 5.16 (1H, d, 3JHH 10.3, NHCH2CH=CH2), 5.22 
(1H, d, 3JHH 17.2, NHCH2CH=CH2), 5.93 (IH, ddt, 3JHH 17.2, 10.3, 5.1, NHCH2CH=CH2); 
oc (151MHz, MeOD) 47.0 (d, 4JcF 6.6, NHCH2CH=CH2), 116.5 (s, NHCH2CH=CH2), 
129.6 (dd, 2JcF 29.9, 2JCF 6.7, C5), 135.9 (d, 5JCF 2.2, NHCH2CH=CH2), 139.8 (dd, 1JcF 
241.0, 3JcF 11.1, C4), 149.4 (dd, 1JcF 232.2, 3JCF 11.1, C6), 158.8 (d, 2JCF 22.1, C3); OF 
(376MHz, MeOD) -102.0 (IF, d, 4hF24.7, F6), -156.6 (IF, d, 4JFF24.7, F5); m/z (ES+) 188 
(100%, [M+Ht), 229 (29, [M+MeCNt). 
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4-(Butylamino )-5, 6-difluoropyridazin-3 (2H)-one 189a and 5-(butylamino )-4, 6-difluoro-
pyridazin-3(2H)-one 189b 
189a 
\NH 
F~F 
~'N~O 
H 
189b 
4,5,6-Trifluoropyridazin-3(2/i)-one (0.50g, 3.33mmol) was dissolved in acetonitrile 
(20 ml) under argon with stirring. n-Butylamine (0.66ml, 6.66mmol) was added dropwise, 
and the mixture stirred at room temperature for 5 hours. After this period water (20m!) was 
added followed by dichloromethane (20 ml), and the organic layer separated. The aqueous 
layer was then extracted with further portions of dichloromethane (2 x 20ml), and the 
combined organic extracts were dried (MgS04), filtered and evaporated under vacuum to 
yield a crude yellow product (0.59g), containing 2 products in a 56:44 ratio by 19F NMR 
analysis. These were then purified by flash column chromatography with ethyl acetate and 
hexane as elutant (1 :2 900ml, followed by 1:1 500ml) to yield the major product 4-
(butylamino)-5,6-difluoropyridazin-3(2H)-one 189a (0.28g, 41%) as white crystals; mp 80 
- 81°C (Found C, 47.3; H, 5.5; N, 20.6; C8H 11N3F20 requires C, 47.3; H, 5.5; N, 20.7%); 
Vmax I cm-1 1030, 1112, 1281, 1378, 1448, 1587, 1644 (CO amide), 2963 (br, NH), 3286 
(CH); 8H (500MHz, CDCh) 0.95 (3H, t, 3JHH 7.4, NHCH2CH2CH2CH3), 1.40 (2H, sextet, 
3JHH 7.4, NHCH2CH2CH2CH3), 1.62 (2H, pent, 3JHH 7.4, NHCH2CR2CH2CH3), 3.51 (2H, 
qd, 3JHH 7.0, 5JHF 2.7, NHCH2CH2CH2CH3), 5.53 (1H, br t, 3JHH 7.0, NHBu), 11.60 (lH, br 
s, ring NH); 8c (125MHz, CDCh) 13.8 (s, NHCH2CH2CH2CH3), 19.9 (s, 
NHCH2CH2CH2CH3), 32.6 (d, 5JcF 2.2, NHCH2CH2CH2CH3), 44.0 (d, 4JcF 5.9, 
NHCH2CH2CH2CH3), 130.8 (dd, 1JcF 258.9, 2JcF 32.5, C5), 132.3 (d, 2JcF 8.7, C4), 149.4 
(dd, 1JcF 230.4, 2JcF 17.0, C6), 160.2 (d, 3JcF 11.3, C3); 8F (376MHz, CDCh) -106.8 (IF, d, 
3hF27.4, F6), -163.5 (IF, d, 3hF27.4, F5); mlz (Ef) 203 (14%, [M]l, 160 (100, [M-Prt), 
147 (29, [M-Bu]l. 
The minor isomer was identified as 5-(butylamino)-4,6-difluoropyridazin-3(2H)-one 
189b, (0.21g, 31%) as white crystals; mp 143- 144°C (Found C, 47.2; H, 5.4; N, 20.7; 
CsHnN3F20 requires C,-47.3;-H.-5.5; N,-20~7-%);vmax-1 cm~ 1 1008, lll5, 11-58; 1~87-, 1375, 
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1439, 1529, 1590, 1643 (CO amide), 2959 (br, NH), 3283 (CH); 8H (500MHz, (CD3)2CO) 
3 3 0.93 (3H, t, JHH 7.4, NHCH2CH2CH2CH3), 1.40 (2H, sextet, JHH 7.4, 
NHCH2CH2CH2CH3), 1.63 (2H, pent, 3JHH 7.1, NHCH2CH2CH2CH3), 3.47 (2H, qd, 3JHH 
7.1, 5JHF 2.8, NHCH2CH2CH2CH3), 5.93 (lH, br s, NHBu), 11.93 (lH, br s, ring NH); 8c 
(125MHz, (CD3)2CO) 14.0 (s, NHCH2CH2CH2CH3), 20.4 (s, NHCH2CH2CH2CH3), 33.3 
(d, 5JcF 2.8, NHCH2CH2CH2CH3), 44.6 (d, 4JCF 6.8, NHCH2CH2CH2CH3), 128.4 (dd, 2JCF 
31.3, 2JcF 6.7, C5), 139.4 (dd, 1JcF 241.7, 3JCF 12.0, C4), 148.2 (dd, 1JcF 230.0, 3JCF 10.4, 
C6), 157.0 (d, 2JcF 22.6, C3); oF (376MHz, CDCh) -101.9 (IF, d, 4hF 23.5, F6), -153.5 (IF, 
4
JFF 23.5, F5); m/z (ES) 204 (100%, [M+Ht), 245 (19, [M+MeCNt). Crystals suitable 
for X-ray diffraction obtained by recrystallisation from acetonitrile. 
4-(Benzy/amino)-5, 6-difluoropyridazin-3 (2H)-one 190a and 5-(benzy/amino)-4, 6-difluoro-
pyridazin-3(2H)-one 190b 
190a 
Ph 
l_NH 
F~F 
~'N~O 
H 
190b 
4,5,6-Trifluoropyridazin-3(2H)-one (0.50g, 3.33mmol) was dissolved in acetonitrile 
(20m!) under argon with stirring. Benzylamine (0.72ml, 6.66mmol) was added dropwise, 
and the mixture stirred at room temperature for I6 hours. After this period water (20ml) 
was added followed by dichloromethane (20m!), and the organic layer separated. The 
aqueous layer was then extracted with further portions of dichloromethane (2 x 20ml), and 
the combined organic extracts were dried (MgS04), filtered and evaporated under vacuum 
to yield a crude yellow product (0.72g), containing 2 products in a 6I :39 ratio by 19F NMR 
analysis. These were then purified by flash column chromatography with ethyl acetate and 
hexane as elutant (1 :2 900ml, followed by 1: I 500ml) to yield the major product 4-
(benzylamino)-5,6-difluoropyridazin-3(2H)-one 190a (0.39g, 49%) as a white solid; mp 
146- 147°C (Found C, 55.8; H, 3.9; N, I7.5. C 11 H9N3F20 requires C, 55.7; H, 3.8; N, 
I7.7%); Vmax I cm·1 I023, 1073, 1123, 1274, 1377, 1449, I507, 158I, 1636 (CO amide), 
2988 (br, NH), 3377; 8H (500MHz, CDCh) 4.69 (2H, dd, 3JHH 6.6, 4JHH 2.2, NHCH2Ph), 
--- ' - - - 3-- -- - - ~~--- - - c - - - - - -_- - - -. --- ~ ~ 
5.88 (lH, br t, JHH 6.6, NHBn), 7.38- 7.30 (5H, m, Ar-H), 11.37 (lH, br s, rmg NH); oc 
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(125MHz, CDCh) 48.3 (d, 4JcF 6.3, CH2), 127.6 (s, ArC), 128.3 (s, ArC), 129.2 (s, ArC), 
132.0 (d, 3JcF 8.6, C4), 131.7 (dd, 1JCF 256.3, 2JCF 32.4, C5), 137.8 (s, C1 '), 149.2 (dd, 1JcF 
229.8, 2JcF 17.7, C6), 160.1 (d, 3JcF 11.7, C3); bp (376MHz, CDCh) -105.9 (lF, d, 3JFF27.5, 
F6), -161.1 (IF, d, 3}pp 27.5, F5); mlz (Eil237 (53%, [M]l, 91 (100, [CH2Pht), 65 
(63). Crystals suitable for X-ray diffraction obtained by recrystallisation from acetonitrile. 
The minor product required further purification by recrystallisation from 
acetonitrile, and was shown to be 5-(benzylamino)-4,6-difluoropyridazin-3(2H)-one 190b 
(0.23g, 29%) as a white solid; mp 175- 176°C (Found C, 55.6; H, 3.9; N, 17.6. C8H 11N4FO 
requires C, 55.7; H, 3.8; N, 17.5%); 8H (500MHz, CDCh) 4.50 (lH, br s, NH), 4.67 (2H, 
dd, 3JHH 6.3, 4JHF 2.5, CH2), 7.31 - 7.42 (5H, m, ArH), 10.63 (IH, br s, ring NH); 8c 
(IOOMHz, DMSO-d6) 46.5 (d, 4JcF 6.5, CH2), 126.6 (s, ArC), 127.0 (s, ArC), I27.0 (dd, 
2Jcp31.3, 6.9, C5), I28.4 (s, ArC), 138.3 (dd, 1Jcp241.4, 3JcF I2.1, C4), 139.4 (d, 5Jcp 1.8, 
CI '), 146.9 (dd, 1JcF 230.8, 3JCF 10.3, C6), I55.7 (d, 2JCF 22.0, C3); 8F (376MHz, CDCh) 
-I01.3 (IF, d, 4JFF 22.9, F6), -150.9 (IF, d, 4JFF 22.9, F4); m!z (Eil237 (12%, [Mt), 91 
(100, [CH2Ph]l. 
4-(N-Buty/-N-methy/amino )-5, 6-difluoropyridazin-3 (2H)-one 191a 
~ F~N, 
~'N~O 
H 
191a 
N-methylbutylamine (O.I58ml, I.33mmol) was mixed with 4,5,6-trifluoropyridazin-
3(211)-one (IOOmg, 0.666mmol) in a Radleys Greenhouse tube under nitrogen. Acetonitrile 
(5ml) was added and the mixture stirred at room temperature for 16 hours. After this 
period the solvent was evaporated, and the residue dissolved in dichloromethane (I Oml). 
Water (I Oml) was added and the organic layer separated on a hydrophobic frit. The 
aqueous layer was then extracted with further portions of dichloromethane (2 x I Oml). The 
combined organic extracts were dried (MgS04), filtered and evaporated on a blowdown 
evaporator to yield crude material which was purified by flash column chromatography 
(Elutant ethyl acetate : hexane- graclient I()% to 33% EtOAc ove,r 29 l]lirmt~s) to yi_eld 4-
- --- ----~- -. -=. -- _-_--.-,- --- -- -- . -- ~- ._ -- - ---- - -
(N-butyl-N-methylamino)-5,6-difluoropyridazin-3(2H)-one 191a (0.067g, 46%) as a white 
I 56 
Chapter 7: Experimental 
solid; mp 78 -79°C (Found [MHt218.10998. C9H13F2N30 requires [MHt 218.10994); 8H 
(400MHz, CDCh) 0.93 (3H, t, 3JHH 7.5, NCH2CH2CH2CH3), 1.32 (2H, sextet, 3JHH 7.5, 
NCH2CH2CH2CH3), 1.61 (2H, pent, 3JHH 7.5, NCH2CH2CH2CH3), 3.17 (3H, d, 5JHF 4.8, 
NMeBu), 3.56 (2H, td, 3JHH 7.5, 5JHF 1.0, NCH2CH2CH2CH3), 11.41 (1H, br s, ring NH); 
8c (100MHz, CDCh) 13.8 (s, NCH2CH2CH2CH3), 19.8 (s, NCH2CH2CH2CH3), 30.4 (d, 
5JcF 1.6, NCH2CH2CH2CH3), 40.0 (d, 4JcF 6.4, NMeBu), 53.4 (d, 4JcF 4.0, 
NCH2CH2CH2CH3), 135.3 (d, 2JcF 8.0, C4), 136.5 (dd, 1JcF 264.4, 2JcF 32.0, C5), 149.0 
(dd, 1JcF 231.7, 2JcF 19.2, C6), 161.6 (d, 3JCF 9.6, C3); 8F (376MHz, CDCh) -107.7 (IF, d, 
3JFF 26.4, F6), -149.4 (IF, 3JrF 26.4, F5); m/z (ESl218 (100%, [M+Ht). 
4-(N-Allyl-N-methylamino)-5,6-difluoropyridazin-3(2H)-one 192a and 5-(N-allyl-N-methyl-
amino)-4,6-difluoropyridazin-3(2H)-one 192b 
N-Methylallylamine (0.127ml, 1.33mmol) was mixed with 4,5,6-tritluoropyridazin-
3(2H)-one (IOOmg, 0.666mmol) in a Radleys Greenhouse tube under nitrogen. Acetonitrile 
(5ml) was added and the mixture stirred at room temperature for 48 hours. After this 
period the solvent was evaporated, and the residue dissolved in dichloromethane (1Om I). 
Water (lOml) was added and the organic layer separated on a hydrophobic frit. The 
aqueous layer was then extracted with further portions of dichloromethane (2 x 1Om I). The 
combined organic extracts were dried (MgS04), filtered and evaporated on a blowdown 
evaporator, followed by purification by flash column chromatography ( elutant cyclohexane 
:ethyl acetate 5:1 to 2:1 gradient over 20 minutes) to yield 4-(N-allyl-N-methylamino)-5,6-
difluoropyridazin-3(2H)-one 192a (0.066g, 49%) as a white solid; mp 95 - 96°C (Found 
[MHt 202.07859. CsH9F2N30 requires [MHt 202.07864); Vmax I cm-1 996, 1074, 1116, 
1177, 1251, 1416, 1482, 1564, 1626 (CO amide), 2921 (br, NH); 8H ( 400MHz, CDC h) 
3.14 (3H, d, 5JHf4.7, NCH3), 4.14 (2H, dd, 3JHH 6.0, 5JHF 1.0, NCH2CH=CH2), 5.24 (IH, d, 
3JHH 16.0, NCH2CH=CH2), 5.24 (IH, d, 3JHH 11.6, NCH2CH=CH2) 5.90 (1H, ddt, 3JHH 
16~0~ 11.6, 6.0, NCfbCH~CH2), -10.66 ( i H, br s, ring NH); 8c (1 OOMHz, CDC h-) 39.4 (d, 
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4JCF 6.4, NCH3), 55.9 (d, 4JeF 2.8, NCH2CH=CHz), 118.0 (s, NCHzCH=CH2), 133.9 (s, 
NHCHzCH=CHz), 135.0 {d, 2JeF 7.2, C5), 137.0 (dd, 1JCF 265.2, 2JCF 31.2, C4), 149.0 (dd, 
1JCF 232.5, 2JeF 19.2, C6), 161.6 (d, 3JeF 9.6, C3); bF (376MHz, CDCb) -107.5 (IF, d, 3JFF 
26.7, F6), -148.4 {IF, dq, 31rF26.7, 5JHF 4.7, F5); mlz (ES+) 202 (100%, [M+H]l. 
The minor isomer 5-(N-allyl-N-methylamino)-4, 6-difluoropyridazin-3(2H)-one 
192b was also obtained (0.0208g, 16%) as a white solid; mp 82 - 84°C (Found [MHt 
202.07865. CsH9F2N30 requires MW 202.07864); bH (400MHz, CDCb) 3.03 (3H, dd, 5JHF 
4.0, 2.5, NCH3), 3.85 (2H, d, 3JHH 6.0, NHCH2CH=CH2), 5.27 (3H, m, NHCH2CH=CH2), 
5.85 (1H, m, NHCHzCH=CHz); be (lOOMHz, CDCh) 39.4 (dd, 4JeF 5.6, 4.8, NCH3) 57.2 
(dd, 4JCF 5.6, 4.0, NHCH2CH=CH2), 118.9 (s, NHCH2CH=CH2), 130.8 (dd, 2JCF28.0, 6.4, 
C5), 132.7 (s, NHCHzCH=CHz), 144.1 (dd, 1JeF 252.5, 3JeF 12.8, C4), 149.3 (dd, 1JeF 
236.5, 3JeF 8.8, C6), 157.7 (d, 2JCF 23.2, C3); bF (376MHz, CDCb) -91.0 {IF, d, 41rF 22.4, 
F6), -139.4 (IF, d, 4lrF22.4, F4); m/z (ESl202 (100%, [M+H]l. 
5, 6-Difluoro-4-(piperidin-1-yl) pyridazin-3 (2H)-one 193a 
Fn~o: I 2' 
N,N 0 
H 
193a 
Piperidine (0.132ml, 1.33mmol) was mixed with 4,5,6-trifluoropyridazin-3(2H)-one 
(1 OOmg, 0.666mmol) in a Radleys Greenhouse tube under nitrogen. Acetonitrile (5ml) was 
added and the mixture stirred at room temperature for 48 hours. After this period the 
solvent was evaporated, and the residue dissolved in dichloromethane (IOml). Water 
(1 Oml) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1 Oml). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator to 
yield crude material which was purified by flash column chromatography ( elutant 
cyclohexane : ethyl acetate 4: I to 2:1 gradient over 20 minutes), followed by mass directed 
automated purification to yield 5,6-difluoro-4-(piperidin-1-yl)pyridazin-3(2H)-one 193a 
(0.074g, 52%) as a white solid; mp 145- 146°C (Found [MHt 216.09426. C9H11 F2N30 
requires [MHt 216.09429); bH (400MHz, CDCb) 1.68 (6H, m, C3'(H) + C4'(I;-I)), 3.54 
~ - - - -~- -- . - - - --- - -- . - -::__. -
(4H, m, C2'(H)), 11.08 {lH, br s, ring NH); be (lOOMHz, CDCb) 24.2 (s, C4'), 26.5 (d, 
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51cF 1.6, C3'), 50.4 (d, 4JCF 4.8, C2'), 135.3 (d, 2JcF 7.2, C4), 137.4 (dd, 1JcF 265.2, 21cF 
31.2, C5), 148.9 (dd, 1JcF 232.5, 2JcF 19.2, C6), 160.9 (d, 3JcF 10.4, C3); ()F (376MHz, 
CDCh) -107.4 (lF, d, 4JFF 27.0, F6), -147.6 (lF, 4JFF 27.0, F5); m/z (ES+) 216 (100%, 
[M+Ht). 
5,6-Difluoro-4-morpho/inopyridazin-3(2H)-one 194a and 4,6-difluoro-5-(4-morpholiny/)-
3(2H)-pyridazinone 194b 
F ("o 
FnN~3' I 2' 
N .... N 0 
H 
194a 
4,5,6-Trifluoropyridazin-3(2H)-one (0.50g, 3.33mmol) was dissolved in acetonitrile 
(20ml) under argon with stirring. Morpholine (0.58ml, 6.66mmol) was added dropwise, 
and the mixture stirred at room temperature for 4.5 hours. After this period water (20ml) 
was added followed by dichloromethane (20ml), and the organic layer separated. The 
aqueous layer was then extracted with further portions of dichloromethane (2 x 20ml), and 
the combined organic extracts were dried (MgS04), filtered and evaporated under vacuum 
to yield a crude yellow product (0.59g). This was purified by recrystallisation from 
acetonitrile to yield 5,6-difluoro-4-morpholinopyridazin-3(2H)-one 194a (0.42g, 59%) as 
white crystals; mp 179 - 180°C (Found C, 44.4; H, 4.2; N, 19.5. CsH9N3F202 requires C, 
44.2; H, 4.2; N, 19.4%); Vmax I cm-1 1002, 1048, 1106, 1246, 1274, 1392, 1451, I574, 1615, 
1644 (CO amide), 2859 (br, NH), 3I45; ()H (400MHz, DMSO-d6) 3.64 (4H, br t, 3JHH 4.5, 
C2'(H)), 3.8I (4H, t, 3JHH 4.5, C3'(H)), I0.33 (1H, br s, ring NH); <>c (IOOMHz, DMSO-d6) 
48.8 (d, 41cF 4.6, C2'), 66.5 (d, 5JCF 1.7, C3'), 133.9 (dd, 2JcF 7.2, 3JCF 2.3, C4), 137.0 (dd, 
11CF 264.8, 2JcF 32.7, C5), 147.4 (dd, 1JCF 226.8, 2JcF I9.2, C6), I59.8 (d, 3JcF 9.1, 4JcF 0.8, 
C3); ()F (376MHz, DMSO-d6) -I09.3 (IF, d, 3JFF 29.5, F6), -I49.0 (IF, 3JFF 29.5, F5); m!z 
(Ell217 ( I6, [M]l, 132 (I 00, [M-morpholino ]l. 
The minor product, 4,6-difluoro-5-(4-morpholiny/)-3(2H)-pyridazinone 194b, was 
also isolated by flash column chromatography with ethyl acetate and hexane (I :4) as 
eluant; (0.090g, I2%) as \\'hit~ crystals; mp I79- I80°C (Found C,_44.2; H, 4.1; N, I9.1. 
CsH9N3F202 requires C, 44.2; H, 4.2; N, I9.4%); Vmax I cm-1 I219, 1368, I450, I639 (CO 
I 59 
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amide), 3000 (br, NH); 8" (400MHz, CDCh) 3.42 (4H, dt, 3JHH 5.8, 5JHF 2.0, C2'(H)), 3.81 
(5H, t, 3JHH 4.8, C3'(H), OH underneath); 8c (IOOMHz, CDCh) 50.3 (dd, 4JCF 4.0, C2'), 
66.8 (d, 5Jcr 1.6, C3'), 130.0 (dd, 2JCF 27.9, 2Jcr 5.6, C5), 145.4 (dd, 1Jcr 255.6, 3Jcr 12.0, 
C4), 149.5 (dd, 1Jcr 237.3, 3Jcr 8.8, C6), 160.9 (d, 2Jcr 23.2, C3); 8r (376MHz, CDCh) -
92.0 (IF, d, 41rr 20.7, F6), -146.9 (IF, d, 41rr 20.7, F4); m/z (ESl218 (100%, [M+Ht). 
4-(Diethylamino)-5,6-difluoropyridazin-3(2H)-one 
dif/uoro-pyridazin-3 (2H)-one 195b 
F ( 
F~N-....../ 
~'N~O 
H 
195a 
195a and 5-(diethylamino)-4,6-
Diethylamine (0.138ml, 1.33mmol) was mixed with 4,5,6-trifluoropyridazin-3(2H)-
one (IOOmg, 0.666mmol) in a Radleys Greenhouse tube under nitrogen. Acetonitrile (5ml) 
was added and the mixture stirred at room temperature for 16 hours. After this period the 
solvent was evaporated, and the residue dissolved in dichloromethane (IOml). Water 
(1 Oml) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1 Oml). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator to 
yield crude material which was purified by mass directed automated purification to yield 4-
(diethylamino)-5,6-difluoropyridazin-3(2H)-one 195a (0.062g, 46%) as a white solid; mp 
98 - 99°C, (Found [MHt 204.09439. CsH11F2N30 requires [MHt 204.09429); Vmax I cm·1 
1046, 1186, 1450, 1661 (CO amide), 2900 (br, NH); 8H (400MHz, CDCh) 1.22 (6H, t, 3JHH 
7.0, NCH2CH3), 3.51 (4H, qd, 3JHH 7.0, 5JHF 1.8, NCH2CH3), 11.06 (IH, br s, ring NH); 8c 
(100MHz, CDCb) 14.2 (d, 5Jcr 2.4, NCH2CH3), 45.8 (d, 4Jcr 4.8, NCH2CH3), 134.2 (d, 
2Jcr 7.2, C4), 136.5 (dd, 1Jcr 263.6, 2Jcr 31.2, C5), 149.1 (dd, 1Jcr 230.9, 2Jcr 19.2, C6), 
161.5 (d, 3Jcr 10.4, C3); 8r (376MHz, CDCh) -108.1 (IF, d, 3Jrr 27.0, F6), -149.2 (IF, 3Jrr 
27.0, F5); mlz (ES+) 204 (100%, [M+Ht). 
The minor isomer 5-(diethy/amino)-4,6-difluoropyridazin-3(2H)-one 195b was also 
isolated (0.012g, 9%) as a white solid; mp 82 - 83°C (Found [MHt 204.09437. 
CsH11F2N30 require~nrvtHt 204-:-69429); vmax Fern"' 109{ 12oo, 1397, 1457, 1571, 1631, 
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2874 (br); 8H (400MHz, CDCh) 1.22 (6H, t, 3JHH 7.0, NCH2CH3), 3.37 (4H, q, 3JHH 7.0, 
NCH2CH3), 11.34 (IH, br s, ring NH); 8c (IOOMHz, CDCb) 13.7 (s, NCH2CH3), 46.4 (dd, 
4JcF 4.8, 4JcF 4.8, NCH2CH3), 129.8 (dd, 2JcF 28.8, 2JcF 7.2, C5), 144.1 (dd, 1JcF 252.5, 3JcF 
12.8, C4), 149.6 (dd, 1JCF 237.3, 3JcF 9.6, C6), 157.4 (d, 2JcF 24.0, C3); 8F (376MHz, 
CDCh) -91.2 (IF, d, 4hF 22.4, F6), -139.9 (IF, 4hF 22.4, F4); m/z (ES+) 204 (100%, 
[M+H]l. 
4-(4-Methoxyphenylamino)-5,6-difluoropyridazin-3(2H)-one 196a 
0~Me ¢3' 2' F 
F~NH 
~'N--lO 
H 
196a 
p-Anisidine (0.16443g, 1.33mmol) was mixed with 4,5,6-trifluoropyridazin-3(2H)-
one (lOOmg, 0.666mmol) in a Radleys Greenhouse tube under nitrogen. Acetonitrile (5ml) 
was added and the mixture stirred at mom temperature for 48 hours. After this period the 
solvent was evaporated, and the residue dissolved in dichloromethane (lOml). Water 
(1Om I) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1Om I). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator, 
followed by purification by flash column chromatography (elutant cyclohexane : ethyl 
acetate 4:1 to 2:1 gradient over 18 minutes) to yield 4-(4-methoxyphenylamino)-5,6-
difluoropyridazin-3(2H)-one 196a (0.102g, 61%) as a white solid; mp 148- 149°C (Found 
[MH]+ 254.07362. C11H9F2N302 requires [MHt 254.07356); 8H (400MHz, CD30D) 3.79 
(3H, s, OCH3), 6.89 (2H, d, 3JHH 8.9, 4JHH 3.3, C3'(H)), 7.17 (2H, dd, 3JHH 8.9, 4JHH 3.0, 
C2'(H)); 8F (376MHz, CD300) -105.2 (IF, d, 3hF 26.6, F6), -147.9 (IF, d, 3JFF 26.6, F5); 
mlz (ESl254 ( 100%, [M+H]l. 
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4-(p-Tolylamino)-5,6-difluoropyridazin-3(2H)-one 197a 
F¢ F~NH 
~'N~O 
H 
197a 
p-Toluidine (0.143g, 1.33mmol) was mixed with 4,5,6-trifluoropyridazin-3(2H)-one 
(100mg, 0.666mmol) in a Radleys Greenhouse tube under nitrogen. Acetonitrile (5ml) was 
added and the mixture stirred at room temperature for 48 hours. After this period the 
solvent was evaporated, and the residue dissolved in dichloromethane (10ml). Water 
(1Om I) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1Om I). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator, 
followed by purification by flash column chromatography (elutant cyclohexane : ethyl 
acetate 4:1 to 2:1 gradient over 18 minutes) to yield 4-(p-tolylamino)-5,6-difluoropyridazin-
3(2H)-one 197a (0.088g, 56%) as a white solid; mp 157- 158°C (Found [MHt 238.07866. 
C11H9F2N30 requires [MHt 238.07864); Vmax I cm-1 1051, 1218, 1269, 1450, 1512, 1571, 
1634 (CO amide), 2929 (br, NH); &H (400MHz, CDCh) 2.37 (3H, s, Ar-CH3), 7.05 (2H, dd, 
3JHH 8.3, 6JHF 3.3, C2'(H)), 7.17 (2H, d, 3JHH 8.3, C3'(H)), 7.25 (lH, br s, NHAr), 11.19 
(lH, br s, ring NH); &c (100MHz, CDCh) 20.9 (s, ArCH3), 122.5 (d, 4JCF 4.0, C1 '), 128.8 
(d, 2JcF 8.8, C4), 129.5 (s, ArC), 131.9 (dd, 1JCF 267.6, 2Jcd2.8, C5), 134.9 (s, ArC), 135.5 
(s, ArC), 148.9 (dd, 1JCF 232.5, 2JcF 17.6, C6), 160.0 (d, 3JcF 10.4, C3); &F (376MHz, 
CDCh) -105.1 (IF, d, 3hF26.4, F6), -142.4 (IF, d, 3hF26.4, F5); m/z (ES-) 236 (100%, [M-
HD. 
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4-(4-Bromophenylamino)-5,6-difluoropyridazin-3(2H)-one 198a 
4-Bromoaniline (3.43g, 20.0mmol) was mixed with 4,5,6-trifluoropyridazin-3(211)-
one (1.50g, IO.Ommol) in a round bottom flask under nitrogen. Acetonitrile (50ml) was 
added and the mixture heated to reflux for I6 hours. After this period the solvent was 
evaporated, and the residue dissolved in dichloromethane (50ml). Water (50ml) was added 
and the organic layer separated. The aqueous layer was then extracted with further portions 
of dichloromethane (3 x 50ml). The combined organic extracts were dried (MgS04), 
filtered and evaporated in vacuo, followed by purification by recrystallisation from 
acetonitrile to yield 4-(4-bromopheny/amino)-5,6-difluoropyridazin-3(2H)-one 198a; 
(1.27g, 42%) as a white solid; mp I62 - 164°C (Found [MH, 79Brt 301.97365. 
C10H6F2N30 requires [MH, 79Brt 301.97351); Vmax I cm-1 1025, 1095, 1217, 1455, 1489, 
1584, 1637 (CO amide), 3002 (br, NH); 8H (400MHz, CDCh) 7.02 (2H, dd, 3JHH 8.3, 6JHF 
4.0, C2'(H)), 7.24 (1H, br s, NHAr) 7.44 (2H, d, 3JHH 8.3, C3'(H)); 8c (lOOMHz, CDCb) 
121.6 (s, ArC), 127.2 (d, 4JCF 4.8, C1 '), 131.8 (d, 2JCF 8.8, C4), 135.4 (s, ArC), 136.2 (dd, 
1JcF 268.4, 21cF 33.6, C5), 140.7 (s, ArC), 152.0 (dd, 1JcF 231.7, 2JCF 17.6, C6), 163.2 (d, 
3JCF 9.6, C3); 8F (376MHz, CDCb) -104.6 (IF, d, 3hF 26.9, F6), -142.4 (IF, d, 3hF 26.9, 
F5); m/z (ES+) 304 (100%, [M+Ht, 81 Br), 302 (96, [M+Ht, 79Br). 
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4-( 4-Fluorophenylamino )-5, 6-difluoropyridazin-3 (2H)-one 199a 
F¢ F~NH 
~'N~O 
H 
199a 
4-Fiuoroaniline (0.74g, 6.66mmol) was mixed with 4,5,6-trifluoropyridazin-3(2H)-
one (0.50g, 3.33mmol) in a round bottom flask under nitrogen. Acetonitrile (50ml) was 
added and the mixture heated to reflux for 16 hours. After this period the solvent was 
evaporated, and the residue dissolved in dichloromethane (25ml). Water (25ml) was added 
and the organic layer separated. The aqueous layer was then extracted with further portions 
of dichloromethane (3 x 25ml). The combined organic extracts were dried (MgS04), 
filtered and evaporated in vacuo, followed by purification by recrystallisation from 
acetonitrile to yield 4-(4-jluorophenylamino)-5,6-difluoropyridazin-3(2H)-one 199a; 
(0.42g, 52%) as a white solid; mp 162 - 163°C (Found C, 49.7; H, 2.6; N, 17.4. 
CsH9N3F202 requires C, 49.8; H, 2.5; N, 17.4%); Vmax I cm-1 1209, 1453, 1511, 1585, 1639 
(CO amide), 3200 (br, NH); DH (500MHz, DMSO-d6) 7.12 (2H, t, 3JHH 8.7, C2'(H)), 7.20 
(2H, m, C3'(H)), 8.80 (1H, br s, NHAr), 12.63 (lH, br s, ring NH); De (125MHz, DMSO-
~) 115.6 (d, 2JcF 22.5, C3'), 124.7 (dd, 3JCF 8.3, 4JcF 3.9, C4), 129.4 (d, 3JCF 8.9, C2'), 132.6 
(dd, 1JcF 263.9, 2Jcd3.7, C5), 136.0 (dd, 3JCF 2.9, 4JcF 1.6, Cl '), 148.2 (dd, 1JcF 224.8, 2JcF 
17.4, C6), 159.5 (d, 1JcF 240.1, C4'), 159.8 (d, 3JCF 9.1, C3); OF (376MHz, CDCb) -103.3 
(IF, d, 3JFF 29.7, F6), -114.3 (IF, m, F4'), -139.7 (IF, d, 31FF 29.7, F5); mlz (ES+) 305 
(100%, [M+MeCN+Na]l, 283 (96, [M+MeCN+Ht, 4), 242 (4, [M+Ht). 
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Me,
5 
F~S'Me ~'N~O 
H 
200 
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A clean, dry round bottomed flask was charged with 4,5,6-Trifluoropyridazin-
3(2/l)-one (0.50g, 3.33mmol) and sodium thiomethoxide (0.47g, 6.66mmol), before being 
purged and filled with argon. The solids were dissolved in acetonitrile (20ml), and the 
mixture stirred at room temperature for 6 hours. After this period water (20ml) was added 
followed by dichloromethane (20ml), and the organic layer separated. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 20m I), and the combined 
organic extracts were dried (MgS04), filtered and evaporated under vacuum to yield a 
crude yellow product (0.59g). This was purified by recrystallisation from acetonitrile to 
yield 6-fluoro-4,5-bis(methylthio)pyridazin-3(2H)-one 200 (0.38g, 55%) as yellow crystals~ 
mp 138- I40°C (Found C, 35.0~ H, 3.4; N, 13.7. C6H7N2FOS2 requires C, 34.9; H, 3.4; N, 
I3.6%); Vmax I cm-1 I 136, 1356, I435, I628 (CO amide), 2833 (br, NH); OH (500MHz, 
CDCb) 2.6I (3H, d, 5JHF 4.0, C5-SCH3), 3.81 (3H, s, C4-SCH3), II.88 (lH, br s, ring NH); 
oc (125MHz, CDCb) I7.0 (s, C4-SCH3), 17.7 (d, 4JCF Il.6, C5-SCH3), 134.7 (d, 2JCF 34.6, 
C5), I42.8 (d, 3JcF 6.5, C4), 152.4 (d, 1JcF 234.3, C6), I59.8 (s, C3); OF (376MHz, CDCb)-
89.5 (IF, s, F6); mlz (Eil206 (6%, [M]l, 29I (52, [M-Me]l, 87 (100), 45 (78). Crystals 
suitable for X-ray diffraction grown by slow evaporation of acetonitrile. 
5-(Butylamino)-6-fluoro-4-morpholinopyridazin-3(2H)-one 201 
~NH [o 
F~N~ ~'N~O 
H 
201 
5,6-Difluoro-4-morpholinopyridazin-3(2/l)-one (200mg, 0.92I mmol) was mixed 
wittt a<;e_tQ_nitrile (3ml)_and n-butylami]lec:(O..l35g,J.84mmol)jn_.a 2-5 mLmicrowave vial, 
which was sealed and the mixture irradiated at 150°C for 30 minutes. After this period the 
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solvent was evaporated, and the residue dissolved in dichloromethane (lOml). Water 
(1 Oml) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1 Oml). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator, 
followed by recrystallisation from acetonitrile to yield 5-(butylamino)-6-jluoro-4-
morpholinopyridazin-3(2H)-one 201 (0.136g, 55%) as a white solid; mp 127 - 128°C 
(Found [MHt 271.15633. C,sH11N4F02 requires [MHt 271.15648); Vmax I em·' 1105, 1166, 
1260, 1370, 1457, 1557, 1610 (CO amide), 2851 (br, NH); oH (400MHz, CDCh) 0.97 (3H, 
t, 3JHH 7.5, NHCH2CH2CH2CH3), 1.41 (2H, sextet, 3JHH 7.5, NHCH2CH2CH2CH3), 1.58 
(2H, pent, 3JHH 7.5, NHCH2CH2CH2CH3), 3.14 (4H, t, 3JHH 5.9, C2'(H)), 3.45 (2H, qd, 3JHH 
6.5, 5JHF 3.5, NHCH2CH2CH2CH3), 3.77 (4H, t, 3JHH 5.9, C3'(H)), 5.53 (lH, br t, 3JHH 6.5, 
NHBu), 11.81 (IH, br s, ring NH); oc (IOOMHz, CDCh) 13.7 (s, NHCH2CH2CH2CH3), 
19.8 (s, NHCH2CH2CH2CH3), 33.0 (d, 5JcF 1.6, NHCH2CH2CH2CH3), 44.2 (d, 4JCF 8.8, 
NHCH2CH2CH2CH3), 48.6 (s, C2'), 67.7 (s, C3'), 125.1 (d, 3JcF 11.2, C4), 138.7 (d, 2JCF 
24.8, C5), 147.5 (d, 1JCF 234.1, C6), 161.5 (m, C3); OF (376MHz, CDCb) -99.2 (IF, s); m/z 
(ES+) 271 (100%, [M+Ht). 
5-( Ally/amino )-6-fluoro-4-morpho/inopyridazin-3 (2H)-one 202 
HNf("o 
F~N_J 
~'N~O 
H 
202 
5,6-Difluoro-4-morpholinopyridazin-3(2H)-one (200mg, 0.921 mmol) was mixed 
with acetonitrile (3ml) and allylamine (0.14ml, 1.84mmol) in a 2-5 ml microwave vial, 
which was sealed and the mixture irradiated at 150°C for minutes. After this period the 
solvent was evaporated, and the residue dissolved in dichloromethane (10ml). Water 
(1 Oml) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x I Oml). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator, 
followed by recrystallisation from acetonitrile to yield 5-(a/lylamino)-6-jluoro-4-
morpholi11opyrlaazb1~1(2H}-one 202 (O.i24g, 56%) as a white soH<l; mp 159 - -I60°C 
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(Found [MHt 255.12506. C11HJsFN402 requires [MHt 255.12518); Vmax I cm-1 1106, 
1166, 1259, 1370, 1491, 1555, 1608 (CO amide), 2802 (br, NH); oH (400MHz, CDCb) 
3.15 (4H, t, 3JHH4.7, C2'(H)), 3.77 (4H, t, 3JHH 4.7, C3'(H)), 4.09 (2H, dt, 3JHH6.5, 5JHF 2.0, 
NHCH2CH=CH2), 5.20 (2H, m, NHCH2CH=CH2), 5.63 (lH, t, 3JHH 6.3, 
NHCH2CH=CH2), 5.92 (1H, m, NHCH2CH=CH2), 11.54 (lH, br s, ring NH); 8c 
(lOOMHz, CDCb) 46.5 (d, 4JCF 9.6, NHCH2CH=CH2), 48.6 (s, C2'), 67.6 (s, C3'), 116.4 
(s), 125.8, (d, 3JcF 10.4, C4), 134.8 (s), 138.4 (d, 2JcF 24.8, C5), 147.5 (d, 1JCF 234.1, C6), 
161.5 (s, C3); 8F (376MHz, CDCh) -98.9 (IF, s); m/z (ES) 509 (100%, [2M+Ht), 255 
(53, [M+Ht). 
5-(Benzylamino )-6-.fluoro-4-morpho/inopyridazin-3 (2H)-one 203 
Ph 
l_NH ('o 
F~NJ 
~,NAo 
H 
203 
5,6-Difluoro-4-morpholinopyridazin-3(211)-one (0.25g, 1.15mmol) was dissolved in 
dry acetonitrile (40ml) under argon with stirring. Benzylamine (0.25ml, 2.30mmol) was 
added dropwise, and the mixture heated to reflux for 72 hours, after which 19F NMR 
indicated complete conversion to products. Water (25ml) and dichloromethane (25ml) 
were added, and the layers separated. The aqueous layer was then extracted with further 
portions of dichloromethane (2 x 25ml), before the combined organic extracts were dried 
(MgS04) and filtered. The solvent was removed in vacuo to yield a crude yellow solid 
(0.17g). This was recrystallised from acetonitrile to yield 5-(benzylamino)-6-.fluoro-4-
morpholinopyridazin-3(2H)-one 203 (0.22g, 62%) as a cream solid; mp 199 - 201°C 
(Found C, 58.8; H, 5.7; N, 18.2. C1sH17N~02 requires C, 59.2; H, 5.6; N, 18.4%); Vmax I 
cm-1 1012, 1115, 1212, 1258, 1443, 1460, 1630 (CO amide), 2878 (br, NH); oH (500MHz, 
CDCh) 1.69 (1H, br s, OH hydroxy-pyridazine tautomer), 3.12 (4H, br t, 3JHH 4.7, C2'(H)), 
3.72 (4H, t, 3JHH 4.7, C3'(H)), 4.66 (2H, dd, 3JHH 6.4, 5JHF 1.8, CH2Ph), 5.82 (lH, t, 3JHH 
6.4, NHBn), 7.26 (2H, d, 3JHH 7.3, C2'(H)), 7.34 (1H, d, 3JHH 7.3, C4'(H)), 7.39 (2H, t, 3JHH 
7.3, C3'(H)), 11.05 (IH, br s, ring NH); oc (125MHz, CDCh) 48.8 (d, 4JCF 9.0, CH2Ph), 
' -. - ' ', ' ' 5 ' - ' ' ' ' - ' ,- ' ' ,_', ' ' ' - .,,_ ' 
48.9 (s), 67:8 (s), 126.7 (d, JcF 10.4, Ar(Cl ')), 127.2 (s, ArC), 128.2 (s, ArC), 129.3 (s, 
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ArC), 138.8 (d, 2JCF 15.2, C5), 138.9 (d, 3JcF 9.0, C4), 147.9 (d, 1JcF 234.0, C6), 161.5 (s, 
C3); C>F (376MHz, CDCh) -98.2 (IF, s); mlz (ESl305 (100%, [M+H]l. 
6-F/uoro-4, 5-dimorpho/inopyridazin-3 (2H)-one 204 
0 eN~ [o 
FnN~3" I 2" 
N,N 0 
H 
204 
5,6-Difluoro-4-morpholinopyridazin-3(2H)-one (200mg, 0.921 mmol) was mixed 
with acetonitrile (3ml) and morpholine (0.160g, 1.84mmol) in a 2-5 ml microwave vial, 
which was sealed and the mixture irradiated at 150°C for 30 minutes. After this period the 
solvent was evaporated, and the residue dissolved in dichloromethane (I Oml). Water 
( 1 Oml) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1 Oml). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator to 
yield 6-jluoro-4,5-dimorpho/inopyridazin-3(2H)-one 204 (0.141g, 54%) as a white solid; 
mp 163- 164°C (Found [MHt 285.13570. C12H11FN403 requires [MHt 285.13575); Vmax I 
cm-1 1026, 1118, 1190, 1241, 1268, 1397, 1415, 1514, 1619 (CO amide); ()H (400MHz, 
CDCh) 3.14 (4H, t, 3JHH4.0, C2'(H)), 3.48 (4H, t, 3JHH 4.8, C2"(H)), 3.79 (8H, m, C3'(H) + 
C3"(H)), 11.47 (lH, br s, ring NH); C>c (lOOMHz, CDCh) 49.9 (s, C2"), 50.3 (dd, 4JCF 4.8, 
5JcF 1.9, C2'), 67.0 (s, C3'), 67.5 (s, C3"), 129.9 (d, 2JCF 27.2, C5), 141.4 (d, 3JcF 11.2, C4), 
154.3 (d, 1JcF 237.3, C6), 161.7 (s, C3); OF (376MHz, CDCh) -94.2 (IF, s); mlz (ESl285 
(1 00%, [M+Ht). 
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5,6-Difluoro-4-morpholinopyridazin-3(2/i)-one (200mg, 0.921mmol) was mixed 
with acetonitrile (3ml) and diethylamine (0.19ml, 1.84mmo1) in a 2-5 ml microwave vial, 
which was sealed and the mixture irradiated at 150°C for minutes. After this period the 
solvent was evaporated, and the residue dissolved in dichloromethane (10ml). Water 
(1 Oml) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1 Oml). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator to 
yield a crude yellow solid. This was then purified by flash column chromatography 
(elutant cyclohexane : ethyl acetate) to yield 5-(diethylamino)-6-jluoro-4-morpholino-
pyridazin-3(2H)-one 205 (0.0613g, 25%) as a white solid; mp 105- 107°C (Found [MHt 
271.15643. C12H19FN402 requires [MHt 271.15648); oH (400MHz, CDCb) 1.05 (6H, t, 
3JHH 6.7, NCH2CH3), 3.11 (4H, q, 3JHH 6.7, NCH2CH3), 3.46 (4H, m, C2'(H)), 3.80 (4H, 
m,C3'(H)), 11.56 (lH, br s, ring NH); oc (lOOMHz, CDCb) 13.1 (s, NCH2CH3), 46.1 (d, 
4JCF 4.8, NCH2CH3), 49.2 (s, C2'), 67.5 (s, C3'), 128.3 (d, 2JcF 28.0, C5), 142.0 (d, 3JCF 
11.2, C4), 155.5 (d, 1JcF 237.3, C6), 161.3 (s, C3); OF (376MHz, CDCb) -94.6 (IF, s); mlz 
(ESl271 (100%, [M+Ht). 
5-(N-Allyl-N-methylamino)-6-jluoro-4-morpholinopyridazin-3(2H)-one 206 
~'\-' [o 
F~N~ 
~'N~O 
H 
206 
5,6-Difluoro-4-morpholinopyridazin-3(2/i)-one (200mg, 0.921 mmol) was mixed 
with acetonitrile (3ml) and N-allylmethylamine (0.18ml, 1.84mmol) in a 2-5 ml microwave 
vial, Which was sealed and ttie mix.ture irradiated at 150°C for minutes. After this period 
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the solvent was evaporated, and the residue dissolved in dichloromethane (IOml). Water 
( 1 Oml) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1 Oml). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator to 
yield 5-(N-allyl-N-methylamino)-6-fluoro-4-morpholinopyridazin-3(2H)-one 206 (0.1 OOg, 
43%) as a white solid; mp 86 - 87°C (Found [MHt 269.14070. C12H17FN40 2 requires 
[MHt 269.14083); Vmax I cm-1 992, 1113, 1232, 1535, 1654 (CO amide), 2859 (br, NH); OH 
(400MHz, CDCh) 2.79 (3H, d, 4JHF 2.8, NMe), 3.45 (4H, t, 3JHH 4.6, C2'(H)), 3.64 (2H, d, 
3JHH 6.3, NCH2CH=CH2), 3.80 (4H, t, 3JHH 4.6, C3'(H)), 5.18 (2H, m, NCH2CH=CH2), 
5.79 (1H, m, NCH2CH=CH2), 11.27 (IH, br s, ring NH); Be (lOOMHz, CDCh) 39.8 (d, 
4JcF 4.8, NMe), 46.3 (s, C2'), 57.4 (d, 4JcF 4.0, NCH2CH=CH2), 67.5 (s, C3'), 118.5 (s, 
NCH2CH=CH2), 130.4, (d, 2JcF 28.0, C5), 133.9 (s, NCH2CH=CH2), 140.7 (d, 3JcF 10.4, 
C4), 154.6 (d, 1JcF 236.5, C6), 161.6 (s, C3); 8F (376MHz, CDCh) -94.5 (IF, s); mlz (ES) 
269 (100%, [M+H]). 
5-(4-Bromophenylamino)-6-fluoro-4-morpholinopyridazin-3(2H)-one 207a and 6-(4-
bromophenylamino )-5-.fluoro-4-morpholinopyridazin-3 (2H)-one 207b 
4-Bromoaniline (0.396g, 2.30mmol) was mixed with sodium hydride (0.09g, 
2.30mmol, 60% dispersion in mineral oil) and THF (l Oml) in a Radleys Carousel tube 
under nitrogen with stirring. 5,6-difluoro-4-morpholinopyridazin-3(2l:l)-one (50mg, 
0.230mmol) was added and the mixture heated to reflux for 64 hours. After this period the 
solvent was evaporated, and the residue dissolved in dichloromethane (1 Oml). Water 
(10ml) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1Om I). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator, 
followed by purification by mass directed automated purification to yield 5-(4-
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bromophenylamino)-6-fluoro-4-morpholinopyridazin-3(2H)-one 207a (0.0091g, 11%) as a 
white solid; mp I78- I79°C (Found ( 9Br, MHt 369.0352I; C14H 14BrFN402 requires 
( 9Br, MH]+ 369.03569); ()H (400MHz, CDCh) 3.27 (4H, t, 3JHH 4.8, C2'(H)), 3.60 (4H, t, 
3JHH 4.8, C3'(H)), 6.I8 (IH, br s, NHArBr), 6.78 (2H, d, 3JHH 8.5, C2"(H)), 7.43 (2H, d, 
3JHH 8.5, C3"(H)), I0.25 (IH, br s, ring NH); <5c (IOOMHz, CDCh) 48.3 (s, C2'), 67.2 (s, 
C3'), II6.2 (s), I21.I (s), I24.8 (d, 2JCF 27.2, C5), 132.0 (s), 137.4 (d, 3JcF 7.2, C4), 138.5 
(s), I49.9 (d, 1JcF 232.5, C6), I60.5 (s, C3); ()F (376MHz, CDCh) -97.9 (IF, s); mlz (ES+) 
37I (IOO%, [81Br, M+H]l, 369 (97, ( 9Br, M+H]l. 
A small sample of the minor isomer 6-(4-bromophenylamino)-5-fluoro-4-
morpholinopyridazin-3(2H)-one 207b was also obtained; (0.0059g, 7%) as a white solid; 
()F (376MHz, CDCh) -I43.6 (IF, s); m/z (ES+) 37I (98%, [81 Br, M+Ht), 369 (100, ( 9Br, 
M+Ht). 
4-( 4-Bromophenylamino )-5-(butylamino )-6-fluoropyridazin-3 (2H)-one 208 
\NH 
F~~~ 
~'N~O ~Br 
H 
208 
4-( 4-Bromopheny lamina)-5 ,6-difluoropyridazin-3(2H)-one (I OOmg, 0.3 3I mmol) 
was added to a 2-5ml microwave vial, along with acetonitrile (3ml) and butylamine 
(0.08I8ml, 0.828mmol). The vial was sealed, and the mixture irradiated at I50°C for 30 
minutes. After this period the solvent was evaporated in a blowdown evaporator, and the 
crude residue dissolved in dichloromethane (IOml). Water (IOml) was added and the 
mixture separated on a hydrophobic frit. The aqueous layer was washed with further 
portions of dichloromethane (2 x IOml). The combined organic extracts were then dried 
over MgS04, filtered and evaporated to yield a crude yellow solid. This was then purified 
by elution through an SCX-2 column with methanol. This yielded 4-(4-
bromophenylamino)-5-(butylamino)-6-jluoropyridazin-3(2H)-one 208 (0.0987g, 90%) as a 
yellow solid; mp I50 - I52°C (Found ( 9Br, MHt 355.05597. Ct4Ht6BrFN40 requires 
( 9Br, MHt-355.05643); ()H (400MHZ~ CDCI:i) 0.82 (3H, t, 3JHH7.3, NHCH2CHiCH:!CH3) 
171 
Chapter 7: Experimental 
1.19 (2H, sextet, 3JHH 7.3, NHCH2CH2CH2CH3), 1.35 (2H, pent, 3JHH 7.3, 
NHCH2CH2CH2CH3), 3.12 (2H, q, 3JHH 6.0, NHCH2CH2CH2CH3)), 3.91 (1H, br t, 3JHH 
6.0, NHBu), 6.58 (2H, d, 3JHH 8.8, C2'(H)), 6.84 (IH, br s, NHAr), 7.31 (2H, d, 3JHH 8.8, 
C3'(H)), 12.00 (1H, br s, ring NH); oc (100MHz, CDCh) 13.5 (s, NHCH2CH2CH2CH3), 
19.6 (s, NHCH2CH2CH2CH3), 32.7 (s, NHCH2CH2CH2CH3), 43.8 (d, 4JcF 4.8, 
NHCH2CH2CH2CH3), 113.44 (s, ArC), 118.5 (s, ArC), 119.2 (d, 3JcF 10.4, C4), 129.5 (d, 
2JCF 27.2, C5), 131.7 (s, ArC), 140.4 (s, ArC), 148.5 (d, 1JCF 230.9, C6), 161.0 (s, C3); OF 
(376MHz, CDCh) -99.9 (IF, s, F6); mlz (ESl355 (100%, [81 Br, M+H]l, 353 (99, C9Br, 
M+H]l. 
4-(4-Bromophenylamino)-5-(al/ylamino)-6-jluoropyridazin-3(2H)-one 209 
LNH 
n H F N ~ N OUBr 
H 
209 
4-( 4-Bromopheny1amino )-5,6-difluoropyridazin-3(2H)-one (1 OOmg, 0.33I mmol) 
was added to a 2-5m! microwave vial, along with acetonitrile (3m!) and allylamine 
(0.0621 ml, 0.828mmol). The vial was sealed, and the mixture irradiated at I50°C for 30 
minutes. After this period the solvent was evaporated in a blowdown evaporator, and the 
crude residue dissolved in dichloromethane (1Om!). Water (I Om!) was added and the 
mixture separated on a hydrophobic frit. The aqueous layer was washed with further 
portions of dichloromethane (2 x I Om!). The combined organic extracts were then dried 
over MgS04, filtered and evaporated to yield a crude yellow solid. This was then purified 
by flash column chromatography (Elutant ethyl acetate : hexane - gradient I 0% to 33% 
EtOAc over 20 minutes. This yielded 4-(4-bromophenylamino)-5-(allylamino)-6-
fluoropyridazin-3(2H)-one 209 (0.0502g, 45%) as a white solid; mp 167 - 168°C (Found 
C9Br, MHt 339.02469. CnH12BrFN40 requires ( 9Br, MHt 339.02513); Vmax I cm·1 I269, 
1303, 1435, I6I8 (CO amide), 2813 (br, NH); oH (400MHz, CDCh) 3.67 (2H, td, 3JHH 6.2, 
5JHF 1.5, NHCH2CH=CH2), 3.94 (IH, dt, 3hnt 6.2, 4JHF 2.8, NHAllyl), 5.06 (IH, m, 
NHCH2CH=CH2), 5.09 (1H, m, NHCH2CH=CH2), 5.66 (1H, m, NHCH2CH=CH2), 6.64 
(2H, d, 3JHH 8.8, C2'(H)), 6.JI (IH, br s, NHAr), 7.37 (2H, d, 3JHH 8.8, C3'(.;)), I1.17 oil, 
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br s, ring NH); oc (lOOMHz, CDCb) 46.2 (d, 4JcF 4.8, NHCH2CH=CH2), 114.2 (s), 117.2 
(s), 119.2 (s), 120.6 (d, 3JcF 9.6, C4), 127.5 (d, 2JcF 27.2, C5), 131.9 (s), 134.2 (s), 139.7 (s), 
148.7 (d, 1JcF 230.9, C6), 160.4 (s, C3); Op (376MHz, CDCb) -99.8 (IF, s, F6); m/z (ES+) 
341 (100%, [81Br, M+H]l, 339 (96, ( 9Br, M+Ht). 
4-( 4-Bromophenylamino )-5-( die thy/amino )-6-.fluoropyridazin-3 (2H)-one 210 
3"(0) 
2" 
nN H 2' F N~3· N 0 ~Br 
H 
210 
4-( 4-bromophenylamino )-5,6-difluoropyridazin-3(211)-one ( 1 OOmg, 0.331 mmol) 
was added to a 2-5ml microwave vial, along with acetonitrile (3ml) and morpholine 
(0.0621 ml, 0.828mmol). The vial was sealed, and the mixture irradiated at 150°C for 30 
minutes. After this period the solvent was evaporated in a blowdown evaporator, and the 
crude residue dissolved in dichloromethane (1 Oml). Water (1Om I) was added and the 
mixture separated on a hydrophobic frit. The aqueous layer was washed with further 
portions of dichloromethane (2 x 1Om I). The combined organic extracts were then dried 
over MgS04, filtered and evaporated to yield a crude yellow solid. This was then purified 
by mass directed automated purification, yielding 4-(4-bromophenylamino)-5-
(diethylamino)-6-jluoropyridazin-3(2H)-one 210 (0.0225g, 18%) as white solid; mp 233-
234°C (Found ( 9Br, MH]+ 369.03531; c,4Hl4BrFN402 requires ( 9Br, MHt 369.03569); 
oH (400MHz, CDCb) 2.99 (4H, m, C2"(H)), 3.24 (4H, t, 3Jilli 4.8, C3"(H)), 6.84 (2H, d, 
3JHH 8.5, C2'(H)), 7.20 (lH, br s, NHAr), 7.45 (2H, d, 3JHH 8.5, C3'(H)), 9.68 (lH, br s, 
ring NH); oc (lOOMHz, DMSO-ck;) 47.9 (d, 4JCF 4.0, C2"), 65.5 (s, C3"), 113.6 (s, ArC), 
122.1 (d, 2JCF 28.8, C5), 123.1 (s, ArC), 130.3 (s, ArC), 131.0 (d, 3JcF 12.7, C4), 138.5 (s), 
152.5 (d, 1JCF 231.7, C6), 159.0 (s, C3); Op (376MHz, CDCb) -92.2 (IF, s, F6); m/z (ES+) 
371 (100%, [81 Br, M+H]l, 369 (95, ( 9Br, M+H]l. 
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4-( 4-Bromophenylamino )-5-( die thy/amino )-6-fluoropyridazin-3 (2H)-one 211 
211 
4-( 4-Bromophenylamino )-5,6-difluoropyridazin-3(211)-one (1 OOmg, 0.331mmol) 
was added to a 2-5ml microwave vial, along with acetonitrile (3ml) and diethylamine 
(0.0856ml, 0.828mmol). The vial was sealed, and the mixture irradiated at 150°C for 30 
minutes. After this period the solvent was evaporated in a blowdown evaporator, and the 
crude residue dissolved in dichloromethane (1 Oml). Water (1 Oml) was added and the 
mixture separated on a hydrophobic frit. The aqueous layer was washed with further 
portions of dichloromethane (2 x 1 Oml). The combined organic extracts were then dried 
over MgS04, filtered and evaporated to yield a crude yellow solid. This was then purified 
by mass directed automated purification, yielding 4-(4-bromophenylamino)-5-
(diethylamino)-6-f/uoropyridazin-3(2H)-one 211 (0.0179g, 15%) as a white solid; mp 
ll0°C (decomp) (Found C9Br, MHt 355.05609. ci4HI6BrFN40 requires ( 9Br, MHt 
355.05643); 8H {400MHz, CDCb) 0.97 {6H, t, 3JHH 7.0, NCH2CH3), 2.93 (4H, q, 3JHH 7.0, 
NCH2CH3), 6.79 (2H, d, 3JHH 8.0, C2'(H)), 7.36 (2H, d, 3JHH 8.0, C3'(H)), 10.65 (1H, br s, 
ring NH); 8c (lOOMHz, CDCh) 13.2 (s, NCH2CH3), 44.4 (d, 4JcF 3.8 NCH2CH3), 116.0 (s, 
ArC), 122.5 {s, ArC), 123.4 (d, 2JcF 27.5, C5), 131.0 (s, ArC), 133.0 (d, 3JCF 12.1, C4), 
138.0 (s, ArC), 154.3 {d, 1JcF 228.5, C6), 158.2 (s, C3); 8F (376MHz, CDCh) -92.8 (IF, s, 
F6); mlz (ESl357 (97%, [81 Br, M+Ht), 355 (100, ( 9Br, M+Ht). 
4-( 4-Bromophenylamino )-5-(ethylthio)-6-f/uoropyridazin-3 (2H)-one 212 
212 
4-(4-Bromophenylamino)-5,6-difluoropyridazin-3(211)-one (100mg, 0.331mmol) 
was added to a 2-5ml microwave vial, along with acetonitrile (3ml) and sodium 
ethanethiolate (0.0696g, 0.828mmol). The vial was sealed, and the mixture irradiated at 
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120°C for 30 minutes. After this period the solvent was evaporated in a blowdown 
evaporator, and the crude residue dissolved in dichloromethane (lOml). Water (lOml) was 
added and the mixture separated on a hydrophobic frit. The aqueous layer was washed with 
further portions of dichloromethane (2 x 1 Oml). The combined organic extracts were then 
dried over MgS04, filtered and evaporated to yield a crude yellow solid. This was then 
purified by elution through silica with ethyl acetate, yielding 4-(4-bromophenylamino)-5-
(ethylthio)-6-jluoropyridazin-3(2H)-one 212 (0.1020g, 90%) as a yellow solid, mp 171 -
173°C (Found C9Br, MHt 343.98589. C 12H11 BrFN30S requires C9Br, MHt 343.98630); 
Vmax I cm-1 1070, 1252, 1462, 1485, 1573, 1633 (CO amide), 3011 (br, NH); OH (400MHz, 
CDCh) 0.92 (3H, t, 3JHH 7.3, SCH2CH3), 2.47 (2H, q, 3JHH 7.3, SCH2CH3), 7.01 (2H, d, 
3JHH 8.6, C2'(H)), 7.43 (2H, d, 3JHH 8.6, C3'(H)), 9.07 (lH, br s, NHAr), 12.52 (IH, br s, 
ring NH); Oc (100MHz, CDCh) 13.9 (s, SCH2CH3), 27.3 (d, 4JcF 3.2, SCH2CH3), 103.2 (d, 
2JCF 40.7, C5), 115.4 (s, ArC), 124.1 (s, ArC), 130.5 (s, ArC), 138.2 (s, ArC), 143.4 (d, 3JcF 
9.6, C4), 154.1 (d, 1JCF 221.3, C6), 156.1 (s, C3); oF (376MHz, CDCh) -86.2 (IF, s, F6); 
m/z (ESl346 (100%, [81 Br, M+H]l, 344 (91, C9Br, M+H]l. 
4, 6-Bis(4-bromophenylamino)-5-jluoropyridazin-3(2fl)-one 213 
¢ F H 
HN~N~ 
~,N_,l,O ~Br 
H 
213 
4-Bromoaniline (0.142g, 0.828mmol) was mixed with sodium hydride (0.033g, 
0.828mmol) in THF (3ml) under argon with stirring. This solution was then transferred to 
a 2-5ml microwave vial containing 4-( 4-bromophenylamino )-5,6-difluoropyridazin-3(211)-
one (1 OOmg, 0.331 mmol). The vial was sealed under argon, and the mixture irradiated at 
120°C for 60 minutes. After this period the solvent was evaporated in a blowdown 
evaporator, and the crude residue dissolved in dichloromethane (lOml). Water (10ml) was 
added and the mixture separated on a hydrophobic frit. The aqueous layer was washed with 
further portions of dichloromethane (2 x 1 Oml). The combined organic extracts were then 
dried over MgS04, filtered and evaporated to yield a crude yellow solid. This was then 
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purified by mass directed automated purification, yielding 4,6-bis(4-bromophenylamino)-5-
jluoropyridazin-3(2H)-one 213 (0.0242g, 16%) as a white solid; mp 160°C (decomp) 
(Found [2 X 79Br, MHt 452.93562. cl6HIIBr2FN40 requires [2 X 79Br, MHt 452.93564); 
Vmax I cm-1 1069, 1226, 1250, 1294, 1482, 1512, 1535, 1592, 1643 (CO amide), 1666,2887 
(br, NH); OH (600MHz, DMSO-d6) 7.05 (2H, dd, 3JHH 8.8, 5JHF 3.7), 7.42 (4H, m), 7.59 
(2H, d, 3JHH 8.8), 8.45 (1H, br s, NHAr), 8.66 (lH, br s, NHAr), 12.34 (1H, br s, ring NH); 
Oc (150MHz, DMSO-d6) 112.2 (s, ArC), 114.0 (s, ArC), 120.2 (s, ArC), 122.2 (s ArC), 
122.3 (s, ArC), 124.5 (s, ArC), 130.9 (s, ArC), 131.2 (s, ArC), 137.5 (d, 1JcF 269.8, C5), 
139.2 (d, 2JcF 13.7, C4), 139.6 (s, ArC), 140.2 (s, ArC), 158.1 (d, 3JcF 9.4, C3); OF 
(376MHz, CDCh) -138.6 (lF, s, F5); mlz (ES+) 457 (24%, [M+Ht (2 x 81 Br)) 455 (46, 
[M+Ht, C9Br + 81Br)), 453 (22, [M+Ht (2 x 79Br)), 129 (61), 119 (1 00). 
4-(N-Butyl-N-methylamino)-5-(buty/amino)-6-jluoropyridazin-3(2H)-one 214 
4-(N-butyi-N-methylamino )-5,6-difluoropyridazin-3(2H)-one (25mg, 0.115mmol) 
was dissolved in acetonitrile (0.75ml) in a 0.5 - 2ml microwave vial. After addition of 
butylamine (0.021 g, 0.298mmol) the vial was sealed and irradiated at 150°C for 80 
minutes. After this period the solvent was evaporated and the crude material dissolved in 
dichloromethane (lOrn!). Water (lOrn!) was added, and the organic layer separated. The 
aqueous portion was washed with further portions of dichloromethane, and the combined 
organic extracts were dried (MgS04), filtered and evaporated to yield a crude yellow 
material. This was purified by elution through an acid functionalised silica column with 
methanol to yield 4-(N-butyl-N-methylamino)-5-(butylamino)-6-jluoropyridazin-3(2H)-one 
214 (22.6mg, 73%) as a white solid; mp 79- 80°C (Found [MHt271.19276. C13H23N4FO 
requires [MHt 271.19287); oH (400MHz, CDCh) 0.90 (3H, t, 3JHH 7.0, 
NCH2CH2CH2CH3), 0.96 (3H, t, 3JHH 7.3, NCH2CH2CH2CH3), 1.35 (6H, m), 1.56 (2H, 
peht, 3J1-m 7.3, NCH2CH2CHiCH3), 2:68 (3H, s, NMe), 3.04 (2H, t, 3JHH 7.5, 
176 
Chapter 7: Experimental 
NMeCH2CHzCHzCH3), 3.41 (2H, qd, 3JHH 6.5, 4JHr 3.0, NHCHzCHzCHzCH3), 5.54 (lH, 
br t, 3JHH 6.5, NHBu), 11.29 {lH, br s, ring NH); De (lOOMHz, CDCh) 13.7 (s, 
NCHzCHzCHzCH3), 13.9 (s, NCHzCHzCHzCH3), 19.8 (s, NCHzCHzCHzCH3), 20.5 (s, 
NCHzCH2CHzCH3), 30.8 (s, NMeCHzCHzCHzCH3), 33.2 (d, 5Jcr 1.6, 
NHCHzCHzCH2CH3), 39.6 (NMe), 44.1 (d, 4Jcr 9.6, NHCHzCH2CHzCH3), 53.6 (s, 
NMeCH2CHzCHzCH3), 126.7 (d, 3Jcr 11.2, C4), 139.4 (d, 2Jcr 24.0, C5), 147.6 (d, 1Jcr 
234.9, C6), 161.4 (s, C3); Dr (376MHz, CDCh) -98.9 (lF, s); mlz (ES) 271 (100%, 
[M+H]}. 
Attempted Lewis acid activation of 4-benzylamino-5,6-difluoropyridazin-3(2H)-one 
4-benzylamino-5,6-ditluoropyridazin-3(2H)-one (0.1 Og, 0.422mmol) was dissolved 
in dry THF (1 Oml) under argon with stirring. Boron trifluoride diethyletherate (0.057ml, 
0.463mmol) was added at 0°C and the mixture allowed to warm to room temperature. 
After 30 minutes diethylamine (0.087ml, 0.843mmol) was added and the mixture heated to 
reflux for 16 hours. After this period 19F NMR of the crude reaction mixture was 
measured, which showed the presence of only the starting material. 
4-(Butylamino)-6-j/uoro-5-morpholinopyridazin-3(2H)-one 217 
(0) 
N H F~N~ 
~'N~O 
H 
217 
4,6-Ditluoro-5-morpholinopyridazin-3(2H)-one (50mg, 0.230mmo1) was mixed 
with acetonitrile (3ml) and n-butylamine (0.0569ml, 0.575mmol) in a 2-5 ml microwave 
vial, which was sealed and the mixture irradiated at 150°C for 30 minutes. After this period 
the solvent was evaporated, and the residue dissolved in dichloromethane (10ml). Water 
(I Oml) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1 Oml). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evapor(ltor, 
foll-owed by elution through an SCX-2 column (Biota~e) with m~thanol to yield 4-
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(butylamino)-6-fluoro-5-morpholinopyridazin-3(2H)-one 217 (0.0596g, 96%) as a white 
solid; mp 150- 151 °C (Found [MHt 271.15623. C15H17N4F02 requires [MHt 271.15648); 
Vmax I cm-1 1008, 1108, 1258, 1350, 1449, 1564, 1607, 1642 (CO amide), 2921 (br, NH); 
oH (400MHz, CDCh) 0.96 (3H, t, 3JHH 7.3, NHCHzCHzCHzCH3), 1.43 (2H, sextet, 3JHH 
7.3, NHCH2CH2CH2CH3), 1.60 (2H, pent, 3JHH 7.3, NHCHzCH2CHzCH3), 3.01 (4H, br t, 
3JHH 4.4, C2'(H)), 3.77 (4H, t, 3JHH 4.4, C3'(H)), 3.79 (2H, t, 3JHH 7.3, 
NHCH2CHzCHzCH3), 5.93 (1H, br s, NHBu), 11.37 (IH, br s, ring NH); De (100MHz, 
CDCh) 13.8 (s, NHCHzCHzCHzCH3), 20.0 (s, NHCHzCHzCH2CH3), 32.7 (s, 
NHCHzCH2CHzCH3), 44.0 (s, NHCH2CH2CHzCH3), 50.9 (d, 4JcF 4.0, C2'), 66.8 (s, C3'), 
114.2 (d, 3JcF 30.4, C4), 141.8 (d, 2JcF 14.4, C5), 157.4 (d, 1JcF 237.3, C6), 159.3 (s, C3); OF 
(376MHz, CDCh) -93.5 (IF, s); m/z (ES+) 271 (100%, [M+H]}. 
4-(Diethylamino)-6-fluoro-5-morpholinopyridazin-3(2H)-one 218 
0 C) ( 
F~N-....../ 
~'N~O 
H 
218 
4,6-Difluoro-5-morpholinopyridazin-3(2H)-one (50mg, 0.230mmol) was mixed 
with acetonitrile (3ml) and diethylamine (0.0595ml, 0.575mmol) in a 2-5 ml microwave 
vial, which was sealed and the mixture irradiated at 150°C for 60 minutes. After this period 
the solvent was evaporated, and the residue dissolved in dichloromethane (lOml). Water 
( 1 Oml) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1 Oml). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator to 
yield a crude yellow solid. This was then purified by mass directed automated purification 
to yield 4-(diethylamino)-6-fluoro-5-morpholinopyridazin-3(2H)-one 218 (0.0311g, 50%) 
as a white solid; mp 140- 142°C (Found [MHt 271.15621. C12H19FN402 requires [MHt 
271.15648); DH (400MHz, CDCh) 1.09 (6H, t, 3JHH 7.3, NCH2CH3), 3.20 (4H, td, 3JHH 4.8, 
5JHF 1.8, C2'(H)), 3.43 (4H, q, 3JHH 7.3, NCH2CH3), 3.78 (4H, t, 3Jm1 4.8, C3'(H)), 10.17 
(1 H, br s, ring l\lH); 8c (1 OOMHz, CDC h) 13.9 (s, NCH2CH3), 45.6"(s,-NCH2CH3), 49.8 (d; 
4JcF 4.0, C2'), 67.2 (s, C3'), 132.0 (d, 2JCF 25.6, C5), 139.7 (d, 3JcF 10.4, C4), 153.5 (d, 1JcF 
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235.7, C6), 162.2 (s, C3); 8F (376MHz, CDCh) -95.3 (IF, s); m/z (ES) 271 (100%, 
[M+Ht). 
4,5-Bis(butylamino)-6-fluoropyridazin-3(2H)-one 219 
\NH 
F~~~ ~'N~O 
H 
219 
5-(butylamino)-4,6-difluoropyridazin-3(2H)-one (50mg, 0.246mmol) was dissolved 
in acetonitrile (1.5ml) in a 0.5- 2ml microwave vial. After addition of butylamine (0.045g, 
0.615mmol) the vial was sealed and irradiated at 150°C for 3 hours. After this period the 
solvent was evaporated and the crude material dissolved in dichloromethane (10m!). Water 
(1Om I) was added, and the organic layer separated. The aqueous portion was washed with 
further portions of dichloromethane (3 x 1 Oml), and the combined organic extracts were 
dried (MgS04), filtered and evaporated to yield a crude yellow material. This was purified 
by mass directed automated purification to yield 4,5-bis(butylamino)-6-jluoropyridazin-
3(2H)-one 219 (28.1mg, 45%) as a colourless oil; (Found [MHt 257.17718, C12H22N4FO 
requires [MHt 257.17722); 8H (400MHz, CDCh) 0.93 (3H, t, 3JHH 7.1, 
NCH2CH2CH2CH3), 0.94 (3H, t, 3JHH 7.1, NCH2CH2CH2CH3), 1.38 (2H, sextet, 3JHH 7.1, 
NCH2CH2CH2CH3), 1.39 (2H, sextet, 3JHH 7.1, NCH2CH2CH2CH3), 1.52 (2H, pent, 3JHH 
7.1, NCH2CH2CH2CH3), 3.41 (2H, pent, 3JHH 7.1, NHCH2CH2CH2CH3), 3.08 (2H, q, 3JHH 
7.1, NCH2CH2CH2CH3), 3.26 (1H, br s, NHBu), 3.28 (2H, q, 3JHH 7.1, 
NCH2CH2CH2CH3), 5.54 (IH, br t, 3JHH 7.1, NHBu), 11.05 (IH, br s, ring NH); 8c 
(lOOMHz, CDCh) 13.8 (s, NCH2CH2CH2CH3, 2"d peak underneath), 20.0 (s, 
NCH2CH2CH2CH3), 20.0 (s, NCH2CH2CH2CH3), 32.6 (s, NCH2CH2CH2CH3), 32.9 (s, 
NCH2CH2CH2CH3), 43.1 (s, NHCH2CH2CH2CH3), 44.1 (d, 41cF 2.4, 
NHCH2CH2CH2CH3), 120.9 (d, 2JcF 31.2, C5), 139.4 (d, 3JcF 10.4, C4), 152.8 (d, 1JcF 
226.9, C6), 159.9 (s, C3); 8F (376MHz, CDCh) -102.6 (IF, s); m/z (ES+) 257 (100%, 
[M+Ht). 
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5-(Cyc/ohexyloxy)-6-jluoro-4-morpholinopyridazin-3(2H)-one 220a and 6-(cyclohexy/oxy)-
5 -jluoro-4 -morpho/ inopyridazin-3 (2H)-one 220 b 
Cyclohexanol (0.23g, 2.30mmol) was mixed with sodium hydride (0.09g, 
2.30mmol, 60% dispersion in mineral oil) and THF (lOml) in a Radleys Carousel tube 
under nitrogen with stirring. 5,6-difluoro-4-morpholinopyridazin-3(2H)-one (50mg, 
0.230mmol) was added and the mixture heated to reflux for 64 hours. After this period the 
solvent was evaporated, and the residue dissolved in dichloromethane (1Om I). Water 
(I Om I) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x 1 Oml). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator, 
followed by purification by mass directed automated purification to yield 5-
(cyclohexyloxy)-6-jluoro-4-morpholinopyridazin-3(2H)-one 220a (0.0127g, 19%) as a 
white solid; mp 175 - 177°C (Found [MHt 298.15604. C1Jf20FN30 3 requires [MHt 
298.15615); 8H (400MHz, MeOD) 1.28- 1.98 (IOH, m, cyclohexyl(H)), 3.53 (4H, t, 3JHH 
4.1, C2'(H)), 3.80 (4H, t, 3JHH 4.1, C3'(H)), 4.10 (IH, m, Cl"(H)); 8c (IOOMHz, CDCh) 
24.1 (s), 25.3 (s), 32.3 (s, C2"), 49.8 (s, C2'), 67.5 (s, C3'), 82.4 (d, 4JcF 4.8, C 1 "), 134.2 (d, 
2JcF 28.8, C5), 139.6 (d, 3JCF 8.8, C4), 152.8 (d, 1JcF 234.9, C6), 161.5 (s, C3); 8F (376MHz, 
CDCh) -99.1 (IF, s); m/z (ES+) 298 (100%, [M+H]l. 
A small sample of the minor isomer 6-(cyclohexyloxy)-5-jluoro-4-
morpho/inopyridazin-3(2H)-one 220b was obtained (0.0082g, 12%) as a white solid; 8H 
(400MHz, CDCh) 1.40-2.05 (IOH, m, cyclohexy1(H)), 3.52 (4H, t, 3JHH 4.6, C2'(H)), 3.78 
(4H, t, 3JHH 4.6, C3'(H)), 4.75 (1H, m, C1"(H)); 8F (376MHz, CDCh) -141.8 (IF, s); m!z 
(ES+) 298 (100%, [M+Ht). 
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4-Bromophenol (0.398g, 2.30mmol) was mixed with sodium hydride (0.090g, 
2.30mmol, 60% dispersion in mineral oil) and THF (I Om I) in a Radleys Carousel tube 
under nitrogen with stirring. 5,6-difluoro-4-morpholinopyridazin-3(2H)-one (50mg, 
0.230mmol) was added and the mixture heated to reflux for 64 hours. After this period the 
solvent was evaporated, and the residue dissolved in dichloromethane (1 Oml). Water 
(I Oml) was added and the organic layer separated on a hydrophobic frit. The aqueous layer 
was then extracted with further portions of dichloromethane (2 x I Om I). The combined 
organic extracts were dried (MgS04), filtered and evaporated on a blowdown evaporator, 
followed by purification by mass directed automated purification to yield 5-(4-
bromophenoxy)-6-jluoro-4-morpholinopyridazin-3(2H)-one 22la (0.0 196g, 23%) as a 
white solid; mp I73- I74°C (Found C9Br, MHt 370.0I921. C14H13BrFN30 3 requires 
C9Br, MHt 370.01971); 8H (400MHz, CDCb) 3.55 (4H, t, 3JHH 4.8, C2'(H)), 3.7I (4H, t, 
3JHH 4.8, C3'(H)), 6.82 (2H, d, 3JHH 9.I, C2"(H)), 7.47 (2H, d, 3JHH 9.1, C3"(H)), 10.62 (lH, 
br s, ring NH); 8c (IOOMHz, CDCh) 49.5 (s, C2'), 67.2 (s, C3'), 116.2 (s, ArC), 116.7 (s, 
ArC), 128.5 (d, 2JCF 30.4, C5), 130.I (s, ArC), 140.0 (d, 3JCF 8.0, C4), I51.7 (d, 1JCF 235.7, 
C6), I55.7 (s, ArC), I60.6 (s, C3); 8F (376MHz, CDCb) -IOI.I (lF, s); m/z (ESl 372 
(98%, [81 Br, M+Ht), 370 (I 00, C9Br, M+Ht). 
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4-(4-Bromophenylamino)-5-(cyclohexy/oxy)-6-jluoropyridazin-3(2H)-one 222a and 4-(4-
bromophenylamino)-6-(cyclohexy/oxy)-5-jluoropyridazin-3(2H)-one 222b 
222a 222b 
4-( 4-bromophenylamino )-5,6-difluoropyridazin-3(2H)-one (1 OOmg, 0.331 mmol) 
was added to a 2-5ml microwave vial, along with tetrahydrofuran (3ml) and cyclohexanol 
(0.0874ml, 0.828mmol). Sodium hydride 0.033lg, 60% in mineral oil, 0.828mmol) was 
added under nitrogen. The vial was sealed after effervescence was completed, and the 
mixture irradiated at 120°C for 60 minutes. After this period the crude mixture was 
analysed by 19F NMR and LC-MS, which showed conversion to products to be only 7%. 
The reaction mixture contained 4-(4-bromophenylamino)-5-(cyclohexyloxy)-6-
jluoropyridazin-3(2H)-one 222a; DF (376MHz, CDCb) -99.6 (IF, s, F6); m/z (ES+) 383 
(98%, [81 Br, M+Hf), 381 (100, ( 9Br, M+Hf), and 4-(4-bromophenylamino)-6-
(cyclohexyloxy)-5-jluoropyridazin-3(2H)-one 222b; DF (376MHz, CDCh) -136.0 (IF, s, 
F5); m/z (ES+) 383 (98%, [81 Br, M+Hf), 381 (100, ( 9Br, M+Hf). 
4-( 4-Bromophenylamino )-6-( allyloxy )-5-jluoropyridazin-3 (2H)-one 223b 
F H ~O~N~ ~'N_,lO ~Br 
H 
223b 
4-(4-Bromophenylamino)-5,6-difluoropyridazin-3(2H)-one 223b (100mg, 
0.331 mmol) was added to a 2-5ml microwave vial, along with acetonitrile (3ml) and allyl 
alcohol (0.0563ml, 0.828mmol). Sodium hydride 0.0331g, 60% in mineral oil, 0.828mmol) 
was added under nitrogen. The vial was sealed after effervescence was completed, and the 
mixture irradiated at 120°C for 60 minutes. After this period the solvent was evaporated in 
a blowdown evaporator, and the crude residue dissolved in dichloromethane (lOml). Water 
( 1 Oml) was added and the mixture s~p_a!_(;lted on a hy~rq}Jhg_!J!c frit. Th"t': ~qu~~()l.l~ lay~r w~s 
washed with further portions of dichloromethane (2 x lOml). The combined organic 
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extracts were then dried over MgS04, filtered and evaporated to yield a crude yellow solid. 
This was then purified by mass directed automated purification, yielding 4-(4-
bromophenylamino)-6-(al/yloxy)-5-jluoropyridazin-3(2H)-one 223b (0.0090g, 9%) as a 
white solid; (Found ( 9Br, MHt 340.00879. C13HttBrFN302 requires ( 9Br, MHt 
340.00914); 8H (400MHz, CDCh) 4.74 (2H, d, 3JHH 5.8, OCH2CH=CH2), 5.32 (IH, dd, 
3JHH 10.5, 2JHH 1.2, OCH2CH=CH2)), 5.43 (IH, dd, 3JHH 17.3, 2JHH 1.2, OCH2CH=CH2), 
6.06 (IH, m, OCH2CH=CH2), 6.95 (2H, dd, 3JHH 8.5, 6JHF 3.5, C2'(H)), 6.99 (IH, br s, 
NHAr), 7.44 (2H, d, 3JHH 8.5, C3'(H)), 10.89 (IH, br s, ring NH); 8c (100MHz, CDCb) 
67.9 (s, OCH2CH=CH2), 117.2 (s), 118.8 (s), 122.9 (d, 2JcF 4.8, C4), 125.6 (s), 131.8 (s), 
131.9 (s), 135.7 (d, 1JcF 271.6, C5), 137.6 (s), 148.5 (d, 2JcF 13.5, C6), 159.6 (d, 3JCF 10.4, 
C3); 8F (376MHz, CDCb) -137.1 (IF, s, F5); m/z (ES+) 342 (98%, [81 Br, M+Ht) 340 (100, 
( 9Br, M+H]l. 
4-(4-Bromophenylamino)-6-jluoro-5-phenoxypyridazin-3(2H)-one 224a 
3" 4"(X 
F-vL~~3' ~'N~O ~Br 
H 
224a 
4-( 4-Bromophenylamino )-5,6-difluoropyridazin-3(2H)-one ( 1 OOmg, 0.331 mmol) 
was added to a 2-5ml microwave vial, along with acetonitrile (3ml) and sodium phenoxide 
(0.096lg, 0.828mmol). The vial was sealed after effervescence was completed, and the 
mixture irradiated at l20°C for 60 minutes. After this period the solvent was evaporated in 
a blowdown evaporator, and the crude residue dissolved in dichloromethane (1 Oml). Water 
(lOml) was added and the mixture separated on a hydrophobic frit. The aqueous layer was 
washed with further portions of dichloromethane (2 x 1 Oml). The combined organic 
extracts were then dried over MgS04, filtered and evaporated to yield a crude yellow solid. 
This was then purified by mass directed automated purification, yielding 4-(4-
bromophenylamino)-6-jluoro-5-phenoxypyridazin-3(2H)-one 224a (0.0087g, 7%) as a 
white solid; mp 164- 166°C (Found ( 9Br, MHt 376.00906. Ct6HttBrFN302 requires ( 9Br 
, MHt 376;00914); 8w(400MHz; CDG:h) 6:50(~2H, d; 3Ji-iH 7.5, C2"(H)); 6.81 (2H; d; 3J1-iH 
8.5, C2'(H)), 6.96 (IH, t, 3JHH 7.5, C4"(H)), 7.14 (2H, t, 3JHH 7.5, C3"(H)) 7.25 (lH, br s, 
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NHAr), 7.27 (2H, d, 3JHH 8.5, C3'(H), 9.81 (IH, br s, ring NH); OF (376MHz, CDCh) 
-100.1 (IF, s, F6); mlz (ES-) 376 (100%, [81 Br, M+H]l374 (92, ( 9Br, M+Ht). 
7.3 Experimental to Chapter 3 
4, 5, 6-Trifluoro-2-pheny/pyridazin-3 (2H)-one 232 
F Ff.:r ~2'0 
lJ3' 
4' 
232 
4,5,6-Trifluoropyridazin-3(2/:1)-one (0.25g, 1.67mmol) was mixed with lead (IV) 
acetate (0.81g, 1.83mmol) and zinc (II) chloride (0.23g, 1.67mmol), which were dissolved 
in anhydrous benzene (20ml) under argon with stirring. The mixture was heated to reflux 
for 8 hours before being allowed to cool. Water (20ml) was added, followed by 
dichloromethane (20ml), and the layers separated. The aqueous layer was then extracted 
with dichloromethane (3 x 20ml) and the combined organic extracts dried (MgS04), 
filtered and evaporated to yield a crude yellow material. This was purified by flash column 
chromatography using hexane and ethyl acetate (4:1) as elutant to yield 4,5,6-trifluoro-2-
phenylpyridazin-3(2H)-one 232 (0.16g, 42%) as a white solid; mp 120- 122°C (Found C, 
52.9; H, 2.2; N, 12.2. C10HsF3N20 requires C, 53.1; H, 2.2; N, 12.4%); oH (500MHz, 
CDCh) 7.43 (IH, t, 3JHH 7.7, C4'(H)), 7.50 (2H, t, 3JHH 7.7, C2'(H)), 7.57 (2H, d, 3JHH 7.7, 
C3'(H)); oc (125MHz, CDCh) 124.9 (s, ArC), 129.2 (s, ArC), 129.2 (s, ArC), 139.0 (ddd, 
1JcF 288.5, 2JcF 33.9, 2JcF 10.3, C5), 139.4 (s, Cl'), 144.9 (ddd, 1Jcp258.4, 2JcF 19.9, 3JcF 
3.9, C4), 145.0 (ddd, 1JCF 251.0, 2JcF26.6, 3JCF 4.7, C6), 155.2 (dd, 2JcF 21.3, 3JCf4.7, C3); 
OF (188MHz, CDCh) -101.2 (IF, dd, 3JFF 27.1, 4JFF 15.4, F6), -133.5 (IF, dd, 3]pF 17.2, 4]pp 
15.4, F4), -145.6 (IF, dd, 3]pp 27.1, 3]pp 17.2, F5); mlz (Eil226 (30%, [M]l, 225 (33, [M-
Ht), 77 (100, [Pht). 
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4,5,6-Trifluoro-2-phenylpyridazin-3(2H)-one (0.25g, 1.11mmol) was mixed with 
sodium methoxide (0.12g, 2.21 mmol) and dissolved in anhydrous methanol (20m I) before 
stirring at room temperature for 8 hours. The solvent was then evaporated and the crude 
material dissolved in dichloromethane (20ml) and water (20ml), before separation of the 
layers. The aqueous layer was then extracted with further portions of dichloromethane (3 x 
20ml), and the organic extracts were combined, dried (MgS04), filtered and evaporated to 
yield a crude yellow material (0.23g), which was purified by recrystallisation from hexane 
to yield 4,6-di.fluoro-5-methoxy-2-phenylpyridazin-3(2H)-one 233b (0.17g, 64%) as a 
white solid; mp 88- 90°C (Found C, 55.2; H, 3.4; N, 12.0. C 11 HsF2N202 requires C, 55.5; 
H, 3.4; N, 11.8%); Vmax I cm-1 1036, 1100, 1417, 1654 (CO amide); 01-1 (500MHz, CDCb) 
4.27 (3H, d, 5JI-IF 4.8, OCH3), 7.38 (1H, t, 3JHI-f8.1, C4'(H4)), 7.54 (2H, t, 3JHH 8.1, C2'(H)), 
7.59 (2H, d, 3JHH 8.1, C3'(H)); oc (125MHz, CDCb) 61.1 (d, 4JcF 8.1, OCH3), 124.9 (s, 
ArC), 128.6 (s, ArC), 129.0 (s, ArC), 136.5 (dd, 2JCF 31.0, 2JcF 6.8, C5), 139.7 (s, C1 '), 
144.7 (dd, 1JcF 256.9, 3JcF 10.5, C4), 147.4 (dd, 1JcF 240.6, 3JCF 8.5, C6), 155.2 (d, 2JcF 
23.8, C3); OF (188MHz, CDCh) -98.3 (IF, dd, 41FF 20.2, F6), -141.0 (IF, dq, 41FF 20.2, 5JI-IF 
4.8, F4); m/z (ESl239 (100%, [M+Ht). 
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4-(Benzylamino)-5,6-difluoro-2-phenylpyridazin-3(2H)-one 234a and 5-(benzylamino)-4,6-
difluoro-2-phenylpyridazin-3(2H)-one 234b 
234a 234b 
4,5,6-Trifluoro-2-phenylpyridazin-3(2/i)-one (0.25g, 1.11mmol) dissolved in 
anhydrous acetonitrile (20ml) before the addition of benzylamine (0.24ml, 2.21 mmol) and 
stirring at room temperature for 8 hours. The solvent was then evaporated and the crude 
material dissolved in dichloromethane (20ml) and water (20ml), before separation of the 
layers. The aqueous layer was then extracted with further portions of dichloromethane (3 x 
20ml), and the organic extracts were combined, dried (MgS04), filtered and evaporated to 
yield a crude brown material (0.29g), which was purified by flash column chromatography 
using hexane and ethyl acetate (4:1) as elutant to yield 4-(benzylamino)-5,6-difluoro-2-
phenylpyridazin-3(2H)-one 234a (0.14g, 40%) as a white solid; mp 116 -117°C (Found C, 
65.3; H, 4.2; N, 13.4. C17H13F2N30 requires C, 65.2; H, 4.2; N, 13.4%); Vmax I cm-1 1131, 
1345, 1449, 1662 (CO amide); OH (500MHz, CDCh) 4.74 (2H, d, 3JHH 6.3, NHCHzPh), 
6.05 (1H, br s, NHBn), 7.33 (3H, m, ArH), 7.38 (3H, m, ArH), 7.46 (2H, t, 3JHH 7.8, 
C3'(H)), 7.57 (2H, d, 3JHH 7.8, C2'(H)); oc (125MHz, CDCh) 48.2 (d, 4JCF6.5, NHCHzPh), 
125.4 (s, ArC), 127.5 (s, ArC), 128.2 (s, ArC), 128.6 (s, ArC), 129.0 (s, ArC), 129.1 (s, 
ArC), 130.5 (dd, 1JcF 260.7, 2JcF 33.3, C5), 132.3 (d, 2JcF 8.8, C4), 137.9 (s, ArC), 140.7 (s, 
ArC), 147.8 (dd, 1JCF 230.8, 2JcF 17.4, C6), 157.8 (d, 3JcF 10.9, C3); OF (658MHz, CDCh)-
104.7 (IF, d, 3JFF 28.9, F6), -162.5 (lF, d, 3JFF 28.9, F5); m/z (ESl314 (100%, [M+Ht). 
The minor isomer 5-(benzylamino)-4,6-difluoro-2-phenylpyridazin-3(2H)-one 234b 
was also isolated (0.09g, 30%) as a white solid; mp 171 - 173°C (Found C, 65.1; H, 4.3; N, 
13.6. C11HnF2N30 requires C, 65.2; H, 4.2; N, 13.4%); Vmax I cm-1 1115, 1357, 1510, 1626; 
OH (700MHz, CDCh) 4.51 (IH, br s, NHBn), 4.69 (2H, dd, 3JHH 6.0, 5JHF 1.9, NHCHzPh), 
7.35 (4H, m, Arlf), 7.41 (2H, rri, ArH), 7.44'(2H, t, 3JHH 82, C3'(H)), 7.60 (2H, d, 3JHH 8.2, 
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C2'(H)); &c (175MHz, CDCh) 48.8 (d, 4Jcp7.2, NHCH2Ph), 124.9 (s, ArC), 126.1 (dd, 2JcF 
31.1, 2JCF 8.4, C5}, 127.9 (s, ArC), 128.2 (s, ArC}, 128.6 (s, ArC), 129.0 (s, ArC), 129.3 (s, 
ArC), 137.5 (s, ArC), 139.8 (dd, 1JcF 245.2, 3JcF 4.1, C4), 140.1 (s, ArC), 146.0 (dd, 1JcF 
243.0, 3JcF 11.0, C6), 155.3 (d, 2JcF 22.8, C3); Op (658MHz, CDCh) -99.5 (IF, d, 3]pp 22.1, 
F6), -146.8 (IF, d, 3JFF 22.1, 5JHF 1.9, F4); mlz (ESl314 (100%, [M+Ht). 
5, 6-Difluoro-4-morpholino-2 -phenylpyridazin-3 (2H)-one 235a 
F f'o F~N_J3" 
~,.,_,l 2" 
N6,N 2'0 
3' 
4' 
235a 
4,5,6-Trifluoro-2-phenylpyridazin-3(2/:l)-one (0.25g, 1.1lmmol) was dissolved in 
anhydrous acetonitrile (20ml) before the addition of morpho line (0.19g, 2.21 mmol) and 
stirring at room temperature for 8 hours. The solvent was then evaporated and the crude 
material dissolved in dichloromethane (20ml) and water (20ml), before separation of the 
layers. The aqueous layer was then extracted with further portions of dichloromethane (3 x 
20ml), and the organic extracts were combined, dried (MgS04), filtered and evaporated to 
yield a crude yellow material (0.27g}, which was purified by recrystallisation from hexane 
to yield 5,6-difluoro-4-morpholino-2-phenylpyridazin-3(2H)-one 235a (0.19g, 58%) as a 
white solid; mp 116- ll8°C (Found C, 57.1; H, 4.5; N, 14.3. C14H13F2N30 2 requires C, 
57.3; H, 4.5; N, 14.3%); Vmax I cm-1 1111, 1260, 1492, 1591, 1626 (CO amide); OH 
(700MHz, CDCh) 3.65 (4H, m, C2"(H)), 3.82 (4H, t, 3JHH 4.7, C3"(H}}, 7.38 (1H, t, 3JHH 
7.6, C4'(H)), 7.46 (2H, t, 3JHH 7.6, C2'(H}), 7.49 (2H, d, 3JHH 7.6, C3'(H)); &c (l75MHz, 
CDCh) 49.8 (d, 4JCF4.4, C2'), 61.1 (d, 5JCF 1.5, C3"), 125.8 (s, ArC), 128.6 (s, ArC), 129.1 
(s, ArC), 134.8 (d, 2JcF 7.5, C4}, 137.4 (dd, 1Jcp268.7, 2JCF 31.7, C5}, 140.8 (s, C1'), 147.3 
(dd, 1JCF 233.6, 2JcF 19.1, C6}, 159.0 (d, 3JcF 9.5, C3); Op (658MHz, CDCh) -105.8 (IF, d, 
4JFF 28.0, F6), -147.5 (IF, dt, 4JFF 28.0, 5JHF 2.3, F4); m/z (EI) 293 (12%, [Mt), 275 (60}, 
222 (46), 208 (53), 86 (40}, 77 (100, [Ph]l. 
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4,5,6-Trifluoropyridazin-3(2H)-one (0.50g, 3.33mmol) and p-toluenesulfonic acid 
(0.05lg, 0.26mmol) were dissolved in tetrahydrofuran (1 Oml) and 3,4-dihydro-2H-pyran 
(0.76ml, 8.33mmol) was added. The mixture was heated to reflux for 5 hours, after which 
it was allowed to cool and the solvent evaporated. The crude material was dissolved in 
ethyl acetate (20ml) and washed with aqueous sodium hydroxide solution (2M, 20ml). The 
aqueous layer was then extracted with ethyl acetate (3 x 20ml) before the combined organic 
extracts were dried (MgS04), filtered and evaporated to yield a crude yellow oil. This was 
purified by flash column chromatography using hexane and ethyl acetate (9: 1, 500ml, 4:1, 
500ml) as elutant to yield 4,5,6-trijluoro-2-(tetrahydro-2H-pyran-2-y/)pyridazin-3(2H)-one 
237 (0.47g, 60%) as a white solid; mp 56 - 58°C (Found C, 46.4; H, 4.0; N, 11.9. 
C9H9F3N202 requires C, 46.2; H, 3.9; N, 12.0%); Vmax I cm-1 1084, 1306, 1458, 1589, 1698 
(CO amide); 8H (500MHz, CDCb) 1.55 (lH, m), 1.66 (3H, m), 2.05 (2H, m), 3.69 (lH, dm, 
2JHH 12.0, 3JHH 2.6, C6'(H)), 4.07 (lH, dm, 2JHH 12.0, C6'(H)), 5.92 (1H, dd, 3JHH 11.3, 3JHH 
1.8, C2'(H)); 8c (125MHz, CDCb) 22.5 (s, C4'), 24.7 (s, CH2), 28.3 (s, CH2), 68.9 (s, C6'), 
83.0 {t, 4JcF 1.5, C2'), 139.1 (ddd, 1JCF 289.0, 2JCF 36.3, 3JcF 11.2, C5), 144.3 (ddd, 1JcF 
269.5, 2JcF 9.6, 3JcF 3.5, C4), 147.4 (ddd, 1JCF 238.6, 2JcF 17.0, 3JcF 3.9, C6), 158.0 (dd, 2JcF 
20.9, 3JcF 4.9, C3); bF (376MHz, CDCh) -100.8 (IF, dd, 3JrF 26.4, 41rF 15.2, F6), -134.7 
(IF, dd, 31rF 15.2, 41rF 15.2, F4), -145.6 (IF, dd, 3JFF26.4, 4JFF 15.2, F5); mlz (EI) 234 (1%, 
[Mt), 150 (18%, [M-THP]l, 85 (100). 
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4-(Butylamino)-5,6-dijluoro-2-(tetrahydro-2H-pyran-2-yl)pyridazin-3(2H)-one 238a and 
5-(butylamino)-4,6-dijluoro-2-(tetrahydro-2H-pyran-2-yl)pyridazin-3(2H)-one 238b 
238a 238b 
A Greenhouse Plus tube was charged with 4,5,6-trifluoro-2-(tetrahydro-2H-pyran-2-
yl)pyridazin-3(2/:l)-one (I OOmg, 0.427mmol) and dissolved in acetonitrile (5ml). 
Butylamine (0.0844ml, 0.854mmol) was added under an atmosphere of nitrogen, and the 
mixture stirred at room temperature for 20 hours. After this period the solvent was 
evaporated in a blowdown evaporator, before being redissolved in dichloromethane (5ml). 
Water (5ml) was added and the organic layer separated on a hydrophobic frit. The aqueous 
layer was washed with further portions of dichloromethane (3 x 5ml), and the organic 
extracts dried over MgS04. After filtration and evaporation, the crude material was 
purified by flash column chromatography (Cyclohexane : ethyl acetate gradient 10% to 
33% ethyl acetate over 20 minutes). This yielded the major isomer 4-(buty/amino)-5,6-
dijluoro-2-(tetrahydro-2H-pyran-2-yl)pyridazin-3(2H)-one 238a (0.0560g, 46%) as a white 
solid; mp 133- 135°C (Found [MHt 288.1524. CnH19F2N302 requires [MHt 288.1510); 
()H (400MHz, CDCh) 0.95 (3H, t, 3JHH 7.4, NHCH2CH2CH2CH3), 1.40 (2H, sextet, 3JHH 
7.4, NHCH2CH2CH2CH3), 1.50- 1.75 (6H, m), 2.03 (IH, m), 2.17 (lH, m), 3.50 (2H, q, 
3JHH 6.5, NHCH2CH2CH2CH3), 3.70 (lH, dt, 2JHH 11.6, 3JHH 1.5, C6'(H)), 4.11 (IH, dd, 
2JHH 11.6, 3JHH 4.0, C6'(H)), 5.52 (IH, br t, 3JHH 6.5, NHCH2CH2CH2CH3), 5.93 (lH, d, 
3JHH 10.5, C2'(H)); <ic (lOOMHz, CDCh) 13.6 (s, NHCH2CH2CH2CH3), 19.7 (s, CH2), 22.7 
(s, CH2), 24.8 (s, CH2), 28.3 (s, CH2), 32.5 (d, 5JcF 2.4, NHCH2CH2CH2CH3), 43.8 (d, 4JCF 
6.4, NHCH2CH2CH2CH3), 68.6 (s, C6'), 83.4 (s, C2'), 129.8 (dd, 1JcF 258.8, 2JcF 33.6, C5), 
131.8 (d, 2JcF 8.8, C4), 147.4 (dd, 1JcF 230.1, 2JcF 16.8, C6), 158.0 (d, 3JCF 11.2, C3); <iF 
(376MHz, CDCh) -105.2 (IF, d, 3JrF 28.7, F6), -165.2 (IF, d, 3hF 28.7, F5); mlz (ES+) 288 
([M+Ht, 70%), 245 (73), 204 ([M-THP+Ht, 100). 
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The minor product was identified as 5-(butylamino)-4,6-difluoro-2-(tetrahydro-2H-
pyran-2-y/)pyridazin-3(2H)-one 238b (0.0423g, 34%) as a white solid; mp II5 - II6°C 
(Found [MHt 288.I5I5. C13H19F2N302 requires [MHt 288.I524); <5H (400MHz, CDCh) 
0.94 (3H, t, 3JHH 7.5, NHCH2CH2CH2CH3), 1.38 (2H, sextet, 3JHH 7.5, 
NHCH2CH2CH2CH3), 1.51 - 1.73 (6H, m), 2.05 (2H, m), 3.45 (2H, qd, 3JHH 9.0, 4JHF 2.0, 
NHCH2CH2CH2CH3), 3.70 (IH, td, 2JHH I1.5, 3JHH 2.5, C6'(H)), 4.06 (IH, m, C6'(H)), 
4.30 (IH, br t, 3JHH 9.0, NHCH2CH2CH2CH3), 5.92 (IH, ddd, 3JHH I0.5, 3JHH 2.0, 4JHH, 
C2'(H)); <5c (IOOMHz, CDCh) 13.6 (s, NHCH2CH2CH2CH3), 19.6 (s, CH2), 22.7 (s, CH2), 
24.8 (s, CH2), 28.3 (s, CH2), 32.5 (d, 5JCF 2.4, NHCH2CH2CH2CH3), 44.2 (d, 4JcF 6.4, 
NHCH2CH2CH2CH3), 68.6 (s, C6'), 81.7 (s, C2'), I26.5 (dd, 2JcF 30.4, 2JCF 8.0, C5), 138.5 
(dd, 1JCF 243.7, 3JCF I0.4, C4), 145.6 (dd, 1JcF 232.5, 3JcF 10.4, C6), I55.3 (d, 2JCF 22.4, 
C3); bF (376MHz, CDCb) -IOO.O (IF, d, 3JFF 22.4, F6), -150.5 (lF, d, 3JFF 22.4, F5); mlz 
(ESl288 (11%, [M+Ht) 245 (45, [M-THP+MeCN]l, 204 (100, [M-THP+Ht). 
6-Fluoro-2-(tetrahydro-2H-pyran-2-y/)-4,5-dimorpholinopyridazin-3(2H)-one 239c 
0 3""() 
2 
... N ("o 
F~NJ3" ~'-~ 2" 3~0 ° 4'u6. 
5' 
239c 
A Greenhouse Plus tube was charged with 4,5,6-trifluoro-2-(tetrahydro-2H-pyran-2-
yl)pyridazin-3(2H)-one (I OOmg, 0.427mmol) and dissolved in acetonitrile (5ml). 
Morpholine (0.075ml, 0.854mmol) was added under an atmosphere of nitrogen, and the 
mixture stirred at room temperature for 20 hours. After this period the solvent was 
evaporated in a blowdown evaporator, before being redissolved in dichloromethane (5ml). 
Water (5ml) was added and the organic layer separated on a hydrophobic frit. The aqueous 
layer was washed with further portions of dichloromethane (3 x 5ml), and the organic 
extracts dried over MgS04• After filtration and evaporation, the crude material was 
dissolved in 1 ml DMSO I Methanol (I: I) and purified by mass directed automated 
purification. This yielded the major isomer 6-fl~oro-2-(tetrahydro-2H-pyran-2-y/)-4,5-
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dimorpholinopyridazin-3(2H)-one 239c (0.0703g, 45%) as a white solid; mp 133- 134°C 
(Found [MHt 369.19311. C17H2sFN404 requires [MHt 369.19326); 8H (400MHz, CDCh) 
1.52 (1H, m), 1.65 (3H,- t (peak underneath), 2JHH 11.8), 2.00 (IH, m), 2.13 (IH, m), 3.11 
(4H, m, C2"/C2"'(H)), 3.40 (4H, t, 3JHH 4.5, C2"/C2"'(H)), 3.68 (lH, dt, 2JHH 11.4, 3JHH 
2.3, C6'(H)), 3.75 (4H, t, 3JHH 4.8, C3"/C3"'(H)), 3.77 (4H, t, 3JHH 4.5, C3"/C3"'(H)), 4.08 
(lH, ddd, 2JHH 11.4, 3JHH 2.0, 2.0, C6'(H)), 5.82 (1H, ddd, 3JHH 10.8, 3JHH 2.0, 4JHH 2.0, 
C2'(H)); 8c (100MHz, CDCh) 22.8 (s, CH2), 24.8 (s, CH2), 28.3 (s, CH2), 49.9 (s, C2"), 
50.0 (d, 4JcF 4.0, C2'"), 67.0 (s, C3"/C3"'/C6'), 67.4 (s, C3"/C3"'/C6'), 68.7 (s, 
C3"/C3"'/C6'), 82.7 (s, C2'), 129.8 (d, 2JCF 28.0, C5), 140.9 (d, 3JCF 11.2, C4), 152.3 (d, 
1JcF 238.1, C6), 159.3 (s, C3); 8F (376MHz, CDCh) -91.4 (lF, s, F6); m/z (ES+) 369 (33%, 
[M+Ht), 285 (100, [M+H-THPt). 
4-(4-Methoxyphenylamino)-5,6-difluoro-2-(tetrahydro-2H-pyran-2-yl)pyridazin-3(2H)-one 
240a 
240a 
A Greenhouse Plus tube was charged with 4,5,6-trifluoro-2-(tetrahydro-2H-pyran-2-
yl)pyridazin-3(2H)-one (1 OOmg, 0.427mmol) and p-anisidine (0.1 052g, 0.854mmol). The 
mixture was dissolved in acetonitrile (5ml) under an atmosphere of nitrogen, and stirred at 
room temperature for 20 hours. After this period the solvent was evaporated in a 
blowdown evaporator, before being redissolved in dichloromethane (5ml). Water (5ml) 
was added and the organic layer separated on a hydrophobic frit. The aqueous layer was 
washed with further portions of dichloromethane (3 x 5ml), and the organic extracts dried 
over MgS04. After filtration and evaporation, the crude material was purified by mass 
directed automated purification by flash column chromatography (Elutant ethyl acetate : 
hexane - 10% to 33% EtOAc over 20 minutes). This yielded the major isomer 4-(4-
methoxyphenylamino)-5,6-difluoro-2-(tetrahydro-2H-pyran-2-yl)pyridazin-3(2H)-one 240a 
(0.0~9g, 20_%) as a whit_(! sol!d; tpp _162 -1§1°~;,(foll_mUMHt 338.13123; c,6H17F2N303 
requires [MHt 338.13107). 8H (400MHz, CDCh) 1.56 (lH, m), 1.67 (3H, m), 1.76 (IH, 
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m), 2.03 (1H, m), 2.10 (1H, d, 2JHH 10.8), 3.72 (lH, ddd, 2JHH 11.4, 3JHH 11.5, 3JHH 2.5, 
C6'(H)), 3.80 (3H, s, CH3), 4.09 (lH, ddd, 2JHH 11.4, 3JHH 2.0, 3JHH 1.8, C6'(H)), 5.96 (1H, 
ddd, 3JHH 10.8, 3JHH 1.8, 4JHH 1.8, C2'(H)), 6.86 (2H, d, 3JHH 8.9, C2"(H)), 7.03 (2H, dd, 
3JHH 8.9, 4JHH 2.3, ArH); 8c (100MHz, CDCh) 22.7 (s, CH2), 24.8 (s, CH2), 28.4 (s, CH2), 
55.5 (s, CH2), 68.7 (s, CH2), 83.0 (s, CH), 114.1 (s, ArCH), 123.8 (dd, 2JCF 30.4, 3JcF 8.0, 
C4), 124.5 (d, 4JcF 3.2), 130.3 (s, ArCH), 131.6 (s, ArC), 140.1 (dd, 1JcF 252.5, 2JcF 10.4, 
C5), 146.0 (dd, 1JcF 234.0, C6), 155.1 (d, 3JcF 21.6), 157.7 (s, ArC); oF (376MHz, CDCh)-
97.4 (IF, d, 3JFF 20.1, F6), -136.1 (IF, d, 3hF 20.1, F5); m/z (ESl338 (45%, [M+Ht), 295 
(60, [M+MeCN-THP]l, 254 (100, [M+H-THPt). 
6-Fluoro-2-(tetrahydro-2H-pyran-2-yl)-4,5-diphenoxypyridazin-3(2H)-one 241c 
241c 
A Greenhouse Plus tube was charged with 4,5,6-trifluoro-2-(tetrahydro-2H-pyran-2-
yl)pyridazin-3(2H)-one (I OOmg, 0.427mmol) and sodium phenoxide (0.0991g, 
0.854mmol). The mixture was dissolved in acetonitrile (5ml) under an atmosphere of 
nitrogen, and stirred at room temperature for 20 hours. After this period the solvent was 
evaporated in a blowdown evaporator, before being redissolved in dichloromethane (5ml). 
Water (5ml) was added and the organic layer separated on a hydrophobic frit. The aqueous 
layer was washed with further portions of dichloromethane (3 x 5ml), and the organic 
extracts dried over MgS04. After filtration and evaporation, the crude material was 
dissolved in 1 ml DMSO I Methanol (1: 1) and purified by mass directed automated 
purification. After elution through a NH2 SPE column to remove residual TF A and solvent 
evaporation, this yielded the major isomer 6-fluoro-2-(tetrahydro-2H-pyran-2-yl)-4,5-
diphenoxypyridazin-3(2H)-one 241c (0.0891g, 55%) as a colourless oil; (Found [MHt 
383.1404. C11H25FN404 requires [MHt 383.1407); oH (400MHz, CDCh) 1.57 (IH, dd, 
2Jm-1 7.0, 3JHH 2.0), 1. 71 (3H, m), 2.05{1H, m), 2.J9 (lH, m); 332 ("IH, td, 2JHH 11.5, ljHH 
2.5, C6'(H)), 4.14 (IH, ddd, 2JHH 11.5, 3JHH 2.5, 3JHH 1.8, C6'(H)), 5.99 (lH, ddd, 3JHH 10.8, 
192 
Chapter 7: Experimental 
31.-rn 2.0, 4JHH 2.0, C2'(H)), 6.83 (2H, dm, 3JHH 6.8, ArH), 6.88 (2H, dd, 3JHH 8.8, 4JHH 1.3, 
ArH), 7.02 (2H, dd, 3JHH 7.3, 7.3, ArH), 7.23 (4H, m, ArH); 8c (IOOMHz, CDCb) 22.7 (s, 
CH2), 24.8 (s, CH2), 28.4 (s, CH2), 68.8 (s, CH2), 82.9 (s, C2'), II6.4 (s, ArC), II6.6 (s, 
ArC), I23.9 (s, ArC), 124.4 (s, ArC), I29.3 (s, ArH), I29.6 (s, ArC), I36.7 (d, 2JcF 31.2, 
C5), I42.8 (d, 3JcF 9.6, C4), I48.6 (d, 1JCF 240.5, C6), I55.4 (s, ArC), I57.4 (s, ArC); Op 
(376MHz, CDCb) -97.2 (IF, s, F6); mlz (ES+) 383 (45%, [M+Ht), 340 (40, [M+MeCN-
THPt), 299 (100, [M+H-THPt). 
4,5-Bis(allyloxy)-6-fluoro-2-(tetrahydro-2H-pyran-2-y/)pyridazin-3(2H)-one 242c 
~0 
Fx~c~ 60 
242c 
A Greenhouse Plus tube was charged with 4,5,6-trifluoro-2-(tetrahydro-2H-pyran-2-
yl)pyridazin-3(2/:l)-one (I OOmg, 0.427mmol), sodium hydride (0.034g, 60% dispersion in 
mineral oil, 0.854mmol) and dissolved in acetonitrile (5ml). Allyl alcohol (0.058ml, 
0.854mmol) was added under an atmosphere of nitrogen, and the mixture stirred at room 
temperature for 20 hours. After this period the solvent was evaporated in a blowdown 
evaporator, before being redissolved in dichloromethane (5ml). Water (5ml) was added 
and the organic layer separated on a hydrophobic frit. The aqueous layer was washed with 
further portions of dichloromethane (3 x 5ml), and the organic extracts dried over MgS04. 
After filtration and evaporation, the crude material was dissolved in Iml DMSO I Methanol 
(I: I) and purified by mass directed automated purification. Residual TF A in the product 
was then removed by passing through an NH2 functionalised SPE column, elution with 
methanol. After solvent evaporation, this yielded the major isomer 4,5-bis(allyloxy)-6-
fluoro-2-(tetrahydro-2H-pyran-2-yl)pyridazin-3(2H)-one 242c (0.046g, 35%) as a 
colourless oil; (Found [MHt 3I1.1401. C1sH19FN204 requires [MHt 311.1407); DH 
(400MHz, CDCb) 1.54 (IH, m), 1.67 (1H, m), 2.01 (1H, m), 2.12 (1H, m), 3.70 (IH, td, 
2
JHH 11.3, 3JHH 2.5, C6'(tl)), 4.10 (lH, ddd, 2h!H 11.3, 3JHH 2.3, 3JHH 2.0,_C6'(H)), 4.79 (2H, 
d, 3JHH 5.8, OCH2CH=CH2), 4.87 (IH, ddd, 3JHH I2.6, 3JHH 6.0, 2JHH 1.3, OCH2CH=CH2), 
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4.95 (1H, ddd, 3JHH 12.6, 3JHH 5.8, 2JHH 1.3, OCH2CH=CH2), 5.29 (2H, ddd, 3JHH 7.6, 4JHH 
1.3, 4hm 1.3, OCH2CH=CH2), 5.36 (1H, dd, 3JHH 17.3, 3JHH 1.3, 4JHH 1.3, C2'(H)), 5.99 
(2H, m, OCH2CH=CH2); oc (IOOMHz, CDCh) 22.8 (s, CH2), 24.8 (s, CH2), 28.4 (s, CH2), 
68.7 (s, CH2), 73.2 (s, CH2), 82.5 (s, C2'), 119.3 (s, CH=CH2), 119.6 (s, CH=CH2), 132.0 
(s, CH=CH2), 132.7 (s, CH=CH2), 138.4 (d, 2JcF 30.4, C5), 141.5 (d, 3JcF 8.8, C4), 149.I 
(d, 1JCF 237.3, C6), 158.7 (s, C3); oF (376MHz, CDCh) -97.6 (IF, s, F6); mlz (ES+) 3IO 
(25%, [M+H]l, 268 (17, [M+MeCN-THP]l, 227 (100, [M+H-THPt). 
5,6-Difluoro-2-(tetrahydro-2H-pyran-2-yl)-4-morpholinopyridazin-3(2H)-one 239a 
F ('o 
FnN~3" I 2" 60 
239a 
A clean, dry round-bottomed flask was charged with 4,5,6-trifluoro-2-(tetrahydro-
2H-pyran-2-yl)pyridazin-3(2H)-one (O.I Og, 0.427mmol) and dissolved in acetonitrile 
(5ml). The mixture was stirred under argon at room temperature for 16 hours. After this 
period the solvent was evaporated and the crude reaction mixture redissolved in 
dichloromethane ( 1 Oml). Water (I Oml) was added and the organic layer separated. The 
aqueous layer was extracted with further portions of dichloromethane (3 x 1 Oml), and the 
organic extracts dried over MgS04• After filtration and evaporation, the crude material was 
purified by flash column chromatography (Hexane : ethyl acetate 4: I). This yielded the 
major isomer 5,6-difluoro-2-(tetrahydro-2H-pyran-2-yl)-4-morpholinopyridazin-3(2H)-one 
239a (0.075g, 58%) as a white solid; mp 86- 81'C (Found C, 51.6; H, 5.7; N, 13.6. 
C13H17F2N303 requires C, 51.8; H, 5.7; N, 14.0%); oH (700MHz, CDCh) 1.53 (IH, d, 2JHH 
8.9), 1.64 (3H, m), 2.01 (IH, m), 2.12 (IH, m), 3.56 (4H, t, 3JHH 4.8, C2"(H)), 3.68 (IH, td, 
2JHH 12.1, 3JHH 2.5, C6'(H)), 3.78 (4H, t, 3JHH 4.8, C3"(H)), 4.09 (IH, dd, 2JHH 12.1, 3JHH 
4.2, C6'(H)), 5.88 (IH, d, 3JHH Il.3, C2'(H)); oc (IOOMHz, CDCb) 23.0 (s, CH2), 25.0 (s, 
CH2), 28.6 (s, Ct-h), 49.8 {q, 4JcF 4.7, C2"), 67.4 (q, 5JcF1.4, C3"), 69.0 (s, G6'), 83.5 (s, 
C2'), 134.3 (d, 2JcF 6.8, C5), 137.7 (dd, 1JcF 269.0, 2JcF 33.0, C4), I46.9 (dd, 1JcF 233.7, 
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2JcF 19.2, C6), 159.2 (d, 3JCF 9.6, C3); bp (376MHz, CDCh) -104.7 (IF, d, 3]pp28.2, F6),-
147.1 (IF, d, 3]pp28.2, F5); mlz (ESl365 (100%, [M+Na+MeCNt). 
5-Ethoxy-4,6-difluoro-2-(tetrahydro-2H-pyran-2-y/)pyridazin-3(2H)-one 243b 
243b 
A clean, dry round-bottomed flask was charged with 4,5,6-trifluoro-2-(tetrahydro-
2H-pyran-2-yl)pyridazin-3(2H)-one (0.25g, 1.07mmol) and sodium ethoxide (0.073g, 
1.07mmol) and dissolved in ethanol (12.5ml). The mixture was stirred under argon at room 
temperature for 16 hours. After this period the solvent was evaporated and the crude 
reaction mixture redissolved in dichloromethane (20ml). Water (20ml) was added and the 
organic layer separated. The aqueous layer was extracted with further portions of 
dichloromethane (3 x 20m!), and the organic extracts dried over MgS04. After filtration 
and evaporation, the crude material was purified by flash column chromatography (Hexane 
:ethyl acetate 4:1). This yielded the major isomer 5-ethoxy-4,6-difluoro-2-(tetrahydro-2H-
pyran-2-y/)pyridazin-3(2H)-one 243b (0.19g, 68%) as a white solid; mp 64- 66°C (Found 
C, 50.5; H, 5.6; N, 10.4. C11H14N2F203 requires C, 50.8; H, 5.4; N, 10.8%); Vmax I cm-1 
1007, 1031, 1080, 1166, 1185, 1379, 1442, 1586, 1660 (CO amide); 8H (400MHz, CDCh) 
1.38 (IH, td, 2JHH7.1, 3JHH 3.2), 1.43 (3H, td, 3JHH 7.0, 6JHF 0.8, OCH2CH3), 1.55 (IH, m), 
1.66 (3H, m), 3.71 (IH, td, 2JHH 11.6, 3JHH 2.6, C6'(H)), 4.08 (1H, dd, 2JHH 11.6, 3JHH 4.1, 
C6'(H)), 4.51 (2H, qd, 3JHH 7.0, 5JHF 3.1, OCH2CH3), 5.92 (IH, d, 2JHH 10.6, C2'(H)); 8c 
(IOOMHz, CDCb) 15.2 (d, 5JcF 2.3, OCH2CH3), 22.6 (s, CH2), 24.7 (s, CH2), 28.3 (s, CH2), 
68.7 (s, C6'), 70.0 (d, 4JcF 7.9, OCH2CH3), 82.3 (dd, 4JcF 1.5, 1.5, C2'), 135.7 (dd, 2JcF 
31.4, 2JcF 6.9, C5), 144.0 (dd, 1 JCF 257.2, 3JcF 1 0.2, C4), 147.3 (dd, 1JcF 239.2, 3JcF 8.9, C6), 
155.8 (d, 2JCF 22.6, C3); bp (376MHz, CDCb) -97.7 (IF, d, 4JFF 20.4, F6), -141.1 (IF, d, 
4JFF 20.4, F4); mlz (ESl324 (15%, [M+Na+MeCN]l, 218 (68, [M-THP±MeCNt), 177 
(79, [M-THP+Ht). 
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6-fluoro-2-(tetrahydro-2H-pyran-2-yl)-4,5-diphenoxypyridazin-3(2H)-one (0.047g, 
0.13lmmol) and p-toluenesulfonic acid (0.025g, 0.13lmmol) were dissolved in distilled 
ethanol (I Oml) under argon with stirring and heated to reflux for 8 hours, after which TLC 
suggested complete consumption of the starting material. The solvent was evaporated and 
the crude reaction mixture redissolved in dichloromethane (I Oml) and water (I Oml) and the 
organic layer separated. The aqueous layer was then extracted with further portions of 
dichloromethane (3 x 1Om I) and the organic extracts were combined, dried (MgS04), 
filtered and evaporated in vacuo to provide a crude yellow material. This was purified by 
elution through a NH2 functionalised solid phase extraction column with methanol to yield 
6-jluoro-4,5-diphenoxypyridazin-3(2H)-one 244 (0.026g, 67%) as a white solid; mp 160-
161°C (Found C, 64.1; H, 3.7; N, 9.1. C16HnN2F03 requires C, 64.4; H, 3.7; N, 9.4%); Vmax 
I cm-1 1001, 1116, 1186, 1227, 1265, 1425, 1486, 1660 (CO amide), 2914 (br, NH); oH 
(500MHz, CDCh) 6.81 (2H, d, 3JHH 8.9, ArH), 6.83 (2H, d, 3JHH 9.3, ArH), 7.05 (IH, t, 3JHH 
7.4, ArH), 7.09 (IH, t, 3JHH 8.3, ArH), 7.21 (2H, t, 3JHH 8.3, ArH), 7.24 (2H, t, 3JHH 9.7, 
ArH); oc (125MHz, CDCh) 116.6 (s, ArC), 116.6 (s, ArC), 124.3 (s, ArC), 124.7 (s, ArC), 
129.6 (s ArC), 129.9 (s, ArC), 138.0 (d, 2Jcr 30.5, C5), 143.2 (d, 3Jcr 9.0, C4), 158.1 (d, 
1Jcr 240.0, C6), 155.4 (d, 4Jcr 1.4), 160.3 (s, ArC), 160.3 (s, ArC); or (376MHz, CDCh)-
98.4 (IF, s, F6); mlz (ES+) 619 (100%, [2M+Na]l, 362 (48, [M+Na+MeCNt). 
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5-(Butylamino)-4,6-difluoro-2-(tetrahydro-2H-pyran-2-yl)pyridazin-3(2H)-one 
(0.020g, 0.070mmol) and p-toluenesulfonic acid (0.013g, 0.070mmol) were dissolved in 
distilled ethanol (I Om!) under argon with stirring and heated to reflux for 8 hours, after 
which TLC suggested complete consumption of the starting material. The solvent was 
evaporated and the crude reaction mixture redissolved in dichloromethane (I Oml) and water 
(I Om!) and the organic layer separated. The aqueous layer was then extracted with further 
portions of dichloromethane (3 x 1Om!) and the organic extracts were combined, dried 
(MgS04), filtered and evaporated in vacuo to provide a crude yellow material. This was 
purified by elution through silica gel with dichloromethane to yield 5-(butylamino)-4,6-
di.fluoropyridazin-3(2H)-one 189b (0.010g, 77%); data as previously. 
6-Fluoro-4,5-dimorpholinopyridazin-3(2H)-one 204 
0 C) [a 
F~N_J 
~'N~O 
H 
204 
6-fluoro-2-(tetrahydro-2H-pyran-2-yl)-4,5-dimorpholinopyridazin-3(2H)-one 
(0.043g, 0.136mmol) and p-toluenesulfonic acid (0.026g, O.I36mmol) were dissolved in 
distilled ethanol (I Om!) under argon with stirring and heated to reflux for 8 hours, after 
which TLC suggested complete consumption of the starting material. The solvent was 
evaporated and the crude reaction mixture redissolved in dichloromethane (1 Oml) and water 
(1 Oml) and the organic layer separated. The aqueous layer was then extracted with further 
portions of dichloromethane (3 x 1 Oml) and the organic extracts were combined, dried 
(MgS04), filtered arid -evaporated in vacuo to provide a crude yellow material. This was 
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purified by elution through silica gel with dichloromethane to yield 6-jluoro-4,5-
dimorpholinopyridazin-3(2H)-one 204 (0.028g, 72%); data as previously. 
7.4 Experimental to Chapter 4 
5,8-Difluoro-1,2,3,4-tetrahydropyrazino[2,3-d]pyridazine 251a and 3,4-difluoro-5,6, 7,8-
tetrahydropyrazino[2,3-c]pyridazine 251b 
HNl Fn~ NH 
N ...-:: 
'N F 
251a 
Tetrafluoropyridazine (0.60g, 3.96mmol) was dissolved in dry acetonitrile (100ml) 
under argon with stirring. Ethylenediamine (0.29ml, 4.4mmol) was added, and the mixture 
stirred at 80°C for 16 hours. The solution was then allowed to cool before the addition of 
water (50ml) and ethyl acetate (30ml). The organic phase was separated and the aqueous 
phase extracted with ethyl acetate (3 x 30ml). The combined organic extracts were dried 
(MgS04), filtered and evaporated in vacuo to yield a crude yellow product (0.46g). This 
contained 2 isomers in the ratio 86 : 14. The crude material was then recrystallised from 
ethyl acetate to yield 5,8-difluoro-1,2,3,4-tetrahydropyrazino[2,3-d]pyridazine 251a 
(0.18g, 26%) as a yellow-cream solid; mp 192- 194°C (Found C, 41.9; H, 3.7%; N, 32.5. 
C6H6N4F2 requires C, 41.9; H, 3.5; N, 32.6%); i>H (400MHz, CDCh) 3.55 (4H, s, CH2CH2), 
4.36 (2H, br s, 2 x NH); bF (376MHz, CDCh) -103.9 (2F, s); mlz (Ell172 (79%, [M],), 
171 ( 100, [M-Ht), 70 (21, [C3H6N2]l, 30 (22), 28 (32, [N2]l. 
The minor isomer 3,4-difluoro-5,6,7,8-tetrahydropyrazino[2,3-c]pyridazine 251b 
was not isolated. 8F (400MHz, CDCh) -92.3 (IF, s), -155.0 (IF, s); mlz (EI+) 172 (100% 
[M+]), 171 (86, [M- Ht), 116 (25), 89 (28), 70 (56, [C3H6N2t), 30 (49), 28 (51, [N2t). 
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5,8-Difluoro-1,2,3,4-tetrahydro-1,4-dimethylpyrazino-[2,3-d]pyridazine 252 
2 Me,~l3 Fba N'! Bl ~ 4a 'Me 
~~,N...-:::5 F 
6 
252 
Tetratluoropyridazine (0.60g, 3.96mmol) was dissolved in dry acetonitrile (IOOml) 
under argon with stirring. N,N'-Dimethylethylenediamine (0.47ml, 4.4mmol) and sodium 
hydrogencarbonate (1.33g, 15.8mmol) were added, and the mixture stirred for 4 hours. 
Water (50ml) was added to quench the reaction, followed by ethyl acetate (30ml). The 
organic phase was separated and the aqueous phase extracted with ethyl acetate (3 x 30ml). 
The combined organic extracts were dried (MgS04), filtered and evaporated in vacuo to 
yield a crude yellow product (0.61 g), which was purified by flash column chromatography 
(elutant ethyl acetate I hexane 1:1) to yield pure 5,8-difluoro-1,2,3,4-tetrahydro-1,4-
dimethylpyrazino-[2,3-d]pyridazine 252 (0.62g, 91 %) as white crystals; mp 169 - 171 °C 
(Found C, 47.9; H, 5.0; N, 27.8.; CsH10N~2 requires C, 48.0; H, 5.0; N, 28.0%); Vmaxl cm-1 
1092, 1159, 1251, 1343, 1410, 1557, 2900 (CH); 8H (400MHz, CDCh) 3.05 (6H, t, 5JHF 
1.9, CH3), 3.20 (4H, s, CH2CH2); 8c (lOOMHz, CDCh) 42.2 (dd, 4JCF 6.0, C2/3), 48.4 (s, 2 
x CH3), 125.8 (t, 2JcF 16.7, C4a,8a), 156.2 (dd, 1JcF 235.2, 4JcF 3.8, C5,8); 8F (376MHz, 
CDCh) -92.1 (2F, s); mlz (Et) 200 (100%, [Mt), 185 (42, [M-Me]}, 156 (20), 42 (76). 
5, 8-Difluoro-2, 3 -dihydro-[ 1, 4] dithiino [2, 3-d]pyridazine 253 
1 2 s~3 Fba ~ Bl ~ 4a 
~~,N...-:::5 F 
6 
252 
Tetratluoropyridazine (0.25g, 1.64mmol) was dissolved in dry acetonitrile (20ml) 
and 1,2-ethanedithiol (0.15ml, 1.81mmol) and sodium hydrogen carbonate (0.28g, 
3.29mmol) were added. The mixture was allowed to stir at room temperature for 2 hours 
before the solvent was evaporated, and the crude reaction mixture redissolved in 
dichloromethane (20ml) and water (20ml). The aqueous layer was separated before 
extraction with further portions of dichloromethane (3 x 20ml). The combined organic 
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extracts were then dried (MgS04), filtered and evaporated in vacuo to provide a crude 
yellow material which was purified by recrystallisation from acetonitrile to yield 5,8-
difluoro-2,3-dihydro-[1,4]dithiino[2,3-d]pyridazine 253 as a white solid (0.29g, 85%); mp 
123 - 125°C (Found C, 34.3; H, 3.2; N, 13.7; C6~N2F2S2 requires C, 34.9; H, 2.0; N, 
13.6%); 81-1 (700MHz, CDCh) 3.41 (4H, s, CH2CH2); 8c (175MHz, CDCh) 25.5 (s, C2/3), 
126.0 (dd, 2JcF 20.0, C4a,8a), 160.0 (dd, 1JCF 242.2, 4JCF 5.1, C5,8); bF (658MHz, CDCh) 
-84.8 (2F, s); mlz (EI) 206 (88%, [M]l, 191 (100), 178 (19, [M-N2]l, 132 (19), 87 (29). 
2-( 4,5, 6-Trifluoropyridazin-3-y/o:xy)ethanol 254 and 4, 5, 6-trifluoropyridazin-3(2H)-one 
182 
F 
F~F 
~'N~O~OH 
254 
F 
F~F 
~'N---lO 
H 
182 
Tetrafluoropyridazine (0.5g, 3.29mmol) was dissolved in concentrated sulfuric acid 
(1 Oml) at 0°C and ethylene glycol (2.5ml) was added dropwise over 30 minutes. The 
mixture was stirred at 0°C for 1 hour before the addition of diethyl ether (50ml) and the 
reaction mixture was poured onto ice (I OOg). The organic layer was separated, and the 
aqueous layer was extracted with further portions of diethyl ether (2 x 50ml). The organic 
extracts were combined, dried (MgS04), filtered and evaporated in vacuo to provide a 
crude yellow material. This was then purified by flash column chromatography using 
hexane and dichloromethane (4:1) as elutant to yield 2-(4,5,6-trifluoropyridazin-3-
ylo:xy)ethanol 254 (0.16g, 25%) as a colourless oil; (Found C, 37.2; H, 2.4; N, 14.7. 
C6HsN2F302 requires C, 37.1; H, 2.6; N, I4.4%); 81-1 (300MHz, CDCh) 2.39 (lH, br s, OH), 
4.04 (2H, m, ArOCH2CH20H), 4.69 (2H, m, ArOCH2CH20H); 8F (282MHz, CDCh) -97.7 
(IF, dd, 3JFF 26.1, 4hF20.3, F6), 146.3 (IF, dd, 3hF I5.9, 4JFF20.3, F4), 151.9 (IF, dd, 3JFF 
26.1, 3JFF 15.9, F5); m/z (ES+) 195 (100%, [M+Ht. 
Also produced was 4,5,6-trifluoropyridazin-3(2H)-one 182 (0.15g, 30%) as white 
crystals; 8F (282MHz, CDCh) -101.7 (IF, dd, 3hF25.7, 4JFF I6.2, F6), -136.9 (IF, dd, 3JFF 
15.5 41rF I6.2, F4), -143.5 (IF, dd, 3JrF 25.7, 3JrF 15.5, F5); 81-1 (300MHz, CDCh) Il.8-
I1.4 (IH, br s, NH); mlz (EI+) I51 (5%, [Mt), 150 (97, [M-H]l, I22 (25), 121 (21), 93 
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(1 00), 74 (68), 31 (I 00, [CF]). Spectral data was in agreement with a known sample of 
this compound. 
3, 4-Difluoro-9, 1 0-dioxa-1, 2 -diaza-anthracene 255 
METHOD A: 
Catechol (0.362g, 3.29mmol) was dissolved in dry THF (20m!) under argon with 
stirring, and the solution was cooled to -78°C. n-BuLi (1.6M in hexanes, 4.llml, 
6.58mmol) was added dropwise, and the solution allowed to stir for 30 minutes. After this 
period tetrafluoropyridazine (0.5g, 3.29mmol) was added and the mixture was allowed to 
slowly warm to room temperature and stirred for 16 hours. Then the reaction was 
quenched by the addition of water (20m!), followed by ethyl acetate (20m!). The aqueous 
layer was separated, then extracted with further portions of ethyl acetate (2 x 20m!). The 
combined organic extracts were then dried (MgS04), filtered and evaporated to yield a 
crude brown solid (0.61g). This was then purified by flash column chromatography 
(elutant = hexane and dichloromethane 10:1 (600ml), followed by 4:1 (300m!) to yield 
pure 4a,9a-Dihydro-9,10-dioxa-1,2-diaza-anthracene 255 (0.43g, 59%) as a white solid; 
mp 146- 148°C (Found C, 54.0; H, 1.9; N, 12.6. C8H11N4FO requires C, 54.1; H, 1.8; N, 
12.6%); Vmax I cm-1 1015, 1035, 1094, 1115 (C-0), 1260 (C-0), 1416, 1464, 1490, 1568, 
1654; 8H (400MHz, CDCb) 7.13-7.06 (m, 4H, ArH); 8c (100MHz, CDCb) 117.0 (s), 
118.1 (s), 126.0 (s), 126.8 (s), 127.0 (s), 133.4 (t, JcF 6.3), 136.8 (dd, 1JcF 283.7, 2JCF 32.0), 
139.5 (d, 1JcF 173.1), 154.5 (s), 156.9 (d, JcF 9.8); DF (376MHz, CDCh) -96.4 (IF, d, 3hF 
25.8), -151.9 (IF, d, 3JFF25.9); mlz(EI) 222 (10%, [M+]), 138 (43), 74 (66), 63 (67), 
62 ( 62), 50 (I 00). 
Minor column fraction contained several products (not isolated separately) 
including 4-butyl-3,5,6-trif/uoropyridazine 256; 8F (282MHz, CDCb) -81.6 (IF, dd, 3JFF 
33.4, 5JFF 22.0), -98.9 (IF, dd, 3JFF 34.2), -129.2 (IF, dd, 3JFF 27.8, 4JFF 23.7); m/z (Et) 190 
(38%, [M+]), 148 (42, fM-Prt), 43 (lOO, [C3H7])), 41" (77); Also, 4,5-dibutyl-3;6-
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difluoropyridazine 251; OF (282MHz, CDCh) -87.5 (IF, s); mlz (Ell228 (29%, [~]), 171 
(14, [M-Bu]l, 157 (27), 144 (48), 43 (100, [C3H1])l, 41 (57). Also unidentified product; 
OF (282MHz, CDCh) -88.2 (IF, t, 3JFF 28.4), -96.2 (IF, dd, 3hF 31.8, 4JFF 24.2), -148.1 (IF, 
t, 3JFF 24.9); m/z (Ell206. 
METHODS: 
Catechol (0.80g, 7.23mmol) was dissolved in tetrahydrofuran at 0°C under argon 
with stirring and added to sodium hydride (0.35g, 14.5mmol, 60% dispersion in mineral 
oil). Tetrafluoropyridazine (l.OOg, 6.58mmol) was added dropwise and the mixture stirred 
at 0°C for 8 hours. After this period the solvent was evaporated, and the crude material 
redissolved in dichloromethane (25ml) and water (25ml). The organic layer was separated 
and the aqueous layer washed with further portions of dichloromethane (3 x 25ml). The 
combined organic extracts were then dried (MgS04), filtered and evaporated in vacuo to 
provide a crude yellow material which was purified by recrystallisation from acetonitrile to 
yield 4a,9a-Dihydro-9,10-dioxa-1,2-diaza-anthracene 255 (1.09g, 75%), data as 
previously. 
3,4-Difluoro-6, 7-dihydro-[1,4]dioxino[2,3-c]pyridazine 258 
F~O) ~,N;LO 
258 
Ethylene Glycol (0.18g, 3.29mmol) was dissolved in dry THF (20ml) under argon 
with stirring, and the solution was cooled to -78°C. n-BuLi (1.6M in hexanes, 4.11ml, 
6.58mmol) was added dropwise, and the solution allowed to stir for 30 minutes. After this 
period tetrafluoropyridazine (0.5g, 3.29mmol) was added and the mixture was allowed to 
slowly warm to room temperature and stirred for 16 hours. Then the reaction was 
quenched by the addition of water (20ml), followed by ethyl acetate (20m I). The aqueous 
layer was separated, then extracted with further portions of ethyl acetate (2 x 20ml). The 
combined organic extracts were then dried (MgS04), filtered and evaporated to yield a 
crude cream solid (0.61g). This contained 3,4-difluoro-6,7-dihydro-[1,4]dioxino[2,3-
c}pyridazine, which was not purified; OH (400MHz, CDCh) 4.46 (2H, t, 3JHH 6.2, CH2), 
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4.54 {2H, t, 3JHH 6.2, CH2); bp {376MHz, CDCb) -101.4 {lF, d, 3Jpp 26.4, F3), -154.5 {lF, d, 
3Jpp26.4, F4); mlz (EI) 174 (12%, [Mt), 90 (71), 62 (100). 
3, 4, 6-Tri.fluoro-5-phenoxypyridazine 259 
F 
F~O~ 
~'N~F v 
259 
Phenol (0.17g, 1.81mmol) was dissolved in tetrahydrofuran (20ml) and sodium 
hydride (0.072g, 1.81mmol, 60% dispersion in mineral oil) was added at 0°C with stirring. 
Tetrafluoropyridazine (0.25g, 1.64mmol) was added dropwise, and the mixture stirred at 
0°C for 8 hours. After this period the solvent was evaporated, and the crude material 
redissolved in dichloromethane (25ml) and water (25ml). The organic layer was separated 
and the aqueous layer washed with further portions of dichloromethane (3 x 25m!). The 
combined organic extracts were then dried (MgS04), filtered and evaporated in vacuo to 
provide a crude yellow material which was purified by flash column chromatography 
(elutant hexane: ethyl acetate 4: 1) to yield 3,4,6-tri.fluoro-5-phenoxypyridazine 259 (0.25g, 
68%) as a colourless oil; (Found C, 53.2; H, 2.5; N, 12.2. C10HsN2F30 requires C, 53.1; H, 
2.2; N, 12.4%); 8H (200MHz, CDCh) 7.04 -7.42 (6H, m, ArH); bp (188MHz, CDCh) -86.2 
(IF, dd, 5Jpp31.2, 314JFF23.7, F3/6), -94.5 {lF, dd, 5]pp31.2, 314]pp23.7, F3/6), -140.4 (lF, 
dd, 3JFF 23.7, 4JFF 23.7, F4); m/z (ESl227 (100%, [M+Ht). 
5, 8-Di.fluoro-1, 2, 3, 4-tetrahydro-1, 4-dimethy/pyrazino [2, 3-d]pyridazine 252 
N,N'-dimethylethylenediamine (0.71ml, 6.58mmol) was dissolved in dry THF 
(~Oml) unqer argon witb, ~irring, and the solujion was cooled to -78°C. n-BuLi ( 1.6M in 
hexanes, 8.22ml, 6.58mmol) was added dropwise, and the solution allowed to stir for 30 
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minutes. After this period tetrafluoropyridazine (l.OOg, 6.58mmol) was added and the 
mixture was allowed to slowly warm to room temperature and stirred for 16 hours. Then 
the reaction was quenched by the addition of water (20ml), followed by ethyl acetate 
(20ml). The aqueous layer was separated, then extracted with further portions of ethyl 
acetate (2 x 20ml). The combined organic extracts were then dried (MgS04), filtered and 
evaporated to yield a crude brown solid (0.6lg). This was then purified by flash column 
chromatography (elutant = hexane and ethyl acetate, 4:1) to yield 5,8-difluoro-1,2,3,4-
tetrahydro-1,4-dimethylpyrazino[2,3-d]pyridazine 252 (0.95g, 72%); data as previously. 
8-Fluoro-1, 2, 3, 4-tetrahydro-1, 4-dimethylpyrazino [2, 3-d] pyridazin-5 ( 6H)-one 263 
,~~3 Fna N4 8 1 ~ 4a ""' 
~aN 50 
H 
263 
4,5,6-Trifluoropyridazin-3(2H)-one (l.OOg, 6.67mmol) was dissolved in acetonitrile 
(50ml) under argon with stirring. N,N'-dimethylethylenediamine (1.43ml, 13.3mmol) was 
added dropwise and the mixture stirred at room temperature for 16 hours. After this period 
the solvent was evaporated, and the crude material redissolved in dichloromethane (50ml) 
and water (50ml). The aqueous layer was separated and washed with further portions of 
dichloromethane (3 x 25ml). The combined organic extracts were dried (MgS04), filtered 
and evaporated in vacuo to yield a crude yellow product (1.08g), which was purified by 
recrystallisation from acetonitrile to yield 8-jluoro-1,2,3,4-tetrahydro-1,4-
dimethylpyrazino[2,3-d]pyridazin-5(6H)-one 263 (1.08g, 82%) as a white solid; mp 159-
161°C (Found C, 48.4; H, 5.7; N, 28.6. C8H11N4FO requires C, 48.5; H, 5.6; N, 28.3%); oH 
(400MHz, CDCh) 2.84 (3H, t, 5JHF 1.7, Nl(CH3)), 2.94 (2H, m, CH2), 3.00 (2H, m, CH2), 
3.18 (3H, s, N4(CH3)), 11.01 (1H, br s, ring NH); oc (IOOMHz, CDCh) 31.1 (N4(CH3)), 
40.9 (s, C3), 43.1 (d, 4JcF 9.1, N1(CH3)), 47.5 (d, 4JCF 6.7, C2), 124.7 (d, 2JcF 27.2, C8a), 
132.6 (d, 3JcF 9.7, C4a), 150.4 (d, 1JcF 230.4, C8), 159.1 (s, C5); OF (376MHz, CDCb) -97.6 
(IF, s); m/z (Elll98 (100%, [M+]), 183 (29, [M- Met), 169 (28), 168 (27, [M- 2Met), 
42 (46). 
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5, 6, 7, 8-Tetrahydro-5, 8-dimethyl-4-morpholinopyrazino[2, 3-c ]pyridazin-3 (2H)-one 264 
6 5 
a
7rnN: r? /N ~ N~3· 
Ba 1 2' 
1 N,N 3 0 
2H 
264 
A 2-5ml microwave vial was charged with 5,6-difluoro-4-morpholinopyridazin-
3(211)-one (0.25g, 1.15mmol) and N,N'-dimethylethylenediamine (0.25ml, 2.30mmol) and 
dissolved in dry acetonitrile (3ml). The mixture was irradiated at 150°C for 20 minutes, 
after which TLC indicated complete conversion of starting material. Water (5ml) and 
dichloromethane (10ml) were added and the layers separated. The aqueous layer was 
washed with a further 2 portions of dichloromethane (2 x 10ml), before the combined 
organic extracts were dried (MgS04), filtered and evaporated in vacuo to yield a crude 
yellow material. This was recrystallised from acetonitrile to yield 5,6, 7,8-tetrahydro-5,8-
dimethyl-4-morpholinopyrazino[2,3-c]pyridazin-3(2H)-one 264 (0.24g, 79%) as white 
crystals; mp > 250°C; (Found C, 54.1; H, 7.2; N, 26.3. C,2H19Ns02 requires C, 54.3; H, 
7.2; N, 26.4%); Vmax I em·' 981, 1108, 1193, 1258, 1367, 1407, 1492, 1611 (CO amide), 
2956 (br, NH); 8H (400MHz, CDCh) 2.83 (3H, s, CH3), 3.17 (2H, t, 3JHH 4.8, C(6/7)H2), 
3.24 (4H, t, 3JHH 4.7, C2'(H)), 3.30 (3H, s, CH3), 3.38 (2H, t, 3JHH 4.8, C(6/7)H2), 3.75 (4H, 
t, 3JHH 4.7, C3'(H)), 9.14 (IH, br s, ring NH). 8c (100MHz, CDCh) 37.6 (s, CH3), 42.2 (s, 
CH3), 47.1 (s, C6/7), 49.5 (s, C2'), 51.6 (s, C6/7), 67.1 (s, C3'), 124.1 (s, ArC), 137.9 (s, 
ArC), 144.3 (s, C8a), 161.3 (s, C3); mlz (ES+) 266 (100%, [M+Ht). 
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4-( 4-F/uoro-phenylamino)-5, 6, 7, 8-tetrahydro-5, 8-dimethylpyrazino {2, 3-c }pyridazin-3 (2H)-
one 265 
/""N_...... 
l txH 2' 
_......N Nu· ~3  
I 4' 
N 0 ° F 
H 
265 
A 0.5-2ml microwave vial was charged with 4-(4-tluorophenylamino)-5,6-
ditluoropyridazin-3(2/1)-one (0.1 Og, 0.415mmol) and N,N' -dimethylethylenediamine 
(0.11 ml, 1.04mmol) and dissolved in dry acetonitrile (I ml). The mixture was irradiated at 
l50°C for 30 minutes, after which TLC indicated complete conversion of starting material. 
Water (5ml) and dichloromethane (10ml) were added and the layers separated. The 
aqueous layer was washed with a further 2 portions of dichloromethane (2 x I Oml), before 
the combined organic extracts were dried (MgS04), filtered and evaporated in vacuo to 
yield a crude yellow material. This was recrystallised from acetonitrile to yield 4-(4-.f/uoro-
pheny/amino)-5,6, 7,8-tetrahydro-5,8-dimethylpyrazino[2,3-c]pyridazin-3(2H)-one 265 
(0.08g, 67%) as white crystals; mp > 250°C (Found C, 58.3; H, 5.7; N, 24.2. C14H16NsOF 
requires C, 58.1; H, 5.6; N, 24.2%); oH (700MHz, CDCb) 2.52 (3H, s, CH3), 2.91 (3H, s, 
CH3), 3.28 (2H, t, 3JHH 6.1, C(6/7)H2), 3.38 (2H, t, 3JHH 6.1, C(6/7)H2), 6.65 (2H, m, 
C2'(H)), 6.80 (IH, br s, NHAr), 6.89 (2H, m, C3'(H)), 11.09 (IH, br s, ring NH). oc 
(175MHz, CDCb) 37.2 (s, CH3), 37.3 (s, CH3), 47.5 (s, C6/7), 51.2 (s, C6/7), 114.9 (d, 2JcF 
22.5, C3'), 117.9 (s, ArC), 118.1 (d, 3JCF 7.7, C2'), 127.9 (s, ArC), 137.4 (s, ArC), 145.3 
(s, ArC), 157.4 (d, 1JCF238.5, C4'), 160.0 (s, C3); OF (658MHz, CDCb) -124.6 (IF, m); mlz 
(ES+) 290 (1 00%, [M+Ht). 
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3-Fluoro-4-morpho/in-4-yl-9, 1 0-dioxa-1 ,2-diaza-anthracene 266 
0 
::c ) 
rtN 10 5 F Qboa '-':: 6 I 2 N9aQ8a...'l 7 
1 9 8 
266 
3,4-Difluoro-9, I 0-dioxa-I ,2-diaza-anthracene (0.20g, 0.900mmol) was dissolved in 
dry acetonitrile (2ml) in a 0.5-2ml microwave vial and morpholine (O.I6ml, I.80mmoi) was 
added. The vial was sealed under argon and irradiated at I50°C for 20 minutes, after which 
dichloromethane (20ml) and water (20mi) were added and the organic layer separated. The 
aqueous layer was then washed with further portions of dichloromethane (3 x 20ml) to give 
a crude yellow material which was purified by flash column chromatography ( elutant 
hexane : ethyl acetate 2: I) to yield 3-Fluoro-4-morpholin-4-y/-9, 1 0-dioxa-1,2-diaza-
anthracene 266 (O.I8g, 7I %) as white crystals; mp 207- 208°C (Found [MHt 290.09345. 
C14H12FN303 requires [MHt 290.09355); 8H (700MHz, CDCh) 3.44 (4H, t, 3JHH 4.4, 
C2'(H)), 3.84 (4H, t, 3JHH 4.4, C3'(H)), 6.94 (lH, d, 3JHH 7.6, ArH), 7.0I (1H, tm, 3JHH 7.6, 
ArH), 7.06 (2H, m, ArH); 8c (175MHz, CDCh) 50.4 (d, 4JcF 4.0, C2'), 67.3 (s, C3'), II6.5 
(s, ArC), II7.7 (s, ArC), 125.2 (s, ArC), I25.9 (s, ArC), I26.0 (d, 2JcF 25.4, C4), 134.6 (d, 
3JcF 8.9, C4a), 139.4 (s, ArC), 140.9 (s, ArC), 153.7 (s, ArC), I59.0 (d, 1JcF237.7, C3); 8F 
(658MHz, CDCh) -86.4 (lF, s); mlz (ES+) 290 (100%, [M+H]). 
3 -Fluoro-4-allylamino-9, 1 0-dioxa-1, 2 -diaza-anthracene 267 
HN) 
Fn'-':: OX) 
N /- I / 
'N 0 "'"' 
267 
3,4-Difluoro-9, I 0-dioxa-I ,2-diaza-anthracene (O.I5g, 0.675mmol) was dissolved in 
dry acetonitrile (2ml) in a 0.5-2ml microwave vial arid allylamine (O.l'Oml, I.J5mmol) was 
207 
Chapter 7: Experimental 
added. The vial was sealed under argon and irradiated at I50°C for 20 minutes, after which 
dichloromethane (20ml) and water (20ml) were added and the organic layer separated. The 
aqueous layer was then washed with further portions of dichioromethane (3 x 20m I) to give 
a crude yellow material which was purified by flash column chromatography ( elutant 
hexane : ethyl acetate 2:1) to yield 3-F/uoro-4-ally/amino-9,1 0-dioxa-1,2-diaza-anthracene 
267 (0.14g, 80%) as white crystals; mp 175 - 177°C (Found C, 60.3; H, 4.0; N, 16.3. 
CnH10N3F02 requires C, 60.2; H, 3.9; N, 16.2%); OH (500MHz, DMSO-dt;) 4.04 (2H, t, 
3JHH5.1, NHCH2CH=CH2), 5.10 (lH, dd, 3JHH 10.3, 2JHH 1.5, NHCH2CH=CH2), 5.I7 (1H, 
dd, 3JHH 17.2, 2JHH 1.5, NHCH2CH=CH2), 5.94 (lH, ddt, 3JHH 17.2, 10.2, 5.1, 
NHCH2CH=CH2), 6.96 (1H, br t, 3JHH 5.I, NHCH2CH=CH2), 7.07 (3H, m, ArH), 7.I2 
(lH, m, ArH); Be (I25MHz, DMSO-d6) 45.7 (d, 4JCF 2.5, NHCH2CH=CH2), 1I5.3 (s), 
116.4 (s), 124.6 (d, 2JcF 28.2, C4), I25.1 (s), 125.2 (s), I27.2 (d, 3JcF 9.6, C4a), I36.1 (s), 
139.4 (s), 140.5 (s), I52.3 (s), 155.2 (d, 1JcF230.4, C3); oF (470MHz, DMSO-dt;) -93.7 (IF, 
s, F3); mlz (ES+) 323 (100%, [M+MeCN+Nat), 260 (68, [M+Ht), 2I9 (69, [M+H-
CH2CH=CH2). 
3-F/uoro-4-ethoxy-9, 1 0-dioxa-1, 2-diaza-anthracene 268 
3,4-Difluoro-9, I 0-dioxa-1 ,2-diaza-anthracene (0.1 Og, 0.45mmol) and sodium 
ethoxide (0.06Ig, 0.90mmol) were dissolved in dry ethanol (2ml) in a 0.5-2ml microwave 
vial. The vial was sealed under argon and irradiated at I50°C for 20 minutes, after which 
dichloromethane (20ml) and water (20ml) were added and the organic layer separated. The 
aqueous layer was then washed with further portions of dichloromethane (3 x 20ml) to give 
a crude yellow material which was purified by flash column chromatography (elutant 
hexane : ethyl acetate 2:1) to yield 3-F/uoro-4-ethoxy-9, 1 0-dioxa-1 ,2-diaza-anthracene 268 
(0.074g, 66%), as white crystals, mp 13I - 133°C (Found C, 58.0; H, 3.7; N, 11.2. 
C13H10NJF02 requires C, 58.1; H, 3.7; N, 11.3%); oH (500MHz, CDCh) 1.49 (3H, t, 3JHH 
7.0, OCI-hCII3), 4.52 (2H, qd, 3JHH 7.0, 5)HF 1.4, QCH2C:H3), 7.00-7.11 (4H, m, ArH); Be 
(125MHz, DMSO-d6) 15.7 (s, OCH2CH3), 70.6 (d, 4JcF 3.9, OCH2CH3), I16.7 (s, ArC), 
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117.8 (s, ArC), 125.4 (s, ArC), 126.1 (s, ArC), 133.6 (d, 2JcF 27.2, C4), 135.1 (d, 3JCF 8.2, 
C4a), 139.2 (s, ArC), 140.7 (s, ArC), 154.0 (d, 4JcF 1.5, C9a), 158.2 (d, 1 JCF 239.5, C3)~ oF 
(470MHz, CDCh) -92.4 (IF, s, F3); mlz (ES+) 249 (100%, [M+Ht) 
3-Fluoro-4-methy/thio-9, I 0-dioxa- I, 2-diaza-anthracene 270 and 3, 4-bis(methy/thio)-9, I 0-
dioxa- I, 2 -diaza-anthracene 269 
SMe 
MeS~O~ ~'N~O~ 
269 
F~O~ 
~'N~oM 
270 
3,4-Difluoro-9, 1 0-dioxa-1 ,2-diaza-anthracene (0.1 Og, 0.45mmol) and sodium 
thiomethoxide (0.063g, 0.90mmol) were dissolved in dry acetonitrile (2ml) in a 0.5-2ml 
microwave vial. The vial was sealed under argon and irradiated at 150°C for 20 minutes, 
after which dichloromethane (20ml) and water (20ml) were added and the organic layer 
separated. The aqueous layer was then washed with further portions of dichloromethane (3 
x 20ml) to give a crude yellow material which could not be separated by flash column 
chromatography ( elutant hexane : ethyl acetate 2: I). The mixture contained 3-Fluoro-4-
methylthio-9,IO-dioxa-I,2-diaza-anthracene 270~ DH (400MHz, CDCb) 2.47 (3H, s, CH3), 
7.00-7.10 (4H, ArH)~ oF(376MHz, CDCh) -78.8 (IF, s)~ mlz (ES+) 251 (100%, [M+Ht)~ 
and also contained 3,4-bis(methylthio)-9,IO-dioxa-I,2-diaza-anthracene 269~ DH (400MHz, 
CDCh) 3.57 (3H, s, CH3), 2.62 (3H, s, CH3), 7.00-7.18 (4H, ArH)~ mlz (ES+) 279 (100%, 
[M+Ht). 
N-(3,5, 6-Trifluoropyridazin-4-y/)benzamidine 274 
Ph 
HN~NH 
F~F 
~,N;LF 
274 
Tetrafluoropyridazine (0.60g, 3.96mmol) was mixed with benzamidine 
hydrochloride (0.68g, 4.35mmol) and sodium hydrogen carbonate (1.32g, l5.8mmol) in 
acetonitrile (J OOml). The resultant mixture was heated to 80<,'£ under argon with stirring 
for 16 hours. After this period, the solvent was evaporated, and the residue dissolved in 
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ethyl acetate (50ml). This was washed with water (25ml) and the aqueous layer extracted 
with ethyl acetate (2 x 25ml). The combined organic extracts were dried (MgS04), filtered 
and evaporated in vacuo to yield a crude brown material (0.81 g), which was purified by 
recrystallisation from ethyl acetate and hexane (1:1) to yield N-(3,5,6-trifluoropyridazin-4-
yl)benzamidine 274 (0.76g, 75%) as a yellow solid; mp 139 - 141°C (Found [MHt 
253.06956. C11H1F3N4 requires [MHt 253.06956); 8H (700MHz, CDCb) 7.41 (1H, br s, 
NH), 7.48 (2H, t, 3JHH 7.2, C3'(H)), 7.56 (IH, t, 3JHH 7.2, C4'(H)), 7.93 (2H, d, 3JHH 7.2, 
C2'(H)), 8.08 (IH, br s, NH); 8c (175MHz, DMSO-d6) 127.6 (s, ArC), 128.4 (s, ArC), 
131.4 (dd, 2JCF 31.4, 10.4, C4), 131.6 (s, ArC), 133.4 (s, ArC), 141.9 (ddd, 1JCF 269.1, 2JcF 
26.8, 3JcF 9.3, C5), 156.2 (dd, 1JcF 235.8, 2JcF 11.4, C6), 159.5 (s, ArC), 160.6 (d, 1JcF 
239.4, C3); 8F (658MHz, DMSO-d6) -86.9 (IF, t, 3hF 27.6, F3/6), -101.0 (IF, t, 3hF 27.6, 
F3/6), -140.0 (IF, t, 3JFF 27.6, F5); mlz (Ell 252 (32%, [M]l, 104 (61, [NHCPh]l, 77 
(1 00, [Ph+]). 
7 -F/uoro-N,N-diisopropyl-2-phenyl-I H-imidazo[ 4, 5-d]pyridazin-4-amine 275 
Ph HN-i F~N ~'~N~ 
A 
275 
N-(3,5, 6-trifluoropyridazin-4-yl)benzamidine (0.1 Og, 0.396mmol) was dissolved in 
dry THF (lOml) under argon with stirring at 0°C, and lithium diisopropylamide (0.44ml, 
1.8M in hexanes, 0.793mmol) was added dropwise. The mixture was allowed to warm to 
room temperature before being heated to 80°C for 2 hours. After this period water (1 Oml) 
was added slowly, followed by ethyl acetate (20ml) and the layers separated. The aqueous 
layer was extracted with ethyl acetate (2 x 20ml), and the combined organic extracts were 
dried (MgS04), filtered and evaporated in vacuo to yield a crude brown product (0.07g, 
76%). Purification was not attempted due to a lack of material and the complex product 
mixture obtained but the major product was identified as 7-jluoro-N,N-diisopropyl-2-
phenyl-IH-imidazo[4,5-d}pyridazin-4-amine 275; 8H (300MHz, CDCb) 5.70 (IH, s, NH), 
7.54- 7.10 (4H, m, ArH), 8.30 (IH, m, ArH); 8F (188MHz, CDCb) -100.0 (IF, s); m/z 
(EI+) 314 ( 100%, [M]l, 210 (8), 131 (25), 117 (22), 92 (20), 91 ( 1 00). 
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N-(7 -Fluoro-2-phenyl-1 H-imidazo[ 4,5-d]pyridazin-4-yl)benzamidine 277 
Ph 
HN-i 
F~NPh ~'N~NANH 
H 
277 
Tetrafluoropyridazine (0.50g, 3.29mmol) was dissolved in acetonitrile (5ml) in a 2-
5m) microwave vial. Benzamidine hydrochloride (1.29g, 8.22mmol) was added and the 
vial sealed. The mixture was heated under microwave irradiation at 150°C for 30 minutes, 
after which 19F NMR showed the formation of a complex product mixture. Purification by 
column chromatography was not possible, however the mixture was shown to contain N-(7-
fluoro-2-phenyl-JH-imidazo[4,5-d]pyridazin-4-yl)benzamidine 277; OF (188MHz, CDCh) 
-80.3 (IF, s); m/z (EI) 332 (8%, [Mt), 295 (37), 269 (58), 267 (100), 127 (59), 125 (81). 
4,7-Difluoro-2-phenyl-JH-imidazo[4,5-d]pyridazine 276 
3 Ph HN~ Ffi3a N1 I~ a 
5 N'N,.;;;7 F 
6 
276 
N-(3,5,6-trifluoropyridazin-4-yl)benzamidine (0.25g, 0.99mmol) was dissolved in 
dry acetonitrile (2.5ml) in a 2-5ml microwave vial, and diisopropylethylamine (0.17ml, 
0.99mmol) was added). The vial was then capped and irradiated at 150°C for 60 minutes. 
After this period water (25ml) was added, followed by dichloromethane (25ml). The layers 
were then separated, and the aqueous layer extracted with 2 further portions of 
dichloromethane (2 x 25ml). The combined organic extracts were dried (MgS04), filtered 
and evaporated to yield a crude yellow material. This was then recrystallised from toluene 
to yield 4,7-difluoro-2-phenyl-JH-imidazo[4,5-d]pyridazine 276 (0.19g, 62%) as yellow 
solid; mp 220°C (decomp.) (Found [MHt 233.06326. CttH6F2N4 requires [MHt 
233.06333); oH (SOOMHz, CDCh) 7.64 (3H, m, ArH), 8.21 (2H, m, ArH); oc (lOOMHz, 
DMSO-d6) 127.5 (s, ArC), 129.0 (s, ArC), 129.7 (s, ArC), 131.0 (s, ArC), 154.8 (d, 21rF 
19.8, C3a,7a), 155.9 (dd, 1JcF 243.4, 4JcF 8.7, ~4,7), 159.0 (s, C2); OF (376MHz, CDCh) 
-89.3 (IF, s); m/z (ES+) 233 ([M+Ht, 100%). 
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1, 4-Difluoro-5, 6, 7,8-tetrahydro-2,3, 4b, 9-tetraaza-.fluorene 218 
Tetrafluoropyridazine (0.50g, 3.28mmol) was mixed with 2-iminopiperidine (0.98g, 
7.22mmol) and sodium hydrogencarbonate (I. lOg, 13.lmmol) in acetonitrile (lOOml) under 
argon. The mixture was stirred at room temperature for 60 hours, after which the solvent 
was evaporated, and the crude mixture dissolved in ethyl acetate (25ml) and water (50ml). 
The aqueous layer was separated and acidified with HCI (10%), then extracted with ethyl 
acetate (2 x 25ml) and dichloromethane (3 x 25ml). The combined organic extracts were 
dried (MgS04), filtered and the solvent evaporated to yield a crude brown product (0.64g), 
which was purified by flash column chromatography with elutant ethyl acetate I 
dichloromethane (2: I), to yield 1,4-difluoro-5,6, 7,8-tetrahydro-2,3,4b,9-tetraaza-jluorene 
278 (0.57g, 82%) as a yellow solid; mp I52- I54°C (Found C, 51.0; H, 3.9; N, 26.7. 
C9H8N~2 requires C, 5I.4; H, 3.8; N, 26.4%); bH (500MHz, CDCh) 2.09 {2H, m), 2.I9 
(2H, m), 3.22 (2H, t, 3JHH 7.0, C8(H)), 4.40 (2H, t, 3JHH 5.8, C5(H)); be {I25MHz, CDCh), 
I9.7 (s), 22.2 (s), 25.6 (s), 45.9 (s, C5), I25.I (dd, 2JcF 28.0, 3JcF Il.7, C4a/9a), 133.5 (dd, 
2JcF 32.9, 3JCF 6.5, C4a/9a), I53.4 {d, 1JCF 237.6, CI/4), I57.6 (d, 1JcF 244.4, CI/4), 157.7 
{s, C8a); 8F (376MHz, CDCh) -92.6 (IF, d, 5hF 32.9), -94.6 {IF, d, 5JFF 32.9); mlz (EI+) 
2IO (100%, [Mt), 209 (36, [M-Ht), 182 (32), I8I (14). 
4, 7-Difluoro-2-methylthiazolo[4,5-d]pyridazine 279 
1 Me s--12 
F 7a N3 
71 ~ 3a 
6N'N,....4 F 
5 
279 
Tetrafluoropyridazine (l.OOg, 6.58mmol) was mixed with thioacetamide (0.54g, 
7.23mmol) and sodium hydrogen carbonate (2.2Ig, 26.3mmol) in acetonitrile (50ml) under 
argon. The inixture was stirred at reflux for 16 hours, <ffter wliich tlie solvent was 
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evaporated, and the crude mixture dissolved in ethyl acetate (25ml) and water (25ml). The 
aqueous layer was separated and acidified with HCI (10%), then extracted with ethyl 
acetate (2 x 25ml) and dichloromethane (3 x 25ml). The combined organic extracts were 
dried (MgS04), filtered and the solvent evaporated to yield a crude brown product, which 
was purified by elution through silica gel with ethyl acetate, followed by recrystallisation 
from acetonitrile, to yield 4, 7-difluoro-2-methylthiazolo[4,5-d]pyridazine 279 (0.76g, 
62%); as yellow solid, mp > 250°C (Found C, 38.9; H, 1.7; N, 22.7. CJ13N3F2S requires C, 
38.5; H, 1.6; N, 22.5%); 8H (700MHz, DMSO-d6) 3.00 (3H, s, CH3); 8c (175MHz, CDCh) 
20.7 (s, CH3), 129.4 (dd, 2JcF 38.8, 3JCF 16.8, C3a/7a), 161.0 (dd, 1JCF 243.0, 4JcF 6.0, C4/7), 
178.9 (s, C2); 8F (658MHz, DMSO-d6) -81.4 (2F, s); mlz (EI+) 187 (30%, [M]l, 117 (24), 
87 (100), 70 (92), 31 (97). 
1, 4-Difluoro-8-methyl-2,3, 4b, 9-tetraaza-jluorene 280 
·.rt FNa Ng 
4 1 "":: 9a 
N ..-:: 
3 'N 1 F 
2 
280 
Tetrafluoropyridazine (0.50g, 3.28mmol) was mixed with 2-amino-3-picoline 
(0.83ml, 8.22mmol) and acetonitrile (lml) in a 2-5ml microwave vial, which was capped 
and sealed. This was irradiated at 150°C for I 0 minutes, after which the solvent was 
evaporated and the residue dissolved in dichloromethane (20ml), and washed with water 
(20ml). The aqueous layer was then extracted with dichloromethane (3 x 20ml) and the 
combined organic extracts were dried (MgS04), filtered, and evaporated in vacuo to yield a 
crude brown product. This was purified by filtration through a small plug of silica gel with 
dichloromethane as elutant, yielding 1,4-difluoro-8-methyl-2,3,4b,9-tetraaza-jluorene 280 
(0.42g, 58%) as a white solid; mp 213 - 215°C (Found [MHt 221.06339. C10H6N4F2 
requires [MHt 221.06333); Vmax I cm-1 976, 1024, 1102, 1165, 1228, 1256, 1281, 1309, 
1379, 1433, 1580; DH (500MHz, CDCh) 2.79 (3H, s, CH3), 7.21 (IH, t, 3JHH 7.2, C6(H)), 
7.59 (IH, d, 3Jm1 7.2, C7(H)), 8.63 (IH, d, 3JHH 7.2, C5(H)); 8c(125MHz, CDCh) 17.7 (s, 
CH3), 115.6 (s, ArC), 119.0 (dd, 2JcF 26.9, 3JcF 11.6, C4a/9a), 125.6 (d, 4JcF 4.9, C5), 130.1 
(s, ArC), 131.8 (s, ArC), 135.3 (dd, 2JcF 35.1, 3JcF 6.2, C4a/9a), 151.9 (m, C8a), 154.0 (dd, 
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1JcF 238.6, 4JcF 2.4, Cl/4), 158.2 (dd, 1JcF 246.9, 4JCF 3.5, Cl/4); 8F (376MHz, CDCb) 
-89.7 (IF, d, 5hF 34.6), -91.6 (IF, d, 51FF 34.6); m!z (EI+) 220 (100%, [Mt); Amax 
(fluorescence) 360nm. 
6-Bromo-1, 4-di.fluoro-8-methyl-2, 3, 4b, 9-tetraaza-jluorene 281 
Tetrafluoropyridazine (0.50g, 3.28mmol) was mixed with 2-amino-5-bromo-3-
methylpyridine (1.68g, 8.20mmol) and acetonitrile (IOml) in a 10-20ml microwave vial, 
which was capped and sealed. This was irradiated at 120°C for 60 minutes, followed by 
irradiation at 150°C for a further 60 minutes to achieve complete conversion. The solvent 
was evaporated and the residue dissolved in dichloromethane (20ml), and washed with 
water (20ml). The aqueous layer was then extracted with dichloromethane (3 x 20ml) and 
the combined organic extracts were dried (MgS04), filtered, and evaporated in vacuo to 
yield a crude brown product. This was purified by filtration through a small plug of silica 
gel with dichloromethane as elutant, then recrystallised from ethyl acetate and hexane (1 :2) 
to yield 6-Bromo-1,4-difluoro-8-methyl-2,3,4b,9-tetraaza-jluorene 281 (0.36g, 40%) as a 
cream solid; mp 215- 2l7°C (Found C, 40.2; H, 2.0; N, 18.5. CwH6N4F2 requires C, 40.2; 
H, 1.7; N, 18.7%); Vmax I cm·1 996, 1028, 1106, 1159, 1247, 1279, 1310, 1326, 1413, 1433, 
1470, 1558; 8H (400MHz, CDCh) 2.78 (3H, s, CH3), 7.66 (IH, s, C5/7(H)), 8.73 (IH, s, 
C5/7(H)); 8c (IOOMHz, CDCh) 17.5 (s, Me), 110.2 (s, C6/7/8), 118.6 (dd, 3JcF 26.9, 2JcF 
11.9, C4a/9a), 125.4 (d, 4JcF 4.6, C5), 131.0 (s, C6/7/8), 135.1 (dd, 2JcF 36.4, 3JcF 6.9, 
C4a/9a), 135.3 (s, C6/7/8), 150.1 (d, 4JcF 2.0, C8a), 153.6 (dd, 1JcF 236.8, 4JCF 2.8, Cl/4), 
158.2 (dd, 1JcF 246.8, 4JcF 3.4, Cl/4); 8F (376MHz, CDCb) -89.0 (IF, d, 51FF 34.8), -90.9 
(IF, d, 5JFF 34.8); m!z (EI+) 300 (100%, [M+, 81 Br]), 298 (93, [~, 79Br]), 219 (62, [M-
Br]l, 154 (26, [Csf2N4t), 102 (40, [C3F2N2t], 90 (30, [C2F2N2]l, 77 (44), 63 (57), 51 
(60), 39 (34). 
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N4,N7 -Dibutyl-2-phenyl-1 H-imidazo[ 4, 5-d}pyridazine-4, 7-diamine 282 
Ph 
H HN-i Bu"N~N ~'N~N~Bu 
H 
282 
4, 7-Difluoro-2-phenyl-1H-imidazo[ 4,5-d]pyridazine (0.1 Og, 0.43mmol) was 
dissolved in acetonitrile ( 1 ml) in a 0.5-2ml microwave vial and n-butylamine (0.085ml, 
0.86mmol) was added and the vial sealed. The mixture was heated under microwave 
irradiation at 150°C for 20 minutes before dichloromethane (I Oml) and water (1 Oml) were 
added and the layers separated. The aqueous layer was then washed with further portions 
of dichloromethane (3 x 1 Oml) and the organic extracts combined, dried (MgS04), filtered 
and evaporated to yield a crude yellow material. This was purified by elution through silica 
gel using ethyl acetate as elutant to yield N4,N7-dibutyl-2-phenyl-JH-imidazo[4,5-
d]pyridazine-4, 7-diamine 282 (0.051 g, 35%) as yellow crystals; mp 173 - 175°C; OH 
(500MHz, CDCh) 0.87 (6H, m, NHCH2CH2CH2CH3), 1.33 (4H, sextet, 3Jilll 7.4, 
NHCH2CH2CH2CH3), 1.61 (4H, pent, 3JHH 7.4, NHCH2CH2CH2CH3), 3.36 (4H, t, 3Jilll 7.4, 
NHCH2CH2CH2CH3), 7.39 (3H, m, C2'/4'(H)), 8.19 (IH, m, C3'(H)); oc (125MHz, 
CDCh) 13.9 (s, NHCH2CH2CH2CH2), 20.3 (s, NHCH2CH2CH2CH2), 31.3 (s, 
NHCH2CH2CH2CH2), 41.7 (s, NHCH2CH2CH2CH2), 116.2 (s), 118.9 (s), 127.3 (s), 129.0 
(s), 129.7(s), 132.7(s), 147.1 (s);m/z(ESl339(100%, [M+Ht). 
4, 7-Bis(methylthio)-2-phenyl-JH-imidazo[4,5-d]pyridazine 283 
Ph 
HN-i 
Me ..... s~N 
~'N~S~Me 
283 
4, 7-Difluoro-2-phenyl-1H-imidazo[ 4,5-d]pyridazine (0.1 Og, 0.43mmol) was 
dissolved in acetonitrile (1ml) in a 0.5-2ml microwave vial and n-butylamine (0.060g, 
0.86mmol) was added and the vial sealed. The mixture was heated under microwave 
irradiation at 150°C for 20 minutes before dichloromethane (1 Oml) and water (1 Oml) were 
added and the layers separated. The aqueous layer was then washed with further portions 
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of dichloromethane (3 x 10ml) and the organic extracts combined, dried (MgS04), filtered 
and evaporated to yield a crude yellow material. This could not be fully purified by flash 
column chromatography using ethyl acetate and hexane (I :2) as elutant. The major product 
was 4,7-bis(methylthio)-2-phenyl-1H-imidazo[4,5-d]pyridazine 283 (0.040g, 32%); OH 
(400MHz, CDCh) 2.21 (3H, s, CH3), 7.06- 7.45 (5H, m, ArH); m/z (ESl 289 (100%, 
[M+Ht). 
Attempted bromination of 4, 7-difluoro-2-phenyl-1 H-imidazo{ 4,5-d]pyridazine 
4,7-Difluoro-2-phenyl-1H-imidazo[4,5-d]pyridazine (0.1 Og, 0.431mmol) was 
dissolved in dry dichloromethane (20ml) and iron filings (0.026g, 0.473mmol) and bromine 
(0 .11 ml, 2.15mmol) were added. The mixture was heated to reflux under argon for 8 hours, 
after which 19F NMR and TLC ofthe reaction mixture confirmed that the starting material 
had been returned. 
4-F/uoro-1-buty/amino-5, 6, 7,8-tetrahydro-2, 3, 4b,9-tetraaza-fluorene 284a and 1-.fluoro-4-
buty/amino-5, 6, 7,8-tetrahydro-2, 3, 4b, 9-tetraaza-fluorene 284b 
Q HQ 
FtiN ~NnN I "':: I "':: 
N,N.....:: N~ N,N.....:: F 
H 
284a 284b 
1 ,4-Difluoro-5,6, 7,8-tetrahydro-2,3,4b,9-tetraaza-fluorene (0.1 Og, 0.48mmol) was 
dissolved in acetonitrile (I ml) in a 0.5-2ml microwave vial and n-butylamine (0.094ml, 
0.95mmol) was added. The vial was sealed and the mixture was heated under microwave 
irradiation at 150°C for 20 minutes. After this period dichloromethane ( 1 Oml) and water 
(1 Oml) were added and the layers separated. The aqueous layer was then washed with 
further portions of dichloromethane (3 x 1 Oml) and the organic extracts combined, dried 
(MgS04), filtered and evaporated to yield a crude yellow material. Purification by flash 
column chromatography using ethyl acetate and hexane (2: 1) as elutant was attempted, 
however it proved impossible to separate the regioisomers. The mixture contained 4-
jluoro-1-biit}'/amiho-5, 6,7,~8-ttFtrahydro-2,3, 4b, 9-tidraaza-fluorene 2843 as a- yellow solid; 
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4-Fluoro-1-methylthio-5,6, 7,8-tetrahydro-2,3,4b,9-tetraaza-j/uorene 286a and 1,4-bis-
(methylthio)-5, 6, 7, 8-tetrahydro-2,3, 4b, 9-tetraaza-j/uorene 286c 
Q 
F~N 
~'N~S~Me 
286a 286c 
1 ,4-Difluoro-5,6, 7,8-tetrahydro-2,3,4b,9-tetraaza-fluorene (0.1 Og, 0.48mmol) was 
dissolved in acetonitrile (lml) in a 0.5-2ml microwave vial and sodium thiomethoxide 
(0.067g, 0.95mmol) was added. The vial was sealed and the mixture was heated under 
microwave irradiation at 150°C for 20 minutes. After this period dichloromethane (1Om I) 
and water (1 Oml) were added and the layers separated. The aqueous layer was then washed 
with further portions of dichloromethane (3 x 1Om I) and the organic extracts combined, 
dried (MgS04), filtered and evaporated to yield a crude yellow material. Attempted 
purification by flash column chromatography using ethyl acetate and hexane (2:1) as 
elutant failed to separate the two products, which were 4-j/uoro-1-methylthio-5,6, 7,8-
tetrahydro-2,3,4b,9-tetraaza-fluorene 286a; OH (500MHz, CDCh) 2.14 (4H, m), 2.80 (3H, 
s, CH3), 3.15 {2H, t, 3JHH 6.9), 4.33 {2H, t, 3JHH 6.5); oF (658MHz, CDCh) -96.3 {lF, s); m/z 
(ES+) 239 (100%, [M+Ht). 
Also produced was 1,4-bis-(methylthio)-5,6, 7,8-tetrahydro-2,3,4b,9-tetraaza-
j/uorene 286c oH (500MHz, CDCh) 2.02 (4H, m), 2.77 (3H, s, CH3), 2.80 (3H, s, CH3), 
3.13 {2H, t, 3JHH6.7), 4.51 {2H, t, 3JHH 6.3); m/z (ES) 267 {100%, [M+Ht). 
4-F/uoro-2 -methyl-7 -morpholinothiazolo [ 4, 5-d]pyridazine 
morpholinothiazolo[4,5-d}pyridazine (287a and 287b) 
287a 
287b 
and 7-j/uoro-2-methy/-4-
4, 7-difluoro-2-methylthiazolo[ 4,5-d]pyridazine (0.1 Og, 0.534mmol) was dissolved 
- ~---
in dry acetonitrile (lml) in a 0.5-2ml microwave vial -and-morpholine--(0~0-5Tm( 
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oH (400MHz, CDCh) 0.93 (3H, t, 3JHH 7.4, NHCH2CH2CH2CH3), 1.44 (2H, sextet, 3JHH 
7.4, NHCH2CH2CH2CH3), 1.67 (2H, pent, 3JHH 7.4, NHCH2CH2CH2CH3), 2.10 (4H, m), 
3.08 (2H, t, 3JHH6.4, C8), 3.62 (2H, q, 3JHH 7.1, NHCH2CH2CH2CH3), 4.30 (2H, t, 3JHI-16.0, 
C5), 5.12 (IH, br t, 3JHH 5.3 NHCH2CH2CH2CH3); Op (658MHz, CDCh) -102.0 (IF, s); mlz 
(ES+) 264 (100%, [M+Ht). 
The minor product was 1-.fluoro-4-butylamino-5, 6,7,8-tetrahydro-2, 3, 4b, 9-tetraaza-
jluorene 284b Op (376MHz, CDCh) -101.7 (IF, s); m/z (ESl264 (100%, [M+Ht). 
4-Fluoro-1-morpholin-4-yl-5, 6, 7, 8-tetrahydro-2, 3, 4b,9-tetraaza-jluorene 285a 
1,4-Difluoro-5,6,7,8-tetrahydro-2,3,4b,9-tetraaza-fluorene (O.lOg, 0.48mmol) was 
dissolved in acetonitrile (1ml) in a 0.5-2ml microwave vial and morpholine (0.083ml, 
0.95mmol) was added. The vial was sealed and the mixture was heated under microwave 
irradiation at 150°C for 20 minutes. After this period dichloromethane (1Om I) and water 
( 1 Oml) were added and the layers separated. The aqueous layer was then washed with 
further portions of dichloromethane (3 x 1 Oml) and the organic extracts combined, dried 
(MgS04), filtered and evaporated to yield a crude yellow material. This was purified by 
flash column chromatography using ethyl acetate and hexane (2:1) as elutant to yield 4-
jluoro-1-morpholin-4-yl-5,6, 7,8-tetrahydro-2,3,4b,9-tetraaza-fluorene 285a (0.095g, 72%) 
as yellow solid; mp 179- 181°C (Found [MH+] 278.14106. C13H16NsFO requires [MHt 
278.14117); oH (500MHz, CDCh) 2.04 (2H, m), 2.14 (2H, m), 3.09 (2H, t, 3JHH 6.4, 
C8(H)), 3.87 (4H, t, 3JHH 4.8, C2'(H)), 4.03 (4H, t, 3JHH 4.8, C3'(H)), 4.33 (2H, t, 3JHH 6.0, 
C5(H)); 8c (125MHz, CDCb), 20.2 (s), 22.6 (s), 25.5 (s), 45.3 (d, 4JcF 2.7, C5), 47.3 (s, 
C2'), 67.2 (s, C3'), 125.1 (d, 2JCF 27.6, C4a), 136.1 (d, 3JcF 5.8, C9a), 151.5 (d, 1JCF 231.6, 
C4), 152.6 (d, 4JcF 2.1, C1), 153.9 (d, 4JCF2.1, C8a); OF (658MHz, CDCb) -101.9 (IF, s); 
mlz (ES+) 278 (100%, [M+H]l. 
217 
Chapter 7: Experimental 
0.587mmol) and DIPEA (0.102mol, 0.587mmol) were added. The vial was sealed and the 
mixture irradiated at 150°C for 20 minutes. After this period the solvent was evaporated 
and the mixture redissolved in dichloromethane (10ml) and water (10ml). The aqueous 
layer was separated and washed with further portions of dichloromethane (3 x 1 Oml). The 
organic extracts were combined, dried (MgS04), filtered and evaporated in vacuo. This 
yielded a mixture of two products, which unfortunately could not be conclusively 
identified. They were most likely 4-.fluoro-2-methyl-7-morpholinothiazolo£4,5-
d]pyridazine and 7-fluoro-2-methyl-4-morpholinothiazolo{4,5-d]pyridazine (287a and 
287b). The major product bH (400MHz, CDCh) 2.86 (3H, s, CH3), 3.84 (4H, t, 3JHH 4.7, 
C2'(H)), 3.99 (4H, t, 3JHH 4.7, C3'(H)); bF (376MHz, CDCh) -85.4 (IF, s); m/z (ES) 255 
(1 00%, [M+Ht). 
The minor product bH (400MHz, CDCh) 2.93 (3H, s, CH3), 3.49 (4H, t, 3JHH 5.1, 
C2'(H)), 4.12 (4H, t, 3JHH 5.1, C3'(H)); bF (376MHz, CDCb) -84.8 (IF, s); mlz (ES) 255 
( 1 00%, [M+H]). 
4-Fluoro-1-methoxy-8-methyl-2,3, 4b, 9-tetraaza-.fluorene 288 
6 7 
~o-
F~a Ng 
4 I ""-:: 9a 
3N,N..-:1 OMe 
2 
288 
1 ,4-Difluoro-8-methyl-2,3,4b,9-tetraaza-fluorene (0.50g, 2.27mmol) was mixed 
with sodium methoxide (0.31g, 5.68mmol) in methanol (3ml) in a 2-5ml microwave vial, 
which was sealed and irradiated at 120°C for 10 minutes. After this irradiation period water 
(15ml) was added, followed by dichloromethane (15ml), and the layers separated. The 
aqueous layer was extracted with dichloromethane (3 x 20ml), and the organic extracts 
were combined, dried (MgS04), filtered and evaporated to yield a crude red brown material 
(0.48g), containing 2 products in a 3: I ratio by 19F NMR. This was purified by flash 
column chromatography (Hexane : Ethyl Acetate 2:1) to yield 4-Fluoro-1-methoxy-8-
methyl-2,3,4b,9-tetraaza-.fluorene 288 (0.21 g, 40%) as a white solid; mp 229 - 231 °C 
(Found C, 56.6; H, 3.9; N, 23.9. C11H9FN40 requires C, 56.9; H, 3.9; N, 24.1 %); Vmax I cm-1 
964, 980, 1030, 1102, 1132, 1168, 1236, 1286, 1320, 1372, 1424, 1466, 1579; bH 
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(500MHz, CDCh) 2.76 (3H, s, C8(CH3)), 4.38 (3H, s, OCH3), 7.08 (I H, t, 3JHH 6.8, 
C6(H)), 7.48 (1 H, dt, 3J1-11-1 6.8, 4JHH 1.0, C7(H)), 8.80 (I H, d, 3 JHH 6.8, C5(H)); Oc ( 125MHz, 
CDCh) 17.6 (s, C8(CH3)), 55.6 (s, OCH3), 114.3 (s), 120.5 (d, 3Jcr 11.4, C9a), 126.0 (s), 
129.1 (s), 130.4 (s), 133.1 (d, 2Jcr36.4, C4a), 150.7 (s, C8a), 154.9 (d, 4JCF 2.0, Cl), 156.8 
(d, 1JCF 247.6, C4); or (376MHz, CDCh) -94.5 (IF, s); mlz (Et) 232 (58%, [M+]), 231 (39, 
[M-Ht), 217 (8, [M-Met), 183 (100). 
The minor product l-F/uoro-4-methoxy-8-methyl-2,3,4b,9-tetraaza-jluorene was 
not isolated pure; oF(200MHz, CDCh) -95.6 (IF, s); m/z (EI+) 232 (94%, [~]), 231 (91, 
[M-Ht), 217 (24, [M-Me]l, 183 (100). 
Ethyl-(4-jluoro-8-methyl-2, 3, 4b, 9-tetraaza-jluoren-1-yl)-amine 289 
Frrct I~ 
N,N~ NHEt 
289 
1 ,4-Difluoro-8-methyl-2,3,4b,9-tetraaza-fluorene (0.50g, 2.27mmol) was mixed 
with ethylamine (2.83ml, 2.0M in THF, 5.68mmol) in a 2-5ml microwave vial, which was 
sealed and irradiated at 120°C for 1 0 minutes. After this irradiation period water (15m!) 
was added, followed by dichloromethane (15ml), and the layers separated. The aqueous 
layer was extracted with dichloromethane (3 x 20m!), and the organic extracts were 
combined, dried (MgS04), filtered and evaporated to yield a crude red brown material 
(0.45g). This was recrystallised from toluene to yield Ethyl-(4-jluoro-8-methyl-2,3,4b,9-
tetraaza-jluoren-J-yl)-amine 289 as yellow solid (0.36g, 65%); mp 127- 129°C (Found 
[MHt 246.11492. C12H12FNs requires [MH+] 246.11495); Vmax I cm-1 1056, 1081, 1108, 
1160, 1231, 1320, 1340, 1401, 1435, 1480, 1583, 1616, 3351 (br, NH); 01-1 (500MHz, 
CDCh) 1.40 (3H, t, 3JHH 6.6, NHCH2CH3), 2.71 (3H, s, ring CH3), 3.77 (4H, quin, 3J1-11-1 6.6, 
NHCH2CH3), 5.53 (IH, br t, 3J1-11-1 6.6, NIIEt), 7.03 (lH, t, 3J1-1H 6.7, C6), 7.40 (lH, dt, 3J1-11-1 
6.7, 4JHH 0.9), 8.51 (lH, d, 3J1-11-1 6.7, C5); Oc (125MHz, CDCh) 14.9 (s, NHCHzCH3), 17.5 
(s, C8(CH3)), 36.5 (s, NHCH2CH3), 114.2 (s), 114.5 (d, 2Jcr 29.5, C4a), 125.5 (d, Jcr 4.2, 
C9a), 128.9 (s), 129.5 (s), 136.3 (d, 4Jcr 4.5, C5), 149.6 (d, 4Jcr 2.7, C8a), 150.2 (d, 1Jcr 
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230.6, C4), I53.I (d, 4JcF 2.0, CI); oF (376MHz, CDCh) -99.4 (IF, s); m/z (EI+) 245 (17%, 
[Mt), 230 (29, [M-Met), I83 (67), 92 (58), 65 (69), 29 (100, [Ett). 
Minor isomer was not isolated, most probably Ethyl-(1-jluoro-8-methyl-2,3,4b,9-
tetraaza-jluoren-4-yl)-amine; oF(200MHz, CDCh) -98.5 (IF, s); mlz (Et) 245 (74, [M+]), 
230 (100, [M-Met), 183 (95). 
Die thy/-( 4-jluoro-8-methy/-2, 3, 4b, 9-tetraaza-jluoren-1-y/)-amine 290 
Frr<t I~ 
N,N..-::: NEt
2 
290 
1 ,4-Ditluoro-8-methyl-2,3,4b,9-tetraaza-tluorene (0.30g, 1.36mmol) was mixed 
with diethylamine (0.35ml, 3.4Immol) in acetonitrile (3ml) in a 2-5ml microwave vial, 
which was sealed and irradiated at I50°C for 12 minutes. After this irradiation period water 
( I5ml) was added, followed by dichloromethane (15ml), and the layers separated. The 
aqueous layer was extracted with dichloromethane (3 x 20ml), and the organic extracts 
were combined, dried (MgS04), filtered and evaporated to yield a crude red brown material 
(0.34g). This was recrystallised from hexane I dichloromethane (4:I) to yield Diethyl-(4-
jluoro-8-methyl-2,3,4b,9-tetraaza-jluoren-1-yl)-amine 290 (0.26g, 70%) as yellow crystals; 
mp 1I1 - I13°C (Found C, 61.7; H, 5.9; N, 25.4. C10Ht;N4F2 requires C, 61.5; H, 5.9; N, 
25.6%); Vmax 1000, I030, I074, I098, 12I7, I237, 1295, 1352, 1429, 1485, 1575, 1638, 
2973 (CH); oH (400MHz, CDCh) 1.3I (6H, t, 3JHH 7.I, NCH2CH3), 2.66 (3H, s, C8(CH3)), 
4.09 (4H, q, 3JHH 7.1, NCH2CH3), 6.95 (1H, t, 3JHH 7.0, C6(H)), 7.31 (lH, d, 3JHH 7.0, 
C7(H)), 8.46 (IH, d, 3JHH 7.0, C5(H)); oc (lOOMHz, CDCh) 13.8 (s, NCH2CH3), 17.3 (s, 
C8(CH3)), 44.0 (s, NCH2CH3), I13.9 (s), I25.1 (d, 3JcF 5.3, C9a), 128.7 (s), 129.2 (s), 
136.6 (d, 4JCF4.6, C5), 148.3 (d, 4JcF2.2, C8a), 150.5 (d, 1JCF228.4, C4), I53.3 (d, 4JcF 1.9, 
Cl); oF (376MHz, CDCh) -I02.7 (IF, s); mlz (EI+) 273 (24%, [M+]), 244 (100, [M-Et]}, 
230 (74, [M-Et-Met), 201 (12, [M-NEt2t), 183 (56), 92 (36); Crystals suitable for X-ray 
diffraction grown from slow evaporation of ethyl acetate and hexane (1 :4). 
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6-Pheny/-1, 4-difluoro-8-methy/-2,3, 4b, 9-tetraaza-:fluorene 291 
FnPhtt 
1-...:::::::: 
N,N/- F 
291 
6-Bromo-1,4-difluoro-8-methyl-2,3,4b,9-tetraaza-fluorene (0.1 Og, 0.334mmol) was 
mixed with phenyl boronic acid (0.045g, 0.367mmol), caesium carbonate (0.22g, 
0.669mmol) and triphenylphosphine (0.0 13g, 0.0502mmol) and palladium (II) acetate 
(0.0038g, 0.0167mmol) and dissolved in degassed toluene and water (10:1) (11ml). The 
mixture was heated to 90°C under argon for 16 hours before being allowed to cool. 
Dichloromethane (I Om I) and water (1Om I) were added and the layers separated. The 
aqueous layer was extracted with further portions of dichloromethane (3 x 1Om I), before 
the organic extracts were dried (MgS04), filtered and evaporated in vacuo to yield a crude 
brown material. This was purified by flash column chromatography (elutant ethyl acetate : 
hexane, 1 :2) to yield 6-Phenyl-1,4-difluoro-8-methyl-2,3,4b,9-tetraaza-jluorene 291 
(0.040g, 41%) as a white solid; mp 197- 198°C (Found [MHt 297.09460. C16H10N4F2 
requires [MHt 297.09463); oH (500MHz, CDCh) 2.86 (3H, s, C8(CH3)), 7.50 (IH, t, 3JHH 
7.9, C4'(H)), 7.55 (2H, t, 3JHH 7.9, C3'(H)), 7.63 (2H, d, 3JHH 7.9, C2'(H)), 7.84 (lH, s, 
C7(H)), 8.73 (lH, s, C5(H)); oF (376MHz, CDCh) -89.1 (IF, d, 5JrF 34.4), -91.0 (IF, d, 5JFF 
34.4); mlz (ES+) 297 (100%, [M+Ht). 
7.5 Experimental to Chapter 5 
4, 5-Dich/oropyridazine-3, 6-dio/294 
Cl 
HOn-...:::::::: Cl 
N /-
'N OH 
294 
A solution of hydrazine hydrate (3l.lml, 0.63mol) was made up in water (400ml) 
and cone. HCl (120ml). Dichloromaleic anhydride (lOOg, 0.60mol) was added with stirring 
under an argon-atmosphere. The suspension was stirred at room temperature-for 1-hour; 
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followed by reflux for 2 hours. A crust formed on the surface of the mixture, which was 
broken up by the addition of a little water. The mixture was allowed to cool and was then 
filtered to obtain 4,5-dich/oropyridazine-3,6-dio/121 294 (98.85g, 91%, as cream solid), 
which was dried under vacuum without any further purification and used in the synthesis of 
tetrachloropyridazine; OH ( 400MHz, CDC h) 1.54 (2H, br s, OH); mlz (EI) 184 ( 12%, [Mt, 
(2 X 37Cl)), 182 (59, [Mt, (1 X 37Cl, 1 X 35Cl)), 180 (100, [Mt, (2 X 35Cl)). 
Tetrach/oropyridazine 292 
Cl 
CI~CI 
~'N~CI 
292 
4,5-dichloropyridazine-3,6-diol (98g, . 0.54mol) was added to phosphorus 
oxychloride and the mixture stirred and refluxed under argon for 7 hours. This was then 
allowed to cool overnight before being poured slowly onto crushed ice (-21). This addition 
was very exothermic and also had an initiation period, so extreme care was necessary. The 
solid product was then filtered off and dissolved in diethyl ether. Water (1 OOml) was added 
and the mixture was separated, dried (MgS04), filtered and the solvent evaporated under 
vacuum to yield a crude cream product (103.09g). This was then recrystallised from 
methanol to yield tetrachloropyridazine 292 (99.03g, 84%) as white crystals; mp 87- 89°C 
(Found C, 22.2; N, 12.8. C4N2C4 requires C, 22.0; N, 12.9%); oc (CDCh, 500MHz) 137.5 
(s, C4/5), 154.6 (s, C3/6); m/z (EI) 222 (7%, [Mt (3 x 37Cl, 1 x 35Cl)), 220 (32, [Mt (2 x 
37Cl, 2 X 35Cl)), 218 (60, [Mt (1 X 37Cl, 3 X 35Cl)), 216 (47, [Mt (4 X 35Cl)). 
3, 5, 6-Trichloro-N-methylpyridazin-4-amine 296 
Me,NH 
CIY.l'-'::.5 Cl 31 N ...-:6 
'N Cl 
296 
Tetrachloropyridazine (l.OOg, 4.59mmol) was dissolved in acetonitrile (25ml) under 
argon with stirring. Methylamine (2.0M in EtOH) (4.6ml, 9.18mmol) was added and the 
·· - mixture-stirred at-room-temperature-for ~5 hours~ -This-period was followed- by-the-slow-
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addition of water (20ml) and acidification of the solution with I 0% HCI, followed by 
extraction with ethyl acetate (3 x 20ml). The combined organic extracts were dried 
(MgS04), filtered and evaporated under vacuum to yield a crude yellow product (0.62g). 
This was then recrystallised from hexane I ethyl acetate (2:3) to yield 3,5,6-trichloro-N-
methylpyridazin-4-amine 296 (0.42g, 43%) as a cream I yellow solid; mp 113 - 1I4°C 
(Found C, 28.6; H, 1.9; N, I9.5. CsH4ChN3 requires C, 28.3; H, 1.9; N, I9.8%); Vmaxl cm-1 
918, 1061, I083, II46, I246, 1346, 1428, 1562, 3333 (br, NH); DH (CDCh, 400MHz) 3.41 
(3H, d, 3JHH 5.5, CH3), 5.26 (IH, br s, NH); De (CDCh, lOOMHz) 33.2 (s, CH3), 1I5.8 (s), 
I42.1 (s), 143.6 (s), I54.8 (s); mlz (EI) 215 (4%, [Mt (2 x 37CI, I x 35CI)), 2I3 (15, [Mt, 
(I x 37CI, 2 x 35CI)), 211 (18, [Mt, (3 x 35CI)), 187 (4, [M-NHMet, (2 x 37CI, 1 x 35CI)), 
185 (15, [M-NHMet (1 x 37CI, 2 x 35CI)), I83 (16, [M-NHMet (3 x 35CI)). 
N-Benzyl-3,5, 6-trichloropyridazin-4-amine 297 
Ph 
l_NH 
Cln~ Cl 
N .....:: 
'N Cl 
297 
Tetrachloropyridazine (l.OOg, 4.59mmol) was dissolved in acetonitrile (25ml) under 
argon with stirring. Benzylamine ( l.Oml, 9 .18mmol) was added and the mixture stirred at 
room temperature for 16 hours. Water (20ml) was added and the solution acidified with 
10% HCI, followed by extraction with ethyl acetate (3 x 20ml). The combined organic 
extracts were dried (MgS04), filtered and evaporated under vacuum to yield a crude yellow 
product (0.86g). This was then recrystallised from hexane I ethyl acetate (2: 1) to yield N-
benzyl-3,5,6-trichloropyridazin-4-amine 297 (0.71g, 54%) as yellow crystals; mp 75 -
77°C (Found C, 46.0; H, 2.9; N, 14.5. C11HsN3Ch requires C, 45.8; H, 2.8; N, I4.6%); Vmax 
I cm-1 1088, 1220, 1270, 1338, 1440, 1560,3317 (br, NH); DH (CDCh, 500MHz) 4.95 (2H, 
d, 3JHH 5.9, NHCH2Ph), 5.42 (1H, br s, NHCH2Ph), 7.29- 7.40 (5H, m, ArH); De (CDCh, 
125MHz) 49.6 (s, NHCH2Ph), 116.8 (s), 127.3 (s, PhCH), I28.2 (s, PhCH), I29.1 (s, 
PhCH), 137.2 (s), I41.4 (s), 144.I (s), 154.8 (s); mlz (EI) 291 (3%, ~ (2 x 37CI, 2 x 35CI), 
289 ( 12, [Mt (I X 37 Cl, 3 X 35C1), 287 (11, [Mt ( 4 X 35CI), 9I ( 1 00, [CH2Ph t), 77 (11, 
224 
Chapter 7: Experimental 
3, 5, 6-Trich/oro-N,N-diethy/pyridazin-4-amine 299 
Tetrachloropyridazine (l.OOg, 4.59mmol) was dissolved in acetonitrile (25ml) under 
argon with stirring. Diethylamine (0.95ml, 9.18mmol) was added and the mixture heated to 
reflux for 16 hours. Water (20ml) was added and the solution acidified with 10% HCl, 
followed by extraction with ethyl acetate (3 x 20ml). The combined organic extracts were 
dried (MgS04), filtered and evaporated under vacuum to yield a crude red-brown product 
(1.04g). This was then recrystallised from hexane (I Oml) to yield 3,5,6-trich/oro-N,N-
diethy/pyridazin-4-amine 299 (0.57g, 49%) as a yellow solid; mp 52 - 54°C (Found C, 
37.7; H, 4.0; N, 16.4; CsHtoNJCb requires C, 37.8; H, 4.0; N, 16.5%); Vmax I cm-1 956, 
1017, 1078, 1114, 1178, 1234, 1281, 1299, 1319, 1380, 1420, 1469, 1508, 1670, 2936 
(CH), 2975 (CH); 8H (CDCb, 500MHz) 1.09 (3H, t, 3JHH 7.1, NHCH2CH3), 3.37 (2H, q, 
3JHH 7.1, NHCH2CH3); 8c (CDCh, 125MHz) 13.9 (s, NHCH2CH3), 45.9 (s, NHCH2CH3), 
133.2 (s), 146.4 (s), 155.1 (s), 155.4 (s); m/z (EI) 257 (3%, [Mt (2 x 37Cl, 1 x 35Cl)), 255 
(9, [Mt (l X 37CI, 2 X 35Cl)), 253 (12, [Mt (3 X 35Cl)), 242 (22, [M-CH3t (2 X 37CI, 1 X 
35Cl)), 240 (63, [M-CH3t (l X 37Cl, 2 X 35Cl)), 238 (60, [M-CH3t (3 X 35Cl)), 214 (15,[M-
CHzCH3t (2 x 37Cl, 1 x 35CI)), 212 (45, [M-CH2CH3t (1 x 37Cl, 2 x 35Cl)), 210 (48, [M-
CH2CH3t (3 x 35Cl)), 29 (l 00, [CHzCH3t). Crystals suitable for X-ray diffraction were 
obtained by recrystallisation from hexane. 
3, 4, 6-Trich/oro-5 -piperidine-1 -yl-pyridazine 300 
4' 
0 3' 2' N 
Cln~ Cl 
N /.: 
'N Cl 
300 
Tetrachloropyridazine (2~00g, 9.17mmol) and piperidine (l.8ml, 18.31mmol) were 
dissolved in acetonitrile (50ml) and_stirred under argon_ at room temperature for 4 hours. 
After TLC indicated complete conversion of starting material, water (20ml) was added, and 
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[Pht), 65 (63). Crystals suitable for X-ray diffraction were obtained from slow 
evaporation of ethyl acetate. 
N-tert-Buty/-3, 5, 6-trich/oropyridazin-4-amine 298 
)tNH 
CI~CI 
~'N~CI 
298 
Tetrachloropyridazine (l.OOg, 4.59mmol) was dissolved in acetonitrile (25ml) under 
argon with stirring. !-Butylamine (0.96ml, 9.18mmol) was added and the mixture stirred at 
room temperature for 16 hours, followed by heating to reflux for a further 8 hours. The 
reaction was quenched by the slow addition of water (20ml), and the solution was acidified 
with 10% HCI, followed by extraction with ethyl acetate (3 x 20m I). The combined 
organic extracts were dried (MgS04), filtered and evaporated under vacuum to yield a 
crude yellow product (0.67g). This was then recrystallised from hexane I ethyl acetate (2:3) 
to yield N-tert-buty/-3,5,6-trich/oropyridazin-4-amine 298 (0.52g, 45%); as a yellow-
orange solid, mp 64- 66°C (Found C, 37.9; H, 3.8; N, 16.3. CsHwChN3 requires C, 37.8; 
H, 4.0; N, 16.5%); Vmaxl cm- 1 986, 1078, 1193, 1212, 1249, 1341, 1462, 1531, 1557, 1614, 
3391 (br, NH); 8H (CDCb, 400MHz) 1.49 (9H, s, (CH3)3), 4.82 (1 H, br s, NH); 8c (CDCh, 
125MHz) 31.4 (s, NC(CH3)J), 57.2 (s, NC(CH3)3), 121.7 (s), 142.9 (s), 148.4 (s), 155.0 (s); 
mlz (EI) 255 (2%, ~ (1 x 37CI, 2 x 35CI)), 253 (2, ~ (3 x 35CI)), 242 (4, [M-CH3t (2 x 
37CI, 1 X 35CI)), 240 (9, [M-CH3t (l X 37CI, 2 X 35CI)), 238 (9, [M-CH3t (3 X 35CI)), 201 
(5, [M-1Bu] (2 x 37CI, 1 x 35CI)), 199 (13, [M_tBu] (1 x 37Cl, 2 x 35CI)), 197 (15, [M-1Bu] (3 
x 
35CI)), 57 (1 00, [t-But), 41 (70, [C(CH3)2t, 29 (27, [C(CH3)t). 
-- ---- ________ ,--
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the solution acidified with I 0% HCl, and the mixture extracted with ethyl acetate (3 x 
20ml). The combined organic extracts were dried (MgS04), filtered and evaporated to 
yield a crude yellow solid (1.48g) which after recrystallisation from ethyl acetate gave 
3,4,6-trich/oro-5-piperidine-1-y/-pyridazine 300 (0.60lg, 25%) as a yellow solid; mp 76-
78°C (Found C, 40.6; H, 3.8; N, 15.6. C9H10CbN3 requires C, 40.6; H, 3.8; N, 15.8%); OH 
(500MHz, CDCb) 1.73 (6H, m, C3'+4'(H)), 3.33 (4H, t, 3JHH 5.3, C2'(H)); oc (125MHz, 
CDCb) 23.7 (s, C4'), 26.2 (s, C3'), 51.9 (s, C2') 129.7 (s), 146.8 (s), 152.8 (s) 155.5 (s); 
mlz (EI+) 271 (3%, [M+]), 270 (5, [M-H]l, 269 (18, [M]l, 268 (48, [M-H]l 267 (53, 
[Mt), 266 (100, [M-Ht), 265 (53, [Mt), 264 (100, [M-Ht), 55 (35, [C4H1t). 
4-(3,5,6-Trich/oro-pyridazine-4-yl)-morpholine 301 
(0):. 
N 
Cln~ ci 
N h 
'N Cl 
301 
Tetrachloropyridazine (2.00g, 9.17mmol) and morpholine (1.60ml, 18.34mmol) 
were dissolved in acetonitrile (50ml) under argon with stirring at room temperature. After 
24 hours TLC indicated complete conversion of starting material, so water (20ml) was 
added and the solution acidified With 10% HCI. This was then extracted with ethyl acetate 
(3 x 20ml) gave a crude yellow product which after recrystallisation from hexane I ethyl 
acetate (1:1) gave 4-(3,5,6-trich/oro-pyridazine-4-y/)-morpho/ine 301 (1.15g, 47%) as 
yellow crystals; mp 101- 103°C (Found C, 35.9; H, 3.0; N, 15.4. C8H8N30Cb requires C, 
35.8; H, 3.0; N, 15.7%); OH (500MHz, CDCb) 3.43 (4H, t, 3JHH 4.5, C2'(H)), 3.86 (4H, t, 
3
JHH 4.5, C3'(H)); oc (125MHz, CDCb) 50.6 (s, C2'), 67.1 (s, C3'), 130.3 (s), 145.5 (s), 
152.7 (s), 155.7 (s); mlz (Ell273 (2%, [M]l, 272 (2, [M-H]l, 271 (15, [M]l, 270 (7, 
[M-H]l, 269 (43, [M]l, 268 (10, [M-H]l, 267 (46, [M]l, 266 (6, [M-H]l, 234 (30, [M-
Cit), 232 (69, [M-Cit), 211 (95, [M-C3H60]l, 209 (100, [M-C3H60t), 148 (36, [M-
C4HsNOCit), 146 (54, [M-C4HsNOCl]l, 117.9 (32), 85 (23, [C4HsNOt), 77 (34). 
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3, 5, 6-Trichloro-N-phenylpyridazin-4-amine 302a and 4, 5, 6-trichloro-N-phenylpyridazin-3-
amine 302b 
302a 
Cl 
Cln--:::::CI 
N ...-:: 
'N 6 
302b 
Tetrachloropyridazine (2.00g, 9.17mmol) was dissolved in acetonitrile (50ml) under 
argon, with stirring. Aniline (0.84ml, 9.17mmol) was added and the mixture stirred, at 
reflux, for 22 hours. After this period, water (20ml) was added and the solution acidified 
with 10% HCI. Ethyl acetate (3 x 20ml) was used to extract the product, which was then 
dried (MgS04), filtered and evaporated to yield a black oil. The oil was partially dissolved 
in DCM. Silica was added to the solution and the solvent was evaporated off. The crude 
product was purified by flash column chromatography (elutant ethyl acetate I hexane 1:5) 
to yield pure products. 
The major product was identified as 3,5,6-trichloro-N-phenylpyridazin-4-amine 
302a (0.25g, 10%) as a pale orange solid; mp 165- 16rc (Found C, 43.7; H, 2.2; N, 15.3. 
C10H6N3Ch requires C, 43.8; H, 2.2; N, 15.3%); oH (400MHz, CDCh) 6.75 (lH, br s, NH), 
7.02 (2H, d, 3JHH 7.7, C3'(H)), 7.26 (1H, t, 3JHH 7.7, C4'(H)), 7.54 (2H, t, 3JHH 7.7 C2'H); 
eSc (lOOMHz, CDCh) 121.3 (s), 123.6 (s, PhC)), 126.5 (s, PhC), 129.3 (s, PhC), 137.8 (s, 
PhC), 139.1 (s), 146.56 (s), 155.5 (s); m/z (Ell279 (2%, [Mt (3 x 37Cl)), 278 (2, [M-Ht 
(3 X 37Cl)), 277 (21, [Mt (1 X 35Cl + 2 X 37Cl)), 276 (6, [M-Ht (1 X 35Cl + 2 X 37Cl)), 275 
(55, [Mt (2 X 35Cl + 1 X 37Cl)), 274 (5, [M-Ht (2 X 35Cl + 1 X 37Cl)), 273 (56, [Mt (3 X 
35Cl)) 177 (48, [CJOH6NCit (1 X 37Cl)), 175 (100, [CJOH6NCit (1 X 35Cl)), 142 (41, 
[C9H6Nt), 89 (20, [C6H3Nt), 77 (82, [C6Hst), 65 (32), 51 (72), 39 (24). 
The minor product was identified as 4,5,6-trichloro-N-phenylpyridazin-3-amine 
302b (0.14g, 6%) as a orange solid; mp 135 - 136°C (Found C, 43.6%; H, 2.3; N, 15.7. 
C10H6N3Cb requires C, 43.8; H, 2.2; N, 15.3%); OH (400MHz, CDCh) 6.96 (lH, br s, NH), 
7.15 (lH, t, 3JHH 7.8, C4'(H)), 7.39 (2H, t, 3JHH 7.8, C2'(H)), 7.68 (2H, d, 3JHH 7.8, C3'(H)); 
oc (lOOMHz, CDCh) 120.9 (s, PhC), 124.6 (s, PhC), 129.4 (s, PhC), 135.2 (s), 138.1 (s, 
P~<=). 14~·"Us1_15~_.2 (s), l54.9 is)_;_ m!_z (£t) 27J _(_1 %~IM(P ~ 37 (;:})2, 27~ 15, [M-J-!tJ3 
X 
37Cl)), 277 (9, [Mt (1 X 35Cl + 1 X 37Cl.)), 276 (34, [M-Ht (1 X 35Cl + 1 X 37Cl)), 275 
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(20, [Mt (2 X 35Cl + I X 37Cl)), 274 (I 00, [M-Ht (2 X 35Cl + I X 37Cl)), 273 (20, [Mt (3 X 
35Cl)), 272 (98, [M-Ht (3 x 35Cl)), I77 (8, [C 10H6NCit (l x 37Cl)), 175 (24, [CwH6NCit 
e5Cl)), 77 (59, [C6Hs]l, 65 (25, [CsHs]l, 51 (58), 39 (18). Crystals suitable for X-ray 
diffraction were grown by slow evaporation of dichloromethane. 
4,6-Dichloro-N3,N3,N5,N5-tetraethylpyridazine-3,5-diamine 303 
303 
3,5,6-trich/oro-N,N-diethy/pyridazin-4-amine (0.50g, 1.96mmol) was dissolved in 
acetonitrile (5ml) under argon with stirring. Diethylamine (0.41ml, 3.92mmol) was added 
and the mixture irradiated in a sealed microwave vial at 150°C for 30 minutes. Water 
(20m!) was added and the solution acidified with 10% HCI, followed by extraction with 
ethyl acetate (3 x 20m!). The combined organic extracts were dried (MgS04), filtered and 
evaporated under vacuum to yield a crude red-brown product. This was then purified by 
flash column chromatography using ethyl acetate and hexane (1 :2) as elutant to yield 4,6-
dichloro-N3,N3,N5,N5-tetraethylpyridazine-3,5-diamine 303 (0.35g, 62%) as a yellow oil; 
(Found C, 49.8; H, 6.8; N, 19.4. C12H2oN4Ch requires C, 49.5; H, 6.9; N, 19.2%); oH 
(CDCb, 400MHz) 0.98 (3H, t, 3JHH 6.8, CH3), 1.13 (3H, t, 3JHH 6.5, CH3), 3.23 (2H, q, 3JHH 
6.8, CH2), 3.38 (2H, q, 3JHH 6.5, CH2); oc (CDCb, 125MHz) 12.9 (s, CH2), 13.9 (s, CH2), 
44.7 (s, CH3), 45.9 (s, CH3), 126.9 (s, ArC), 145.5 (s, ArC), 149.2 (s, ArC), 161.0 (s, ArC); 
mlz (EI) 294 (1%, M+ (2 x 37Cl), 292 (6, M+ (1 x 37Cl, 1 x 35Cl)), 290 (10, ~ (2 x 35Cl)), 
72 (70, [NEht), 29 (100, [CH2CH3]l. 
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5, 8-Dichloro-1 ,2, 3, 4-tetrahydro-1, 4-dimethylpyrazino [2, 3-d}pyridazine 304a and 3, 4-
dichloro-5,6, 7,8-tetrahydro-5,8-dimethylpyrazino[2,3-c]pyridazine 304b 
2 '~134 
c'Oa N a1 ~ ' 
7N'N....-;5 Cl 
6 
304a 
Cl I CI~N) ~'N~N 
I 
304b 
Tetrachloropyridazine ( l.OOg, 4.59mmol) was dissolved in acetonitrile ( 1 OOml) 
under argon with stirring. N,N'-dimethylethylenediamine (0.54ml, 5.05mmol) was added 
and the mixture stirred at room temperature for 65 hours. At the end of this period, water 
(25ml) was added and the solution acidified with 10% HCl, followed by extraction with 
ethyl acetate (4 x 25ml). The combined organic extracts were dried (MgS04), filtered and 
evaporated under vacuum to yield a crude red-brown product (0.98g). This was then 
purified by flash column chromatography (Elutant = Hexane : Ethyl Acetate ( 1: 1 - 1200ml) 
followed by Hexane : Ethyl Acetate (1 :2 - 600ml). This yielded 2 products in an isomer 
ratio of2.66: 1 from the crude 1H NMR. 
The major product was 5,8-dichloro-1,2,3,4-tetrahydro-1,4-dimethylpyrazino{2,3-
d]pyridazine 304a (0.34g, 32%) as a cream solid; mp 143.5- 146°C (Found C, 41.2; H, 
4.3; N, 23.8. CsH10N4Ch requires C, 41.2; H, 4.3; N, 24.0%); Vmax I cm-1 984, 1037, 1074, 
1115, 1213, 1240, 1307, 1331, 1362, 1420, 1450, 1491, 2878 (CH); OH (CDCh, 500MHz) 
3.05 (3H, s, CH3), 3.07 (2H, s, CH2CH2); <>c (CDCh, 100MHz) 42.7 (s, CH2CH2), 46.1 (s, 
CH3), 135.7 (s, C4a/8a), 146.0 (s, C5/8); mlz (EI) 233 (0.4%, [Mt (1 x 37Cl, 1 x 35Cl)), 231 
(1.6, [Mt (2 x 35Cl)), 91 (100). Crystals suitable for X-ray diffraction were obtained from 
slow evaporation of ethyl acetate. 
The minor product was 3,4-dich/oro-5,6, 7,8-tetrahydro-5,8-dimethylpyrazino[2,3-
c]pyridazine 304a (0.18g, 17%) as a cream solid; mp 121- 123°C (Found C, 42.5; H, 4.7; 
N, 22.7; CsH10N4Ch requires C, 41.2; H, 4.3; N, 24.0%); OH (CDCb, 400MHz) 3.40 (2H, 
m, CH2), 3.35 (2H, m, CH2), 3.20 (3H, s, CH3), 3.16 (3H, s, CH3); <>c (CDCh, 100MHz) 
36.9 (s, CH2), 41.8 (s, CH2), 45.4 (s, CH3), 50.1 (s, CH3), 134.4 (s), 136.9 (s), 145.5 (s), 
150.5 (s), 153.9 (s); m/z (Et) 217 ([M-Met, 1%), 106 (28), 85 ([CsH9N2+], 29), 71 
([C3H1N2t, 34), 49 (32), 47 (100), 35 (72). 
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Ph 
HN.j___NH 
CI~CI 
~'N~CI 
305 
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Tetrachloropyridazine (l.OOg, 4.59mmol) was dissolved in acetonitrile (lOOml) 
under argon with stirring. Benzamidine hydrochloride (0.79g, 5.05mmol) and sodium 
hydrogen carbonate ( 1.54g, 18.36mmol) were added and formed a suspension, which was 
heated to 80°C for 22 hours. After this period a yellow solution was obtained, from which 
the solvent was evaporated and the residue dissolved in ethyl acetate (50ml). This was 
washed with water (25ml), and the aqueous layer extracted with ethyl acetate (3 x 25ml). 
The combined organic extracts were dried (MgS04), filtered and evaporated in vacuo to 
yield a crude brown material. This was recrystallised from ethyl acetate and hexane (1:1) 
to give N-(3,5,6-trichloropyridazin-4-yl)benzamidine 305 (0.58g, 43%); as yellow solid, 
mp 179- 181°C (Found C, 43.5; H, 2.6; N, 18.8; C11 H7N4Cb requires C, 43.8; H, 2.3; N, 
18.6%). ()H (400MHz, DMSO-dt;) 7.16 (lH, br s, NH), 7.61 - 7.46 (4H, m, ArH + NH), 
7.97 (2H, d, 3JHH 7.4, ArH); be (IOOMHz, DMSO-dt;) 128.0 (s), 128.8 (s), 131.9 (s), 133.9 
(s), 148.6 (s), 151.2 (s), 153.9 (s), 157.1 (s); m/z (EI+) 304 (6%, M+ (2 x 37Cl, 1 x 35Cl)), 
302 (17, M+ (1 X 37Cl, 2 X 35Cl)), 300 (17, ~ (3 X 35Cl)), 269 (4, [M- Cit, (2 X 37Cl)), 
267 (20, [M - Cit, (1 X 37Cl, I X 35Cl)), 265 (32, [M - Cit, (2 X 35Cl)), 104 (100, 
[PhCNH]l, 77 (80, [Ph ]l, 51 (3 7). 
Attempted lithiation of tetrachloropyridazine 
Cl 
CI~CI 
~'N~CI 
n-Buli I t-Buli 
II .. 
Tetrachloropyridazine (1g, 4.59mmol) was dissolved in THF (20ml) under argon 
with stirring, and the mixture cooled to -78°C. n-Butyllithium ( 4.59mmol) was added 
dropwise, and the solution was observed to darken to a deep brown. After stirring for 2 
hours, water (1 Oml) was added, and the solution allowed to warm to room temperature. 
- The mix_tllre _ _1Ya~ then_yxt[acted wjJh~dic_blpr_omethane c(3~ X 20m I), _and_the_ combined_ -
organic extracts were dried (MgS04), filtered and evaporated to yield a tarry, brown 
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material. GC and 13C NMR analysis showed this to be an extremely complex mixture, so 
product purification was not attempted. 
3,4,5-Trich/oro-6-pheny/pyridazine 311a and 3,4,6-trich/oro-5-pheny/pyridazine 311b 
I~ Cl Cl Cl 
N,N~ Cl Cl 
311a 311b 
Tetrachloropyridazine (2.00g, 9.I8mmol), phenyl boronic acid (1.12g, 9.I8mmol), 
caesium carbonate (5.98g, I8.35mmol) and Pd(PPh3) 4 (0.53g, 0.46mmol, 5mol%) were 
dissolved in dry toluene (50ml) that has been degassed by the freeze-pump-thaw technique. 
The mixture was then heated to reflux for I6 hours, before being allowed to cool to room 
temperature. Water (50ml) was added, and the mixture extracted with dichloromethane (3 
x 50ml). The combined organic extracts were dried (MgS04), filtered and evaporated in 
vacuo to yield a crude brown material (2.34g). This was then purified by flash column 
chromatography (Hexane : DCM, 2:I) to yield the major product 3,4,5-trich/oro-6-
pheny/pyridazine 311a (0.76g, 32%) as white crystals; mp 98- IOI°C (Found C, 46.4; H, 
2.2; N, I0.5. CttHsNJCb requires C, 46.3; H, 1.9; N, 10.8%); Vmaxl cm-1 1059, 1077, 1169, 
1225, 1268, 1277, 1442, 1474, 1487; DH (CDCh, 500MHz) 7.29 (2H, dd, 3JHH 7.0, 3JHH 4.1, 
C3'(H), 7.55 (3H, m, C2'+4'(H)); 8c (CDCb, 125MHz) 116.0 (s), 128.5 (s, PhC), 129.1 (s, 
PhC), 130.3 (s, PhC), 132.1 (s, PhC), 138.1 (s), 141.4 (s), 155.6 (s); mlz (Eil264 (1%, M+ 
(3 X 37Cl)), 262 (18, ~ (2 X 37Cl, 1 X 35Cl), 260 (48, M+ (1 X 37Cl, 2 X 35Cl), 258 (46, M+, 
3 X 35Cl), 236 (1, [M-N2t (3 X 37Cl)), 234 (15, [M-N2t (2 X 37Cl, I X 35Cl), 232 (40, [M-
N2t (I X 37Cl, 2 X 35Cl), 230 (38, [M-N2t, 3 X 35Cl), I97 (42), I95 (58), I60 (100). 
The minor isomer was 3,4,6-trich/oro-5-pheny/pyridazine 311b (0.2Ig, 9%) as 
white solid; mp I19 -I21°C (Found C, 46.5; H, 2.2; N, 10.4. CttHsNJCb requires C, 46.3; 
H, 1.9; N, I0.8%); Vmaxl cm-1 1020, I072, I262, 3567; bH (CDCb, 400MHz) 7.53 (3H, m, 
C3'+4'(H)), 7.72 (2H, m, C2'(H)); eSc (CDCh, IOOMHz) 128.4 (s), I28.5 (s, PhC), 129.5 
(s, PhC), 130.3 (s, PhC), 134.0 (s, PhC), 136.8 (s), 157.9 (s), 159.8 (s); m/z (EI+) 264 (2%, 
[Mt (3 X 37Cl)), 262 (20, [Mt (2 X 37Cl, I X 35Cl), 260 (53, [Mt (1 X 37Cl, 2 X 35Cl), 258 
(50~fMt,{3 X 31GJ));-l9'7-("33kl95(40),-l60tiOO)- . ---
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3, 4,5-Trich/oro-6-p-to/y/pyridazine 312a 
Me 
Cl 
Cl 
312a 
Tetrachloropyridazine ( I.OOg, 4.59mmol), p-tolyl boronic acid (0.62g, 4.59mmol), 
caesium carbonate (2.99g, 9.I8mmol) and Pd(PPh3) 4 (0.27g, 0.23mmol, 5mol%) were 
dissolved in dry toluene (50ml) that has been degassed by the freeze-pump-thaw technique. 
The mixture was then heated to reflux for 16 hours, before being allowed to cool to room 
temperature. Water (20m!) was added, and the mixture extracted with dichloromethane (3 
x 20m!). The combined organic extracts were dried (MgS04), filtered and evaporated in 
vacuo to yield a crude brown material. Purification was attempted by flash column 
chromatography (Hexane : DCM, 2: I), however the major product was not isolated pure. It 
is likely the major product was 3,4,5-trich/oro-6-p-to/y/pyridazine 312a (0.30g, 24%); 8H 
(400MHz, CDCb) 2.31 (3H, s, CH3), 7.18 (4H, m, ArH); mlz (EI) 278 (6%, [Mt (3 x 
37Cl)), 276 (53, [Mt (2 X 37Cl, I X 35CI), 274 (70, [Mt (I X 37Cl, 2 X 35CI), 272 (6I, [Mt, 
3 X 35Cl), I73 (100), 139 (80), 86 (58). 
3, 4, 5-Trich/oro-6-styry/pyridazine 313a 
Tetrachloropyridazine (l.OOg, 4.59mmol), (Z)-phenyl-vinyl boronic acid (0.68g, 
4.59mmol), caesium carbonate (2.99g, 9.18mmol) and Pd(PPh3) 4 (0.27g, 0.23mmol, 
5mol%) were dissolved in dry toluene (50ml) that has been degassed by the freeze-pump-
thaw technique. The mixture was then heated to reflux for 16 hours, before being allowed 
to cool to room temperature. Water (20ml) was added, and the mixture extracted with 
dichloromethane (3 x 20ml). The combined organic extracts were dried (MgS04), filtered 
and evaporated in vacuo to yield a crude brown material. Purification was attempted by 
flash column chromatography (Hexane : DCM, 2: I), however the major product was not 
- isolated-pure; cl t--is~l ikely "the-major-product -was'-3';4;5~trichloro=6=styijilpyridazine -3l3a 
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(0.43g, 33%); 8H (400MHz, CDCh) 7.34 (3H, m, ArH), 7.38 (1H, d, 3JHH 16.6, CH=), 7.58 
(2H, d, 3JHH 8.0, ArH), 8.12 (IH, d, 3JHH 16.6, CH=); 8c (100MHz, CDCb) 118.4 (s), 128.0 
(s), 129.0 (s), 129.9 (s), 135.6 (s), 136.0 (s), 137.5 (s), 139.7 (s), 152.7 (s), 155.6 (s); mlz 
(EI) 290 (4%, [Mt (3 X 37CI)), 288 (22, [Mt (2 X 37Cl, 1 X 35Cl), 286 (100, [Mt (1 X 37CI, 
2 X 35CI)), 284 (80, [Mt' (3 X 35CI)), 258 (33), 150 (41). 
234 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
References 
References 
C. Schmuck and D. Rupprecht, Synthesis, 2007, 3095. 
J. A. Joule and K. Mills, 'Heterocyclic Chemistry', Blackwell Science Ltd., 2000. 
D. E. Pearson, W. W. Hargrove, J. K. T. Chow and B. R. Suthers, J. Org. Chern., 
1961, 26, 789. 
C. K. McGill and A. Rappa, Adv. Heterocycl. Chern., 1988, 44, 1. 
J. F. Bunnett and R. E. Zahler, Chern. Rev., 1951, 49, 273. 
M. Schlosser and T. Rausis, Helv. Chim. Acta, 2005, 88, 1240. 
K. L. Servis, J. Am. Chern. Soc., 1965, 87, 5495. 
K. L. Servis, J. Am. Chern. Soc., 1967, 89, 1508. 
J. F. Bunnett, E. W. Garbisch and K. M. Pruitt, J. Am. Chern. Soc., 1957, 79, 385. 
J. A. Zoltewicz and L. W. Deady, J. Am. Chern. Soc., 1972, 94, 2765. 
T. J. Curphey and K. S. Prasad, J. Org. Chern., 1972, 37, 2259. 
J. Frank and A. R. Katritzky, J. Chern. Soc., Perkin Trans. 2, 1976, 1428. 
M. J. Cook, A. R. Katritzky, P. Linda and R. D. Tack, J. Chern. Soc., Perkin Trans. 
2, 1972, 1295. 
C. W. Bird, Tetrahedron, 1992, 48, 7857. 
E. d. Olmo, B. Barboza, M. I. Ybarra, J. L. Lopez-Perez, R. Carron, M. A. Sevilla, 
C. Boselli and A. S. Feliciano, Bioorg. Med. Chern. Lett., 2006, 16, 2786. 
J.-M. Contreras, Y. M. Rival, S. Chayer, J.-J. Bourguignon and C. G. Wermuth, J. 
Med. Chern., 1999, 42, 730. 
L. M. Bedoya, E. d. Olmo, R. Sancho, B. Barboza, M. Beltran, A. E. Garcia-
Cadenas, S. Sanchez-Palomino, J. L. Lopez-Perez, E. Munoz, A. S. Feliciano and J. 
Alcami, Bioorg. Med. Chern. Lett., 2006, 16, 4075. 
V. M. Loh, X.-1. Cockcroft, K. J. Dillon, L. Dixon, J. Drzewiecki, P. J. Eversley, S. 
Gomez, J. Hoare, F. Kerrigan, I. T. W. Matthews, K. A. Menear, N. M. B. Martin, 
R. F. Newton, J. Paul, G. C. M. Smith, J. Vile and A. J. Whittle, Bioorg. Med. 
Chern. Lett., 2005, 15, 2235. 
X.-1. Cockcroft, K. J. Dillon, L. Dixon, J. Drzewiecki, F. Kerrigan, V. M. Loh, N. 
M. B. Martin, K. A. Meneara and G. C. M. Smith, Bioorg. Med. Chern. Lett., 2006, 
----------------- ----------------- -- -- ----
16, 1040. 
235 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
References 
M.G. N. Russell, R. W. Carling, J. R. Atack, F. A. Bromidge, S.M. Cook, P. Hunt, 
C. Isted, M. Lucas, R. M. McKernan, A. Mitchinson, K. W. Moore, R. Narquizian, 
A. J. Macaulay, D. Thomas, S.-A. Thompson, K. A. Wafford and J. L. Castro,.!. 
Med. Chern., 2005, 48, 1367. 
A. Akahane, H. Katayama, T. Mitsunaga, T. Kato, T. Kinoshita, Y. Kita, T. 
Kusunoki, T. Terai, K. Yoshida andY. Shiokawa,.!. Med. Chern., 1999,42,779. 
C.-K. Ryu and J. Y. Lee, Bioorg. Med. Chern. Lett., 2006, 16, 1850. 
V. D. Piaz, C. Vergelli, M.P. Giovannoni, M.A. Scheideler, G. Petrone and P. 
Zaratin, II Farmaco, 2003, 58, 1063. 
K. M. K. Swamy, M.S. Park, S. J. Han, S. K. Kim, J. H. Kim, C. Lee, H. Bang, Y. 
Kim, S.-J. Kima and J. Yoon, Tetrahedron, 2005, 61, 10227. 
H. Becker, S. B. King, M. Taniguchi, K. P.M. Vanhessche and K. B. Sharpless,.!. 
Org. Chern., 1995, 60, 3940. 
Y. Wang, Z.-Y. Yang, Q. Wang, Q.-K. Cai and K.-B. Yu, Journal of 
Organometallic Chemistry, 2005, 690, 4557. 
F. Thebault, A. J. Blake, C. Wilson, N. R. Champness and M. Schroder, New.!. 
Chern., 2006,30, 1498. 
I. A. Gural'skiy, P. V. Solntsev, H. Krautscheid and K. V. Domasevitch, Chern. 
Commun., 2006,4808. 
K. V. Domasevitch, I. A. Gural'skiy, P. V. Solntsev, E. B. Rusanov, H. 
Krautscheid, J. A. K. Howard and A. N. Chernega, Dalton Trans., 2007, 3140. 
S. A. Abubshait, Molecules, 2007, 12, 25. 
X. Yang and P. Knochel, Org. Lett., 2006,8, 1941. 
E. Bertounesque, T. Imbert and C. Monneret, Tetrahedron, 1996, 52, 14235. 
E. Bertounesque, P. Meresse, C. Monneret and J.-C. Florent, Tetrahedron Lett., 
2007, 48, 5781. 
G. Minetto, L. R. Lampariello and M. Taddei, Synlett., 2005, 2743. 
K. C. Nicolaou, W. E. Barnette and R. L. Magolda,.!. Am. Chern. Soc., 1979, 101, 
766. 
P. G. Baraldi, A. Bigoni, B. Cacciari, C. Caldari, S. Manfredini and G. Spalluto, 
Synthesis, 1994, 1158. 
G. A. Marriner,. S. A. G~tllU!r, 1!.-Y ._.Tang and f\1._!._ Krisc_!l~,.!. {Jrg. Cl_lem.,_ 2001, 
69, 1380. 
236 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
References 
N. Saracoglu, Tetrahedron, 2007,63,4199. 
R. A. Carboni and R. V. Lindsey, .1. Am. Chern. Soc., 1959, 81, 4342. 
E. Gomez-Bengoa, M.D. Helm, A. Plant and J.P. A. Harrity, .1. Am. Chern. Soc., 
2007, 129, 2691. 
J. Cioslowski, J. Sauer, J. Hetzenegger, T. Karcher and T. Hierstetter, J. Am. Chern. 
Soc., 1993, 115, 1353. 
F. Thalhammer, U. Wallfahrer and J. Sauer, Tetrahedron, 1990,31,6851. 
T. J. Sparey and T. Harrison, Tetrahedron Lett., 1998, 39, 5873. 
S. M. Sakya, K. K. Groskopt and D. L. Boger, Tetrahedron Lett., 1997, 38, 3805. 
D. L. Boger, R. P. Schaum and R. M. Garbaccio, .1. Org. Chern., 1998, 63, 6329. 
J. S. Panek and B. Zhu, Tetrahedron Lett., 1996, 37, 8151. 
Z. K. Wan, G. H. C. Woo and J. K. Snyder, Tetrahedron, 2001,57,5497. 
R. Nomak and J. K. Snyder, Tetrahedron Lett., 2001,42, 7929. 
M. Girardot, R. Nomak and J. K. Snyder, .1. Org. Chern., 1998,63, 10063. 
R. Hoogenboom, B. C. Moore and U.S. Schubert, .1. Org. Chern., 2006, 71,4903. 
H. Xie, L. Zu, H. R. Oueis, H. Li, J. Wang and W. Wang, Org. Lett., 2008, 10, 
1923. 
I. Collins, .1. Chern. Soc., Perkin Trans. 1, 2000, 2845. 
I. Collins, .1. Chern. Soc., Perkin Trans. 1, 2002, 1921. 
L. KUrti and B. Czak6, 'Strategic Applications ofNamed Reactions in Organic 
Synthesis', Elsevier, 2005. 
S. Nara, J. Martinez, C. G. Wermuth and I. Parrot, Syn/ett., 2006, 3185. 
B. U. W. Maes, P. Tapolcsanyi, C. Meyers and P. Matyus, Curr. Org. Chern., 2006, 
10,377. 
T. L. Draper and T. R. Bailey, .1. Org. Chern., 1995, 60, 748. 
B. U. W. Maes, G. L. F. Lemiere, R. Dommisse, K. Augustyns and A. Haemers, 
Tetrahedron, 2000, 56, 1777. 
E. Sotelo, A. Coelho and E. Ravifia, Chern. Pharm. Bull., 2003, 51, 427. 
A. Coelho, E. Sotelo and E. Ravifia, Tetrahedron, 2003, 59, 2477. 
A. Coelho, E. Sotelo, H. Novoa, 0. M. Peeters, N. Blaton and E. Ravifia, 
Tetrahedron Lett., 2004, 45. 
S_._§£hrot~J,_ C. St9pk ~pdJ.__]3ach, Tetr_ahl!_tf!Qf1,)._Q_Q_5, ~~. 22fl~- 2.'}._67 '-- _ 
E. Sotelo and E. Ravifia, Synlett., 2002, 223. 
237 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
80 
81 
82 
83 
84 
85 
86 
References 
A. F. Littke and G. C. Fu,Angew. Chern., Int. Ed. Engl., 2002,41,4176. 
B. U. W. Maes, J. Kosmrlj and G. L. F. Lemiere, J. Heterocycl. Chern., 2002, 39, 
535. 
S. Lin, Z. Liu andY. Hu, J. Comb. Chern., 2007, 9, 742. 
D. S. Chekmarev, A. E. Stepanova and A. N. Kasatkin, Tetrahedron Lett., 2005, 46, 
1303. 
B. U. W. Maes, 0. R'kyek, J. Kosmrlj, G. L. F. Lemiere, E. Esmans, J. Rozenski, R. 
A. Dommisse and A. Haemers, Tetrahedron, 2001,57, 1323. 
E. Sotelo, A. Coelho and E. Ravifia, Tetrahedron Lett., 2003, 44, 4459. 
0. R'kyek, B. U. W. Maes, T. H. M. Jonckers, G. L. F. Lemiere and R. A. 
Dommisse, Tetrahedron, 2001,57, 10009. 
Y. Gong and W. He, Heterocycles, 2004, 62, 851. 
D. J. Aldous, S. Bower, N. Moorcroft and M. Todd, Synlett., 2001, 150. 
F. Mongin, L. Mojovic, B. Guillamet, F. Tn!court and G. Qm5guiner, J. Org. Chern., 
2002, 67' 8991. 
K. M. Clapham, A. S. Batsanov, R. D. R. Greenwood, M. R. Bryce, A. E. Smith and 
B. Tarbit, J. Org. Chern., 2008, 73, 2176. 
M.D. Helm, J. E. Moore, A. Plant and J.P. A. Harrity, Angew. Chern., Int. Ed. 
Engl., 2005, 44, 3389. 
M.D. Helm, A. Plant and J.P. A. Harrity, Org. Biomol. Chern., 2006,4,4278. 
D. K. Heldmann and J. Sauer, Tetrahedron Lett., 1997, 38, 5791. 
J. Sauer and D. K. Heldmann, Tetrahedron, 1998, 54, 4297. 
M. Schlosser, Angew. Chern., Int. Ed. Engl., 2005, 44, 376. 
A. Turck, N. Pie, F. Mongin and G. Queguiner, Tetrahedron, 2001, 57, 4489. 
F. Chevallier and F. Mongin, Chern. Soc. Rev., 2008, 37, 595. 
A. Lepretre, A. Turck, N. Pie and G. Queguiner, Tetrahedron, 2000, 56, 3709. 
A. Lepretre, A. Turck, N. Pie, P. Knochel and G. Queguiner, Tetrahedron, 2000, 56, 
265. 
F. Buron, N. Ple, A. Turck and F. Marsais, Synlett., 2006, 1586. 
K. Shen, Y. Fu, J.-N. Li, L. Liu and Q.-X. Guo, Tetrahedron, 2007, 63, 1568. 
N. Pie, A. Turck, K. Couture and G. Queguiner, J. Org. Chern., 1995, 60, 3781. 
87 
__ ___A._ S~ggi(), F. ~_bevallier,_M. Yaultier and f, Mongin,J~ Org._C_h_em.,_2007,_12,_ 
6602. 
238 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
100 
101 
102 
103 
104 
105 
106 
107 
108 
109 
References 
V. Snieckus, Chern. Rev., 1990, 90, 879. 
F. Toudic, A. Turck, N. Pie, G. Queguiner, M. Darabantu, T. Lequeux and J. C. 
Pommelet, J. Heterocycl. Chern., 2003, 40, 855. 
L. Mojovic, A. Turck, N. Pie, M. Dorsy, B. Ndzi and G. Queguiner, Tetrahedron, 
1996. 
N. Le-Fur, L. Mojovic, N. Pie, A. Turck and F. Marsais, Tetrahedron, 2005, 61, 
8924. 
A. Turck, N. Pte, P. Pollet, L. Mojovic, J. Duflos and G. Queguiner, J. Heterocycl. 
Chern., 1997,34,621. 
C. Fruit, A. Turck, N. Pie, L. Mojovic and G. Queguiner, Tetrahedron, 2002, 58, 
2743. 
U. J. Scheele, S. Dechert and F. Meyer, Tetrahedron Lett., 2007, 48, 8366. 
S. Ding, N. S. Gray, X. Wu, Q. Ding and P. G. Schultz, J. Am. Chern. Soc., 2002, 
124. 
J. Huang and E. J. Corey, Org. Lett., 2003, 5, 3455. 
J. W. Lyga,J. Heterocycl. Chern., 1988,25,17571760. 
P. Matyus, B. U. W. Maes, Z. Riedl, G. Haj6s, G. L. F. Lemiere, P. Tapolcsanyi, K. 
Monsieurs, 0. Elias, R. A. Dommisse and G. Krajsovszky, Synlett., 2004, 1123. 
N. Haider and G. Heinisch, Heterocycles, 1993,35,519. 
J. M. Chezal, E. Moreau, 0. Chavignon, C. Lartigue, Y. Blache and J. C. Teulade, 
Tetrahedron, 2003, 59, 5869. 
J. Feixas, M.P. Giovannoni, C. Vergelli, A. Gavalda, N. Cesari, A. Grazianoa and 
V. D. Piaz, Bioorg. Med. Chern. Lett., 2005, 15, 2381. 
J. C. Gonzalez-G6mez, L. Santana and E. Uriarte, Tetrahedron, 2003, 59, 8171. 
G. Seitz, L. Gorge and S. Dietrich, Tetrahedron Lett., 1985, 26, 4355. 
G. Seitz, S. Dietrich, L. Gorge and J. Richter, Tetrahedron Lett., 1986, 27, 2747. 
E. B. Frolov, F. J. Lakner, A. V. Khvat and A. V. lvachtchenko, Tetrahedron Lett., 
2004,45, 4693. 
D. S. Wise and R.N. Castle, J. Heterocycl. Chern., 1974, 11, 1001. 
C. 0. Okafor, R.N. Castle and D. S. Wise, J. Heterocycl. Chern., 1983,20, 1047. 
J. Barltrop and T. C. Owen, Heterocycles, 1988,27,2175. 
C. 0. Okaforand R. N._C!l_s_!l_~,_J.lfejgoc)l_cl. Chern., 1983,_2(), 199_. __ 
239 
110 
Ill 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
123 
124 
125 
126 
127 
128 
References 
S.-D. Cho, S.-Y. Song, Y.-D. Park, J.-J. Kim, W.-H. Joo, M. Shiro, J. R. Falck, D.-
S. Shina and Y.-J. Yoon, Tetrahedron Lett., 2003,44,8995. 
S.-D. Cho, Y.-D. Park, J.-J. Kim, W.-H. Joo, M. Shiro, L. Esser, J. R. Falck, C. 
Ahn, D.-S. Shin and Y.-J. Yoon, Tetrahedron, 2005, 60, 3763. 
J.P. Chupp, C. R. Jones and M. L. Dahl, J Heterocycl. Chern., 1993,30, 789. 
F. Yoneda, T. Ohtaka andY. Nitta, Chern. Pharrn. Bull., 1965, 13, 580. 
F. Yoneda, T. Ohtakaand Y. Nitta, Chern. Pharrn. Bull., 1966,14,698. 
D. E. Ames and R. J. Ward, J Chern. Soc., Perkin Tram. I, 1975,534. 
I. Collins, J. L. Castro and L. J. Street, Tetrahedron Lett., 2000, 41, 781. 
K. T. J. Loones, B. U. W. Maes, C. Meyers and J. Deruytter, J Org. Chern., 2006, 
71,260. 
P. Tapolcsanyi, G. Krajsovszky, R. And6, P. Lipcsey, G. Horvath, P. Matyus, Z. 
Riedl, G. Haj6s, B. U. W. Maes and G. L. F. Lemiere, Tetrahedron, 2002,58, 
10137. 
B. Dajka-Halasz, K. Monsieurs, 0. Elias, L. Karolyhazy, P. Tapolcsanyi, B. U. W. 
Maes, Z. Riedl, G. Haj6s, R. A. Dommisse, G. L. F. Lemiere, J. Kosmrlj and P. 
Matyus, Tetrahedron, 2004, 60, 2283. 
G. M. Brooke, J Fluorine Chern., 1997, 86, 1. 
R. D. Chambers, J. A. H. MacBride and W. K. R. Musgrave, J Chern. Soc. C, 1968, 
2116. 
R. D. Chambers, J. A. H. MacBride and W. K. R. Musgrave, in 
'Fluoroaminopyridazines', UK, 1974. 
R. D. Chambers, C. D. Hewitt, M. J. Silvester and E. Klauke, J Fluorine Chern., 
1986, 32, 389. 
R. D. Chambers and M. Y. Gribble, J Chern. Soc., Perkin Tram. I, 1973, 1411. 
R. D. Chambers, Y. A. Cheburkov, J. A. H. MacBride and W. K. R. Musgrave, J 
Chern. Soc. C, 1971,532. 
S. L. Bell, R. D. Chambers, M. Y. Gribble and J. R. Maslakiewicz, J Chern. Soc., 
Perkin Trans. I, 1973, 1716. 
R. D. Chambers, M. Y. Gribble and E. Marper, J Chern. Soc., Perkin Trans. I, 
1973, 1710. 
1!_. P~ ~h_li!llber~, S_._ PaJtimnon_(lqd Q. 1}. ~R_~ght,J Chem, §qc., f_erkifi_Trll_YI§_. I, 
1974,2673. 
240 
129 
130 
131 
132 
133 
134 
135 
136 
137 
138 
139 
140 
141 
142 
143 
144 
145 
References 
W. Dmowski and A. Haas, J. Chern. Soc., Perkin Trans. I, 1988, 1179. 
R. D. Chambers, J. S. Waterhouse and D. L. H. Williams, J. Chern. Soc., Perkin 
Trans. 2,1977,585. 
R. D. Chambers, M. J. Seabury, D. L. H. Williams and N. Hughes, J. Chern. Soc., 
Perkin Trans. I, 1988,255. 
R. D. Chambers, P. A. Martin, G. Sandford and D. L. H. Williams, J. Fluorine 
Chern., 2008, 129, 998. 
R. D. Chambers, J. A. H. MacBride and W. K. R. Musgrave, J. Chern. Soc. C, 1968, 
2989. 
S. Purser, P.R. Moore, S. Swallow and V. Gouverneur, Chern. Soc. Rev., 2008, 37, 
320. 
H.-J. Bohm, D. Banner, S. Bendels, M. Kansy, B. Kuhn, K. MUller, U. Obst-Sander 
and M. Stahl, ChemBioChem, 2004, 5. 
B. Schwartz, D. G. Drueckhammer, K. C. Usher and S. J. Remington, Biochemistry, 
1995, 34, 15459. 
C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Adv. Drug Deliv. 
Rev., 1997,23, 3. 
W. K. Hagmann, J. Med. Chern., 2008, 51, 4359. 
B. E. Smart, J. Fluorine Chern., 2001, 109, 3. 
D. O'Hagan, Chern. Soc. Rev., 2008,37,308. 
J. Olsen, P. Seiler, B. Wagner, H. Fischer, T. Tschopp, U. Obst-Sander, D. W. 
Banner, M. Kansy, K. MUller and F. Diederich, Org. Biomol. Chern., 2004,2, 1339. 
E. Schweizer, A. Hoffmann-Roder, K. Scharer, J. A. Olsen, C. Fah, P. Seiler, U. 
Obst-Sander, B. Wagner, M. Kansy and F. Diederich, ChemMedChem, 2006, 1, 
611. 
K. MUller, C. Faeh and F. Diederich, Science, 2007,317, 1881. 
M. B. v. Niel, I. Collins, M.S. Beer, H. B. Broughton, S. K. F. Cheng, S.C. 
Goodacre, A. Heald, K. L. Locker, A. M. MacLeod, D. Morrison, C. R. Moyes, D. 
O'Connor, A. Pike, M. Rowley, M.G. N. Russell, B. Sohal, J. A. Stanton, S. 
Thomas, H. Verrier, A. P. Watt and J. L. Castro, J. Med. Chern., 1999, 42, 2087. 
G. L. Grunewald, M. R. Seim, J. Lu, M. Makhoul and K. R. Criscione, J. Med. 
Chem.,2006,,A2,~223~ _ _ _ 
241 
146 
147 
148 
149 
150 
151 
152 
153 
154 
155 
156 
157 
158 
159 
160 
161 
162 
References 
J. T. Kohrt, K. J. Filipski, W. L. Cody, C. Cai, D. A. Dudley, C. A. V. Huis, J. A. 
Willardsen, L. S. Narasimhan, E. Zhang, S. T. Rapundalo, K. Saiya-Cork, R. J. 
Leadley and J. J. Edmunds, Bioorg. Med. Chern. Lett., 2006, 16, I 060. 
C. A. Hargreaves, 'Polyfluoropyridyl Glycosyl Donors', University of Durham, 
Durham, 2005. 
R. B. Martin, 'Hard & Soft Acids and Bases', Wiley, 2006. 
M. B. Smith and J. March, 'March's Advanced Organic Chemistry', Wiley, 2001. 
M. G. Moloney, 'Structure and Reactivity in Organic Chemistry', Blackwell, 2008. 
J.-J. Kim, Y.-D. Park, S.-D. Cho, H.-K. Kim, H. A. Chung, S.-G. Lee, J. R. Falck 
and Y.-J. Yoon, Tetrahedron Lett., 2004, 45, 8781. 
R. D. Bryant, F. A. Kunng and M.S. South, J Heterocycl. Chern., 1995,32, 1473. 
A. Baron, G. Sandford, R. Slater, D. S. Yufit, J. A. K. Howard and A. Vong, J Org. 
Chern., 2005, 70, 9377. 
G. Sandford, R. Slater, D. S. Yufit, J. A. K. Howard and A. Vong, J Org. Chern., 
2005, 70, 7208. 
M. W. Cartwright, G. Sandford, J. Bousbaa, D. S. Yufit, J. A. K. Howard, J. A. 
Christopher and D. D. Miller, Tetrahedron, 2007, 63, 7027. 
G. M. Brooke, R. D. Chambers, C. J. Drury and M. J. Bower, J Chern. Soc., Perkin 
Trans. 1, I993, 2201. 
R. D. Chambers, P. A. Martin, J. S. Waterhouse, D. L. H. Williams and B. 
Anderson, J Fluorine Chern., I 982, 20, 507. 
M. W. Cartwright, 'Highly Functionalised Fused Heterocycle Synthesis from 
Fluoropyridines', Durham University, Durham, 2006. 
H. Suschitzky, in 'Perchloroaromatic compounds', London I New York, 1974. 
W. S. Lee, Y. J. Yoon and S. K. Kim, J Heterocycl. Chern., 2000, 37, 1591. 
J.D. Cook, B. J. Wakefield and C. J. Clayton, Chern. Cornrnun., 1967, 150. 
J. Liu, A. E. Fitzgerald and N. S. Mani, J Org. Chern., 2008, 73, 2951. 
242 
